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Abstract 
This PhD Thesis proposes the discovery and development of new drugs inspired by 
bioactive natural products, which represent valid platforms for the generation of new 
chemical entities of pharmaceutical interest. Thus, the combination of structural and 
functional diversity allows for the identification of new compounds with better biological 
profiles than the natural counterparts. In order to select suitable synthetic targets, we focused 
on natural products that are able to offer promising expectations in the biomedicinal field, 
with new mechanisms of biological action and intriguing molecular structures that could 
represent the basis of new scaffolds of pharmaceutical interest. In particular, the selected 
natural products are a microbial polyketide termed (-)-depudecin, and cyclopeptide and 
cyclodepsipeptide-type compounds from marine origin, the solomonamides A-B and the 
celebesides A-C. In this PhD Thesis we have established synthetic strategies oriented to the 
target, but with the possibility of the extension of such strategies to the construction of a 
molecular diversity through the generation of analogues. For the synthesis of (-)-depudecin, 
a unique and unexplored histone deacetylase (HDAC) inhibitor with antitumoral 
detransforming activity, we have established a new total synthesis utilizing an olefin cross-
metathesis (CM) reaction as the key step, which was successfully achieved in a convergent 
and brief manner to provide (-)-depudecin in only 12 steps and 26% overall yield. In addition, 
the synthetic route was amenable to stereochemical and functional modifications, allowing 
the preparation of two stereoisomers of (-)-depudecin, the 10-epi-depudecin and its 
enantiomer, as well as homodepudecin and several truncated analogues which were used for 
a structure-activity relationship (SAR) study in order to identify new leads based on 
depudecin. In the case of the solomonamides, we have developed a synthetic strategy that 
comprises two phases: a) a cyclisation phase for the construction of the [15]-membered ring 
contained in these marine cyclopeptides utilizing an olefin ring-closing metathesis (RCM) as 
the key reaction; and b) an oxidation phase to give access to the natural products, representing 
a flexible and diversity-oriented route that would allow for the generation of a variety of 
analogues via oxidative transformations. In addition, we identified several structurally related 
solomonamide precursors possessing significant cytotoxicities against various tumor cell 
lines in the low M range. In particular, one of these precursors showed potent antiangiogenic 
effect in vitro and in vivo, suggesting the potential therapeutic application of solomonamide 
derivatives as inhibitors of the persistent and deregulated angiogenesis that characterizes 
cancer and other pathologies. For the last target, the celebesides, [26]-membered 
cyclodepsipeptides with anti-HIV activity, we envisioned a ring closure process based on a 
RCM reaction to access their macrocyclic core. We have established a synthetic strategy for 
the preparation of the peptidic chain contained in these natural products by use of the solid-
phase peptide technology, while the synthesis of the polyketide fragment contained in the 
celebeside A was achieved in a stereoselective manner.  
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List of Abbreviations 
 
A  
Å angstrom 
Ac acetyl 
aq aqueous 
 
B 
 
BAIB (diacetoxy)iodobencene 
BAE bovine aortic endothelial 
Bn benzyl 
br broad 
Bu butyl 
 
C 
 
c concentration for specific rotation measurements 
ºC degree Celsius 
13C NMR carbon nuclear magnetic resonance 
CM 
CTC 
cross-metathesis 
2-chlorotrityl chloride 
CSA camphorsulfonic acid 
 
D 
 
 NMR chemical shift in parts per million 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DIBAL-H diisobutyl aluminium hydride 
DIC N,N-diisopropylcarbodiimide 
DIPEA diisopropyl ethyl amine 
DMAP 4-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
 
E 
 
EDCI 1-ethyl-3-(3’-dimethylaminopropyl)carbodiimide.HCl 
equiv equivalent 
Et 
 
ethyl 
G  
g gram(s) 
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H 
h hour(s) 
HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid  
hexafluorophosphate 
1H NMR proton nuclear magnetic resonance 
Hz 
HIV 
Hertz 
human immunodeficiency virus 
 
I 
 
IC50 
 
J 
half maximal inhibitory concentration 
 
J coupling constant 
 
L 
 
L litro 
LDA lithium diisopropylamide 
 
M 
 
m multiplet 
 micro 
MHz megahertz 
min minute(s) 
mol mol(s) 
mp melting point 
m/z 
 
N 
mass-to-charge ratio 
 
N normal 
NMR nuclear magnetic resonance 
 
P 
 
PCC pyridinium chlorochromate 
pH hydrogen ion concentration in aqueous solution 
ppm parts per million 
pyr pyridine 
 
Q  
q quartet 
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R  
RCM ring-closing metathesis 
Rf retention factor 
Red-Al sodium bis(2-methoxyethoxy)aluminium hydride 
 
S 
 
s singlet 
SAE Sharpless asymmetric epoxidation 
Super-H lithium triethylborohydride 
 
T 
 
t triplet 
TBAF tetrabutylammonium fluoride 
TBDPS tert-butyldiphenylsilyl 
TBHP tert-butyl hydroperoxide 
TBS tert-butyldimethylsilyl 
TEA triethyl amine 
TEMPO 2,2,6,6-tetramethyl-1-pyperidineiloxy 
tert tertiary 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMS trimethylsilyl 
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1.1. Total Synthesis of Natural Products via Metathesis Reactions 
The outstanding and impressive level that organic synthesis has reached in the last 
few decades, especially in the field of the total synthesis of natural products, can be 
largely explained by the emergence, design and development of powerful catalysts, which 
are capable of promoting striking transformations in highly efficient and selective 
fashions. In fact, the ability of many of them to forge C-C bonds between or within highly 
functionalized and sensitive compounds has allowed for the preparation of complex 
frameworks, whose access were previously hampered by the limitations of conventional 
synthetic methods. Among the myriad of recent catalysts, those developed and designed 
to promote metathesis reactions have had a profound impact and created a real revolution 
in the field of total synthesis, by virtue of their ability to promote a stunning number of 
synthetic transformations, depending on the nature of the starting materials and reaction 
conditions. Metathesis reactions 1  include the alkene, enyne and alkyne metathesis 
reactions, together with multiple variants of polyalkenic or polyalkenynic systems as 
starting precursors involved in cascade processes.2 Among these, the alkene metathesis 
reaction (section A in Scheme 1), in which cyclic olefins or linear alkenes are formed 
through ring closing metathesis (RCM), cross-metathesis (CM) process, or their different 
guises (stereoselective, rearrangement, tethered or relay-ring closing metatheses), is the 
most extensively employed.  
 
 
 
Scheme 1. Metathesis Reactions in Organic Synthesis 
                                                          
1 Metathesis reactions not only include alkene-, enyne- and alkyne-metatheses, but also carbonyl-olefin metathesis, which will not be 
included in this chapter. For representative reviews about these reactions see: (a) Ravindar, L.; Lekkala, R.; Rakesh, K. P.; Asiri, A. 
A.; Marwani, H. M.; Quin, H.-L. Org. Chem. Front. 2018, 5, 1381-1391. (b) Ludwig, J. R.; Schindler, C. S. Synlett 2017, 28, 1501-
1509.    
2 Handbook of Metathesis, Vols. 1, 2, 3; Grubbs, R. H., Ed.; Wiley-VCH: Weinheim, 2003 (First Edition), 2015 (Second Edition). 
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Indeed, these transformations occupy a privileged position in modern organic 
synthesis. Less frequently used but no less important are the enyne and alkyne metatheses 
(sections B and C in Scheme 1), which have also become valuable synthetic reactions 
with additional advantages over alkene metatheses. Such is the case of enyne metathesis 
involved in cascade processes or the case of alkyne metathesis owing to the versatility of 
the alkyne group by allowing for further transformations, thus considerably expanding 
the structural diversity of the products that can be formed. 
 
Certainly, behind the success of all these processes are the unique catalysts 
themselves that enable these transformations.  Since the discovery of the first well-defined 
tungsten carbene catalyst by Katz 3  and the elucidation of the mechanism of alkene 
metathesis by Chauvin4 in the 70s, key innovations were the Schrock catalyst 1 in 19905 
and the discovery of the ruthenium-based catalyst 2 by Grubbs in 1993. 6  These 
discoveries marked the beginning of an extraordinary and burgeoning race towards more 
efficient catalysts in terms of activity, stability and functional-group tolerance, 
represented by the ruthenium species 3-147,8,9,10,11,12,13,14,15,16,17,18 (Figure 1). These 
highly efficient catalysts are representative members of three generations of ruthenium 
complexes, in which the introduction of an N-heterocyclic carbene (NHC) ligand (cases 
of 4, 6-14) resulted in an increase in the catalytic activity and thermal stability of the 
catalysts. The catalysts, developed between 1996-2007, gave rise to the rational design of 
new catalysts to enable both stereoselective and stereoretentive metathesis processes, 
leading to the molybdenum, tungsten and ruthenium carbene complexes 15-27, among 
others.19,20,21,22 
                                                          
3 McGinnis, J.; Katz, T. J.; Hurwitz, S. J. Am. Chem. Soc. 1976, 98, 605-606. 
4 Hérisson, J.-L.; Chauvin, Y. Makromol. Chem. 1971, 141, 161-176. 
5 Schrock, R. R.; Murdzek, J. S.; Bazan, G. C.; Robbins, J.; DiMare, M.; O´Regan, M. J. Am. Chem. Soc. 1990, 112, 3875-3886. 
6 Fu, G. C.; Nguyen, S. T.; Grubbs, R. H. J. Am. Chem. Soc. 1993, 115, 9856-9857. 
7 Schwab, P.; France, M. B.; Ziller, J. W.; Grubbs, R. H. Angew. Chem. Int. Ed. 1995, 34, 2039-2041. 
8 Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953-956. 
9 Harrity, J. P. A.; La, D. S.; Cefalo, D. R.; Visser, M. S.; Hoveyda, A. H. J. Am. Chem. Soc. 1998, 120, 2343-2351. 
10 Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2000, 122, 8168-8179. 
11 Wakamatsu, H.; Blechert, S. Angew. Chem. Int. Ed. 2002, 41, 2403-2405. 
12 Fürstner, A.; Grabowski, J.; Lehmann, C. W. J. Org. Chem. 1999, 64, 8275-8280. 
13 Jafarpour, L.; Schanz, H.-J.; Stevens, E. D.; Nolan, S. P. Organometallics 1999, 18, 5416-5419. 
14 Grela, K.; Harutyunyan, S.; Michrowska, A. Angew. Chem. Int. Ed. 2002, 41, 4038-4040. 
15 Zhan, Z. J. US Patent No. US20070043180A1, 2007; Chem. Abstr. 2007, 146, 142834. 
16 Stewart, I. C.; Ung, T.; Pletnev, A. A.; Berlin, J. M.; Grubbs, R. H.; Schrodi, Y. Org. Lett. 2007, 9, 1589-1592. 
17 Love, J. A.; Morgan, J. P.; Trnka, T. M.; Grubbs, R. H. Angew. Chem. Int. Ed. 2002, 41, 4035-4037. 
18 Williams, M. J.; Kong, J.; Chung, C. K.; Brunskill, A.; Campeau, L.-C.; McLaughlin, M. Org. Lett. 2016, 18, 1952-1955. 
19 (a) Malcolmson, S. J.; Meek, S. J.; Sattely, E. S.; Schrock, R. R.; Hoveyda, A. H. Nature 2008, 456, 933-937. (b) Lee, Y.-L.; 
Schrock, R. R.; Hoveyda, A. H. J. Am. Chem. Soc. 2009, 131, 10652-10661. (c) Sattely, E. S.; Meek, S. J.; Malcolmson, S. J.; Schrock, 
R. R.; Hoveyda, A. H. J. Am. Chem. Soc. 2009, 131, 943-953. (d) Yu, M.; Wang, C.; Kyle, A. F.; Jakubec, P.; Dixon, D. J.; Schrock, 
R. R.; Hoveyda, A. H. Nature 2011, 479, 88-93. (e) Wang, C.; Haeffner, F.; Schrock, R. R.; Hoveyda, A. H. Angew. Chem. Int. Ed. 
2013, 52, 1939-1943. 
20 Jiang, A. J.; Simpson, J. H.; Müller, P.; Schrock, R. R. J. Am. Chem. Soc. 2009, 131, 7770-7780. 
21 Rosebrugh, L. E.; Herbert, M. B.; Marx, V. M.; Keitz, B. K.; Grubbs, R. H. J. Am. Chem. Soc. 2013, 135, 1276-1279. (b) Cannon, 
J. S.; Grubbs, R. H. Angew. Chem. Int. Ed. 2013, 52, 9001-9004. 
22 (a) Khan, R. K. M.; Torker, S.; Hoveyda, A. H. J. Am. Chem. Soc. 2013, 135, 10258-10261. (b) Koh, M. J.; Khan, R. K. M.; Torker, 
S.; Yu, M.; Mikus, M. S.; Hoveyda, A. H. Nature 2015, 517, 181-186. 
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Figure 1. Common Catalysts Used for Alkene and Enyne Metathesis Reactions: Evolution of their Design 
and Development 
 
Additions to this armory of valuable catalysts, are the water-soluble catalysts in 
form of PEGylated complexes23 or ruthenium-based catalysts supported on activated 
surfaces, 24  which expand even further the scope and applications of the chemistry, 
particularly in regards to addressing environmental concerns.25 All these catalysts are 
appropriate for alkene and enyne-metatheses. 26  Interestingly, for the latter case, the 
process can be also effected by other transition metal-based catalysts such as those based 
on Pt, Pd or Ir via a completely different mechanism. A separate case is the alkyne 
metathesis reaction, which despite the mechanistic similarity with alkene metathesis, 
requires a different type of catalysts. Indeed, in this case, the variety of catalysts available 
is not as great as those developed for the alkene metathesis reactions, as will be discussed 
in more detail later in the alkyne metathesis section.  Together with the prominent activity 
and stability of the aforementioned catalysts, other features that have been improved in 
the evolution of catalyst design,27 is the exceptional functional group tolerance that all 
these catalysts display, which in turn has positioned them as one of the most powerful 
synthetic tools in the modern organic synthesis. Consequently, total synthesis has 
                                                          
23 Hong, S. H.; Grubbs, R. H. J. Am. Chem. Soc. 2006, 128, 3508-3509. 
24 Kingsbury, J. S.; Garber, S. B.; Giftos, J. M.; Gray, B. L.; Okamoto, M. M.; Farrer, R. A.; Fourkas, J. T.; Hoveyda, A. H. Angew. 
Chem. Int. Ed. 2001, 40, 4251-4256. 
25 (a) Lin, Y. A.; Chalker, J. M.; Davis, B. G. Angew. Chem. Int. Ed. 2009, 10, 959-969. (b) Burtscher, D.; Grela K. Angew. Chem. 
Int. Ed. 2009, 48, 442-454. 
26 All these metal carbene complexes are indeed precatalysts or initiators rather than catalysts because these are not recovered 
unchanged at the end of the process. Being generally accepted the term “catalyst” in the literature, we have opted to use this term 
along the chapter. 
27 For an excellent review about the evolution of the catalyst design, see: Hoveyda, A. H. J. Org. Chem. 2014, 79, 4763-4792. 
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enormously benefitted from the metathesis reactions, as demonstrated by the extensive 
use of these reactions in their intramolecular and intermolecular versions. In fact, a flurry 
of contributions in which the metathesis reaction represents either the key step for the 
successful completion of a synthesis or as a useful and efficient synthetic tool employed 
along the synthetic course is a growing component of the organic chemistry literature.  
 
Given the relevance and impact of this reaction in the field of organic chemistry, 
a large number of reviews, books and book chapters have been devoted to all aspects of 
these reactions. Among all the excellent reviews focused on the applications of metathesis 
reactions in natural products synthesis,28 some key contributions by Nicolaou,29 Pérez-
Castells30 and Prunet31 in 2005, 2006 and 2011, respectively, are notable. Recently, a 
review published in 2017 by Vanderwal 32  is noteworthy, wherein the most relevant 
contributions in the field of the last years were highlighted, but in a very generic form. 
On the other hand, an excellent book was published dealing with metathesis reactions in 
the synthesis of natural products, covering all the aspects of these reactions in the field of 
total synthesis up to 2010.33 In addition, numerous reviews have been published on very 
specific items, dealing with a particular type of metathesis reaction or a particular kind of 
natural products.34 In light of this publication landscape, the current chapter intends to act 
as an introduction to this PhD Thesis, in which a metathesis reaction has been used as the 
key step towards the total syntheses of bioactive natural products. In this context, the 
current chapter covers the recent advances reported in the field of total synthesis, in which 
a metathesis reaction has been essential for the completion of the synthesis, for the period 
2012-2018, with particular emphasis on recent pioneering contributions, as well as 
exciting applications in the context of total synthesis, showing the power that this 
chemistry has to offer and the prospects that it provides for the future.    
 
1.2. Alkene Metathesis in Total Synthesis 
1.2.1. Total Syntheses Based on a Ring-Closing Metathesis Reaction 
The ring-closing metathesis (RCM) reaction is one of the most employed 
methodologies to construct cyclic systems, becoming a common synthetic tool in the 
                                                          
28 Selected reviews on applications of the metathesis reactions in total synthesis: (a) Ivin, K. J. J. Mol. Cat. A: Chemical 1998, 133, 
1-16. (b) Prunet, J. Angew. Chem. Int. Ed. 2003, 42, 2826-2830. (c) Schrock, R. R.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2003, 42, 
4592-4633. (d) Mulzer, J.; Öhler, E. Topics Organomet. Chem. 2004, 13, 269-366. (e) Rouge dos Santos, A.; Kaiser, C. R. Quim. 
Nova, 2008, 31, 655-668. (f) Hoveyda, A. H.; Malcolmson, S. J.; Meek, S. J.; Zhugralin, A. R. Angew. Chem. Int. Ed. 2010, 49, 34-
44. (g) Fürstner, A. Chem. Commun. 2011, 47, 6505-6511. (h) Lei, X.; Li, H. Top. Curr. Chem. 2012, 327, 163-196. (i) Bose, S.; 
Ghosh, S. Proc. Indian Natn. Sci. Acad. 2014, 80, 37-54.  
29 Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. Angew. Chem. Int. Ed. 2005, 44, 4490-4527. 
30 Gradillas, A.; Pérez-Castells, J. Angew. Chem. Int. Ed. 2006, 45, 6086-6101. 
31 Prunet, J. Eur. J. Org. Chem. 2011, 3634-3647. 
32 Vanderwal, C. D.; Atwood, B. R. Aldrichimica Acta 2017, 50, 17-27. 
33 Metathesis in Natural Product Synthesis, Cossy, J.; Arseniyadis, S.; Meyer, C., Ed.; Wiley-VCH: Weinheim, 2010. 
34 Selected reviews on metathesis reactions in synthesis of specific types of natural products: (a) Mulzer, J.; Öhler, E.; Enev, V. S.; 
Hanbauer, M. Adv. Synth. Catal. 2002, 344, 573. (b) Felpin, F.-X.; Lebreton, J. Eur. J. Org. Chem. 2003, 3693-3712. (c) Mutlak, H.; 
Hassan, A. Chem. Commun. 2010, 46, 9100-9106. (d) Morzycki, J. W. Steroids 2011, 76, 949-966. (e) Demonceau, A.; Dragutan, I.; 
Dragutan, V.; Le Gendre, P. Curr. Org. Synth. 2012, 9, 779-790. (f) Bajwa, N.; Jennings, M. P.; Strategies and Tactics in Organic 
Synthesis, 2012, 8, 153-169. (g) Yu, X.; Sun, D. Molecules 2013, 18, 6230-6268. (h) Nguyen, T. V.; Hartmann, J. M.; Enders, D. 
Synthesis 2013, 45, 845-873. (i) Lazarski, K. E.; Moritz, B. J.; Thomson, R. J. Angew. Chem. Int. Ed. 2014, 53, 10588-10599. (j) 
Wojtkielewicz, A. Curr. Org. Synth. 2013, 10, 43-66. (k) Fuwa, H.; Sasaki, M. Bull. Chem. Soc. Jpn. 2016, 89, 1403-1415. (l) Jacques, 
R.; Pal, R.; Parker, N. A.; Sear, C. E.; Smith, P. W.; Ribaucourt, A.; Hodgson, D. M. Org. Biomol. Chem. 2016, 14, 5875-5893. 
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modern organic synthetic laboratory. Indeed, a practically limitless array of carbocyclic 
or heterocyclic ring systems, including small, medium and large-sized rings, can be 
constructed utilizing this transformation. In the context of total synthesis, the preparation 
of small- and medium-sized rings usually plays a complementary role implemented along 
the synthetic path. However, in the case of macrocyclic systems, the RCM reaction 
commonly constitutes a crucial step for the completion of the synthesis. For this reason, 
in this section, we would like to highlight representative examples reported in the last few 
years in which the RCM reaction was the key step.  
 
As a first series of examples in this category, it is worth mentioning the polyketide-
type compounds ripostatins B (28)35 and A (29),36 FD-895 (30),37 cruentaren A (31),38 
pikromycin (32),39 zampanolide (33),40 amphidinolide G (34),41 palmerolide A (35),42 
ecklonialactone B (36), 43  gambieric acid A (37), 44  nominal gobienine A (38), 45 
trienomycins A (39) and F (40),46 13-demethyllyngbyasolide B (41),47 incednam (42),48 
sekothrixide (43),49 aspicillin (44),50 macrolide fragment of FD-891 (45),51  carolacton 
(46), 52  cytospolide P (47), 53  pectenotoxin (48), 54  Sch725674 (49), 55  aspergillide B 
(revised structure, 50), 56  iriometolide 3a (51), 57  paecilomycin B (52), 58  fidaxomicin 
(53),59 exiguolide (54),60 neopeltolide (55),61 methynolide (56)62 and iriomoteolide-2a 
(57)63 (Figure 2).  
 
                                                          
35 (a) Glaus, F.; Altmann, K.-H. Angew. Chem. Int. Ed. 2012, 51, 3405-3409. (b) Winter, P.; Hiller, W.; Christmann, M. Angew. Chem. 
Int. Ed. 2012, 51, 3396-3400. (c) Tang, W.; Prusov, E. V. Angew. Chem. Int. Ed. 2012, 51, 3401-3404. 
36 Tang, W.; Prusov, E. V. Org. Lett. 2012, 14, 4690-4693. 
37 Villa, R.; Mandel, A. L.; Jones, B. D.; La Clair, J. J.; Burkart, M. D. Org. Lett. 2012, 14, 5396-5399. 
38 Kusuma, B. R.; Brandt, G. E. L.; Blagg, B. S. J. Org. Lett. 2012, 14, 6242-6245. 
39 Oh, H.-S.; Kang, H.-Y. J. Org. Chem. 2012, 77, 1125-1130. 
40 Ghosh, A. K.; Cheng, X.; Bai, R.; Hamel, E. Eur. J. Org. Chem. 2012, 4130-4139. 
41 Hara, A.; Morimoto, R.; Iwasaki, Y.; Saitoh, T.; Ishikawa, Y.; Nishiyama, S. Angew. Chem. Int. Ed. 2012, 51, 9877-9880. 
42 Pawar, A. B.; Prasad, K. R. Chem. Eur. J. 2012, 18, 15202-15206. 
43 Becker, J.; Butt, L.; von Kiedrowski, V.; Mischler, E.; Quentin, F.; Hiersemann, M. Org. Lett. 2013, 15, 5982-5985. 
44 Fuwa, H.; Ishigai, K.; Hashizume, K.; Sasaki, M. J. Am. Chem. Soc. 2012, 134, 11984-11987. 
45 Kondoh, A.; Arlt, A.; Gabor, B.; Fürstner, A. Chem. Eur. J. 2013, 19, 7731-7738. 
46 Del Valle, D. J.; Krische, M. J. J. Am. Chem. Soc. 2013, 135, 10986-10989. 
47 Fuwa, H.; Yamagata, N.; Saito, A.; Sasaki, M. Org. Lett. 2013, 15, 1630-1633. 
48 Takada, A.; Uda, K.; Ohtani, T.; Tsukamoto, S.; Takahashi, D.; Toshima, K. J. Antibiot. 2013, 66, 155-159. 
49 Terayama, N.; Yasui, E.; Mizukami, M.; Miyashita, M.; Nagumo, S. Org. Lett. 2014, 16, 2794-2797. 
50 Saidhareddy, P.; Ajay, S.; Shaw, A. K. RSC Adv. 2014, 4, 4253-4259. 
51 Kanoh, N.; Kawamata, A.; Itagaki, T.; Miyazaki, Y.; Yahata, K.; Kwon, E.; Iwabuchi, Y. Org. Lett. 2014, 16, 5216-5219. 
52 (a) Hallside, M. S.; Brzozowski, R. S.; Wuest, W. M.; Phillips, A. J. Org. Lett. 2014, 16, 1148-1151. (b) Kuilya, T. K.; Goswami, 
R. K. Org. Lett. 2017, 19, 2366-2369. 
53 Chatterjee, S.; Guchhait, S.; Goswami, R. K. J. Org. Chem. 2014, 79, 7689-7695. 
54 Fujiwara, K.; Suzuki, Y.; Koseki, N.; Aki, Y.-i.; Kikuchi, Y.; Murata, S.-i.; Yamamoto, F.; Kawamura, M.; Norikura, T.; Matsue, 
H.; Murai, A.; Katoono, R.; Kawai, H.; Suzuki, T. Angew. Chem. Int. Ed. 2014, 53, 780-784. 
55 (a) Bali, A. K.; Sunnam, S. K.; Prasad, K. R. Org. Lett. 2014, 16, 4001-4003. (b) Sharma, B. M.; Gontala, A.; Kumar, P. Eur. J. 
Org. Chem. 2016, 1215-1226. 
56 Pradhan, T. R.; Das, P. P.; Mohapatra, D. K. Synthesis 2014, 46, 1177-1184. 
57 Kumar, S. M.; Prasad, K. R. Chem. Asian J. 2014, 9, 3431-3439. 
58 Ohba, K.; Nakata, M. Org. Lett. 2015, 17, 2890-2893. 
59 (a) Kaufmann, E.; Hattori, H.; Miyatake-Ondozabal, H.; Gademann, K. Org. Lett. 2015, 17, 3514-3517. (b) Miyatake-Ondozabal, 
H.; Kaufmann, E.; Gademann, K. Angew. Chem. Int. Ed. 2015, 54, 1933-1936. 
60 (a) Li, H.; Xie, H.; Zhang, Z.; Xu, Y.; Lu, J.; Gao, L.; Song, Z. Chem. Commun. 2015, 51, 8484-8487. (b) Zhang, Z.; Xie, H.; Li, 
H.; Gao, L.; Song, Z. Org. Lett. 2015, 17, 4706-4709. 
61 Yu, M.; Schrock, R. R.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2015, 54, 215-220. 
62 Suzuki, T.; Fujimura, M.; Fujita, K.; Kobayashi, S. Tetrahedron 2017, 73, 3652-3659. 
63 Sakamoto, K.; Hakamata, A.; Tsuda, M.; Fuwa, H. Angew. Chem. Int. Ed. 2018, 57, 3801-3805. 
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Figure 2. Selected Macrocyclic Polyketides Synthesized via a RCM Reaction (Yields refer only to the 
RCM reaction) 
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Figure 3. Selected Alkaloids and Cyclodepsipeptides Synthesized via a RCM Reaction (Yields refer only 
to the RCM reaction) 
 
In addition, the group of alkaloids and cyclodepsipeptides are illustrated with the 
examples of manzamine A (58),64 isoschizogamine (59),65 vertine (60),66 haliclamide 
(61), 67  5-epi-torrubiellutin (62), 68  petrosin (63), 69  the YM-254890 analogue 64, 70 
nannocystins A (65) and A0 (66), 71  nakadomarin A (67), 72  marineosin A (68), 73 
kanamienamide (69)74 and 15-epi-aetheramide A (70)75 (Figure 3).  
 
Finally, among the total syntheses of terpenes, which employ the RCM reaction, 
particularly noteworthy are the syntheses of 17-deoxyprovidencin (71),76  uprolide G 
acetate (72),77 terreumol C (73),78 pavidolide B (74)79 and boscartin F (75)80 (Figure 4). 
As an indication of the effectiveness of the RCM processes, the yields achieved in many 
cases were reasonable to excellent (44-99% yields), with some exceptions with lower 
                                                          
64 Jakubec, P.; Hawkins, A.; Felzmann, W.; Dixon, D. J. J. Am. Chem. Soc. 2012, 134, 17482-17485. 
65 Miura, Y.; Hayashi, N.; Yokoshima, S.; Fukuyama, T. J. Am. Chem. Soc. 2012, 134, 11995-11997. 
66 Chausset-Boissaire, L.; Árvai, R.; Cumming, G. R.; Guénée, L.; Kündig, E. P. Org. Biomol. Chem. 2012, 10, 6473-6479. 
67 Pfeiffer, B.; Speck-Gisler, S.; Barandun, L.; Senft, U.; de Groot, C.; Lehmann, I.; Ganci, W.; Gertsch, J.; Altmann, K.-H. J. Org. 
Chem. 2013, 78, 2553-2563. 
68 Mahipal, B.; Singh, A.; Ummanni, R.; Chandrasekhar, S. RSC Adv. 2013, 3, 15917-15927. 
69 Toya, H.; Satoh, T.; Okano, K.; Takasu, K.; Ihara, M.; Takahashi, A.; Tanaka, H.; Tokuyama, H. Tetrahedron 2014, 70, 8129-8141. 
70 Rensing, D. T.; Uppal, S.; Blumer, K. J.; Moeller, K. D. Org. Lett. 2015, 17, 2270-2273. 
71 Huang, J.; Wang, Z. Org. Lett. 2016, 18, 4702-4705. 
72 Clark, J. S.; Xu, C. Angew. Chem. Int. Ed. 2016, 55, 4332-4335. 
73 Xu, B.; Li, G.; Li, J.; Shi, Y. Org. Lett. 2016, 18, 2028-2031. 
74 Reddy, D. P.; Zhang, N.; Yu, Z.; Wang, Z.; He, Y. J. Org. Chem. 2017, 82, 11262-11268. 
75 Revu, O.; Prasad, K. R. J. Org. Chem. 2017, 82, 438-460. 
76 Toelle, N.; Weinstabl, H.; Gaich, T.; Mulzer, J. Angew. Chem. Int. Ed. 2014, 53, 3859-3862. 
77 Zhu, L.; Liu, Y.; Ma, R.; Tong, R. Angew. Chem. Int. Ed. 2015, 54, 627-632. 
78 Frichert, A.; Jones, P. G.; Lindel, T. Angew. Chem. Int. Ed. 2016, 55, 2916-2919. 
79 Zhang, P.-P.; Yan, Z.-M.; Li, Y.-H.; Gong, J.-X.; Yang, Z. J. Am. Chem. Soc. 2017, 139, 13989-13992.  
80 Matsuzawa, A.; Shiraiwa, J.; Kasamatsu, A.; Sugita, K. Org. Lett. 2018, 20, 1031-1033. 
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yields (17-34%), and in general excellent stereoselectivities, with some exceptions 
(ecklonialactone, fidaxomycin, iriomoteolide-2a, nakadomarin A), for which the isomeric 
ratios are indicated.  
 
 
Figure 4. Selected Terpenes Synthesized via a RCM Reaction (Yields refer only to the RCM reaction) 
 
In addition to the previous contributions, we can find in the literature other cases 
that deserve a more detailed description. A first example is the synthesis by Brimble et 
al. of palmyrolide A (76), 81  a macrolide isolated from Leptotyngbya cf. sp. and 
Oscillatoria sp. that displays interesting neuroprotective properties, combined with low 
cytotoxicity.  The synthesis was initially based on a RCM reaction of a starting enamide 
precursor; however, this RCM attempt failed despite screening of a wide variety of 
reaction conditions. As a consequence of these disappointing results, the authors 
considered a sequential RCM/olefin isomerization from the diolefin 77, with the 
possibility that the desired isomerization may occur in the presence of the corresponding 
Grubbs catalyst. However, despite the RCM reaction of diolefin 77 proceeding efficiently 
when treated with the Grubbs-II catalyst (4) to give macrocycle 78, the isomerization was 
not observed. This result led the authors to force the isomerization by subsequent 
treatment of the RCM product with carbonylchlorohydridotris(triphenylphosphine)-
ruthenium (II), which then afforded the natural product 76 in a good overall yield. This 
synthetic study constituted the first reported isomerization of an N-allylated tertiary amide 
in a macrocyclic setting and, furthermore, allowed the revision of the structure of the 
natural product, which was erroneously assigned to the initial proposed structures 79 and 
80 (Scheme 2).  
 
                                                          
81 (a) Wadsworth, A. D.; Furkert, D. P.; Sperry, J.; Brimble, M. A. Org. Lett. 2012, 14, 5374-5377. (b) Wadsworth, A. D.; Furkert, 
D. P.; Brimble, M. A. J. Org. Chem. 2014, 79, 11179-11193.  
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Scheme 2. Total Synthesis of Palmyrolide A (76) (Brimble et al. 2012)81 
 
A second relevant example is from Carreira et al., who in a stereodivergent-
oriented approach described the synthesis of the four diastereoisomers of 9-
tetrahydrocannabinol (81) via a RCM reaction from the acyclic precursors 82. 82 
Interestingly, the four stereoisomers of 82 were efficiently prepared by an elegant and 
novel dual catalytic process based on the use of a set of two chiral catalysts (Ir/(P, olefin) 
and a secondary amine) for the enantioselective allylation of 5-methyl-5-hexenal. The 
RCM reaction of each stereoisomer of 82 was achieved under very mild conditions (25 
°C) with the Grubbs II catalyst (4) to provide the corresponding THC precursors 83 in 
excellent 85-92% yields, which were transformed into the final products in three 
additional steps (Scheme 3). Previous syntheses of 9-THC (81) and related cannabinoid-
type compounds have also employed the RCM reaction to construct the cyclohexene ring 
containing in these intriguing natural products.83  
 
The construction of medium-sized rings containing cyclobutanes represents a 
challenging ring-closing metathesis due to the highly strained character of the resulting 
bicyclic system. Despite this potential difficulty, the RCM reaction has proven to be 
highly efficient in many cases. An instructive example of this is demonstrated in the 
synthesis of the polycyclic xanthone-type antibiotic IB-00208 (84), reported by Martin et 
al.84 Thus, the synthesis of the key cyclobutenone 86 was successfully achieved via a 
RCM reaction of precursor 85 when subjected to the Grubbs-II catalyst (4). The resulting 
cyclobutenone was rearranged to the desired xanthone 87 under thermal conditions and 
represents a general route to construct polycyclic benzoquinones. A few more steps then 
converted the xanthone 87 into the targeted natural product 84 (Scheme 4).  
                                                          
82 Schafroth, M. A.; Zuccarello, G.; Krautwald, S.; Sarlah, D.; Carreira, E. M. Angew. Chem. Int. Ed. 2014, 53, 13898-13901. 
83 (a) Trost, B. M.; Dogra, K. Org. Lett. 2007, 9, 861-863. (b) Song, Y.; Hwang, S.; Gong, P.; Kim, D.; Kim, S. Org. Lett. 2008, 10, 
269-271. 
84 Yang, J.; Knueppel, D.; Cheng, B.; Mans, D.; Martin, S. F. Org. Lett. 2015, 17, 114-117. 
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Scheme 3. Total Synthesis of 9-THC ((R,R)-81) and its Stereoisomers (Carreira et al. 2014)82 
 
 
Scheme 4. Total Synthesis of IB-00208 (84) (Martin et al. 2015)84 
 
As another example of the use of the RCM reaction to fashion cyclobutane-
containing polycyclic systems, we highlight the total synthesis of the cytotoxic 
meroterpenoid psiguadial B (88) by Reisman et al.85  in which the RCM reaction of 
diolefinic cyclobutane 89, carried out with the HG II catalyst (6) in the presence of 1,4-
benzoquinone, afforded in an excellent 93% yield the corresponding tricyclic derivative 
90. After a formidable chemoselective hydrogenation of 90, which was accomplished in 
an excellent 90% yield by the action of Crabtree´s catalyst, the resulting product 91 was 
carried towards the natural product in four additional steps (Scheme 5).  
                                                          
85 Chapman, L. M.; Beck, J. C.; Wu, L.; Reisman, S. E. J. Am. Chem. Soc. 2016, 138, 9803-9806. 
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Scheme 5. Total Synthesis of Psiguadial B (88) (Reisman et al. 2016)85 
 
A stunning example of the power of the RCM reaction can be found in the 
construction of strained ring systems via a transannular process as applied in the recent 
synthesis of the cembranolides sarcophytonolide H (92) and isosarcophytonolide D (93) 
by Takamura et al.86 These natural products, isolated from the soft coral of the genus 
Sarcophyton, exhibit potent antifouling activities against the larval settlement of barnacle 
Balanus amphirite with EC50 values in the low g/mL range. In these syntheses, the 
construction of the butenolide contained in the macrocyclic framework, which is a 
structural feature of this class of diterpenes, was achieved via a RCM reaction of the 
corresponding precursors 94 and 96 by treatment with the HG II catalyst (6) in toluene at 
100 °C. The efficiency of these processes is quite remarkable, given both the steric 
encumbrance around the ring closure site and the complexity of the system. The 
completion of the synthesis of both natural products was carried out in three additional 
steps from the RCM products (Scheme 6).  
 
Further evidence for the utility of the RCM reaction in the construction of 
sterically crowded and highly functionalized ring systems is provided by the recent total 
synthesis of the highly oxidized diterpenoids ryanodol (97) and related diterpenes, natural 
products that display powerful pharmacological and insecticidal activities via their 
interactions with the ryanodine receptors.87 The synthesis of the C-ring of ryanodol was 
undertaken by Inoue et al. via the RCM reaction of the precursor 99,88 prepared from the 
allylic diketone 98 in three steps, with a 58% yield over four steps, to obtain advanced 
precursor 100. Remarkably, once again, the presence of unprotected functionalities was 
well tolerated under these ruthenium-catalyzed reaction conditions, thus underscoring the 
                                                          
86 Takamura, H.; Kikuchi, T.; Endo, N.; Fukuda, Y.; Kadota, I. Org. Lett. 2016, 18, 2110-2113. 
87 Chuang, K. V.; Xu, C.; Reisman, S. E. Science 2016, 353, 912-915. 
88 (a) Nagatomo, M.; Koshimizu, M.; Masuda, K.; Tabuchi, T.; Urabe, D.; Inoue, M. J. Am. Chem. Soc. 2014, 136, 5916-5919. (b) 
Koshimizu, M.; Nagatomo, M.; Inoue, M. Angew. Chem. Int. Ed. 2016, 55, 2493-2497. (c) Masuda, K.; Koshimizu, M.; Nagatomo, 
M.; Inoue, M. Chem. Eur. J. 2016, 22, 230-236. 
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mildness and efficiency of these reactions in a complex setting. From compound 100, the 
completion of the synthesis of ryanodol (97) was accomplished in ten additional steps 
with minimal difficulty (Scheme 7).  
 
 
Scheme 6. Total Synthesis of Sarcophytonolide H (92) and Isosarcophytonolide D (93) (Takamura et al. 
2016)86 
 
 
 
Scheme 7. Total Synthesis of Ryanodol (97) (Inoue et al. 2016)88 
 
Within the stereoselective RCM processes, the use of chiral catalysts, such as the 
catalysts 15-22 designed by Hoveyda et al. (see Figure 1), allows for the preparation of 
enantiomerically enriched products.89 Their applications and level of enantioselective 
control is nicely illustrated in the synthesis of the alkaloid deoxoapodine (101), a member 
of a family of alkaloids that share the pentacyclic aspidosperma core. This asymmetric 
synthesis was devised by Movassaghi et al. based on a desymmetrization process of the 
                                                          
89 For reviews on catalytic enantioselective olefin metathesis see: (a) Ref. 27. (b) Montgomery, T. P.; Johns, A. M.; Grubbs, R. H. 
Catalysts 2017, 7, 87 (1-38). 
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achiral triolefin 102.90 Thus, achiral compound 102 was subjected to the catalytic activity 
of the chiral molybdenum pyrrolide complex 17, which proved to be efficient in terms of 
chemical yield and stereoselectivity in the synthesis of quebrachamine,91 however, in this 
case, the catalyst offered only moderate enantioselectivity (e.r. = 82:18). This 
stereochemical outcome was likely influenced by the presence of the amide group in the 
starting precursor, which could coordinate with the transition metal resulting in a 
consequent reduction of the catalytic activity. In light of these results, an exploration of 
other chiral catalysts led to the observation that as the size of the halide substituent on the 
complex increased, the level of enantioselectivity was improved, with a 93:7 ratio of 
enantiomers being achieved when the diodo complex 19 was employed. As the natural 
product possessed the opposite configuration, this result was extended to the enantiomer 
catalyst ent-19 to obtain the product 103 with the configuration of the natural product in 
92% yield and with an enantiomeric ratio of 94:6. With the key product 103 in hand, the 
synthetic route to the natural product was delineated through the pentacyclic derivative 
104, which was prepared in an efficient manner from 103 according to the steps indicated 
in Scheme 8. From pentacycle 104, seven additional steps were required for completion 
of the synthesis of deoxoapodine (101) (Scheme 8).  
 
 
 
Scheme 8. Total Synthesis of Deoxoapodine (101) (Movassaghi et al. 2017)90 
 
Despite the excellent functional group tolerance and the low sensitivity to steric 
hindrances displayed by these catalysts, we can find in the literature numerous examples 
in which steric factors appear to play a crucial role in unsuccessful ring closure reactions. 
This is the case for compound 105, which was devised as a potential precursor for the 
synthesis of the natural product pseudotabersonine (106) by Martin et al.92 Thus, when 
105 was treated with different ruthenium catalysts, including Grubbs-I (3), Grubbs-II (4), 
HG II (6) or even, the Grubbs-Stewart catalyst (12), which is especially reactive towards 
                                                          
90 Kang, T.; White, K. L.; Mann, T. J.; Hoveyda, A. H.; Movassaghi, M. Angew. Chem. Int. Ed. 2017, 56, 13857-13860. 
91 Sattely, E. S.; Meek, S. J.; Malcolmson, S. J.; Schrock, R. R.; Hoveyda, A. H. J. Am. Chem. Soc. 2009, 131, 943-953. 
92 Cheng, B.; Sunderhaus, J. D.; Martin, S. F. Tetrahedron 2015, 71, 7323-7331. 
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sterically hindered olefins, the desired product 107, resulting from a double RCM process 
was not observed, instead obtaining the mono-cyclized product 108 in moderate yields, 
together with degradation products. The authors explored structural modifications of the 
precursor, by increasing its reactivity by removing the ester group, together with a 
complete optimization study of the RCM reaction. This extensive study led the authors to 
define a set of suitable structural requisites and reaction conditions to enable the targeted 
product. Accordingly, having established 109 as a suitable precursor, when this 
compound was treated with the HG II (6) catalyst in toluene at 100 °C, the desired 
metathesis product 110 was obtained in a 90% yield albeit as an inseparable mixture of 
cis/trans isomers in a 7:10 ratio. After transformation of the diastereomeric mixture 110 
into the reduced product 111, the isomers could be separated, and then, the required cis 
isomer taken forward to completion of the natural product in three more steps (Scheme 
9).   
 
 
Scheme 9. Total Synthesis of Pseudotabersonine (106) (Martin et al. 2015)92 
 
A noteworthy case is the natural product soraphen A1 (112), whose antimicrobial, 
antifungus, antidiabetes and anticancer properties has prompted great interest. 
Preliminary synthetic efforts conducted by Ciufolini et al.,93 based on a RCM reaction 
were met with failure for various acyclic precursors (113-116). Reasoning that steric 
factors were responsible for the failed reactions, Kalesse et al.94 attempted the RCM 
reactions at less sterically encumbered sites, but the results were similarly unfruitful for 
precursor 121. However, the RCM reaction of the desmethoxy precursor 123, explored 
                                                          
93 Vincent, G.; Mansfield, D. J.; Vors, J.-P.; Ciufolini, M. A. Org. Lett. 2006, 8, 2791-2794. 
94 Lu, H.-H.; Hinkelmann, B.; Tautz, T.; Li, J.; Sasse, F.; Franke, R.; Kalesse, M. Org. Biomol. Chem. 2015, 13, 8029-8036. 
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by Micalizio et al.,95 provided in high yield the macrocycle 124 with Grubbs-II catalyst 
(4), proof that steric factors were responsible for the previous failures. From compound 
124, the authors completed the synthesis of the soraphen analogue 125. (Scheme 10).   
 
 
 
Scheme 10. Synthetic Attempts of Soraphen A1 (112) via RCM and Synthesis of the C11-Desmethoxy 
Analogue 125 (Micalizio et al. 2013)95 
 
A paradigmatic example in which the RCM reaction proved to be completely 
useless was in the synthesis of the bryostatins. The well-known fascinating synthesis of 
the bryostatins by Trost et al. was preceded by an initial attempt of its total synthesis via 
a RCM reaction of the diolefins 126 and 127.96 However, after extensive screening of 
different catalysts and conditions, Trost et al. were unable to obtain the corresponding 
macrocycles 128 and 129. Furthermore, the implementation of the relay RCM (RRCM) 
strategy, as we will describe later, did not provide the expected macrocyclic olefin, when 
the RRCM precursor 130 was subjected to different ruthenium-based catalysts, providing 
instead the macrocyclic product 131 as a result of the incorporation of the extended olefin 
onto the final cyclization product. Having ascribed the importance of steric hinderance, 
imposed by the presence of the gem-dimethyl system at the allylic position, as the reason 
                                                          
95 Canterbury, D. P.; Scott, K. E. N.; Kubo, O.; Jansen, R.; Cleveland, J. L.; Micalizio, G. C. ACS Med. Chem. Lett. 2013, 4, 1244-
1248. 
96 Trost, B. M.; Yang, H.; Dong, G. Chem. Eur. J. 2011, 17, 9789-9805. 
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for these disappointing results, Thomas et al. recently have studied the RCM reaction in 
model systems of the bryostatins in which the gem-dimethyl group was removed.97 In 
their study, the RCM reaction of model compound 132 by exposure to the Grubbs-II 
catalyst (4) furnished the macrocyclic compound 133, albeit in a poor 17% yield (Scheme 
11). These results are an indication of the serious hurdles that this class of systems 
presents for the metathesis reaction.  
 
 
 
Scheme 11. Synthetic Studies on Bryostatins via RCM reactions (Trost et al. 2011; and Thomas et al. 
2017)96,97 
 
A recent example in which a RCM reaction was combined with a final CM 
reaction to append the side chain in a stereoselective manner is the synthesis of the 
halogenated marine metabolites chlorofucins (134-135) and bromofucins (136-137) by 
Paton et al.98 These natural products belong to the family of the bioactive acetogenins 
isolated from the Laurencia red algae that have generated great synthetic interest, 
particularly in the development of efficient methodologies for the regio- and stereo-
controlled construction of the medium-ring oxacycle that characterize these appealing 
natural products.99 Furthermore, for the chlorofucins (134-135) and bromofucins (136-
                                                          
97 Dumeunier, R.; Gregson, T.; MacCormick, S.; Omori, H.; Thomas, E. J. Org. Biomol. Chem. 2017, 15, 2768-2783. 
98 Kim, B.; Sohn, T.-i.; Kim, D.; Paton, R. S. Chem. Eur. J. 2018, 24, 2634-2642. 
99 Fujiwara, K. Top. Heterocycl. Chem. 2006, 5, 97-148. 
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137), their absolute configurations were not established so their asymmetric syntheses 
could unambiguously confirm their proposed configurations. Thus, the formation of the 
common oxocene derivative 139 was efficiently undertaken by exposure of the acyclic 
precursor 138 to the Grubbs II catalyst (4). For the incorporation of the halogen with 
concomitant intramolecular etherification, oxocene 139 was previously transformed into 
the alcohol 140 in an excellent overall yield and stereoselectivity. With this compound in 
hand, treatment with t-BuOCl or NBS efficiently furnished the corresponding chloro and 
bromo bicyclic ethers, which were prepared for the key CM reaction by transformation 
into the terminal olefins 141 and 142, respectively. For the E-selective installation of the 
enyne moiety, the authors carried out a CM reaction of compounds 141 and 142 with 
crotonoaldehyde in the presence of the Grubbs-II catalyst (4) to yield the corresponding 
(E)-,-unsaturated aldehydes, which after a final reaction with lithium TMS-
diazomethane delivered the final products 135 and 137 in 74 and 61% overall yields, 
respectively. For the synthesis of the (Z)-isomers, the authors applied the Lee 
methodology,100 based on a cross metathesis with enyne 145 in the presence of the HG 
(II) catalyst (6) for the direct delivery of the (Z)-isomers of both natural products 134 and 
136 in good yields, albeit in modest stereoselectivities in favor of the Z-isomer (3.8:1 
mixture for 134; 4:1 for 136) (Scheme 12). Finally, the described stereodivergent strategy 
to the chlorofucins and bromofucins allowed confirmation of the absolute configurations 
of these natural products by comparison of the spectroscopic properties and optical 
rotations of the synthetic compounds with those reported for the natural products.   
 
Metathesis-based methodologies have been used in combination with other 
innovative technologies in organic synthesis laboratories. Indeed such a case is 
continuous flow technology, which has been recently implemented in combination with 
metathesis reactions to enhance their synthetic value.101 An interesting application of this 
can be found in the total synthesis of neomarchantin A (146), a natural product belonging 
to the macrocyclic bisbibenzyl family, which has been paid much attention from chemical 
and biological standpoints due to its intriguing structural and biological features. For 
example, these compounds exhibit a wide range of biological activities, including 
antibacterial, antimycotic, antitumoral and antiviral activities. The total synthesis of 
neomarchantin A (146), described by Collins et al.102 represents the first synthesis of this 
natural product, which is based on a RCM reaction of the diolefin 147, to obtain the 
corresponding macrocyclic derivative in a modest 43% yield when HG II catalyst (6) was 
employed in toluene at 110 °C. Interestingly, when the cyclization reaction was done in 
continuous flow, the yield of the macrocyclic product could be increased to a 49% yield. 
Final hydrogenation and methyl ether cleavage afforded the targeted natural product in 
88% overall yield (Scheme 13).  
                                                          
100 Hansen, E. C.; Lee, D. Org. Lett. 2004, 6, 2035-2038. 
101 (a) Monfette, S.; Eyholzer, M.; Roberge, D. M.; Fogg, D. E. Chem. Eur. J. 2010, 16, 11720-11725. (b) Skowerski, K.; Czarnocki, 
S. J.; Knapkiewicz, P. ChemSusChem 2014, 7, 536-542. 
102 Morin, E.; Raymond, M.; Dubart, A.; Collins, S. K. Org. Lett. 2017, 19, 2889-2892. 
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Scheme 12. Total Synthesis of Chlorofucins (134, 135) and Bromofucins (136, 137) (Paton, Kim et al. 
2018)98 
 
 
 
Scheme 13. Total Synthesis of Neomarchantin A (146) (Collins et al. 2017)102 
 
As a final example for this section, an interesting strategy was delineated for the 
synthesis of the cyclopropane fattic acid (+)-majusculoic acid (148), an interesting 
secondary metabolite with significant antifungal activity, by Zhang et al.103 Accordingly, 
the authors devised a stereoselective cyclopropanation from the C2-symmetric 14-
membered dilactone according to previously performed DFT calculations that revealed a 
preference of the -faces of both olefins for the attack of the corresponding 
cyclopropanating reagents. For the synthesis of the required dilactone 150, the authors 
envisioned an unusual RCM dimerization from diolefinic monomer 149. To this aim, after 
an extensive study in which an array of catalysts, solvents and temperatures were 
screened, the authors found the Grubbs-II catalyst (4) in refluxing dichloromethane as the 
                                                          
103 Chen, R.; Li, L.; Lin, N.; Zhou, R.; Hua, Y.; Deng, H.; Zhang, Y. Org. Lett. 2018, 20, 1477-1480. 
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best condition reactions to obtain the dilactone 150 (53%), accompanied by the 
monomeric RCM product 151 in a 26% yield. With the dilactone 150 in hand, it was 
possible to demonstrate the reliability of the theoretical predictions regarding the 
stereochemical outcome of the cyclopropanation. Indeed, the formation of the 
biscyclopropane 152 was realized in 80% yield as a single stereoisomer when 150 was 
treated with diazomethane in the presence of palladium diacetate. The dimerization 
process was then continued by a dedimerization process by opening of the dilactone 152 
with N,O-dimethylhydroxylamine and reduction of the resulting Weinreb amide to the 
aldehyde 153. In a final sequence of eight steps, in which the awkward (E,Z)-bromodiene 
system was installed via the new Kocienski-Julia-type reagent 154 developed by the same 
authors, the synthesis was complete, obtaining a product which matched all the 
spectroscopic and physical properties with those reported for the natural product, except 
for the optical rotation, which was the opposite. Therefore, this asymmetric synthesis 
allowed the confirmation of the absolute configuration for the natural product that 
corresponded to ent-148, as initially proposed (Scheme 14). 
 
 
 
Scheme 14. Total Synthesis of (+)-Majusculoic Acid (148) (Zhang et al. 2018)103 
  
1.2.2. Total Syntheses Based on a Cross-Metathesis Reaction 
In contrast to the RCM reactions, the cross-metathesis (CM) reaction has received 
less attention in the field of total synthesis, probably due to the inherent difficulties of the 
intermolecular assembly of two alkenes, in which dimerization processes compete 
substantially. Despite these difficulties, the appealing features of the metathesis reactions 
in terms of functional-group tolerance and mild reaction conditions have prompted 
intense research activity with the goal of minimizing the chemo- and stereoselective 
issues associated with this modality.  
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Figure 5. Selected Natural Products Synthesized via a CM Reaction (Yields refer only to the CM reaction) 
 
As a consequence, CM reactions have emerged as a common chain-elongation 
method to append small side chains or to assemble linear complex molecular frameworks. 
Concerning the stereoselectivity of the reaction, the thermodynamic control that governs 
these reactions leads to the preferred formation of the E-alkene. Within the field of total 
synthesis, several interesting syntheses of natural products have been reported in which 
the CM represented the key step for the coupling of the important fragments of the 
molecule, thus allowing the completion of the synthesis. Among the most outstanding 
contributions of the last few years are the total syntheses of the fluorinated cryptophycin 
155,104 FD-891 (156),105 murisolin (157),106 ledoglucomides A (158) and B (159),107 
epicoccamide D (160),108 synargentolide B (161),109 homaline (162),110 bitungolide F 
(163),111 penarolide (164),112 cytospolide D (165),113 goniocin (166),114 cryptomoscatone 
F1 (167),115 curvicollide C (168),116 proposed structures for cryptorigidifoliol K (169a-
d),117 and alotaketal A (170)118 (Figure 5).  
 
                                                          
104 Weiβ, C.; Bogner, T.; Sammet, B.; Sewald, N. Beilst. J. Org. Chem. 2012, 8, 2060-2066. 
105 Yadav, J. S.; Das, S. K.; Sabitha, G. J. Org. Chem. 2012, 77, 11109-11118. 
106 Persich, P.; Kerschbaumer, J.; Helling, S.; Hildmann, B.; Wibbeling, B.; Haufe, G. Org. Lett. 2012, 14, 5628-5631. 
107 Reddy, C. R.; Jithender, E.; Prasad, K. R. J. Org. Chem. 2013, 78, 4251-4260. 
108 Yajima, A.; Kawajiri, A.; Mori, A.; Katsuta, R.; Nukada, T. Tetrahedron Lett. 2014, 55, 4350-4354. 
109 Konda, S.; Bhaskar, K.; Nagarapu, L.; Akkewar, D. M. Tetrahedron Lett. 2014, 55, 3087-3089. 
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However, there are some specific cases that deserve a more detailed description. 
As a first example within this category is the formal total synthesis of spirangien A (171), 
a highly potent cytotoxic spiroketal isolated from the prolific myxobacterium Sorangium 
cellulosum. Among the various total syntheses described for this natural product, the one 
reported by Rizzacasa et al.119 utilized a CM reaction in the union of the olefins 172 and 
173 under the assistance of the Grela-Grubbs-Hoveyda catalyst (10). This CM reaction 
afforded the E-enone 174 in an excellent 80% yield, providing a straightforward 
alternative to the use of a Horner-Wadsworth-Emmons reaction, which requires 
additional steps for the preparation of the required phosphonate. In this way, the backbone 
of the spiroketal core found in the natural product was constructed, requiring only six 
additional steps for the rapid and efficient preparation of the spiroketal precursor 176. 
From the advanced spiroketal precursor 176, the completion of the natural product was 
reported earlier by Paterson et al. (Scheme 15).120  
 
Scheme 15. Formal Total Synthesis of Spirangien A (171) (Rizzacasa et al. 2013)119 
 
Another case of note is represented by the total synthesis of mueggelone (177), an 
inhibitor of fish embryo larval development. After several total syntheses reported for this 
interesting natural product, some of which required around 20 steps, Meshram et al.121 
described a convergent total synthesis utilizing only 8 steps in the longest linear sequence, 
featuring a final CM step in which olefins 178 and 179 were assembled by treatment with 
the Grubbs II catalyst (4) to directly deliver the natural product in a 40% yield (Scheme 
16).  
                                                          
119 Gregg, C.; Gunawan, C.; Ng, A. W. Y.; Wimala, S.; Wickremasinghe, S.; Rizzacasa, M. A. Org. Lett. 2013, 15, 516-519. 
120 Paterson, I.; Findlay, A. D.; Noti, C. Chem. Asian J. 2009, 4, 594-611. 
121 Kumar, D. A.; Meshram, H. M. Synth. Commun. 2013, 43, 1145-1154. 
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Scheme 16. Total Synthesis of Mueggelone (177) (Meshram et al. 2013)121 
 
The prominent antitumor activities of spliceostatin E (180) and related 
compounds, such as spliceostatin A (181) and FR901464 (182), have elicited great 
interest in their syntheses. Among them, the total syntheses developed by Ghosh et al. is 
based on a CM reaction,122 representing a brilliant example of the power and robustness 
of the methodology. The ability of these natural products to inhibit the cellular splicing 
process, an essential step for the gene expression, renders them a novel class of anticancer 
products. In fact, spliceostatin E (180) and FR901464 (182) exhibit potent anticancer 
activities in the ranges from 1.5 to 4.1 and from 0.6 to 3.4 nM, respectively, against 
various human cancer cell lines. The syntheses of both compounds were achieved via a 
final key CM that efficiently joined fragments 183 and 184 for spliceostatin E (180)122 
and 185 and 186 for spliceostatin A (181),123 in 71 and 57% yields, respectively, with 
both reactions displaying exquisite chemo- and stereo-selectivities. A final acidic 
treatment of compound 181 afforded the natural product 182 (Scheme 17). 
 
 
Scheme 17. Total Synthesis of Spliceostatins E (180) and A (181) and FR901464 (182) (Ghosh et al. 2013 
and 2014)122,123 
 
 
                                                          
122 Ghosh, A. K.; Veitschegger, A. M.; Sheri, V. R.; Effenberger, K. A.; Prichard, B. E.; Jurica, M. S. Org. Lett. 2014, 16, 6200-6203. 
123 (a) Ghosh, A. K.; Chen, Z.-H. Org. Lett. 2013, 15, 5088-5091. (b) Ghosh, A. K.; Chen, Z.-H.; Effenberger, K. A.; Jurica, M. S. J. 
Org. Chem. 2014, 79, 5697-5709. 
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Scheme 18. Total Synthesis of Mycalolides A (187) and B (188) (Kigoshi, Kita et al. 2015)124 
 
An excellent example that illustrates the advantage that the CM reaction can offer, 
especially for macrocyclic compounds, over a RCM reaction, are the synthesis of the 
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natural products mycalolides A (187) and B (188) by Kigoshi et al.124 Both compounds, 
isolated from the marine sponge Mycale sp., are members of a family of natural products 
characterized by the presence of a trisoxazole macrocycle with potent cytotoxic activities 
as a consequence of actin-depolymerizing activity. A first attempt at the total synthesis 
was carried out by the authors via a RCM reaction of the diolefins 189a and 189b. 
However, despite this reaction affording the macrocyclic derivatives 190a and 190b in 
reasonably good yields (40-76% depending on the employed catalysts and solvents), the 
reaction was not stereoselective in both cases, providing a mixture of the E:Z isomers in 
the 1:1 to 1.9:1.0 range of ratios. This proportion could be increased to a 2.7:1.0 ratio in 
favor of the required E-olefin when the desilylated derivative 189b was employed as the 
starting precursor.  As an alternative, the authors attempted a CM/macrolactonization 
approach which proved to be more efficient. Thus, when a mixture of olefins 191 and 192 
was subjected to the catalytic action of the HG-II catalyst (6) in refluxing 
dichloromethane, the olefin 193 was obtained in an impressive 77% yield and in an 
improved 5:1 mixture of the E:Z isomers. After the CM step, a Yamaguchi 
macrolactonization was conducted to prepare the corresponding macrolactone in a 
remarkable 77% yield, which was finally directed to the natural products mycalolides A 
(187) and B (188) in ten additional steps (Scheme 18). 
 
The scope of the CM reaction has been expanded to conjugated dienes by Altmann 
et al.125 during their synthetic studies directed towards the aglycone of tiacumicin B (194), 
a macrocylic antibiotic with potential application against Mycobacterium tuberculosis 
and whose total synthesis was not reported when the studies were published. Thus, 
combination of olefin 195 and the conjugated diene 196 in the presence of the HG-II 
catalyst (6) provided a 56% yield of compound 197 as an inseparable mixture of E/Z 
isomers in a 6.7:1 ratio. The preparation of ester 199 was followed by a Suzuki 
macrocyclization, to afford the macrocyclic aglycone derivative of tiacumicin B 200 in a 
73% yield. Global desilylation of the macrocyclic derivative 200 was performed with 
NEt3•3HF to obtain tiacumicin B aglycone 194. Soon after this publication, Gademann et 
al. reported the total synthesis of tiacumicin B, also named fidaxomicin or lipiarmycin 
A3 (53), based on a RCM strategy, as depicted in Figure 2.59 In addition to the Altmann 
synthetic studies, closely related strategies have been reported by Zhu 126  and, very 
recently, by Roulland et al., 127  also using CM reactions. The former achieved the 
assembly of olefin 201 and diene 202, while the second carried out the assembly of olefin 
204 with diene 205 to yield the corresponding CM products 203 and 206 in 38 and 39% 
yields, respectively and with stereoselectivities comparable to those obtained by Altmann. 
However, unlike the studies of Altmann, in these later cases the authors found serious 
difficulties, mainly with the subsequent removal of the employed protecting groups 
within the products 203 and 206, thus forcing them to explore different synthetic 
                                                          
124 Kita, M.; Oka, H.; Usui, A.; Ishitsuka, T.; Mogi, Y.; Watanabe, H.; Tsunoda, M.; Kigoshi, H. Angew. Chem. Int. Ed. 2015, 54, 
14174-14178. 
125 Glaus, F.; Altmann, K.-H. Angew. Chem. Int. Ed. 2015, 54, 1937-1940. 
126 Erb, W.; Grassot, J.-M.; Linder, D.; Neuville, L.; Zhu, J. Angew. Chem. Int. Ed. 2015, 54, 1929-1932. 
127 Jeanne-Julien, L.; Masson, G.; Astier, E.; Genta-Jouve, G.; Servajean, V.; Beau, J.-M.; Norsikian, S.; Roulland, E. Org. Lett. 2017, 
19, 4006-4009. 
                                                                                                                       Chapter 1                                                               
47 
 
strategies in both cases, to overcome these synthetic hurdles and to reach the targeted 
tiacumicin B aglycone 194 (Scheme 19).  
 
 
Scheme 19. Total Synthesis of Tiacumicin B aglycone (194) by Altmann (2015)125 and Synthetic Studies 
by Zhu (2015)126 and Roulland (2017)127 
 
Another relevant contribution of the use of the CM reaction in total synthesis was 
recently published by Takahashi et al. for the total synthesis of aromin (207),128 a member 
belonging to the wide family of the Annonaceous acetogenins, isolated from the 
Annonaceae plants and which exhibits a broad spectrum of biological activities including 
anticancer, antibiotic, immunosuppressive, antifeedant and pesticidal activities. Aromin 
(207), isolated together with aromicin in 1996 by McLaughlin, has been recognized as an 
antitumoral compound with a significant cytotoxicity profile against various tumor cell 
lines, albeit lower compared to other acetogenins. The synthetic work by Takahashi, 
based on his previous synthetic work, is interesting for two reasons. On one hand, they 
                                                          
128 Takahashi, S.; Satoh, D.; Hayashi, M.; Takahashi, K.; Yamaguchi, K.; Nakamura, T.; Koshino, H. J. Org. Chem. 2016, 81, 11222-
11234. 
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demonstrated the utility of the CM reaction by using the Grubbs 2nd generation catalyst 
(4) to connect a terminal olefin and an enone to construct the corresponding linear E-
enone. On the other hand, this work also led to the structural revision of aromin (207) 
(Scheme 20). 
 
Thus, the assembly of olefin 208 and enone 209 proceeded smoothly when they 
were exposed to the Grubbs II catalyst (4) to provide the E-enone 210 in 68% yield and 
excellent stereoselectivity. With this compound 210 in hand, the authors accomplished 
the completion of the proposed structure for aromin in four additional steps in a 73% 
overall yield. Surprisingly, the spectroscopic and physical properties of the synthetic 
material 207 was notably different from those reported for the natural aromin. According 
to the detected discrepancies found in the 1H NMR spectra, the authors suggested a 
structural difference around the central THF ring and, for this reason, they prepared the 
stereoisomer 211, according to a similar synthetic sequence as for 207, but once again, 
the NMR data were inconsistent with those of the natural product.  After an exhaustive 
comparative analysis of the NMR data of a wide set of acetogenins possessing a 4-
hydroxyl group adjacent to the -lactone ring, together with a detailed analysis of the MS 
fragmentations, the authors were led to propose the structure of the natural product 
montanacin D (212), whose synthesis was similarly accomplished by the same authors 
according to the same CM strategy, for the revised structure for aromin (Scheme 20).129  
 
 
Scheme 20. Total Synthesis of Proposed Structure for Aromin (207) and its Structural Revision (Takahashi 
et al. 2016)128, 129 
                                                          
129 Takahashi, S.; Hongo, Y.; Tsukagoshi, Y.; Koshino, H. Org. Lett. 2008, 10, 4223-4226. 
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A final example within this section is represented by the interesting synthetic 
strategy reported by Pietruszka et al. for the synthesis of putaminoxins B/D (213), 
identified as a C-9 epimeric mixture and whose absolute configurations were not yet 
established.130 In order to unambiguously establish their absolute configurations, the four 
possible stereoisomers 213a-d were prepared by a CM reaction of dimers (S,S)- and 
(R,R)-214, previously prepared by a dimerization CM reaction of the corresponding 
monomers, with olefins (S)- and (R)-215. The choice to use the dimers 214 instead of the 
corresponding monomeric olefins was justified because better yields were obtained for 
the desired cross-metathesis products 216 versus CM reactions with the monomers, in 
which the dimeric products 214 were the main compounds detected. Indeed, when each 
isomer of 214 was treated with the corresponding (S)- and (R)-215, in the presence of the 
Grubbs-II catalyst (4), the corresponding products 216a-d were obtained in 36, 72, 24 
and 83% yields, respectively. Then, each isomer was subjected to a sequence, that 
included basic treatment, a Yamaguchi macrolactonization and final THP protecting 
group removal to provide all the possible stereoisomers of the macrolactone 213 in high 
yields. With all the isomers in hand, an extensive spectroscopic study, in which the 
authors compared the NMR data collected from all these compounds with those reported 
for the natural products, resulted in disappointment. This was due to the inability to 
correlate the resulting NMR data of the synthetic compounds with those reported for the 
natural products, thus leading the authors to reconsider the initially proposed structures 
for putaminoxins B/D. Intriguingly, after a thorough inspection of the NMR data of 
related nonenolides, they found that the data reported for the natural products 
hypocreolide A (217) and aspinolide A (218) matched with those reported for the natural 
products putaminoxins B/D (Scheme 21). 
 
 
Scheme 21. Total Synthesis and Structural Studies of Putaminoxins B/D (213) (Pietruszka et al. 2017)130 
 
                                                          
130 Bisterfeld, C.; Holec, C.; Böse, D.; Marx, P.; Pietruszka, J. J. Nat. Prod. 2017, 80, 1563-1574. 
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1.2.3. Strategies for Selective and Efficient Metathesis Reactions of Alkenes 
1.2.3.1. Temporary Tethered Ring-Closing Metathesis 
A highly inventive and clever strategy to transform the intermolecular character 
of the cross-metathesis of alkenes into an intramolecular variant has been explored by 
means of the development of temporary tethers, through which, the corresponding 
olefinic partners can be transiently coupled. This strategy not only provides the advantage 
of the improved efficiency, that is a feature of the RCM versus the CM reaction, but also 
the possibility of controlling the geometry of the resulting double bond, to favor the Z-
olefin when a strained ring is temporarily formed. However, this strategy is limited to 
molecular structures in which a possible linkage of the tether system is present, usually 
in form of hydroxyl groups at allylic or homoallylic positions. Due to the versatility, 
stability and ease of cleavage, silicon-based tethers have been the most employed for this 
strategy. In fact, the temporary silicon-tethered RCM (TST-RCM) was described initially 
by Grubbs and Fu in 1992.131 Thus, in order to favor the formation of the Z-isomer, a 
temporary [7]-membered ring is required, for which the silicon tethered is represented by 
precursor A. In case of precursor B, whose RCM would deliver a [8]-membered ring, the 
preference would be the formation of the E-isomer (Scheme 22, part A).  
 
 
Scheme 22. General Temporary Silicon-tethered RCM (TST-RCM) Reactions and Selected Natural 
Products Synthesized via this Strategy 
                                                          
131 Fu, G. C.; Grubbs, R. H. J. Am. Chem. Soc. 1992, 114, 5426-5427. 
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In 2012, the applications of silicon-tethered RCM in synthesis of natural products 
was reviewed132 and, as a consequence, in the present section, we will focus on recent 
examples published after 2012, together with other cases of tethered RCM reactions based 
on other tethers and their applications in the total synthesis of natural products. Some 
relevant contributions to this field are those by Kobayashi,133 Hoye134 and Evans,135 as 
well as numerous syntheses of natural products belonging to the family of 6-substituted 
5,6-dihydro--pyrone, such as hyptolide (219), 136  pectinolide C (220) 137  and 
umuravumbolide (221),138 all of which have been efficiently achieved according to this 
strategy from precursors 222, 223 and 224, respectively (Scheme 22, part B).  
 
In addition to silicon-tethered RCM reactions containing a O-Si-O linkage, this 
strategy has also been utilized with substrates containing an O-Si-C linkage, in which an 
oxidative or base-induced ring cleavage step is required after the RCM reaction. 
Prominent amongst these cases is the recent synthesis of the potent cytotoxic natural 
product amphidinolide V (225) by Lee et al., 139  in which the stereo-controlled 
construction of the existing double bonds was devised utilizing a tethered RCM of silyl 
ether 229 that provided the RCM product 230 in 96% yield, which was then subjected to 
an allylic 1,3-transposition mediated by Re2O7 to afford siloxane 231 as an 85:15 E/Z 
inseparable mixture in a 85% yield. The presence of the trimethylsilyl group in the 1,3-
diene subunit was proven to be critical to prevent unwanted side reactions during the 
metathesis reaction. The RCM precursor 229 was prepared beforehand via an enyne RCM 
of silyl ether 226 to furnish a cyclic siloxene type A, according to the general reaction 
depicted in Scheme 23, which was opened by treatment with methyllithium, to deliver 
compound type B. The resulting alcohol 227 was then coupled with silane 228 via a 
dehydrogenative reaction, mediated by a catalytic amount of (Xantphos)CuCl and in the 
presence of lithium tert-butoxide, to afford the targeted precursor 229 in an excellent yield 
and exquisite control of the double bonds geometry. With compound 231 in hand, the 
authors proceeded with the connection of the other fragment of the molecule via a cross-
aldol condensation to provide aldehyde 232 in seven steps, followed by a Yamaguchi 
macrolactonization that provided macrocyclic 233. The completion of the synthesis from 
this advanced precursor was then executed in five steps, consisting of a Sharpless 
asymmetric epoxidation from the corresponding allylic alcohol, reductive opening of the 
resulting diepoxy alcohol and final removal of the trimethylsilyl group (Scheme 23).  
 
 
                                                          
132 Cusak, A. Chem. Eur. J. 2012, 18, 5800-5824. 
133 Matsui, R.; Seto, K.; Fujita, K.; Suzuki, T.; Nakazaki, A.; Kobayashi, S. Angew. Chem. Int. Ed. 2010, 49, 10068-10073. 
134 Hoye, T. R.; Jeon, J.; Kopel, L. C.; Ryba, T. D.; Tennakoon, M. A.; Wang, Y. Angew. Chem. Int. Ed. 2010, 49, 6151-6155. 
135 Evans, P. A.; Cui, J.; Gharpure, S. J.; Polosukhin, A.; Zhang, H. R. J. Am. Chem. Soc. 2003, 125, 14702-14703. 
136 Chowdhury, P. S.; Kumar, P. Eur. J. Org. Chem. 2013, 4586-4593. 
137 Kumar, T. V.; Shankaraiah, G.; Babu, K. S.; Rao, J. M. Tetrahedron Lett. 2013, 54, 1397-1400. 
138 Kumar, T. V.; Reddy, G. V.; Babu, K. S.; Rao, J. M. Tetrahedron: Asymm. 2013, 24, 594-598. 
139 Volchkov, I.; Lee, D. J. Am. Chem. Soc. 2013, 135, 5324-5327. 
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Scheme 23. Total Synthesis of Amphidinolide V (225) (Lee et al. 2013)139 
 
The use of this strategy for the selective construction of a trisubstituted (Z)-olefin 
is nicely illustrated in the synthesis of the important antimitotic agent epothilone B (234), 
in which the required Z-olefin at the C12-C13 bond has been a critical issue, and which 
different solutions across the vast number of reported synthesis of this natural product 
have been found. 140  Thus, whereas a conventional RCM of an advanced diolefin 
precursor was devoid of stereoselectivity, a silicon-tethered RCM reaction initially 
explored by Mülzer et al. provided the required Z-isomer with a remarkable 5:1 selectivity 
albeit through a long synthetic sequence.141 In a shorter and rapid approach, Lin et al. 
explored the RCM reaction through the formation of a bissiloxane-tethered precursor, to 
secure the double bond geometry.142 To this aim, the precursor 237, efficiently prepared 
by joining segments 235 and 236, was subjected to the Grubbs-II catalyst (4) to yield the 
corresponding RCM product 238 in nearly quantitative yield (95%) as a 1.7:1 mixture of 
                                                          
140 (a) Jung, J.-C.; Kache, R.; Vines, K. K.; Zheng, Y.-S.; Bijoy, P.; Valluri, M.; Avery, M. A. J. Org. Chem. 2004, 69, 9269-9284. 
(b) Prantz, K.; Mulzer, J. Angew. Chem. Int. Ed. 2009, 48, 5030-5033. 
141 Gaich, T.; Mulzer, J. Org. Lett. 2005, 7, 1311-1313. 
142 Wang, J.; Sun, B.-F., Cui, K.; Lin, G.-Q. Org. Lett. 2012, 14, 6354-6357. 
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Z:E isomers, which could be separated after selective cleavage of the silicon-tethered by 
reaction with HF•pyr. Notably, despite the moderate selectivity of the RCM reaction, the 
required aldehyde 239 in form of the pure Z-isomer was obtained in 40% over three steps, 
representing the most step-economic synthesis reported thus far. From aldehyde 239, the 
completion of the synthesis of epothilone B was accomplished in an efficient manner in 
6 steps, with a TiCl4-mediated aldol reaction and a Yamaguchi macrolactonization as the 
key steps (Scheme 24).  
 
 
 
Scheme 24. Total Synthesis of Epothilone B (234) (Lin et al. 2017)142 
 
The extension of the concept of a temporary tethered RCM to other groups such 
as esters or acetals would expand the synthetic opportunities that this strategy might offer. 
One such application is elegantly illustrated with the total syntheses of amphidinolides 
T1, T3 and T4 by Clark and coworkes.143 As amphidinolide V, discussed above, the 
amphidinolides T1, T3 and T4 are also macrolides isolated from marine dinoflagellates 
with potent cytotoxic activities. Structurally, the so named amphidinolides of the T series 
are characterized by the presence of a trisubstituted tetrahydrofuran. In the case of 
amphidinolide T1 (240), the synthesis of the C1-C11 fragment was initially attempted by 
utilization of a CM reaction to connect the corresponding olefins, but all attempts were 
thwarted to obtain the desired CM product. The implementation of a tethered RCM 
strategy to prepare this fragment was then attempted via a temporary ester, for which 
diolefin ester 241 was prepared, but again, the reaction was found to be unsuccessful, 
instead obtaining the RCM product 242. In light of these discouraging results, the use of 
                                                          
143 Clark, J. S.; Romiti, F. Angew. Chem. Int. Ed. 2013, 52, 10072-10075. 
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a salicylate spacer as an alternative ester-tether RCM was explored; indeed the treatment 
of 243 with the Hoveyda-Grubbs I catalyst (5) afforded an isomeric mixture (E/Z = 1.2:1) 
of the lactone 244 in an impressive 96% yield. The removal of the spacer group was 
carried out by base treatment, followed by a chemoselective hydrogenation to complete 
the western fragment of the natural product in form of the product 245. The coupling of 
this fragment with the eastern fragment provided access to the corresponding seco acid, 
which was subjected to a Yamaguchi macrolactonization to provide 246, representing the 
macrocyclic core of the amphidinolides T. The completion of the synthesis of this natural 
product was achieved with the hydrosilylation of the alkyne present in 246 using the 
ruthenium catalyst [CpRu(MeCN)3]PF6 that afforded a 1:1 mixture of isomeric Z-
vinylsilanes 247 and 248, which could be separated by chromatography. Whereas, 252 
was transformed into amphidinolide T1 (240) via epoxidation of the vinylsilane, followed 
by a Fleming-Tamao oxidation, the product 248 provided amphidinolides T3 and T4 
under the same synthetic sequence (Scheme 25).  
 
 
Scheme 25. Total Synthesis of Amphidinolides T (Clark et al. 2013)143 
                                                                                                                       Chapter 1                                                               
55 
 
The ester-tethered RCM was similarly used in the synthesis of polyacetylene-type 
metabolites, such as the atractylodemaynes C (249) and F (250) by Schmidt et al.144 as a 
way of controlling the geometry of the depicted double bonds. According to a tandem 
RCM/base-induced eliminative ring opening, carried out in one pot, the authors were able 
to construct a E,Z-diene derivative, found in these natural products. Thus, when 
compound 251 was treated with the Grubbs-II catalyst (4), followed by NaHMDS and 
Meerwein´s salt, compound 252 was obtained in a 73% overall yield through 
intermediates A, B and C. Starting from the resulting ester 252, the installation of the 
enediyne moiety of the atractylodemaynes C and F was achieved without issues via 
alkynyl homologation and a Sonogashira coupling (Scheme 26). 
 
 
 
Scheme 26. Total Synthesis of S-Atractylodemaynes C (249) and F (250) (Schmidt et al. 2017)144 
 
As an alternative to the silicon tethered RCM reaction, the use of acetals to connect 
both olefinic partners has also been developed and recently applied in the synthesis of a 
stereoisomer of squamocin K (253), the 14,21-di-epi isomer 254 by Hou et al. 145 
Squamocin K, as other Annonaceous acetogenins, displays a wide range of biological 
activities, such as antitumor, antiparasitic, pesticidal, antimicrobial and 
immunosuppressive activities, by virtue of its inhibition of mitochondrial complex I. In 
this synthetic proposal, precursor 255, readily prepared from a C2 symmetric diene diol, 
was treated with the Grubbs-II catalyst (4) to obtain the resulting RCM product, as a result 
of a multiple RCM process. In a second step, the assembly of the resulting polyene and 
10-chloro-1-decene was induced by treatment again with the Grubbs-II catalyst (4) to 
deliver the complete framework of this class of natural products in form of compound 
256. Finally, the completion of the synthesis of this stereoisomer of squamocin K was 
                                                          
144 Schmidt, B.; Audörsch, S. J. Org. Chem. 2017, 82, 1743-1760. 
145 Liu, C.-W.; Yeh, T.-C.; Chen, C.-H.; Yu, C.-C.; Chen, C.-S.; Hou, D.-R.; Guh, J.-H. Tetrahedron 2013, 69, 2971-2976. 
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achieved in 12 additional steps, including the formation of the required tetrahydrofurane 
rings, via previous activation of the resulting hydroxyl groups as mesyl derivatives and 
subsequent intramolecular displacements to afford 257, and the final introduction of the 
unsaturated lactone (Scheme 27).  
 
 
 
Scheme 27. Total Synthesis of 14,21-di-epi-squamocin K (254) (Hou et al. 2013)145 
 
A unique tether for a RCM reaction was employed by Hanson in the synthesis of 
strictifolione (258),146  a natural product isolated from the stem bark of Cryptocaria 
stritifolia with antifungal activities. In their synthesis, the authors used a phosphate-tether 
that allowed in one pot, a sequential RCM, CM and a chemoselective hydrogenation 
process, followed by a one-pot, sequential reductive allylic transposition/tether removal 
and final CM. To this end, olefinic phosphate 259 was treated with the HG II catalyst (6) 
and then, after solvent evaporation, addition of cis-stilbene in DCE and heating at 60 °C 
for 2 h. The subsequent chemoselective diimide reduction provided phosphate 260 in 52% 
overall yield. The following one-pot protocol was initiated with the reaction of 260 with 
Pd(OAc)2 in the presence of formic acid, cesium carbonate and PPh3 to produce a 
reductive allylic transposition, followed by addition of methyl sulfate and treatment of 
LiAlH4 to furnish diol 261 in 65% overall yield. A final CM reaction with vinyl lactone 
262 in the presence of the HG II catalyst (6) provided the natural product strictifolione 
258 in a 77% yield (Scheme 28, part A).  
 
In a similar strategy, the same authors described the synthesis of the antifungal 
macrolide Sch-725674 (49),147 wherein the phosphate 263 was treated in a similar one-
pot RCM/CM/chemoselective hydrogenation sequence as described for 259, with the use 
of alkene 264 to obtain compound 265 in a 59% yield. The removal of the phosphate 
tether was accomplished by treatment with LiAlH4 and, then, after a sequence of 
transformations, including selective protection of the 1,3 diol system as an acetal, a 
Sharpless asymmetric epoxidation of the resulting allylic alcohol, a selective tosylation 
                                                          
146 Jayasinghe, S.; Venukadasula, P. K. M.; Hanson, P. R. Org. Lett. 2014, 16, 122-125. 
147 Bodugam, M.; Javed, S.; Ganguly, A.; Torres, J.; Hanson, P. R. Org. Lett. 2016, 18, 516-519. 
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of the primary alcohol and introduction of the acryloyl unit, provided compound 266. 
This compound was set up for a reductive opening process, which was carried out in one 
pot by sequential treatment with NaI, Zn and acidic work-up, to deliver diolefin 267. In 
contrast to a direct RCM reaction of diolefinic triol 267, carried out by Prasad et al. (See 
Figure 2), that afforded the natural product in a modest 36%, Hanson et al. found that 
prior protection of compound 267 as the MOM derivative resulted in a more efficient 
RCM process to provide the final product 49 in 84% yield after removal of the protecting 
groups with TFA (Scheme 28, part B). 
 
 
 
Scheme 28. Total Synthesis of Strictifolione (258) and Sch-725674 (49) (Hanson et al. 2014, 2016)146,147 
 
1.2.3.2. Relay Ring-Closing Metathesis  
Since the pioneering work of the Hoye group on the relay ring-closing metathesis 
(RRCM) concept in 2004,148 and the first application in total synthesis by the Porco group 
in the same year,149 many syntheses have benefited enormously from this strategy as a 
method to surmount the instances in which the RCM reactions proved ineffective or 
                                                          
148 Hoye, T. R.; Jeffrey, C. S.; Tennakoon, M. A.; Wang, J.; Zhao, H. J. Am. Chem. Soc. 2004, 126, 10210-10211. 
149 Wang, X.; Bowman, E. J.; Bowman, B. J.; Porco, J. A. Jr. Angew. Chem. Int. Ed. 2004, 43, 3601-3605. 
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sluggish, mainly due to steric factors, as well as electronic factors.150 A representative 
example to illustrate the implementation of this strategy and its dramatic effect can be 
found in the recent synthesis of the cytotoxic natural product penostatin B (268) by the 
Shishido group. 151  Having devised a RCM strategy for the preparation of the 
dihydropyran system contained in the natural product, the examination of this reaction 
with the acyclic precursor 269 by using various catalysts and different reaction conditions 
provided the desired unsaturated -lactone 270 in a modest 46% yield, as the best case, 
when the HG-I catalyst (5) was employed. In an effort to improve upon this yield, the 
authors made use of the relay RCM strategy, for which precursors 271 and 272 were 
prepared. The treatment of these compounds with the same catalyst provided the RCM 
product 273 in improved 78 and 83% yields from 271 and 272, respectively, 
demonstrating the synthetic value of this strategy. With compound 273 in hand, the 
introduction of the alkenyl appendage was successfully achieved from acetyl pyranoside 
274, via vinyl stannane 275 in a high stereoselective manner. Finally, the manipulation 
towards the final product was undertaken in six additional steps (Scheme 29). 
 
 
 
Scheme 29. Total Synthesis of Penostatin B (268) (Shishido et al. 2012)151 
 
In the development of an enabled and flexible strategy for the synthesis of the 
cyclodepsipeptidic-like natural products related to the jasplakinolide/geodiamolide 
family, Waldmann et al. designed a divergent solid phase synthesis for this class of 
compounds based on a unique RRCM strategy on solid phase to construct the macrocyclic 
core, directing the catalyst´s action to the required break point.152 With the preparation of 
a PS resin for the linkage of the peptidic chain, which carried a diene unit, the acyclic 
precursor loaded onto the resin (resin 276) was synthesized in an efficient manner. The 
                                                          
150 For a review on RRCM, see: Wallace, D. J. Angew. Chem. Int. Ed. 2005, 44, 1912-1915. 
151 Fujioka, K.; Yokoe, H.; Yoshida, M.; Shishido, K. Org. Lett. 2012, 14, 244-247. 
152 Arndt, H.-D.; Rizzo, S.; Nöcker, C.; Wakchaure, V. N.; Milroy, L.-G.; Bieker, V.; Calderon, A.; Tran, T. T. N.; Brand, S.; Dehmelt, 
L.; Waldmann, H. Chem. Eur. J. 2015, 21, 5311-5316. 
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subsequent reaction with the Grubbs-II catalyst (4) delivered the protected 
cyclodepsipeptide 277 in 34% yield as a 1:1.2 mixture of a separable E/Z isomers, through 
the formation of the carbene intermediate A with the concomitant release of resin 278. 
The removal of the protecting groups of each pure isomer afforded natural product 
seragamide A (279) and its Z-isomer. In a similar fashion, a collection of jaspamide 
analogues was generated for biological studies as antitumor agents (Scheme 30).  
 
 
 
Scheme 30. Total Synthesis of Seragamide A (E-279) and Related Cyclodepsipeptides (Waldmann et al. 
2015)152 
 
1.2.3.3. Stereoselective Alkene Metathesis 
The reversible nature of olefin metathesis represents a practically insurmountable 
barrier to access to the often energetically less favored Z-olefin. As a consequence, the 
design and development of catalysts capable of providing high Z selectivity, either in 
RCM as in CM reactions, represents an important challenge. To this aim, initial efforts 
by Schrock, Hoveyda et al. have been focused largely on the modification of the ancillary 
ligands bound to the metal center and have led to the identification of the first Z-selective 
catalysts based on molybdenum and tungsten (catalysts 15-22 in Figure 1).153 In this 
family of catalysts, the introduction of a bulky aryloxy moiety forces the substituents on 
the generated metallacyclobutane intermediate (A) (Scheme 31) all syn to yield the Z-
olefin in a kinetically controlled process.  
                                                          
153 Wang, C.; Yu, M.; Kyle, A. F.; Jakubec, P.; Dixon, D. J.; Schrock, R. R.; Hoveyda, A. H. Chem. Eur. J. 2013, 19, 2726-2740. 
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Scheme 31. Applications of Z-Selective RCM Reactions in Total Synthesis 
 
On the other hand, the advent of ruthenium-based catalysts (for example catalyst 
23 in Figure 1), in which bulky aryl groups are introduced on the N-heterocyclic carbene, 
by Grubbs et al. allowed similar access to a Z-selective process through intermediates 
type B.154  The E-isomers, despite their formation being generically favored in these 
reactions for thermodynamic reasons, there are numerous cases in which the small energy 
difference between the E and the Z isomers, results in a mixture of both geometric 
isomers. In view of this situation, the development of catalysts that promote kinetically 
E-selective processes represents a new challenge. In response to this requirement, Grubbs 
et al. have described the first catalysts capable of generating E-olefins starting from E-
olefins as the reactants.155 This new generation of catalysts is termed stereoretentive 
olefin metathesis catalysts, which feature the presence of a cyclic catecholthiolate unit 
(catalysts 24-27 in Figure 1)22,156 and proceed through intermediates type C. To this 
arsenal of valuable and useful catalysts developed in the last few years one must also add 
                                                          
154 Herbert, M. B.; Suslick, B. A.; Liu, P.; Zou, L.; Dornan, P. K.; Houk, K. N.; Grubbs, R. H. Organometallics 2015, 34, 2858-2869. 
155 (a) Johns, A. M.; Ahmed, T. S.; Jackson, B. W.; Grubbs, R. H.; Pederson, R. L. Org. Lett. 2016, 18, 772-775. (b) Ahmed, T. S.; 
Grubbs, R. H. J. Am. Chem. Soc. 2017, 139, 1532-1537. 
156 (a) Montgomery, T. P.; Ahmed, T. S.; Grubbs, R. H. Angew. Chem. Int. Ed. 2017, 56, 11024-11036. (b) Montgomery, T. P.; 
Grandner, J. M.; Houk, K. N.; Grubbs, R. H. Organometallics 2015, 36, 3940-3953. 
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chiral catalysts, with which it is possible to perform asymmetric olefin metathesis,157 as 
described in Scheme 8. A detailed description of the design and development of these 
new selective catalysts, as well as their applications in synthesis of natural products, has 
been widely covered in various reviews.158 Nevertheless, we would like to summarize in 
this section relevant examples of selective RCM and CM reactions as representative 
applications that prove the synthetic validity and potential of these new generation of 
catalysts. Thus, in Scheme 31 are summarized examples of Z-selective RCM 
reactions156,159 and in Scheme 33 cases of Z-selective CM reactions160 in the field of the 
total synthesis.  
 
 
Scheme 32. Applications of Z-Selective CM Reactions in Total Synthesis 
                                                          
157 (a) Hartung, J.; Dornan, P. K.; Grubbs, R. H. J. Am. Chem. Soc. 2014, 136, 13029-13037. (b) Yu, M.; Schrock, R. R.; Hoveyda, A. 
H. Angew. Chem. Int. Ed. 2015, 54, 215-220. 
158 (a) Herbert, M. B.; Grubbs, R. H. Angew. Chem. Int. Ed. 2015, 54, 5018-5024. (b) Werrel, S.; Walker, J. C. L.; Donohoe, T. J. 
Tetrahedron Lett. 2015, 56, 5261-5268. 
159 Mangold, S. L.; Grubbs, R. H. Chem. Sci. 2015, 6, 4561-4569. 
160 (a) Mangold, S. L.; O´Leary, D. J.; Grubbs, R. H. J. Am. Chem. Soc. 2014, 136, 12469-12478. (b) Dornan, P. K.; Wickens, Z. K.; 
Grubbs, R. H. Angew. Chem. Int. Ed. 2015, 54, 7134-7138. (c) Luo, S.-X.; Cannon, J. S.; Taylor, B. L. H.; Engle, K. M.; Houk, K. 
N.; Grubbs, R. H. J. Am. Chem. Soc. 2016, 138, 14039-14046. (d) Dornan, P. K.; Lee, D.; Grubbs, R. H. J. Am. Chem. Soc. 2016, 138, 
6372-6375. (e) de Léséleuc, M.; Godin, E.; Parisien-Collette, S.; Lévesque, A.; Collins, S. K. J. Org. Chem. 2016, 81, 6750-6756. (f) 
Xu, C.; Shen, X.; Hoveyda, A. H. J. Am. Chem. Soc. 2017, 139, 10919-10928. 
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Particularly relevant is the synthesis of prostaglandin F2 (298) according to the 
recent strategy developed by Hoveyda et al.163f based on the original and brilliant concept 
of  methylene capping. This strategy was designed to broaden the scope of the Z-selective 
cross-metathesis protocols, which is inefficient with olefins containing allylic or 
homoallylic alcohols, aryl groups, aldehydes or carboxylic acid susbtituents. Having 
identified Z-butene (297) as a suitable capping agent, respective treatments of trihydroxy 
olefin 295 and unsaturated carboxylic acid 296 with alkene 297 and the Ru dithiolate 
catalyst 25, followed by mixing and treatment with additional catalyst 25 under reduced 
pressure, afforded prostaglandin F2 (298) in 59% yield and >98:2 selectivity in favor of 
the desired Z-olefin (Scheme 32). The use of this capping agent avoids the formation of 
the unstable methylidene species in favor of a more stable substituted carbene, allowing 
the use of substrates without resorting to protecting groups. This elegant strategy was 
similarly used for the synthesis of Z-macrocyclic alkenes. 
 
 
 
Scheme 33. Total Synthesis of Disorazole C1 (300) (Hoveyda et al. 2014)161 
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An outstanding application of these selective catalysts in the synthesis of complex 
natural products is the synthesis of disorazole C1 (300),161 a secondary metabolite that 
displays excellent anticancer and antifungal profiles, described by Hoveyda et al. The 
presence of the (Z,Z,E)-1,3,5-triene unit demands an exquisite level of geometric control 
for a stereoselective synthesis of this fragment. In an initial approach, the authors prepared 
the Z-vinyl iodide 302 and the E,Z-diene 304 in excellent yields and complete 
stereoselectivity by using the catalyst 16 from the terminal olefins 301 and 303, 
respectively. However, after coupling of both fragments via a Suzuki reaction, the 
subsequent dimerization process failed to form the resulting coupling product. Therefore, 
the authors decided to assemble the acid derived from ester 303 and vinyl iodide 305 and 
the resulting ester 306 transformed into the Z-boronic ester 307, mediated by the catalyst 
18. With this compound in hand, the authors conducted the dimerization process in a 
carefully optimized reaction, where the choice of palladium catalyst, base and solvent 
was critical to obtaining a good yield (60%) of the resulting [30]-membered ring protected 
disorazole C1. Final desilylation provided the coveted natural product 300 (Scheme 33). 
 
1.2.3.4. Alkene Metathesis in Tandem Reactions 
The design of suitable multifunctional molecules that enable the triggering of a 
cascade of events, including a sequential alkene metathesis process or a combination of 
an alkene metathesis with other types of reactions in a well-defined order would provide 
a formidable increase in structural complexity in a single operation. As a consequence, 
we can find in the literature a large number of total syntheses and synthetic approaches 
in which alkene metathesis processes in cascade sequences, by combination of 
ROM/RCM or RCM/CM reactions, have been applied.162 An initial interesting synthetic 
application of these processes in total synthesis is found in the formal total syntheses of 
dysiherbaine (308) and neodysiherbaine A (309) by Lee et al.163  through an elegant 
ROM/RCM tandem process from bicyclic compound 310, which was prepared in 
enantiomerically pure form through a stereoselective Diels-Alder reaction, followed by 
resolution of the racemic mixture. This compound 310 underwent an initial ROM process, 
that delivered a ruthenium intermediate A, followed by a RCM reaction when subjected 
to the Grubbs-II catalyst (4), to yield bicyclic derivative 311, which represents the core 
skeleton of dysiherbaine and related compounds with the correct relative stereochemistry. 
The need to selectively oxidize the cyclic olefin in the presence of the terminal alkene 
found in compound 311 forced the authors to increase the difference of reactivities 
between the olefins by the preparation of the enol acetate 312, prepared in the same way 
as 311, but in the presence of vinyl acetate and using Hoveyda-Grubbs II catalyst (6) for 
a final CM with vinyl acetate. In this way, compound 312 was obtained in an excellent 
95% yield, generating a very well differentiated electronic environment between both 
                                                          
161 Speed, A. W. H.; Mann, T. J.; O´Brien, R. V.; Schrock, R. R.; Hoveyda, A. H. J. Am. Chem. Soc. 2014, 136, 16136-16139. 
162 For a recent review about the use of metathesis cascade reactions in synthesis of natural products, see: Han, J.-C.; Li, C.-C. Synlett 
2015, 26, 1289-1304. 
163 Lee, H.-Y.; Lee, S.-S.; Kim, H. S.; Lee, K. M. Eur. J. Org. Chem. 2012, 4192-4199. 
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alkenes for further selective functionalization. In fact, the authors succeeded in the 
preparation of advanced precursor 313 via transformation of the enol acetate into a 
temporary alcohol, followed by dihydroxylation of the cyclic olefin, protection of the 
resulting diol as an acetal, oxidation of the primary alcohol to the acid and esterification. 
The resulting product 313 was utilized by Sasaki et al.164 in their total syntheses of the 
natural products dysiherbaine (308) and neodysiherbaine A (309), thus representing the 
formal synthesis of both natural products (Scheme 34).  
 
 
 
Scheme 34. Formal Total Synthesis of Dysiherbaine (308) and Neodysiherbaine A (309) (Lee et al. 2012)163 
 
Particularly interesting are the syntheses of clusianone (314) and clavilactone A 
(318) which utilize combinations of cascade processes of metathesis reactions. In the case 
of clusianone (314), a natural product isolated from C. congestiflora with antiviral activity 
against HIV and Epstein-Barr virus, its synthesis was envisaged by Plietker et al.165 from 
tricyclic derivative 317, prepared from bicyclic compound 316 via an 
allylation/intramolecular Claisen-condensation-benzoylation sequence. Thus, when 317 
was treated with the Grubbs-II catalyst (4) in the presence of isoamylene, the natural 
product clusianone (314) was obtained in a 65% yield as the result of a tandem ROM/CM 
process. The preparation of the bicycle[4.3.1]undecenone derivative 316 via a RCM 
reaction from 315, was conceived by the authors as a way of controlling the 
stereochemical outcome in favor of the desired cis-relative configuration of the final 
product due to the conformationally restricted environment imposed by the bicyclic 
system. The subsequent ROM reaction, followed by a CM reaction, in the presence of 2-
methyl-2-butene, allowed the unmasking of the prenylated side chains present in the final 
product (Scheme 35).  
                                                          
164 Shoji, M.; Akiyama, N.; Tsubone, K.; Lash, L. L.; Sanders, J. M.; Swanson, G. T.; Sakai, R.; Shimamoto, K.; Oikawa, M.; Sasaki, 
M. J. Org. Chem. 2006, 71, 4227-4231. 
165 Horeischi, F.; Guttroff, C.; Plietker, B. Chem. Commun. 2015, 51, 2259-2261. 
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Scheme 35. Total Synthesis of Clusianone (314) (Plietker et al. 2015)165 
 
The same strategy was employed by these authors in the synthesis of guttiferone 
A.166 For the clavilactones, a family of natural products structurally characterized by a 
rigid 10-membered macrocycle fused to a hydroquinone and to an ,-epoxy--lactone, 
the cyclobutenecarboxylate 319 was devised by Takao et al. as an appropiate precursor 
to promote a tandem ROM/RCM reaction mediated by a ruthenium-based catalyst.167 In 
fact, when 319 was treated with the Grubbs-I catalyst (3), the desired ROM/RCM product 
320 was obtained, but in only 28% yield, due to the formation of the dimer 321 in 15% 
yield, together with recovered starting material in 47% yield. In an attempt to improve 
upon this modest result, the authors found that exposure of dimer 321 to the Grubbs-II 
catalyst (4) in ethylene atmosphere produced the desired product 320 in good yields. In 
practice, this tandem process was accomplished in one pot by sequential treatment of 319 
with the Grubbs-I catalyst (3) in the presence of 2,6-dichloro-1,4-benzoquinone, followed 
by the treatment with the Grubbs-II catalyst (4) in atmospheric ethylene at 80 °C to 
provide the final product 320 in 81% overall yield. The formation of the oxirane ring was 
carried out in a highly chemo- and stereoselective fashion by reaction of m-CPBA with 
the cyclic olefinic bis-silylether derivative, obtained from 320 by reduction and bis-
silylation of the resulting diol. The resulting epoxide 322 was then reacted with the 
Grubbs-II catalyst (4) to obtain the macrocyclic derivative 323 in a notable 83% yield. 
The completion of the synthesis of clavilactone A (318) was efficiently accomplished in 
four additional steps, mainly functional groups interconversions, through quinone 324 
that corresponds to clavilactone B. In a similar synthetic sequence, the same authors 
prepared the originally proposed structure of clavilactone D (325),168 which led to its 
structural revision, identifying 326 as the correct structure (Scheme 36). 
                                                          
166 Horeischi, F.; Biber, N.; Plietker, B. J. Am. Chem. Soc. 2014, 136, 4026-4030. 
167 Takao, K.-i.; Nanamiya, R.; Fukushima, Y.; Namba, A.; Yoshida, K.; Tadano, K.-i. Org. Lett. 2013, 15, 5582-5585. 
168 (a) Takao, K.-i.; Nemoto, R.; Mori, K.; Namba, A.; Yoshida, K.; Ogura, A. Chem. Eur. J. 2017, 23, 3828-3831. (b) Takao, K.-i.; 
Mori, K.; Kasuga, K.; Nanamiya, R.; Namba, A.; Fukushima, Y.; Nemoto, R.; Mogi, T.; Yasui, H.; Ogura, A.; Yoshida, K.; Tadano, 
K.-i. J. Org. Chem. 2018, 83, 7060-7075. 
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Scheme 36. Total Synthesis of Clavilactones A (318), B (324) and D (326) (Takao et al. 2013 and 
2018)167,168 
 
A cascade process that involves an alkene metathesis with other types of reactions 
has also been explored. As such, an application is the tandem CM/oxa-Michael 
cyclization employed by Krische et al. in the synthesis of the C2-symmetric natural 
product cyanolide A (327), 169  a potent molluscicidal agent against the water snail 
Biomphalaria glabrata, which actually is a vector of the human parasitic disease 
schistosomiasis. Thus, when diol 328 was treated with the Hoveyda-Grubbs II catalyst 
(6), in the presence of vinylethyl ketone, the compound 329 was obtained in 76% yield 
as a 10:1 mixture of diastereoisomers. This pyrane derivative is the result of an initial 
double CM reaction, followed by an oxa-Michael cyclization. In a second CM round, 
compound 329 was treated with the Blechert catalyst (7) in an ethylene atmosphere to 
yield olefin 330 in 70% yield. A few more steps from 330 completed a concise total 
synthesis of cyanolide A (327) (Scheme 37).  
 
Another such application is the synthesis of the tetrahydropyrane containing 
natural products decytospolides A (331) and B (332) by Kommu et al.170 which was 
rapidly achieved when the hydroxyl olefin 333 was subjected to treatment of the 
Hoveyda-Grubbs II catalyst (6) in the presence of ethylvinyl ketone to provide the pyranes 
334 and 335 in a 78% combined yield and as a 9:1 mixture of stereoisomers, in favor of 
                                                          
169 Waldeck, A. R.; Krische, M. J. Angew. Chem. Int. Ed. 2013, 52, 4470-4473. 
170 Kammari, B. R.; Bejjanki, N. K.; Kommu, N. Tetrahedron: Asymm. 2015, 26, 296-303. 
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the desired 2,6-cis-pyrane 335. Removal of the benzyl group of 335 afforded 
decytospolide A (331), whose acetylation provided decytospolide B (332) (Scheme 38).  
 
 
 
Scheme 37. Total Synthesis of Cyanolide A (327) (Krische et al. 2013)169 
 
 
 
 
Scheme 38. Total Synthesis of Decytospolides A (331) and B (332) (Kommu et al. 2015)170 
 
An interesting approach towards the synthesis of isoquinoline-type alkaloids, such 
as oxychelerythrine (336a), oxysanguinarine (336b), oxynitidine (336c) and oxyvicine 
(336d) has been described by Sutherland et al. 171  based on a tandem Overman 
rearrangement/RCM for rapid access to amino-substituted 1,4-dihydronaphtalene 
scaffolds, which represent key precursors for the synthesis of the benzo[c]phenanthridine 
system found in these natural products. The one-pot Overman rearrangement/RCM was 
efficiently achieved after extensive optimization, finding that when 337 was converted 
into the corresponding trichloroacetimidate, heated to 160 °C in the presence of potassium 
carbonate and then submitted to the action of the Grubbs-II catalyst (4) at room 
                                                          
171 Calder, E. D. D.; McGonagle, F. I.; Harkiss, A. H.; McGonagle, G. A.; Sutherland, A. J. Org. Chem. 2014, 79, 7633-7648. 
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temperature, the corresponding 1,4-dihydronaphtahlene 338 was obtained in 81% yield. 
From this privileged compound, the authors completed the syntheses of the alkaloids 
336a-d after aromatization of 338, followed by coupling with the corresponding 2-
bromobenzoic acid derivatives and an intramolecular biaryl Heck coupling reaction in a 
very high efficient manner. In the final Heck coupling (step h of the sequence), Sutherland 
et al. employed the more stable Hermann-Beller palladacycle catalyst, given the very high 
temperature (160 °C) required for the intramolecular coupling of their precursors 339a-d 
(Scheme 39). A related tandem Overman rearrangement and ring-closing enyne 
metathesis, followed by a Diels-Alder reaction was utilized by the same authors in the 
synthesis of amino-substituted indanes and tetralins.172 
 
 
 
Scheme 39. Total Synthesis of Oxybenzo[c]phenanthridine Alkaloids 336a-d (Sutherland et al. 2014)171 
 
1.3. Enyne Metathesis in Total Synthesis 
As in previous sections, in this section we will focus on recent contributions 
recorded in the last few years (2012-present), taking into account that the ring-closing 
enyne metathesis (RCEYM) reaction has been similarly covered in numerous reviews.173 
1.3.1. Total Syntheses Based on a Ring-Closing Enyne Metathesis Reaction 
The synthetic value of an intramolecular metathesis reaction of an enyne 
(RCEYM) is due to the versatility that is offered by the resulting cyclic dienes, which can 
be utilized in subsequent transformations, such as cycloaddition reactions. On the other 
hand, in contrast to other metathesis processes, the enyne metathesis can be promoted by 
other metal catalysts, such as Pt2+, Pt4+ or Ir, or even Lewis acids, by a different 
mechanism but with the same result. Interestingly, in contrast to the alkene RCM, for the 
                                                          
172 Grafton, M. W.; Farrugia, L. J.; Sutherland, A. J. Org. Chem. 2013, 78, 7199-7207. 
173 Selected reviews of enyne metathesis in synthesis of natural products: (a) Mori, M. Materials 2010, 3, 2087-2140. (b) Mori, M. 
Adv. Synth. Catal. 2007, 349, 121-135. (c) Dragutan, I.; Dragutan, V.; Demonceau, A.; Delaude, L. Curr. Org. Chem. 2013, 17, 2678-
2720. 
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enyne RCM, the mode of the ring closure can be different depending on the size of the 
cyclic system.174 Thus, whereas in small and medium-sized rings, the cyclization pathway 
goes through an exo-mode that delivers the product type A, in a macrocylization process, 
the ring closure can go through an endo-pathway, owing to the increased flexibility of the 
large ring system, that should afford the product type B.  
 
 
 
Scheme 40. Different Pathways of the Ring-Closing Enyne Metathesis and Total Synthesis of 6-
Deoxyerythronolide B (340) (Krische et al. 2014)175 
 
A clear example of the formation of this class of type B compounds is the 
synthesis of 6-deoxyerythronolide B (340) by Krische et al.,175 who prepared macrocyclic 
342 in 89% yield when the enyne 341 was treated with the HG-II catalyst (6) in an 
atmosphere of ethylene at 110 °C, with no detection of regioisomers. With the formation 
of the 14-membered macrocycle, the completion of the synthesis of the 
deoxyerythronolide B (340) was delineated through a synthetic sequence that included 
selective oxidation of the exocyclic double bond, reduction of the resulting enone through 
a Ni-catalyzed conjugate reduction, stereoselective methylation of the resulting ketone 
343 and final removal of the protective groups via catalytic hydrogenation (Scheme 40). 
Given the usual involvement of the enyne RCM products in subsequent transformations 
                                                          
174 A general review about enyne metathesis: Diver, S. T.; Giessert, A. J. Chem. Rev. 2004, 104, 1317-1382. 
175 Gao, X.; Woo, S. W.; Krische, M. J. J. Am. Chem. Soc. 2013, 135, 4223-4226. 
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of the resulting diene in a tandem process, the majority of cases found in the literature 
correspond to this category and will be discussed later in section 1.3.3. 
1.3.2. Total Syntheses Based on an Enyne Cross Metathesis Reaction 
Several problems are associated with the selectivity of an intermolecular enyne 
metathesis, for example alkene-alkene and alkyne-alkyne metathesis processes can 
compete with the alkene-alkyne coupling, as well as the possible formation of geometric 
E/Z mixtures. Indeed, these problems are the likely reasons for the limited use of this 
modality of metathesis versus the intramolecular variant. Due to the scarcity of examples 
in which an enyne cross-metathesis is employed in the realm of total synthesis, it is worth 
emphasizing those where the reaction has been successfully applied. Such a case is the 
synthesis of amphidinolide P (344) by Diver,176  in which an enyne cross-metathesis 
allowed access to the main backbone of the natural product.  
 
Scheme 41. Total Synthesis of Amphidinolide P (344) (Diver et al. 2015)176 
 
In practice, alkyne 345 and alkene 346 were coupled by treatment with the HG-II 
catalyst (6) at low temperature (-20 °C) to give diene 347 in 72% yield and as a 4.5:1 E/Z 
mixture of geometric isomers. The completion of the synthesis was achieved according 
to the Williams protocol177 to obtain pure amphidinolide P (344) in 38% overall yield. 
Surprisingly, when the authors attempted the synthesis of this natural product via an 
                                                          
176 Jecs, E.; Diver, S. T. Org. Lett. 2015, 17, 3510-3513. 
177 Williams, D. R.; Myers, B. J.; Mi, L. Org. Lett. 2000, 2, 945-948. 
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enyne RCM, they failed to obtain any ring closure product, either from 348 or from the 
more stable TMS derivative 349. However, when 348 was subjected to the Grubbs-II 
catalyst (4) in an ethylene atmosphere, they could obtain, in almost quantitative yield, the 
1,3-diene 350, which was envisioned as a suitable precursor for a final RCM step. In this 
case, the authors observed that the RCM reaction of its corresponding silyl enol ether, 
compound 351, with the Grubbs-II catalyst (4) proceeded in a better yield, compared with 
the direct RCM reaction of the diene 350, likely due to the introduction of additional 
rigidity in the system that would favor the connection of the involved alkenes. The RCM 
product, obtained as a mixture of the corresponding silyl enol ether and ketone, was 
transformed into amphidinolide P (344) by reaction with HF•pyr in 67% yield over two 
steps (Scheme 41). This contribution joins the synthesis by Lee based on a RCM 
approach.178   
 
1.3.3. Enyne Metathesis in Tandem Reactions 
Among the different variants of the metathesis reactions that employ enynes as 
starting precursors, those that involve the enyne metathesis as part of a cascade process 
have been the most exploited, due to their great potential for the generation of complex 
polycyclic systems in a single step. Given the synthetic consequences of such processes, 
enyne metathesis in cascade processes has occupied a strategic position in the synthesis 
of natural products containing complex polycyclic systems and the topic of several 
comprehensive reviews.179 One finds two well-differentiated types of tandem processes 
involving enyne metathesis: a) Multiple intramolecular metathesis reactions in a 
programmed polyenyne system. In this case, the polyenyne precursor is properly designed 
to trigger a highly orchestrated cascade that ensures the right regiochemical outcome, 
once the initial metal carbene is formed in the right position; and b) a tandem process 
consisting of an initial enyne ring-closing metathesis, followed by a second reaction, 
usually a cycloaddition reaction, of the resulting diene. In the first case, we find a relevant 
example in the formal synthesis of englerin A (352) by Parker et al.180 (Scheme 42). 
 
                                                          
178 Hwang, M.-h.; Han, S.-J.; Lee, D.-H. Org. Lett. 2013, 15, 3318-3321. 
179 (a) Li, J.; Lee, D. Eur. J. Org. Chem. 2011, 4269-4287. (b) Kotha, S.; Meshram, M.; Tiwari, A. Chem. Soc. Rev. 2009, 38, 2065-
2092. (c) Kaliappan, K. P. Lett. Org. Chem. 2005, 2, 678-686. 
180 Lee, J.; Parker, K. A. Org. Lett. 2012, 14, 2682-2685. 
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Scheme 42. Total Synthesis of Englerin A (352) (Parker et al. 2014)180 
The intriguing structure of this natural product, in conjunction with its striking 
pharmaceutical properties, has prompted intense research activity directed towards its 
total synthesis, as well as the generation of analogues for medicinal chemistry studies. 
Among the seminal and elegant contributions developed for the synthesis of this natural 
product, the one by Parker was based on a ene-yne-ene metathesis cyclization in a tandem 
process. In order to secure the initiation process in the right direction, the authors 
developed a relay metathesis cascade from precursor 353, in form of a diastereoisomeric 
mixture, which was readily available from geraniol in seven steps. Thus, when compound 
353 was treated with the Stewart-Grubbs catalyst (12), the expected tricyclic derivative 
354 was obtained in a 77% combined yield of both stereoisomers, which could be 
separated by chromatographic methods. The power of this tandem metathesis reaction is 
reflected by the fact that only the guaiadiene system was generated in a strict order of 
events through ruthenium carbenes species A and B due to the triggering effect exerted 
by the terminal allyl ether. The formation of the oxygen bridge present in the natural 
product was then accomplished by means of an oxymercuration and subsequent 
demercuration process that afforded the advanced intermediate 355. The transformation 
of this compound into englerin A (352) has already been described  by Echavarren in 
seven steps (Scheme 42).181  
 
                                                          
181 Molawi, K.; Delpont, N.; Echavarren, A. M. Angew. Chem. Int. Ed. 2010, 49, 3517-3519. 
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Scheme 43. Total Synthesis of Kempenone 356 (Metz et al. 2017)183 
 
Another representative and unique example is the synthesis of the complex 
tetracyclic diterpenes belonging to the kempene family, such as the kempenone 356, 
which was isolated from the defense secretion of higher termites Nasutitermes octopolis. 
In contrast to the long multistep approaches reported by Paquette and Deslongchamps for 
the construction of the tetracyclic core of these terpenes,182  Metz et al. reported the 
preparation of this polycyclic system in one step and in excellent yield from the dienyne 
357, prepared from the Wieland-Miescher ketone in 20 steps.183 Thus, exposure of 357 to 
the Grubbs-II catalyst (4) afforded the tetracyclic derivative 358 in an astonishing 97% 
yield. Whereas the reduction of the resulting tetracyclic ketone 358 with L-selectride 
provided the alcohol 359 with the opposite stereochemistry of the natural product, 
reduction of the bicyclic ketone precursor 357 provided the correct diastereoisomer 360 
under the same reduction conditions. In a similar way as 357, dienyne 360 was subjected 
to the treatment of the Grubbs-II catalyst (4) to obtain the tetracyclic alcohol 361 in almost 
quantitative yield (99%). From this compound, the synthesis of the kempenone 356 was 
achieved in 9 additional steps (Scheme 43). 
 
Yet another instructive example for this section is the elegant synthesis of (±)-
morphine (372) by Smith et al.,184 in which the intricate pentacyclic system contained in 
this fascinating natural product was generated utilizing a cascade ene-yne-ene ring 
closing metathesis of the highly functionalized benzofuran 363, prepared in just six steps 
from commercially available starting materials. In the crucial metathesis event, the 
catalytic action of the HG-II catalyst (6) smoothly promoted a sequential cascade of 
events, initiated with an enyne-RCM reaction, that generated the ruthenium alkylidene 
intermediate A, and continued with a final RCM reaction to produce tetracyclic 
compound 364. Despite this product being isolated in an impressive 94% yield, the 
authors decided to continue with the synthetic sequence without isolation of the resulting 
                                                          
182 (a) Paquette, L. A.; Sauer, D. R.; Cleary, D. G.; Kinsella, M. A.; Blackwell, C. M.; Anderson, L. G. J. Am. Chem. Soc. 1992, 114, 
7375-7387. (b) Caussanel, F.; Wang, K.; Ramachandran, S. A.; Deslongchamps, P. J. Org. Chem. 2006, 71, 7370-7377. 
183 Wang, Y.; Jäger, A.; Gruner, M.; Lübken, T.; Metz, P. Angew. Chem. Int. Ed. 2017, 56, 15861-15865. 
184 Chu, S.; Münster, N.; Balan, T.; Smith, M. D. Angew. Chem. Int. Ed. 2016, 55, 14306-14309. 
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tetracycle 364. The compound was then subjected to a 1,6-addition reaction by treatment 
with TFA and then sodium carbonate. As a result, a 10:1 mixture of compounds 
corresponding to neopinone (365) and codeinone (366) was obtained. The treatment of 
this mixture with HCl, followed by a NaOH work-up, allowed for the isomerization of 
neopinone (365) to codeinone (366). The reduction of 366 with sodium borohydride 
afforded codeine (367) as a single diastereoisomer and in 65% overall yield from 363. 
Finally, demethylation of codeine with boron tribromide yielded racemic morphine (362) 
in 86% yield (Scheme 44).  
 
 
Scheme 44. Total Synthesis of (±)-morphine (362) (Smith et al. 2016)185 
 
An interesting example of the synthetic application of domino metathesis in the 
field of the alkaloid-type natural products is the recent syntheses of virgidivarine (368) 
and virgiboidine (369), which are piperidine and piperidino-quinolizidine alkaloids 
isolated from the leaves of African leguminosae Virgilia divaricata and Virgilia 
oroboides and whose biological activities have not been studied. Blechert et al.185 planned 
the construction of the common dipiperidine core of these natural products via a ene-ene-
yne ring-rearrangement metathesis (RRM) from the dienic system represented by 
compound 370, foreseeing an initial ROM process of the cyclopentene unit, followed by 
a double alkene RCM-enyne RCM process of the resulting ROM intermediate. Thus, 
when precursor 370, prepared from cis-cyclopent-2-en-1,4-diol via enzymatic 
desymmetrization, was exposed to the HG-II catalyst (6) under ethylene atmosphere, 
compound 371 was obtained in a remarkable 83% yield, according to the expected 
mechanistic course delineated by the authors. Combined with the tandem metathesis 
reactions, the resulting metathesis product was transformed into the aldehyde 372 by an 
oxidative treatment, in a 33% overall yield in one pot. From this aldehyde, both alkaloids 
were prepared, requiring 10 steps to synthesize virgidivarine (368), followed by the 
synthesis of virgiboidine (369), after a final lactamization reaction of 368 with EDC 
(Scheme 45).  
                                                          
185 Kress, S.; Weckesser, J.; Schulz, S. R.; Blechert, S. Eur. J. Org. Chem. 2013, 1346-1355. 
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Scheme 45. Total Synthesis of Virgidivarine (368) and Virgiboidine (369) (Blechert et al. 2013)185 
 
With regards to recent examples, special attention is deserved for the synthesis of 
the anticancer alkaloids flueggine A (373) and virosine B (374) by the Li group.186 These 
compounds, belonging to the securinega family, possess unique structural features and 
interesting biological properties that cover a wide range of activities. The synthesis of 
these compounds was based on an elegant RRCM of a dienyne system for the controlled 
construction of the core structure represented by norsecurinine (380). Thus, their 
syntheses were envisioned to proceed via a 1,3-dipolar cycloaddition between 
norsecurinine (380) and nitrone 381, which would be prepared from norsecurinine 380 
by oxidative treatment with m-CPBA (Scheme 46). 
                                                          
186 Wei, H.; Qiao, C.; Liu, G.; Yang, Z.; Li, C.-c. Angew. Chem. Int. Ed. 2013, 52, 620-624. 
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Scheme 46. Total Synthesis of Flueggine A (373) and Virosaine B (374) (Li, Yang et al. 2013)186 
 
In a similar strategy towards the related alkaloid securinine, Honda et al. 187 
attempted its synthesis through a tandem RCM of the dienyne 375. However, when this 
precursor was reacted with different ruthenium catalysts, such as the Grela-Grubbs-
Hoveyda (10), the desired -lactone 376 was not detected, obtaining instead the -lactone 
377 in 69% yield. The preference of the catalyst to react with the butenyl group rather 
than the acrylate moiety, through intermediate A, could explain the outcome of this 
reaction. In an attempt to favor the formation of the required ruthenium complex at the 
less reactive alkene, Li et al. proposed the trienyne 378 as a suitable precursor to promote 
the preferential formation of intermediate C through the initiation of the reaction at the 
less sterically encumbered terminal olefin. In fact, when compound 378 was subjected to 
the action of the Zhan-1 b catalyst (11), among others, compound 379 was obtained in a 
reproducible and acceptable 64% yield.  The completion of the synthesis of norsecurinine 
was undertaken in 3 additional steps, allylic bromation, Boc deprotection and a 
                                                          
187 Honda, T.; Namiki, H.; Kaneda, K.; Mizutani, H. Org. Lett. 2004, 6, 87-89. 
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nucleophilic cyclization under basic conditions. After some additional experimentation, 
the authors found out that this transformation could be achieved in only one step by 
exposure of the resulting bromide to the acid AgSbF6 in an improved 85% yield. Finally, 
the preparation of the nitrone 381 from norsecurinine (380), according to the Magnus 
protocol,188 was followed by a cycloaddition reaction with 380 to obtain natural product 
flueggine A (373) in a 77% yield. In a related approach, they also prepared virosaine B 
(374) by an intramolecular cycloaddition of nitrone 383, prepared from the isomer 
allonorsecurinine 382 in three steps (Scheme 46).   
 
In the second group of the cascade reactions involving enyne-RCM processes, we 
wish to highlight those that combine the metathesis reaction with a Diels-Alder 
cycloaddition of the resulting diene as a way for the construction of a bicyclic system in 
a rapid and efficient fashion. Within this category of tandem reactions, the synthesis of 
the norsesquiterpene-type alkaloids, such as the anticancer alkaloid 384, which were 
isolated from the culture of mushroom-forming fungus Flammulina velutipes, was 
accomplished using a tandem enyne-RCM/Diels-Alder/aromatization sequence in one-
pot by Reddy et al.189 Thus, the treatment of the acyclic precursor 385 with the Grubbs-I 
catalyst (3) in toluene at 50 °C was followed by a Diels-Alder reaction with dimethyl 
acetylene-dicarboxylate (DMAD) and then, treatment with DDQ of the resulting Diels-
Alder adduct 386, which was not isolated, to provide the final compound 387 in a 
moderate 42% overall yield. The elaboration of this product towards the final alkaloid 
384 was accomplished without issues in three additional steps with a 49% overall yield 
(Scheme 47). 
 
 
Scheme 47. Total Synthesis of the Norsesquiterpene Alkaloid 384 (Reddy et al. 2014)189 
 
1.4. Alkyne Metathesis in Total Synthesis 
1.4.1. Total Syntheses Based on a Ring-Closing Alkyne Metathesis Reaction 
The wide range of reactivities that alkynes possess, compared with alkenes, 
imparts the alkyne metathesis as a very powerful tool with a broader field of synthetic 
                                                          
188 Magnus, P.; Rodríguez-López, J.; Mulholland, K.; Matthews, I. Tetrahedron 1993, 49, 8059-8072. 
189 Kashinath, K.; Jadhav, P. D.; Reddy, D. S. Org. Biomol. Chem. 2014, 12, 4098-4103. 
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opportunities. Thus, some advantages of alkynes over alkenes include the stereo-
controlled partial reduction of the triple bond, which allows stereoselective access to the 
E or the Z-alkene, and its excellent reactivity against electrophilic metals such as Ag, Pt 
or Hg, which allows for further functionalization. On the other hand, the catalysts required 
for the alkyne metathesis reactions are completely different. From the first Mortreux 
system developed in 1974,190 the evolution towards more efficient, stable and functional 
group tolerant catalysts, developed firstly by Schrock (catalyst 388) 191  and later by 
Fürstner (catalysts 389)192 (Figure 6), has propelled the alkyne metathesis reaction to 
become an excellent synthetic tool for the generation of macrocyclic structures as applied 
to the synthesis of natural products and bioactive compounds.  
 
 
 
Figure 6. Common Catalysts Used for Alkyne Metathesis Reactions 
 
Since the first example of an alkyne ring-closing metathesis in 1999 by 
Fürstner,193 we can find in the literature many applications of this type of reaction in the 
preparation of complex macrocyclic natural products, some of the which has been linked 
to the development of even more efficient and stable catalysts in the last years (catalysts 
390-394).194  As for the catalysts used in alkene metathesis, the catalysts for alkyne 
metathesis are precatalysts, which are activated to form the active species responsible for 
catalytic action. In fact, precatalysts 389 or 394 are activated by reaction with CH2Cl2 to 
form in situ the corresponding monochloro derivatives, which are the catalytically active 
species.195 One of the main architects of the responsible for the spectacular irruption of 
this reaction in modern organic synthesis has been Fürstner, who not only by his seminal 
contributions in total synthesis but also in his work on the development of new catalysts 
                                                          
190 Mortreux, A.; Blanchard, M. J. Chem. Soc. Chem. Commun. 1974, 786-787. 
191 Schrock, R. R.; Clark, D. N.; Sancho, J.; Wengrovius, J. H.; Rocklage, S. M.; Pedersen, S. F. Organometallics 1982, 1, 1645-1651. 
192 Fürstner, A.; Mathes, C.; Lehmann, C. W. J. Am. Chem. Soc. 1999, 121, 9453-9454. 
193 Fürstner, A.; Guth, O.; Rumbo, A.; Seidel, G. J. Am. Chem. Soc. 1999, 121, 11108-11113. 
194 (a) Schaubach, S.; Gebauer, K.; Ungeheuer, F.; Hoffmeister, L.; Ilg, M. K.; Wirtz, C.; Fürstner, A. Chem. Eur. J. 2016, 22, 8494-
8507 and references therein. (b) Wu, X.; Tamm, M. Beilstein J. Org. Chem. 2011, 7, 82-93. 
195 Fürstner, A.; Mathes, C.; Lehmann, C. W. Chem. Eur. J. 2001, 7, 5299-5317. 
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has reached spectacular progress and promoted the field. During his prolific and 
impressive research career, many reviews have been reported about this reaction covering 
the main contributions of the Fürstner group as well as of other groups.196  The last 
contributions reported in the period 2015-2017 however have not been covered and thus 
will be reviewed in this section.   
 
Thus, selected examples are illustrated in Scheme 48, in which the natural 
products lactimidomycin (395),197  mandelalide A (396),198  amphidinolide F (397),199 
brefeldin A (398),200  leidodermatolide (399),201  tulearin A (400)202  or brominated 4-
pyrone-type natural products203 (for example 401) were efficiently synthesized from their 
corresponding acyclic dialkynes and that provided the corresponding alkyne macrocycles 
(402-407) in good to excellent yields.  
 
  
Scheme 48. Selected Natural Products synthesized via a RCAM reaction by the Fürstner Group (period 
2013-present) 
                                                          
196 Selected reviews on alkyne metathesis: (a) Fürstner, A. Angew. Chem. Int. Ed. 2014, 53, 8587-8598. (b) Fürstner, A. Angew. Chem. 
Int. Ed. 2013, 52, 2794-2819. (c) Zhang, W.; Moore, J. S. Adv. Synth. Catal. 2007, 349, 93-120. (d) Fürstner, A.; Davies, P. W. Chem. 
Commun. 2005, 2307-2320. 
197 Micoine, K.; Persich, P.; Llaveria, J.; Lam, M.-H.; Maderna, A.; Loganzo, F.; Fürstner, A. Chem. Eur. J. 2013, 19, 7370-7383. 
198 (a) Willwacher, J.; Fürstner, A. Angew. Chem. Int. Ed. 2014, 53, 4217-4221. (b) Willwacher, J.; Heggen, B.; Wirtz, C.; Thiel, W.; 
Fürstner, A. Chem. Eur. J. 2015, 21, 10416-10430. 
199 (a) Valot, G.; Regens, C. S.; O´Malley, D. P.; Godineau, E.; Takikawa, H.; Fürstner, A. Angew. Chem. Int. Ed. 2013, 52, 9534-
9538. (b) Valot, G.; Mailhol, D.; Regens, C. S.; O´Malley, D. P.; Godineau, E.; Takikawa, H.; Phillipps, P.; Fürstner, A. Chem. Eur. 
J. 2015, 21, 2398-2408. 
200 Fuchs, M.; Fürstner, A. Angew. Chem. Int. Ed. 2015, 54, 3978-3982. 
201 Mailhol, D.; Willwacher, J.; Kausch-Busies, N.; Rubitski, E. E.; Sobol, Z.; Schuler, M.; Lam, M.-H.; Musto, S.; Loganzo, F.; 
Maderna, A.; Fürstner, A. J. Am. Chem. Soc. 2014, 136, 15719-15729. 
202 Lehr, K.; Schulthoff, S.; Ueda, Y.; Mariz, R.; Leseurre, L.; Gabor, B.; Fürstner, A. Chem. Eur. J. 2015, 21, 219-227. 
203 Hoffmeister, L.; Fukuda, T.; Pototschnig, G.; Fürstner, A. Chem. Eur. J. 2015, 21, 4529-4533. 
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In the depicted representative cases, the alkynes were reduced to the 
corresponding E-alkenes (cases of natural products 395, 398 and 400), Z-alkenes (cases 
of 396 and 399) or even, not transformed such as the cases of the 4-pyrone 401. For the 
particular case of amphidinolide F (397), the alkyne was subjected to a hydration reaction 
to obtain a ketone under platinum catalysis. Similarly relevant are the syntheses of WF-
1360F (408),204 cruentaren A (31)205 and haliclonin A (409),206 reported by the Altmann, 
Barrett and the Huang research groups, respectively, in which after the alkyne macrocycle 
formation via a RCAM reaction, the resulting macrocyclic alkynes (410-412) were 
reduced to the E-olefin for the case of 410 or to the Z-olefins by means of a Lindlar 
catalyst-mediated hydrogenation for 411 and 412 (Scheme 49). 
 
More intriguing and challenging are the cases in which introduction of a methyl 
group into the alkyne is required to be transformed into a methyl-branched alkene in a 
regio- and stereo-controlled manner. Such cases can be found in the synthesis of the 
natural products 5,6-dihydrocineromycin B (413), disciformycins B (414) and 
nannocystin Ax (415) by the Fürstner group.  
 
 
 
Scheme 49. Selected Natural Products synthesized via a RCAM reaction by other Research Groups (period 
2013-present) 
                                                          
204 Neuhaus, C. M.; Liniger, M.; Stieger, M.; Altmann, K.-H. Angew. Chem. Int. Ed. 2013, 52, 5866-5870. 
205 Fouché, M.; Rooney, L.; Barrett, A. G. M. J. Org. Chem. 2012, 77, 3060-3070. 
206 Guo, L.-D.; Huang, X.-Z.; Luo, S.-P.; Cao, W.-S.; Ruan, Y.-P.; Ye, J.-L.; Huang, P.-Q. Angew. Chem. Int. Ed. 2016, 55, 4064-
4068. 
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To this aim, the recent methodology developed by the same group, based on the 
ruthenium-catalyzed trans-hydrostannation of alkynes, was envisioned as a solution to 
this synthetic problem given the excellent levels of regioselectivity exhibited by this 
reaction when applied to unprotected propargyl alcohol derivatives. Thus, for the case of 
5,6-dihydrocineromycin B (413),207 when alkyne 416, obtained from the corresponding 
acyclic dialkyne by reaction with the molybdenum alkylidyne complex 392, was 
desilylated by reaction with HF, the resulting propargyl alcohol was treated with Bu3SnH 
in the presence of the ruthenium catalyst [Cp*RuCl2]n. As a result, the corresponding a-
alkenylstannane was obtained as a single isomer. Having introduced the stannyl group, a 
Stille reaction was carried out by exposure to copper thiophene-2-carboxylate (CuTC), 
[Ph2PO2][NBu4] and [Pd(PPh3)4] in the presence of methyl iodide to afford the final 
natural product (413) in excellent yield. It is important to highlight the importance of the 
order of addition and stoichiometry of the reactants in this reaction to avoid undesired 
protodestannation processes. In a similar situation, the macrocyclic alkyne 417, 208 
obtained in excellent yield from its corresponding dialkyne precursor by reaction with 
precatalyst 394, required the installation of the methyl group for the synthesis of 
disciformycins A and B, interesting macrolides-type antibiotics with considerable activity 
against resistant Gram-positive bacteria (Scheme 50). 
 
As the previous case, the transformation of compound 417 into its hydroxyl 
derivative was followed by a rapid trans-hydrostannation reaction. In contrast to the 
previous case, as to other numerous examples carried out by the Fürstner group, on this 
occasion a 3:1 mixture of stannyl regioisomers, in favor of 418, was obtained, likely due 
to the competing interactions of the hydroxyl group, via hydrogen bonding, with the 
ruthenium catalyst and with the neighboring ester carbonyl group. In addition to this lack 
of regioselectivity, the observation that the stannyl derivative was quite sensitive forced 
the authors to continue with the crude product mixture to the following step, which 
consisted of a methylation reaction. Once again, this reaction proved to be sluggish, as a 
mixture of products was obtained under conventional conditions. In light of these 
unsatisfactory results, the authors decided to use stoichiometric amounts of the methyl 
donor [(cod)Pd(Cl)Me] to obtain the desired product 419 in a 20% overall yield after four 
steps from 417. Final glycosidation and global deprotection provided the elusive 
disciformycin B (415) in the first instance, and then disciformycin A after an 
isomerization reaction. Similarly challenging proved to be the synthesis of nannocystin 
Ax (415),209 a cytotoxic cyclodepsipeptide isolated from myxobacteria. After a successful 
alkyne RCM reaction that provided macrocyclic alkyne 420 in a 66% yield by the action 
of catalyst 390, the OH-directed hydrostannation was achieved by sequential desilylaton 
and treatment with Bu3SnH, in the presence of catalytic amounts of [Cp*RuCl2]n, to 
obtain the corresponding stannane 421 as a single regio- and stereo-isomer. The 
methylation was then achieved according to previous conditions to provide the desired 
methyl derivative in a reasonable good yield (70%). The methylation of the hydroxyl 
                                                          
207 Rummelt, S. M.; Preindl, J.; Sommer, H.; Fürstner, A. Angew. Chem. Int. Ed. 2015, 54, 6241-6245. 
208 Kwon, Y.; Schulthoff, S.; Dao, Q. M.; Wirtz, C.; Fürstner, A. Chem. Eur. J. 2018, 24, 109-114. 
209 Meng, Z.; Souillart, L.; Monks, B.; Huwyler, N.; Herrmann, J.; Müller, R.; Fürstner, A. J. Org. Chem. 2018, 83, 6977-6994. 
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group proved to be similarly challenging, finding, after extensive experimentation, that 
the methyl ester 422 provided a proper source of electrophilic methyl by its in situ 
generation in a gold-catalyzed cyclization. Final reductive cleavage of the phenacyl group 
furnished the targeted natural product 415 (Scheme 50).  
 
 
Scheme 50. Selected Natural Products synthesized via a RCAM/Hydrostannation reactions by the Fürstner 
Group 
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Scheme 51. Selected Natural Products synthesized via a RCAM/Gold Catalysis by the Fürstner Group (I) 
 
Beyond the transformation of the alkyne into an alkene or even a methyl-
substituted alkene, as discussed before, the reactivity of the alkyne functional group 
allows the construction of a heterocyclic ring, providing extraordinary opportunities to 
access more complex structural systems compared to the alkene chemistry. These post-
metathetic transformations have been similarly explored by Fürstner et al. in the synthesis 
of a plethora of natural products. In this set of new synthetic opportunities, the recent 
syntheses of enigmazole A (423),210 polycavernoside A (424),211 kendomycin (425)212 
                                                          
210 Ahlers, A.; de Haro, T.; Gabor, B.; Fürstner, A. Angew. Chem. Int. Ed. 2016, 55, 1406-1411. 
211 Brewitz, L.; Llaveria, J.; Yada, A.; Fürstner, A. Chem. Eur. J. 2013, 19, 4532-4537. 
212 Hoffmeister, L.; Persich, P.; Fürstner, A. Chem. Eur. J. 2014, 20, 4396-4402. 
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and lytharanidine (426)213 represent excellent examples of this synthetic potential. In all 
these cases, the macrocyclic alkynes (427-430) were synthesized from their 
corresponding acyclic dialkynes. From these alkynes, in the cases of enigmazole A, 
polycavernoside A and kendomycin, a trasannular pyrane (for enigmazole A) and a furan 
ring (for polycavernoside A and kendomycin) were constructed by activation of the 
alkyne with gold-based catalysts (431-433)214 to provide compounds 434-436. In the 
cases of polycavernoside A and kendomycin, the syntheses were formal, having been 
described by Lee215 and Mulzer216 from advanced precursors 435 and 437, respectively. 
On the other hand, for the synthesis of lytharanidine, formation of a piperidine ring was 
required, which was achieved by a sequence of redox isomerization, followed by 
transannular aza-Michael addition from macrocyclic alkyne 430 (Schemes 51 and 52).  
 
 
 
Scheme 52. Selected Natural Products synthesized via a RCAM/Gold Catalysis by the Fürstner Group (II) 
 
An intriguing last case is the synthesis of ivorenolide B (438) by the Fürstner 
group based upon a macrocyclization of a diterminal diyne to prepare the 1,3-diyne 
system found in this unprecedented natural product.217 Ivorenolide B belongs to a family 
                                                          
213 Gebauer, K.; Fürstner, A. Angew. Chem. Int. Ed. 2014, 53, 6393-6396. 
214 Fürstner, A. Acc. Chem. Res. 2014, 47, 925-938. 
215 Woo, S. K.; Lee, A. J. Am. Chem. Soc. 2010, 132, 4564-4565. 
216 Magauer, T.; Martin, H. J.; Mülzer, J. Chem. Eur. J. 2010, 16, 507-519. 
217 Ungeheuer, F.; Fürstner, A. Chem. Eur. J. 2015, 21, 11387-11392. 
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of macrolides isolated from the stem bark of Khaya ivorensis, which has been reported to 
inhibit concanavalin A-induced T-cell and lipopolysaccharide-induced B cell 
proliferations. This noteworthy biological activity confers it a clinical application as an 
immunosuppressive agent comparable to cyclosporine A. The synthesis of Fürstner et al. 
was delineated according to a RCAM reaction of the diterminal acyclic dyine 439, which 
by treatment with catalyst 390 furnished in a remarkable 82% yield the desired [17]-
membered ring 440 with the embedded 1,3-diyne unit and no detection of side products 
derived from ring contraction or oligomerization processes. The subsequent epoxidation, 
performed in a regio- and stereoselective manners with m-CPBA, followed by silyl ether 
deprotection provided the targeted ivorenolide B (438) (Scheme 53). This synthesis 
improved notably with the contribution by Yue et al.,218 which, based on a RCM reaction, 
provided the macrocyclic lactone 441 as a 1.5:1 mixture with the E-olefin as the major 
isomer. Despite this stereochemical problem, Yue´s synthesis allowed confirmation of 
the absolute configuration of the natural product (Scheme 53). 
 
 
Scheme 53. Total Synthesis of Ivorenolide B (438) (Fürstner et al. 2015)217 
 
1.4.2. Other Types of Alkyne Metathesis Reactions 
To conclude this chapter, it is necessary to mention that, as in alkene metathesis 
reactions, we can find also examples of the use of the alkyne cross-metathesis219 or 
tethered RCAM reactions.220 Despite the power and scope that the alkyne metathesis 
demonstrates, utilization of these alkyne metathesis variants in the context of total 
synthesis is not well represented, with most examples being found mainly in 
polymerization reactions. 221  Nevertheless, given the potential and efficiency of the 
methodology, there is no doubt that the trend will be an increase in the use of this 
chemistry in the construction of natural products.   
                                                          
218 Wang, Y.; Liu, Q.-F.; Xue, J.-J.; Zhou, Y.; Yu, H.-C.; Yang, S.-P.; Zhang, B.; Zuo, J.-P.; Li, Y.; Yue, J.-M. Org. Lett. 2014, 16, 
2062-2065. 
219 For a recent representative example see: Ralston, K. J.; Ramstadius, H. C.; Brewster, R. C.; Niblock, H. S.; Hulme, A. S. Angew. 
Chem. Int. Ed. 2015, 54, 7086-7090. 
220 For a recent representative example see: Guy, A.; Oger, C.; Heppekausen, J.; Signorini, C.; De Felice, C.; Fürstner, A.; Durand, 
T.; Galano, J.-M. Chem. Eur. J. 2014, 20, 6374-6380. 
221 Zhang, W.; Moore, J. S. Macromolecules 2004, 37, 3973-3975 and references therein. 
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1.5. Summary 
As amply demonstrated in the literature, metathesis reactions are recognized as 
one of the most important and powerful reactions in the last decades rendering their main 
inventors the Nobel Prize in 2005. The synthetic value and great potential of these 
reactions have been driven by the tremendous progress witnessed in the last years 
regarding the design and development of efficient and stable catalysts based on 
metallocarbenes. As a consequence, these reactions enjoy broad scope, generality and a 
great deal of flexibility for structural diversity. Furthermore, as proof of these features is 
their extensive utilization in the field of organic synthesis, with particular impact in the 
total synthesis of natural products. These reactions in their different modalities (alkene, 
enyne and alkyne-metathesis reactions), versions (intra- and inter-molecular reactions), 
and strategies (tethered-, relay-, stereoselective metathesis, among others) have become 
a standard tool in the modern organic synthesis laboratory, being determinant in the 
completion of a wide array of natural products. In the current chapter we have 
demonstrated the increasing value and flurry of synthetic opportunities that these 
reactions provide.  
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The current PhD Thesis proposes the discovery and development of new drugs 
inspired by bioactive natural products which represent valid platforms for the generation 
of new chemical entities of pharmaceutical interest. Thus, the combination of structural 
and functional diversity allows for the identification of new compounds with better 
biological profiles than the natural counterparts. In order to select suitable synthetic 
targets, we focused on natural products that are able to offer promising expectations in 
the biomedicinal field, with new mechanisms of biological action and intriguing 
molecular structures that could represent the basis of new scaffolds of pharmaceutical 
interest. In particular, the selected natural products are a microbial polyketide termed (-)-
depudecin, and cyclopeptide and cyclodepsipeptide-type compounds from marine origin, 
the solomonamides A-B and the celebesides A-C. The scarcity of these natural products 
and the difficult accessibility from their natural sources have hampered further studies 
towards their biological and chemical profile. Despite the scarcity of the material, the 
preliminary biological evaluations of these natural products revealed very interesting 
biological properties. The intriguing preliminary biological profiles of the selected 
compounds, the requirement to have more material for further biological studies and to 
gain insight into their mechanisms of action and to confirm their novel and unprecedented 
molecular structures justify a research plan that could generate new knowledges from the 
chemical and biological standpoints. From the synthetic perspective, the selected natural 
products share an olefin metathesis reaction as the key step of their syntheses, which will 
be showed in detail in their respective chapters.  
 
Thus, the following specific objectives were established for this PhD Thesis: 
 
Objective 1. The establishment of flexible and convergent synthetic strategies towards 
the total synthesis of the selected natural products.  
Objective 2. The implementation of the previously established synthetic routes to the 
generation of analogues of the selected natural products. 
Objective 3. The biological evaluation of the synthetic natural products and analogues. 
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3.1. Isolation, Structure and Biology of Depudecin 
The disclosure and recognition of the crucial role of histone deacetylases (HDAC) 
and histone acetyl transferases (HAT) in the regulation of gene expression, which occurs 
through a tight control of the acetylation state of histones, has generated significant 
interest in their utility as new promising targets for cancer therapies.222 Thus, whereas the 
acetylated histones lead to a local expansion of chromatin, increasing the accessibility of 
regulatory proteins to DNA, the action of HDACs produces positively-charged histones 
that increase their affinities with DNA and, thereby, block the transcription of anti-tumor 
genes.223 HDACs are the enzymes responsible for the removal of the acetyl group from 
lysine residues of histones and other proteins; and are comprised of 18 isoforms grouped 
into four different classes (I-IV).224 The inhibition of these enzymes in the context of a 
neoplastic epigenome, in which they are overexpressed and play important roles in 
promoting cancer progression,225 leads to the restoration of a normal epigenetic state and 
induces the expression of tumor-suppresive genes.226 Consequently, inhibitors of HDAC 
(HDACi) have attracted considerable attention from the scientific community as novel 
potential anticancer agents. 227  An indication of this interest is the flurry of activity 
directed towards the design and synthesis of inhibitors, which have been classified into 
five categories according to their modes of action.228 As a consequence of this intense 
activity, three of them (vorinostat, belinostat and romidespin) have been recently 
approved by the FDA for clinical anticancer therapies, whereas a remarkable number of 
other HDACi have undergone clinical trials for the treatment of a variety of hematological 
malignancies and solid tumors.229 The fact that other proteins, including transcription 
factors, DNA repair enzymes, signal transduction and inflammation mediators, among 
others, are also substrates of HDACs, further demonstrates their involvement in a wide 
variety of biological processes, including cell cycle and mitosis, DNA damage repair, 
cellular stress responses, protein degradation, cytokine signalling, immunity, 
inflammation, angiogenesis, apoptosis and cell invasion.230 In fact, HDACs are involved 
not only in cancer, but also in other pathologies such as neurological diseases, immune 
disorders231 and infections.232 On the other hand, the general lack of isoform selectivity 
                                                          
222 (a) Norton, V. G.; Imai, B. S.; Yau, P.; Bradbury, E. M. Cell 1989, 57, 449–457. (b) Turner, B. M. Cell 2002, 111, 285–291. (c) 
Huang, L. J. Cell Physiol. 2006, 209, 611–716. (d) Minucci, S.; Pelicci, P. G. Nat. Rev. Cancer 2006, 6, 38–51. (e) Jenuwein, T.; 
Allis, C. D. Science 2001, 293, 1074–1080. 
223 Brandl, A.; Heinzel, T.; Krämer, O. H. Biol. Cell 2009, 101, 193–205. 
224 Gregoretti, I. V.; Lee, Y. M.; Goodson, H. V. J. Mol. Biol. 2004, 338, 17-31. 
225 (a) Muller, B. M.; Jana, L.; Kasajima, A.; Lehmann, A.; Prinzler, J.; Budczies, J.; Winzer, K. J.; Dietel, M.; Weichert, W.; Denkert, 
C. BMC Cancer 2013, 13, 215. (b) Wilson, A. J.; Byun, D. S.; Popova, N.; Murray, L. B.; L’Italien, K.; Sowa, Y.; Arango, D.; Velcich, 
A.; Augenlicht, L. H.; Mariadason, J. M. J. Biol. Chem. 2006, 281, 13548–13558. 
226 Taunton, J.; Hassig, C. A.; Schreiber, S. L. Science 1996, 272, 408–411. 
227 (a) Newkirk, T. L.; Bowers, A. A.; Williams, R. M. Nat. Prod. Rep. 2009, 26, 1293–1320. (b) Miller, T. A.; Witter, D. J.; Belvedere, 
S. J. Med. Chem. 2003, 46, 5097–5116. (c) Meinke, P. T.; Liberator, P. Curr. Med. Chem. 2001, 8, 211–235. (d) Monneret, C. Eur. J. 
Med. Chem. 2005, 40, 1–13. 
228 (a) Iakshmi, A.; Madhusudhan, T.; Kumar, D. P.; Padmavathy, J.; Saravanan, D.; Kumar, Ch. P. Int. J. Pharm. Sci. Rev. Res. 2011, 
10, 38-44. (b) Carafa, V.; Nebbioso, A.; Altucci, L. Rec. Patents Anti-Cancer Drug Discov. 2011, 6, 131–145. 
229 (a) West, A. C.; Johnstone, R. W. J. Clin. Invest. 2014, 124, 30-39. (b) Ververis, K.; Hiong, A.; Karagiannis, T. C.; Licciardi, P. 
V. Biol. Targets Ther. 2013, 7, 47-60. (c) Ma, X.; Ezzeldin, H. H.; Diasio, R. B. Drugs 2009, 69, 1911-1934. (d) New, M.; Olzscha, 
H.; La Thangue, N. B. Mol. Oncol. 2012, 6, 637–656. 
230 Haberland, M.; Montgomery, R. L.; Olson, E. N. Nat. Rev. Genet. 2009, 10, 32-42. 
231 (a) Falkenberg, K. J.; Johnstone, R. W. Nat. Rev. Drug Discov. 2014, 13, 673-691. (b) Kazantsev, A. G.; Thompson, L. M. Nat. 
Rev. Drug Discov. 2008, 7, 854-868. 
232 (a) Ouaissi, M.; Ouaissi, A. J. Biomed. Biotechnol. 2006, 2006, 13474-13483. (b) Rotili, D.; Simonetti, G.; Savarino, A.; Palamara, 
A. T.; Migliaccio, A. R.; Mai, A. Curr. Top. Med. Chem. 2009, 9, 272-291. 
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exhibited by current inhibitors towards the HDAC family,233,234 which are involved in a 
plethora of biological functions, explains the diverse biological effects that they may 
produce,235 thus reducing their therapeutic window by promoting undesirable side effects 
and toxicity. 
 
In this context, (-)-depudecin (442), isolated from the culture broths of the fungus 
Alternaria brassicicola in 1992 236  and later, from the weed pathogen Nimbya 
scirpicola,237 has been identified as a selective inhibitor of histone deacetylases I and II 
with an IC50 in the low M range, according to biological studies carried out by Schreiber 
et al.238 In contrast to representative HDACi, such as 443-447 (Figure 7, A), depudecin 
represents a unique inhibitor of these enzymes by virtue of its molecular structure, 
featuring the presence of two oxirane rings separated by a trans double bond.  
 
 
Figure 7. Molecular Structures of (-)-Depudecin (442) and Other HDAC Inhibitors (A) and Synthetic 
Intermediates Prepared by Schreiber et al. (B).  
                                                          
233 (a) Balasubramanian, S.; Verner, E.; Buggy, J. J. Cancer Lett. 2009, 280, 211-221. (b) Wang, Y.; Stowe, R. L.; Pinello, C. E.; Tian, 
G.; Madoux, F.; Li, D.; Zhao, L. Y.; Li, J.-L.; Wang, Y.; Wang, Y.; Ma, H.; Hodder, P.; Roush, W. R.; Liao, D. Chem. Biol. 2015, 22, 
273-284. (c) Bradner, J. E.; West, N.; Grachan, M. L.; Greenberg, E. F.; Haggarty, S. J.; Warnow, T.; Mazitschek, R. Nat. Chem. Biol. 
2010, 6, 238-243. (d) Thaler, F.; Mercurio, C. ChemMedChem 2014, 9, 523-536. 
234 For the design of inhibitors by computational methods, see: (a) Sangeetha, S.; Ranjitha, S.; Murugan, K.; Kumar, G. R. Trends 
Bioinformat. 2013, 6, 25-44. (b) Wang, D.; Helquist, P.; Wiest, O. J. Org. Chem. 2007, 72, 5446-5449. (c) Vadivelan, S.; Sinha, B. 
N.; Rambabu, G.; Boppana, K.; Jagarlapudi, S. A. R. P. J. Mol. Graph. Model. 2008, 26, 935-946. 
235 (a) Manal, M.; Chandrasekar, M. J. N.; Priya, J. G.; Nanjan, M. J. Bioorg. Chem. 2016, 67, 18-42. (b) Marks, P. A. Biochim. 
Biophys. Acta 2010, 1799, 717-725. (c) Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Nat. Rev. Drug Discov. 2006, 5, 769-784.  
236 Matsumoto, M.; Matsutani, S.; Sugita, K.; Yoshida, H.; Hayashi, F.; Terui, Y.; Nakai, H.; Uotani, N.; Kawamura, Y.; Matsumoto, 
K.; Shoji, J.; Yoshida, T. J. Antibiot. 1992, 45, 879–885. 
237 Tanaka, M.; Ohra, J.; Tsujino, Y.; Sawaji, Y.; Fujimori, T. Biosci. Biotech. Biochem. 1994, 58, 565–566. 
238 Kwon, H. J.; Owa, T.; Hassig, C. A.; Shimada, J.; Schreiber, S. L. Proc. Natl. Acad. Sci. USA 1998, 95, 3356–3361. 
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Originally discovered as part of a biological screen directed towards the 
identification of antitumour agents with detransforming activity, 239  depudecin was 
identified as a bioactive metabolite capable of reverting the transformed morphology of 
tumor cells NIH3T3, doubly transfected with v-ras and v-src oncogenes.240 The ability 
of depudecin to regulate the cytoskeletal architecture of tumoral cells is due to the 
restoration of the actin stress fiber.  
 
This biological activity elicited a great biomedical and biological interest241 by 
virtue of its potential as an antitumor agent and as a molecular probe 242  for the 
investigation of signalling pathways that regulate the actin stress fiber, as well as for 
further understanding the biological roles of HDACs. Depudecin induced not only 
morphological changes but also cell cycle arrest and cellular differentiation, which could 
be attributed to its inhibition against HDAC243 as mentioned above. It is likely that its 
inhibitory action against HDAC is a result of the presence of biologically reactive oxirane 
rings that could block the active site of the enzymes through the irreversible formation of 
a covalent bond between the nucleophlic residues within the active site and the oxirane 
rings.244 In fact, Schreiber demonstrated that the epoxy and hydroxyl groups of depudecin 
were essential for the biological activity, as the synthetic analogue 450 showed very weak 
activity, and 448 and 449 were completely inactive against transformed NIH3T3 cells 
(Figure 7, B).245 Furthermore, depudecin also exhibited remarkable anti-angiogenesis 
activity that endowed it with potent anti-proliferative activity against HUVEC.246 Finally, 
in addition to its antitumor properties, depudecin was also identified as a potent anti-
protozoal agent against Neospora caninum, without any side effects for the host cell.247 
 
3.2. Chemistry of Depudecin 
Despite the intriguing biological activities of depudecin and its unique molecular 
structure, it is rather surprising that only one total synthesis has been reported so far, by 
the group of Schreiber in 1995 (Scheme 54).24 Although this synthesis was a long linear 
synthesis, it was able to provide enough amounts of synthetic (-)-depudecin for further 
biological studies. As depicted in Scheme 54, the synthesis was based on an asymmetric 
methodology that used a one-pot procedure for the stereoselective conversion of syn-
vicinal diols 448 into trans-epoxides 449, proceeding in 23 steps with an overall yield of 
0.7% from (-)-diethyl D-tartrate (451). This synthesis also required the previously 
                                                          
239 Itazaki, H.; Nagashima, K.; Sugita, K.; Yoshida, H.; Kawamura, Y.; Yasuda, Y.; Matsumoto, K.; Ishii, K.; Uotani, N.; Nakal, H.; 
Terui, A.; Yoshimatsu, S.; Ikenishi, Y.; Nakagawa, Y. J. Antibiot. 1990, 43, 1524–1532. 
240 Sugita, K.; Yoshida, H.; Matsumoto, M.; Matsutani, S. Biochem. Biophys. Res. Commun. 1992, 182, 379–387. 
241 Biosynthetic studies of Depudecin: (a) Chooi, Y.-H.; Tang, Y. J. Org. Chem. 2012, 77, 9933-9953. (b) Wight, W. D.; Kim, K. -; 
Lawrence, C. B.; Walton, J. D. MPMI 2009, 22, 1258–1267. 
242 (a) Salisbury, C. M.; Cravatt, B. F. J. Am. Chem. Soc. 2008, 130, 2184-2194. (b) Wang, C.; Schroeder, F. A.; Wey, H.-Y.; Borra, 
R.; Wagner, F. F.; Reis, S.; Kim, S. W.; Holson, E. B.; Haggarty, S. J.; Hooker, J. M. J. Med. Chem. 2014, 57, 7999-8009. 
243 (a) Montero-Melendez, T.; Dalli, J.; Perretti, M. Cell Death Different. 2013, 20, 567-575. (b) Raynal, N. J.-M.; Si, J.; Taby, R. F.; 
Gharibyan, V.; Ahmed, S.; Jelinek, J.; Estécio, M. R. H.; Issa, J.-P. J. Cancer Res. 2012, 72, 1170-1181. 
244 A possible similar irreversible inhibition has been demonstrated for the potent HDAC inhibitors trapoxins: Taunton, J.; Collins, J. 
L.; Schreiber, S. L. J. Am. Chem. Soc. 1996, 118, 10412-10422. 
245 Shimada, J.; Kwon, H. J.; Sawamura, M.; Schreiber, S. L.  Chem. Biol. 1995, 2, 517–525. 
246 Oikawa, T.; Onozawa, C.; Inose, M.; Sasai, M. Biol. Pharm. Bull. 1995, 18, 1305–1307. 
247 Kwon, H. J.; Kim, J.-H.; Kim, M.; Lee, J.-K.; Hwang, W.-S.; Kim, D.-Y. Veter. Parasitol. 2003, 112, 269-276. 
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preparation of the phosphonate 453  in order to obtain the linear chain with the trans 
double bond contained in the natural depudecin, through a Wittig-Horner reaction with 
aldehyde 452 (Scheme 54).   
 
 
 
Scheme 54. Total Synthesis of (-)-Depudecin (Schreiber et al. 1995)245 
 
Prompted by its striking biological properties and enticing structure, we decided 
to initiate a research program directed towards the synthesis of natural depudecin and 
analogues. Our initial synthetic plan was based on a linear synthetic strategy, whose 
retrosynthetic analysis is depicted in Scheme 55, and was recently culminated with the 
total synthesis of (-)-depudecin.248 Accordingly, we envisioned triepoxy alcohol 455 as a 
direct precursor of depudecin via an epoxide reductive elimination process. For the 
preparation of 455, we devised the use of a new class of chiral sulfonium salts (457 and 
ent-457), developed in our laboratories,249,250 for the stereoselective construction of the 
oxirane rings contained in the natural product. Thus, we prepared triepoxy amide 458 in 
a remarkable 51% overall yield over 6 steps and with complete stereoselectivity from 
,-unsaturated aldehyde 456, involving a sequential formation of a diepoxide system 
mediated by sulfonium salt 457. From this highly valuable tri-epoxide amide, the 
completion of the synthesis of depudecin was achieved without problems through 
triepoxy alcohol 455 proceeding in 17 steps and 19% overall yield from (+)-methyl D-
lactate (462) (Scheme 55). 
                                                          
248 García-Ruiz, C.; Cheng-Sánchez, I.; Sarabia, F. Org. Lett. 2015, 17, 5558-5561. 
249 (a) Sarabia, F.; Chammaa, S.; García-Castro, M.; Martín-Gálvez, F. Chem. Commun. 2009, 5763-5765. (b) Sarabia, F.; Vivar-
García, C.; García-Castro, M.; Martín-Ortiz, J. J. Org. Chem. 2011, 76, 3139-3150. (c) Sarabia, F.; Vivar-García, C.; García-Castro, 
M.; García-Ruiz, C.; Martín-Gálvez, F.; Sánchez-Ruiz, A.; Chammaa, S.  Chem. Eur. J. 2012, 18, 15190–15201. 
250 Synthetic applications of sulfonium salts 457 and ent-457: (a) Sarabia, F.; Martín-Gálvez, F.; Chammaa, S.; Martín-Ortiz, L.; 
Sánchez-Ruiz, A. J. Org. Chem. 2010, 75, 5526–5532. (b) Sarabia, F.; Chammaa, S.; García-Ruiz, C. J. Org. Chem. 2011, 76, 2132–
2144. (c) Martín-Gálvez, F.; García-Ruiz, C.; Sánchez-Ruiz, A.; Valeriote, F. A.; Sarabia, F. ChemMedChem 2013, 8, 819–831. (d) 
Sarabia, F.; Martín-Gálvez, F.; García-Ruiz, C.; Sánchez-Ruiz, A.; Vivar-García, C.  J. Org. Chem. 2013, 78, 5239-5253. (e) Sarabia, 
F.; Vivar-García, C.; García-Ruiz, C.; Sánchez-Ruiz, A.; Pino-González, M. S.; García-Castro, M.; Chammaa, S.  Eur. J. Org. Chem. 
2014, 3847–3867. (f) García-Ruiz, C.; Cheng-Sánchez, I.; Sarabia, F.  Synthesis 2016, 48, 1655-1662. 
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Scheme 55. Total Synthesis of (-)-Depudecin: The Linear Approach (Sarabia et al. 2015)248 
 
In order to develop an improved and expeditious access to natural depudecin, as 
well as to access additional analogues for further biological screenings, we decided to 
explore a synthetic alternative based on a olefin cross-metathesis strategy as a shorter and 
more convergent approach.  
 
3.3. Total Synthesis of (-)-Depudecin based on an Olefin Cross-Metathesis 
Approach 
For the new synthesis of depudecin, we conceived of a convergent approach 
wherein an olefin cross-metathesis reaction would serve as the key step to join the 
terminal olefins 460 and 461. Thus, according to the retrosynthetic analysis depicted in 
Scheme 56, (-)-depudecin (442) could be obtained again from a triepoxy alcohol (459 in 
this case) via an epoxide reductive elimination process251 in the synthetic direction. This 
triepoxy alcohol 459, in turn, could be delivered from a key olefin cross-metathesis of 
compounds 460 and 461. The preparation of these metathesis precursors was envisioned 
to be readily feasible from the commercially available (+)-methyl-D-lactate (462) and cis-
2-buten-1,4-diol (463), respectively. The synthesis of the required precursors proceeded 
as shown in Scheme 56.  
 
                                                          
251 Nicolaou, K. C.; Duggan, M. E.; Ladduwahetty, T. Tetrahedron Lett. 1984, 25, 2069-2072. 
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Scheme 56. The Convergent Approach to (-)-Depudecin via Olefin Cross-Metathesis: Synthesis of the 
Precursors 
 
Thus, we begun with the synthesis of 460 starting from 462, which was 
transformed into epoxy alcohol 464 via a Sharpless asymmetric epoxidation (SAE),252 
from the corresponding allylic alcohol. 253  From epoxy alcohol 464, the synthesis 
continued by a two step sequence, involving oxidation and Wittig reaction, to obtain 460 
in a 50% overall yield. For the other key fragment 461, we planned to start from the 
known epoxy alcohol 465,254 obtained from cis-2-buten-1,4-diol (463) in 4 steps. From 
465, the construction of the second oxirane ring was achieved via the sulfonium salt 457 
by reacting the aldehyde derived from a Parikh-Doering oxidation of 465,255 to obtain 
diepoxy amide 466 in a remarkable 73% over two steps and complete stereoselectivity.250f 
Subsequent reduction of 466 with Red-Al, followed by a Wittig reaction, afforded alkene 
461 in 50% yield over 2 steps. Alternatively, diepoxy olefin 461 was also obtained via a 
Sharpless asymmetric epoxidation (SAE) of allylic alcohol 468, resulting from the 
reduction of the ,-unsaturated aldehyde 467, to provide diepoxy alcohol 469, which 
                                                          
252 Katsuki, T.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 5974-5976. 
253 Stivala, C. E.; Zakarian, A. Org. Lett. 2009, 11, 839-842. 
254 (a) Bhunia, N.; Das, B. Synthesis 2015, 47, 1499-1509. (b) Eppley, A. W.; Totah, N. I. Tetrahedron 1997, 53, 16545-16552. 
255 Parikh, J. R.; Doering, W. E. J. Am. Chem. Soc. 1967, 89, 5505-5507. 
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was transformed into the olefin 461 in 60% yield over two steps (Scheme 56). 
Comparatively, the overall yields for both synthetic routes are similar (36.5 and 31%, 
respectively), with the advantage of the sulfonium salt route being shorter than the SAE 
path. 
 
With both key fragments in hand, we investigated the viability of the cross-
metathesis reaction. For the assembly of both epoxy olefin units, a cross-metathesis of 
alkenes under the influence of the Hoveyda-Grubbs 2nd generation catalyst (6) (see 
Figure 1 in Chapter 1) was initially attempted.256 The result was the cross-metathesis 
product 470, however in a very low yield (15%), and with the homodimerization 
compound 471, as the major product (60%). Various reaction conditions and 
stochiometries of the involved alkenes were evaluated, including second cycles of 
metathesis, but these failed to improve the yield of the desired product in all cases. Despite 
the yield of this reaction being variable and generally modest, we were able to access 459 
by a selective deprotection step of the primary alcohol, which was accomplished in the 
presence of TsOH, resulting in the key triepoxy alcohol 459, in a 50% yield (Scheme 57).  
 
 
 
Scheme 57. The Convergent Approach to (-)-Depudecin via Olefin Cross-Metathesis: Completion 
 
Despite these discouraging results, we decided to press forward with the synthetic 
strategy by exploring the cross-metathesis from different precursors. To this aim, we 
reasoned that the placement of a more bulky protected group on the hydroxyl group of 
the lactate fragment could reduce the dimerization process thus favoring the cross-
                                                          
256 For related olefin cross-metathesis reactions involving epoxy olefins see: (a) Xiong, Z.; Corey, E. J. J. Am. Chem. Soc. 2000, 122, 
4831-4832. (b) McDonald, F. E.; Wei, X.  Org. Lett. 2002, 4, 593-595. 
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metathesis reaction. Therefore, we considered a second attempt with the TBDPS 
derivative 473, prepared in the same way as for 460 from the known epoxy alcohol 472.248 
On the other hand, we decided to use the unprotected diepoxy olefin 474, as the other 
metathesis precursor, with the purpose of obtaining a product more closer to depudecin, 
and without the requirement of additional selective deprotection steps. 
 
To our delight, the crucial cross-metathesis reaction between precursors 473 and 
474, in the presence of HG-II (6) catalyst in refluxing dichloromethane, proceeded 
smoothly to afford the coveted cross-metathesis product 455 in a reasonable and 
reproducible 50% yield, exclusively as the E-isomer, with no detection of the 
corresponding dimer of 473 (Scheme 57). With compound 455 in hand, we proceeded to 
completion of the synthesis of (-)-depudecin. To this end, we initially attempted a 
straightforward synthesis of depudecin derivative 477 from triepoxy alcohol 455 through 
a titanocene-assisted epoxide reductive opening.257 In this event, triepoxy alcohol 455 
was subjected to the combined action of Cp2TiCl2/Zn. Unfortunately, the result of this 
reaction was a complex mixture of decomposition products, with none of the desired 
protected depudecin 477 detected. Similarly discouraging was the attempt of preparing 
iodide 476 directly from 455 by treatment with iodine/Ph3P in the presence of imidazole, 
which also resulted in a complex mixture of degradation products. Given these 
unsuccessful results in our attempt to shorten the number of steps for the completion of 
the synthesis of depudecin, we returned to our synthetic sequence employed in our first 
total synthesis. Fortunately, we were able to improve the yields of the subsequent 
transformations after optimization of the reaction conditions. Thus, the alcohol 455 was 
converted into the corresponding alcohol 477, through tosylation and subsequent 
displacement of the intermediate tosylate 475 with NaI, to obtain iodide 476, which was 
then subjected to treatment with BuLi and no further purification. As a result, the resulting 
alcohol 477 was obtained in a 90% overall yield over three steps from 455. The final 
deprotection step provided natural depudecin (442), similarly in an improved yield (90% 
versus 86% in our first total synthesis) (Scheme 57). The physical and spectroscopic 
properties of synthetic 442 were in accordance to those reported for the natural 
compound.15,23 
 
In light of these encouraging results, we devised the possibility of a direct cross-
metathesis reaction between olefin 473 and diolefin 478 that would furnish the direct 
precursor 477 in a single step (Scheme 58). It is important to consider that this metathesis 
reaction is prone to give a mixture of different products, due to the presence of two 
terminal olefins in 478. However, a possible coordination involving the allylic alcohol 
and the catalyst could arrest the catalytic cycle at this terminal olefin to favor the 
metathesis in the desired direction.258 To this end, we proceeded with the synthesis of 
compound 478, whose synthesis was more difficult than initially expected, despite its 
                                                          
257 Yadav, J. S.; Shekharam, T.; Gadgil, V. R. J. Chem. Soc. Chem. Commun. 1990, 843-844. 
258 Despite a coordination between the allylic alcohol and the catalyst has been proposed to justify the failure of the cross-metathesis 
reaction (see Gurjar, M. K.; Yakambram, P. Tetrahedron Lett. 2001, 42, 3633-3636), there is some controversy at this respect because 
other authors have reported the opposite effect for this type of systems. In this case, see: Maishal, T. K.; Sinha-Mahapatra, D. K.; 
Paranjape, K.; Sarkar, A. Tetrahedron Lett. 2002, 43, 2263-2267.  
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small size. Initially, we attempted the direct reductive opening of diepoxy alcohol 474, 
again by the action of a titanocene reducing agent. As in the case for compound 455, the 
reaction was completely unsuccessful.  
 
 
 Scheme 58. A Direct Cross-Metathesis Approach to (-)-Depudecin: Synthesis of Precursor 478 
 
Thus, we proceeded with the preparation of iodide 479 by direct iodination of 474 
to obtain 479 albeit in a poor yield (25%), due to the formation of the diiodide 480 in a 
47% yield, as the main product. Despite this disappointing yield, iodide 479 was subjected 
to the action of BuLi to provide the targeted diolefin 478, in almost quantitative yield. 
Given the poor yield of the iodination step, we attempted the synthesis of this compound 
via a tosylate derivative. However, the result was similarly disappointing due to 
competing ring opening reactions of the oxirane with the halides present in the reaction 
mixture, during both the tosylation, as well as during the nucleophilic iodination step. The 
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low yielding conversion of diepoxy alcohol 474 to the target 478, through iodide 479, 
prompted us to investigate various other synthetic alternatives. Thus, in a second attempt, 
we prepared epoxy alcohol 482259 from 465, in order to construct the hydroxy allylic 
system via a vinyl magnesium bromide addition to the resulting aldehyde. However, after 
oxidation of 482, the reaction with the Grignad reagent failed to deliver the desired 
product (Scheme 58, part A).  
 
In a third alternative route, we chose to test the approach involving early stage 
installation of the allylic alcohol system, in order to construct at a later time, the terminal 
olefin adjacent to the epoxide. Thus, starting from 469, which was readily obtained from 
diepoxy amide 466, compound 484 was efficiently synthesized and then elaborated for 
the introduction of the other terminal olefin. In particular, after protection of 484 as a 
TBDPS ether, the selective deprotection of the primary alcohol of the resulting bis-silyl 
ether 485 afforded, unfortunately, compound 486 as a result of the opening of the resulting 
epoxy alcohol by another epoxy alcohol molecule. Finally, in a fourth attempt, from 
iodide 483, we decided to prepare olefin 479 prior to the reductive opening process. Thus, 
desilylation of iodide 483 was followed by an oxidation step of the resulting alcohol 487, 
followed by a Wittig reaction, to afford 479 in a modest 47% overall yield. From iodide 
479, the synthesis of 478 proceeded in a similar manner as described above (Scheme 58, 
part B). With the diolefin 478 in hand, the cross-metathesis reaction was attempted under 
the same conditions as previously described for the synthesis of 455. To our dismay, the 
reaction was completely unsuccessful, with the formation of a complex mixture of 
compounds and no detection of any cross-metathesis product, such as the desired 477. In 
a modified attempt to obtain additional direct precursor of depudecin, we tried the cross-
metathesis of olefins 473 and 479. Unfortunately, the result was similarly disappointing 
with no detection of the desired product 476 (Scheme 59). 
 
 
 
Scheme 59. Attempts of the Direct Cross-Metathesis Approach 
 
                                                          
259 Epoxy alcohol 482 has been described in the literature, being prepared by other methodology: Al-Rawi, S.; Hinderlich, S.; Reutter, 
W.; Giannis, A. Angew. Chem. Int. Ed. 2004, 43, 4366-4370. 
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3.4. Synthesis of Stereoisomeric Analogues of (-)-Depudecin and 
Homodepudecin 
Due to the previous unsatisfactory results, the direct approach to depudecin was 
abandoned in favor of the route described in Scheme 57. Having secured a cross-
metathesis strategy for this natural product, we decided to pursue depudecin analogues 
utilizing this methodology. Since the oxirane rings appears to be essential and required 
for the biological activity of depudecin, we decided to retain these functional groups 
within the designed analogues, considering therefore depudecin stereoisomers as the most 
interesting and promising compounds from a biological standpoint. In this sense, we 
considered as prime candidates the 10-epi analogue of depudecin, compound 498, and the 
enantiomer, (+)-depudecin (ent-442), which would be obtained from the readily available 
(-)-ethyl L-lactate (488) as a common starting material 
 
 
 
Scheme 60. Total Synthesis of 10-epi-depudecin (498) 
.  
In the case of the 10-epi analogue of depudecin, the synthesis of the precursor 493 
was carried out from (-)-ethyl L-lactate (488) in an efficient and stereoselective manners 
(54% yield over 7 steps) via a tandem Wittig-Martin260/SAE, according to the sequence 
depicted in Scheme 60.261  Then, following on our previously developed strategy to 
                                                          
260 Harcken, C.; Martin, S. F. Org. Lett. 2001, 3, 3591-3593. 
261 The synthesis of allylic alcohol 491 has been described in the literature according to a slightly modified protocol: Crimmins, M. 
T.; Jacobs, D. L. Org. Lett. 2009, 11, 2695–2698. 
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depudecin, we subjected 493 to a cross-metathesis reaction with 474 to afford product 
494 in a reasonable 55% yield. From 494, the completion of depudecin analogue 498 
followed the same synthetic sequence as for (-)-depudecin (442) through compounds 495-
497 and in similar yields (Scheme 60). 
 
Finally, for the synthesis of the enantiomer of depudecin, the compounds ent-473 
and ent-474 were prepared without any difficulty via Sharpless asymmetric epoxidation 
for ent-473, from the corresponding allylic alcohol 491, through epoxy alcohol ent-472,262 
and via chiral sulfonium salt ent-457 for ent-474. Both olefinic precursors were then 
joined via a cross-metathesis reaction to afford ent-455 in a 52% yield, which was taken 
on to (+)-depudecin (ent-442) as described above for the natural product (Scheme 61).  
 
 
 
Scheme 61. Synthesis of (+)-depudecin (ent-442) 
 
In addition, we extended this methodology to the synthesis of homodepudecin 
506, a new structural analogue of (-)-depudecin (Scheme 62). Its synthesis started from 
epoxy alcohol 500, previously obtained from (S)-Roche ester (499) in 5 steps,249c which 
was transformed into epoxy alkene 501 in 79% over 2 steps. The olefinic precursor 501 
was subjected to a cross-metathesis reaction with diepoxy alkene 474 to afford 502 in 
50% yield. The completion of the synthesis of homodepudecin 506 from 502 was 
achieved through the same synthetic sequence described above for (-)-depudecin (442). 
 
                                                          
262 Epoxy alcohol ent-472 was prepared via Sharpless asymmetric epoxidation from 491 in similar yield and stereoselectivity as 
described by us for the synthesis of 472 reported in reference 248. 
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Scheme 62. Synthesis of Homodepudecin (506) 
 
3.5. Synthesis of Cyclopropyl and Truncated Analogues of Depudecin 
Once we achieved the total syntheses of (-)-depudecin and its stereoisomeric 
analogues, (+)-depudecin and the epimer at C10 position, as well as homodepudecin, we 
focused on the extension of the previous synthetic strategy, based on the olefin cross-
metathesis reaction, for the generation of cyclopropyl depudecin analogues. The 
substitution of the oxirane rings by cyclopropyl rings could allow us to prove if the 
epoxides are essential upon the biological activity in an analogue that keeps the same 
spatial conformation that the natural product. In addition, we will be able to complete a 
structure-activity relationship (SAR) study in order to identify new leads based on 
depudecin.263 With this objective in mind, we envisioned the synthesis of the cyclopropyl 
depudecin analogues 507-509 as shown in Scheme 63, part A, via an olefin cross-
metathesis reaction of precursors 473/510 and 474/511. The installation of the 
cyclopropyl rings was planned through a Charette enantioselective cyclopropanation264 
mediated by the chiral dioxaborolane 512. Thus, we started with the preparation of the 
required cross-metathesis precursors. For the consecution of compound 511, allylic 
alcohol 513 was treated with Et2Zn, CH2I2 and borolane 512 (Charette’s reaction 
conditions) to obtain 514 in high yield (89%). Subsequent Parikh-Doering oxidation of 
the alcohol 514, followed by a Wittig reaction and TBS deprotection provided alkene 516 
in moderate yields. Thus, alcohol 516 was transformed into the corresponding aldehyde, 
which was subjected to a subsequent Wittig reaction to yield ,-unsaturated aldehyde 
517 in a disappointing 1% yield over two steps. This unforeseen difficulty found working 
                                                          
263 For a review about the benefits of the cyclopropyl moiety in preclinical/clinical drugs see: Talele, T. T. J. Med. Chem. 2016, 59, 
8712–8756. 
264 For a review of cyclopropanation strategies see: Ebner, C.; Carreira, E. M. Chem. Rev. 2017, 117, 11651–11679. 
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with these substrates was probably due to their highly volatile character that could explain 
the low yield obtained in the synthetic sequence (Scheme 63, part B). 
 
 
Scheme 63. Retrosynthetic Analysis of Cyclopropyl Depudecin Analogues (A) and Attempts towards the 
Synthesis of Precursor 511 (B) 
 
With the aim to obtain the cross-metathesis precursor 511 in an efficient manner, 
we decided to avoid the preparation of the problematic aldehyde 517. With this purpose, 
we started the synthesis from the known -unsaturated alcohol 518,265 which was 
subjected to a Charette cyclopropanation to yield cyclopropyl derivative 519 in an 
excellent 98% yield. Then, a two-steps sequence, involving an oxidation and a Wittig 
reaction, provided 520, which was treated with TBAF to obtain allylic alcohol 521. To 
our delight, a final Sharpless asymmetric epoxidation of 521 provided metathesis 
precursor 511 in a 71% yield. In parallel to these synthetic works, we carried out the 
preparation of the required second metathesis precursor, compound 510, from allylic 
alcohol 522 via a Charette cyclopropanation under the same reactions conditions showed 
above, followed by the introduction of the alkene moiety through an oxidation/Wittig 
reaction sequence without difficulty (Scheme 64, part A). For the assembly of 
cyclopropyl olefin units 511 and 510, a cross-metathesis of alkenes under the influence 
of the HG-II (6) catalyst in refluxing dichloromethane was attempted. However, despite 
the use of the same reactions conditions employed in the synthesis of (-)-depudecin and 
related analogues showed above, in this case the reaction met with failure, without 
detection of the expected metathesis product 525, instead starting material together with 
degradation products were obtained. Additional attempts that included more forcing 
conditions (toluene, 100 ºC) and other catalysts (Grubbs 1st and 2nd generations, Hoveyda-
Grubbs 1st generation) were thwarted, with similar results than before. These 
disappointing results pointed out that the cyclopropyl rings may play a key role in the 
                                                          
265 Dias, L. C.; de Luca, Jr. E. C. J. Org. Chem. 2017, 82, 3019–3045. 
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outcome of this reaction. In a last attempt, we carried out the cross-metathesis reaction of 
compounds 511 and 473 under the same reaction conditions for related cases. 
Unfortunately, the result of this reaction was similar as the previous case, with no 
detection of the desired compound 524 (Scheme 64, part B).  
 
 
Scheme 64. Towards the Synthesis of Cyclopropyl Depudecin Analogues via Cross-Metathesis Reaction: 
Synthesis of Precursors 510 and 511 (A) and Attempts of the Cross-Metathesis Reaction (B) 
 
Due to the failure of the cross-metathesis reaction, we decided to use a linear 
strategy in order to access these cyclopropyl analogues. This new synthetic plan was 
based on the retrosynthetic analysis depicted in Scheme 65, Part A. Thus, the key 
precursors 524-526 could be achieved via Sharpless asymmetric epoxidation (SAE) from 
the allylic alcohols 527-529. In turn, 527-529 could be obtained through a SAE or 
Charette cyclopropanation from -unsaturated alcohol 530 or 531 followed by a 
subsequent homologation reaction. With this synthetic plan in mind, we started with the 
synthesis of -unsaturated ester 533 from epoxy alcohol 473 through a two-steps 
sequence involving a Parikh-Doering oxidation followed by a Wittig reaction yielding 
533 in 47% over two steps. The next seemingly simple reduction of this ester however 
proved more problematic than expected. For example, treatment of 533 with DIBAL-H 
provided a complex mixture of degradation products, with no detection of the expected 
alcohol 530. Others attempts of reduction, for example the use of 1.0 equiv of DIBAL-H 
to obtain the corresponding aldehyde 534 met in failure with similar results as the 
previous case. We surmised that the reason of the failure of this reduction was due to the 
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epoxide opening as a side reaction.266 This hypothesis was confirmed when we carried 
out the reduction of the -unsaturated ester 535, under the same reaction conditions 
than for 533, yielding in this case the desired alcohol 531 in 77% yield. Unfortunately, 
on this occasion, the subsequent Sharpless asymmetric epoxidation (SAE) of 531 did not 
yield the expected epoxy alcohol 536, instead a complex mixture of degradation products 
were obtained. Several attempts of this reaction confirmed the difficulties of such SAE 
(Scheme 65, Part B). 
 
 
Scheme 65. Towards the Synthesis of Cyclopropyl Depudecin Analogues via Linear Strategy: 
Retrosynthetic Analysis (A) and Attemps of Synthesis of 530 and 531 (B) 
 
                                                          
266 For epoxide opening competing with ester reduction in a similar structural system see: Takamura, H.; Wada, H.; Lu, N.; Kadota, 
I. Org. Lett. 2011, 13, 3644–3647. 
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The failures of the cross-metathesis reaction in the convergent strategy as well as 
the reduction and SAE reactions in the linear strategy towards the cyclopropyl depudecin 
analogues forced us to abandon the preparation of these analogues in favour of truncated 
depudecin analogues. The design of these new analogues was based on structural 
modifications which would allow us to complete a preliminary structure-activity 
relationship (SAR) study for depudecin. With this aim, we decided to prepare truncated 
analogues which could retain or modify the hydroxyl groups, the oxirane rings and/or the 
olefins contained in the natural depudecin in order to test the effect of these functional 
groups upon the biological activity. Futhermore, the stereochemistry of the designed 
analogues could be modified or retained. The proposed truncated depudecin analogues 
537-544 are shown in Figure 8. 
 
 
Figure 8. Proposed Truncated Depudecin Analogues 
 
With this purpose, for the synthesis of analogue 537 we started from ,-
unsaturated ester 545 obtained from allylic alcohol 522 in two steps, which was 
transformed into -unsaturated alcohol 546  by use of DIBAL-H in a 90% yield. 
However, the next Sharpless asymmetric epoxidation (SAE) of 546 did not provided the 
corresponding epoxy alcohol 547. The result of this SAE was similarly than for 
previously shown allylic alcohol 531, instead a complex mixture of degradation products 
were obtained. In order to avoid this problematic SAE, we decided to carry out the 
epoxidation reaction by use of m-CPBA, obtaining epoxy alcohol 548 in a 88% yield as 
a 1:1 inseparable mixture of diastereoisomers. Then, 548 was transformed into ,-
unsaturated aldehyde 549 in a 63% yield over two steps and was followed by DIBAL-H 
reduction of 549 to provide allylic alcohol 550 in a 68% yield. In this case, the SAE 
provided diepoxy alcohol 551 (~72%, impurified with (+)-DET after column 
chromatography) which was undertaken under a similar three-steps sequence as in 
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previous cases (tosyl protection/iodation/reductive elimination) to obtain allylic alcohol 
554 in a 85% overall yield. To complete the synthesis, a final TBDPS deprotection step 
by treatment of 554 with TBAF afforded depudecin analogue 555 as a inseparable mixture 
of isomers (ratio 1:1). Despite this stereochemical outcome, this mixture of isomers could 
be of interest for the planned SAR study (Scheme 66). 
 
 
Scheme 66. Towards the Synthesis of Truncated Depudecin Analogues: Synthesis of Analogue 555 
 
The synthetic efforts towards analogue 539 started from epoxy alcohol 472 which 
was transformed into diepoxy alcohol 558 in four steps and good yields, as shown in steps 
a)-d) in Scheme 67. Then, diepoxy alcohol 558 was oxidized to the corresponding 
aldehyde and was followed by treatment with excess of Ph3P=CHCHO to afford the 
-unsaturated aldehyde 559 in a modest 31% yield over two steps. Once again, as 
in the previous case for the reduction of -unsaturated ester 533, the next seemingly 
simple reduction of aldehyde 559 was found to be very problematic. Thus, a first attempt 
of reduction of 559 with DIBAL-H afforded a complex mixture of degradation products, 
with no detection of alcohol 560. We surmised that the reason of the failure of this 
reduction was due to the competition of the 1,2- and 1,4-hydride additions. Others 
attempts of reduction, for example the selective 1,2-reduction under Luche’s conditions267 
or even the selective reduction by the action of 9-BBN268 met in failure with similar 
results as the previous case. Indeed, the same problem was found in the the preparation 
of depudecin analogue 543 during the reduction of the -unsaturated aldehyde 561 
                                                          
267 Luche, J. L. J. Am. Chem. Soc. 1978, 100, 2226-2227. 
268 Krishnamurthy, S.; Brown, H. C. J. Org. Chem. 1977, 42,1197-1201. 
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in order to obtain alcohol 562 (Scheme 67). Similarly disappointing were the synthetic 
attempts towards analogues 538, 3-epi-538, 542, 544 and 3-epi-544, for which the last 
TBDPS deprotection step did not afford the expected products, instead a complex mixture 
of unidentified degradation products were obtained in all cases (Scheme 68). 
 
 
Scheme 67. Towards the Synthesis of Truncated Depudecin Analogues: Attempts towards the Synthesis 
of Analogues 539 and 543 
 
In light of these discouraging results, we focused our efforts in the synthesis of 
the last two remaining proposed truncated depudecin analogues, compounds 540 and 541 
(Scheme 69). For this purpose, we decided to take advantage of the chemistry of 
sulfonium salts in order to avoid the problems that appeared in the reduction reactions of 
-unsaturated esters or aldehydes as well as in the SAE of -unsaturated 
alcohols, that proved more problematic than expected. Thus, we started from epoxy amide 
564 269  which was subjected to a two-steps sequence, involving a Red-Al reduction 
followed by a Wittig-Martin reaction, to yield -unsaturated ester 570 in 28% yield 
over two steps. Subsequent reduction of 570 by treatment with DIBAL-H afforded allylic 
alcohol 571, albeit in a poor yield (22%). To complete the synthesis, TBDPS group in 
                                                          
269 Epoxy amide 564 was prepared in exactly the same manner as its enantiomer reported in reference 248. 
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571 was removed by use of TBAF to obtain depudecin analogue 540 in a 40% yield 
(Scheme 69).  
 
 
Scheme 68. Towards the Synthesis of Truncated Depudecin Analogues: Attempts towards the Synthesis 
of Analogues 538, 3-epi-538, 542, 544 and 3-epi-544 
 
For the consecution of depudecin analogue 541, we started from allylic alcohol 
ent-522, which was subjected to a Swern oxidation to obtain the corresponding aldehyde. 
The crude obtained aldehyde was then reacted with the sulfonium salt ent-457 to obtain 
epoxy amide 572 in 57% over two steps. Epoxy amide 572 was treated with Red-Al and 
the resulting epoxy aldehyde reacted with sulfonium salt ent-457 to obtain diepoxy amide 
573 in a 38% over two steps. Then, treatment of diepoxy amide 573 with Red-Al followed 
by NaBH4 afforded the corresponding diepoxy alcohol which was then tosylated to obtain 
574 in 27% over three steps from 573. Subsequent iodide displacement of the tosyl group 
in 574 was followed by a reductive epoxide opening process by the action of BuLi to 
provide 576 in 90% yield. Finally, a deprotection step of the TBDPS group in 576 
afforded depudecin analogue 541 in 20% yield (Scheme 69). 
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Scheme 69. Towards the Synthesis of Truncated Depudecin Analogues: Synthesis of Analogues 540 and 
541 
 
3.6. Biological Evaluation of (-)-Depudecin and Analogues 
At this stage of the work, where we were able to complete the synthesis of natural 
depudecin as well as various analogues, we decided to stop the synthetic work and explore 
the biological activities of the synthesized compounds. In collaboration with the group of 
Prof. Ana R. Quesada from the Molecular Biology and Biochemistry Department of 
Málaga University, we carried out preliminary biological evaluations based on the 
measure of the antitumoral properties of the selected compounds against a panel of 
various tumor cell lines. The selected compounds for this study were the (-)-depudecin 
(442), its enantiomer, (+)-depudecin (ent-442), the 10-epi-depudecin (498) and the 
truncated analogues 540, 541 and 555 (Figure 9). In a preliminary evaluation, we 
examined the cytotoxicity activity of such compounds using four different cancer cell 
lines (HL-60, MDA-MB-231, HT-1080 and U87MG), as well as a primary culture of non 
transformed bovine aorta endothelial (BAEC) cells to test antiangiogenic effect270 (Table 
1).  
                                                          
270 Cárdenas, C; Quesada, A. R.; Medina, M. A. Cell. Mol. Life Sci. 2006, 63, 30833089. 
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Figure 9. Synthesized (-)-Depudecin and Analogues Submitted to Biological Evaluation 
 
Table 1. In vitro Antitumor Activities of Depudecin and Analogues against Various Tumor Cell Lines and 
BAEC (IC50, M)a 
Compound BAECb HL60c MDA-MB-231d HT-1080e U87MGf 
(-)-depudecin (442) 24,1  3,5 28,7  6,4 45  11,8 44,9  3,9 85,6  0.6 
(+)-depudecin (ent-442) > 100 78,6  6,7 > 100 > 100 > 100 
10-epi-depudecin (498) 37,5  7,5 31,1  1,7 53,8  6,3 43,3  3,1 > 100 
540 52,1  5,0  46,8  6,2 61,1  3,2 50,5  0,7 84,6  6,9 
541 38,0  7,5 34,3  9,6 55,6  1,4 42,63  2,9 > 100 
555 > 100  39,8  6,7  > 100 > 100 > 100 
[a] In vitro cytotoxicities were determined according to the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye 
reduction assay. The IC50 values were obtained from semilogarithmic dose-response plots as the concentration of compound yielding 
a 50% of cell survival. [b] BAEC: Non transformed bovine aortic endothelial cells. [c] HL60: Human promyelocytic leukemia. [d] 
MDA-MB-231: Human breast adenocarcinoma. [e] HT1080: Human fibrosarcoma. [f] U87MG: Gioblastoma.  
 
The results of these biological evaluations clearly revealed that (-)-depudecin 
(442) displayed the best biological values for the series in the moderate M range against 
all the tumoral cell lines. In addition, (-)-depudecin (442) was also cytotoxic against the 
endothelial cells line (BAEC), which may indicate a putative antiangiogenic effect of this 
compound.270 The analogues 10-epi-depudecin (498), 540 and 541 showed a close IC50 
value compared with (-)-depudecin. In contrast, the enantiomer of depudecin (ent-442) 
and analogue 555 were practically devoid of antitumor activity, except for the HL-60 cell 
line in the case of 540, but moderately.  
 
From these results it is important to highlight the importance of the 
stereochemistry upon the biological activity, as concluded when biological activities of 
(+)-depudecin (ent-442) and (-)-depudecin (442) are compared. However, by considering 
the activities of other analogues, especially compounds 540 and 541, it is difficult to 
conclude that the stereochemistry is the only determinant for the observed biological 
activities due to the antitumor activities are not significantly different except for (+)-
depudecin and compound 555. We could conclude safely that the C-10 stereochemistry 
of (-)-depudecin is not important by comparing the activity with that of compound 498. 
On the other hand, the similar IC50 values of analogue 541 compared with (-)-depudecin 
(442) in almost all the cancer cell lines tested, including BAEC, clearly shows that the 
simultaneous presence of the two epoxide groups is not essential upon the biological 
activity, due to the removal of a epoxide group in analogue 541 did not cause the loss of 
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the antitumoral activity. Finally, when (+)-depudecin (ent-442) is compared with 
analogue 540, we can concluded that the terminal allylic system is not key upon the 
biological activity since the isomer 540 showed best values of inhibition for all the cancer 
cell lines tested. 
 
3.7. Summary 
In conclusion, we have established a new synthesis of (-)-depudecin (442), which 
greatly improves upon our previous linear synthesis. Comparatively, whereas the first 
total synthesis, reported by Schreiber, required 23 linear steps from (-)-diethyl D-tartrate 
(451), with an overall yield of 0.7%, our first linear synthesis from (+)-methyl D-lactate 
(462) was achieved in 17 steps in a 19% overall yield (Scheme 70). As continuation of 
our previous work, we have developed a second generation synthetic route to depudecin 
utilizing an olefin cross-metathesis reaction as the key step, which was successfully 
achieved in a convergent manner to provide (-)-depudecin (442) in only 12 steps and 26% 
overall yield from 462. In addition, the synthetic route was amenable to stereochemical 
and functional modifications, allowing the preparation of two stereoisomers of (-)-
depudecin, the 10-epi-depudecin (498) and its enantiomer (ent-442), as well as 
homodepudecin (506), which represent unique analogues that will further assist us to 
evaluate the influence of the stereochemistry and functional modifications upon 
biological activity.  
 
 
Scheme 70. Summary of the Syntheses of Depudecin and Analogues  
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Futhermore, we have complemented the set of analogues with the preparation of 
truncated analogues 540, 541 and 555. The synthesized products (-)-depudecin, (+)-
depudecin, 10-epi-depudecin and the truncated analogues were biologically evaluated 
against several tumor cell lines, including endothelial cells and the results led us to 
complete a preliminary structure-activity relationship (SAR) study for this intriguing 
natural product concluding that: a) the C-10 stereochemistry of the product is not essential 
upon the biological activity; b) the presence of at least one of the epoxide groups is key 
upon the biological activity, but it is not necessary the simultaneous presence of both 
epoxides; and c) the terminal allylic alcohol system is not essential, and it can be 
substitued by its isomer (Figure 10). 
 
 
Figure 10. Preliminary Structure-Activity Relationship (SAR) study of Depudecin  
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† Part of this chapter has been published as the following journal papers: (a) Cheng-Sánchez, I.; García-Ruiz, C.; Sarabia, F. 
Tetrahedron Lett. 2016, 57, 3392-3395. (b) Cheng-Sánchez, I.; Carrillo, P.; Sánchez-Ruiz, A.; Martínez-Poveda, B.; Quesada, A. 
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Cheng-Sánchez, I.; Guerra, J.; Tobia, C.; López-Romero, J. M.; Sarabia, F.; Medina, M. A.; Quesada, A. R. Mar. Drugs 2019,17, 
228 (1-18). 
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4.1. Isolation, Structure and Biology of the Solomonamides 
The discovery of new natural products offers significant opportunities for the 
identification and development of new leads and scaffolds in medicinal chemistry, as well 
as a great deal of fascination for organic chemists by virtue of their structural diversity 
and challenging molecular frameworks that many of them exhibit.271 In particular, the 
marine world represents a uniquely rich source of new bioactive metabolites with 
unprecedented structures, fascinating biological profiles and valuable therapeutic 
potential272. The increasing interest for compounds of marine origin in biomedical and 
pharmaceutical research derives from the potential clinical applications exhibited by 
them, according to their antitumoral, antiinflammatory, antiangiogenic and/or 
antimicrobial properties reported.273 
 
Marine organisms and more specific sponges, which are considered the largest 
remaining source of undiscovered natural products, produce a variety of unique chemical 
classes with wide biological profiles due to the conditions that differ significantly from 
terrestrial environments, which include aggressive, exigent and competitive surroundings 
that lead to the production of potent active molecules.274 Among the myriad of sources 
for marine natural products, particularly prolific is the marine sponge Theonella swinhoei, 
which has proven to be an impressive source of secondary metabolites,275 providing at 
least nine different classes of natural products. In addition to the very well-known and 
important polyketide swinholide, discovered 30 years ago,276  the Theonella genus is 
notable for providing a wide range of bioactive peptidic-type natural products, including 
acyclic peptides (polytheonamides and koshikamides), cyclic peptides (kombamide, 
orbiculamide, barangamide, cupolamide, perthamides, etc..), large-ring bicyclic peptides 
such as the theonellamides, depsipeptides (koshikamides, papuamides, nagahamide or 
theopapuamide) and glycopeptides. 277  As further proof of the value of the genus 
Theonella as an outstanding and bountiful source of new peptides, Zampella et al. recently 
isolated two new cyclopeptides termed the solomonamides A (577) and B (578), from a 
Solomon islands collection. These cyclopeptides possessed unique molecular structures 
and potent in vivo anti-inflammatory activities.278 An exhaustive spectroscopic analysis 
of both compounds facilitated the elucidation of their intricate cyclic structures, revealing 
                                                          
271 (a) Samuelsson, G.; Lars, B. Drugs of Natural Origin; Swedish Pharmaceutical Press: Stockholm, 2017, 7th edition. (b) Nicolaou, 
K. C.; Chen, J. S.; Dalby, S. M. Bioorg. Med. Chem. 2009, 17, 22902303. (c) Grabley, S.; Thiericke, R. Drug Discovery from Nature; 
Springer-Verlag: Berlin, 2000. 
272 (a) Blunt, J. W.; Copp, B. R.; Keyzers, R. A.; Munro, M. H. G.; Prinsep, M. R. Nat. Prod. Rep. 2017, 34, 235294 and references 
therein. 
273 (a) Ercolano, G., De Cicco, P., Ianaro, A. Mar. Drugs 2019, 17, 31 (1-31). (b) Zhang, H., Dong, M., Chen, J., Wang, H., Tenney, 
K., Crews, P. Mar. Drugs 2017, 15, 351 (1-29). (c) Martínez-Poveda, B., Quesada, A.R., Medina, M.Á. Mar. Drugs 2017, 15, 325 (1-
13). (d) Calcabrini, C.; Catanzaro, E.; Bishayee, A.; Turrini, E.; Fimognari, C. Mar. Drugs. 2017, 15, 310 (1-34). (e) Ruocco ,N., 
Costantini, S., Palumbo, F., Costantini, M. Mar Drugs 2017, 15, 173 (1-16). (f) Máximo, P., Ferreira, L.M., Branco, P., Lima, P., 
Lourenço, A. Mar. Drugs 2016, 14, 139 (1-71). (g) García-Vilas, J.A., Martínez-Poveda, B., Quesada, A.R., Medina, M.Á. Mar. 
Drugs 2016, 14, 1 (1-12). 
274 Gogineni, V.; Hamann, M. T.; Biochim. Biophys. Acta 2018, 1862, 81196. 
275 Wegerski, C. J.; Hammond, J.; Tenney, K.; Matainaho, T.; Crews, P. J. Nat. Prod. 2007, 70, 8994. 
276 Carmely, S.; Kashman, Y. Tetrahedron Lett. 1985, 26, 511514. 
277 Festa, C.; De Marino, S.; Sepe, V.; Monti, M. C.; Luciano, P.; D’Auria, M. V.; Débitus, C.; Bucci, M.; Vellecco, V.; Zampella, A. 
Tetrahedron 2009, 65, 1042410429 and references therein. 
278 Festa, C.; De Marino, S.; Sepe, V.; D’Auria, M. V.; Bifulco, G.; Débitus, C.; Bucci, M.; Vellecco, V.; Zampella, A. Org. Lett. 
2011, 13, 1532-1535. 
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the presence of three conventional amino acids (D-Ala, Gly and L-Ser) and an 
unprecedented 4-amino(2’-amino-4’-hydroxyphenyl)-3,5-dihydroxy-2-methyl-6-
oxohexanoic acid (ADMOA) and the corresponding 5-deoxy derivative (AHMOA) for 
solomonamides A and B, respectively. The absolute configurations were tentatively 
established by a combination of spectroscopic and theoretical methods, which resulted in 
the proposal of the depicted absolute configurations as the most likely (Figure 11). Not 
surprisingly, these interesting and novel cyclopeptides were found to possess interesting 
biological properties. Solomonamide A (577) displayed potent anti-inflammatory activity 
in vivo, causing a significant 60% reduction of inflammation at a very low dose (100 
μg/Kg). Unfortunately, the extreme scarcity of the solomonamides has precluded a 
thorough biological evaluation. In fact, the anti-inflammatory activity of solomonamide 
B (578) was not evaluated due to limited amounts. In this regard, the chemical synthesis 
of these intriguing natural products could represent the solution for this ‘problem of 
supply’.279 
 
 
Figure 11. Initially Proposed Molecular Structures of Solomonamides A and B 
 
4.2. Chemistry of the Solomonamides 
The extreme scarcity of the isolated solomonamides from the natural sources is a 
drawback for further pharmacological assays. This difficulty to access large amounts of 
these compounds from their natural sources makes quite difficult to gain insight into their 
biological profiles and mechanism of action and justifies the chemical synthesis of these 
natural products. Thus, the chemical synthesis of these unexplored cyclopeptides could 
represent a solution to provide enough amounts of material to carry out extensive 
biological studies and confirm their initially proposed structures. As a consequence, by 
the time we initiated this research project, the solomonamides had been elicited interest 
with the publication of some synthetic approaches,280 including the synthesis of a deoxy 
analogue of solomonamide B.281 In parallel with the development of our research work, 
two new synthetic approaches were published,282 culminating with the total synthesis of 
                                                          
279 For a review about the termed ‘problem of supply’ that has hampered the development of natural-products derived drugs see: 
Newman, D.J. Pharmacol. Ther. 2016, 162, 19. 
280 (a) Kashinath, K.; Vasudevan, N.; Reddy, D. S. Org. Lett. 2012, 14, 62226225. (b) Kavitha, N.; Kumar, V. P.; Chandrasekhar, S. 
Tetrahedron Lett. 2013, 54, 21282130.  (c) Reddy, D. S.; Kormirishetty, K.; Natrajan, V. WO Patent 2014083578 A1, Nov 27, 2013. 
281 Vasudevan, N.; Kashinath, K.; Reddy, D. S. Org. Lett. 2014, 16, 61486151. 
282 (a) Kashinath, K.; Dhara, S.; Reddy, D. S. Org. Lett. 2015, 17, 20902093. (b) Kavitha, N.; Chandrasekhar, S. Org. Biomol. Chem. 
2015, 13, 62426248. 
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solomonamide B (578),283 and later solomonamide A (577),284 by the Reddy group. Very 
recently, the same group has reported the preparation of some stereoisomers of 
solomonamide macrocycles, by changing the stereochemical pattern of the non-peptide 
fragment AHMOA.285 More importantly, the total syntheses of solomonamides A and B 
led to the revision of the initially proposed structures for 577 and 578, with the correction 
of the configurations at C-3 and at C-4 positions to the (3S, 4S)-isomer (compound 580) 
instead of the proposed (3R, 4R) for solomonamide B (578) and the correction of the 
configuration at C-3, C-4 and C-5 to the (3S, 4S, 5S)-isomer (compound 579) instead of 
the proposed (3R, 4R, 5R) for solomonamide A (577) (Figure 12). 
 
 
 
Figure 12. Revised Structures of Solomonamides A and B (Reddy et al. 2016 and 2018)283, 284 
 
From the retrosynthetic point of view, the total syntheses of solomonamides 
accomplished by Reddy et al. were based on a key intramolecular Heck reaction to obtain 
the macrocyclic core of the solomonamides, represented by compound 581 in Scheme 
71. Thus, the synthesis started from D-methionine aldehyde 583, previously prepared 
from D-methionine 582, which was transformed into acid 584 in 5 steps, involving a 
Brown’s crotylation as the key reaction to generate the required syn-1,2-amino alcohol 
system. Then, acid 584 was coupled with the amine derived from peptide 585 to obtain 
iodo derivative 586 in a 73% yield over two steps, followed by the acetal deprotection to 
afford 587 in a modest 40% yield. The key intramolecular Heck reaction was then carried 
out by the action of Pd(OAc)2 in presence of triethylamine in a high diluted acetonitrile 
solution at 75 ºC to obtain compound 581 in a 53% yield. From macrocyclic 581, the 
synthesis of 578 was achieved in five additional steps in a 29% overall yield, involving a 
Boc deprotection, a peptide coupling with serine derivative 588, a key regioselective 
Wacker oxidation to install the ketone group and a final removal of protecting groups by 
hydrogenolysis and TFA (Scheme 71). 
                                                          
283 Kashinath, K.; Jachak, G. R.; Athawale, P. R.; Marelli, U. K.; Gonnade, R. G.; Reddy, D. S. Org. Lett. 2016, 18, 31783181. 
284 Jachak, G.; Athawale, P. R.; Agarwal, H.; Barthwal, M. K.; Lauro, G.; Bifulco, G.; Reddy, D. S. Org. Biomol. Chem. 2018, 16, 
91389142. 
285  Jachak, G. R.; Athawale, P. R.; Choudhury, R.; Kashinath, K.; Reddy, D. S. Chem. Asian J. 2019, just accepted. DOI: 
10.1002/asia.201901075 
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Scheme 71. Total Synthesis of the Initially Proposed Structure of Solomonamide B (578) via 
Intramolecular Heck Reaction (Reddy et al. 2016)283 
 
From the retrosynthetic point of view, the total syntheses of solomonamides 
accomplished by Reddy et al. were based on a key intramolecular Heck reaction to obtain 
the macrocyclic core of the solomonamides, represented by compound 581 in Scheme 
71. Thus, the synthesis started from D-methionine aldehyde 583, previously prepared 
from D-methionine 582, which was transformed into acid 584 in 5 steps, involving a 
Brown’s crotylation as the key reaction to generate the required syn-1,2-amino alcohol 
system. Then, acid 584 was coupled with the amine derived from peptide 585 to obtain 
iodo derivative 586 in a 73% yield over two steps, followed by the acetal deprotection to 
afford 587 in a modest 40% yield. The key intramolecular Heck reaction was then carried 
out by the action of Pd(OAc)2 in presence of triethylamine in a high diluted acetonitrile 
solution at 75 ºC to obtain compound 581 in a 53% yield. From macrocyclic 581, the 
synthesis of 578 was achieved in five additional steps in a 29% overall yield, involving a 
Boc deprotection, a peptide coupling with serine derivative 588, a key regioselective 
Wacker oxidation to install the ketone group and a final removal of protecting groups by 
hydrogenolysis and TFA (Scheme 71). However, the spectroscopic data for synthetic 
solomonamide B did not match with those reported for the natural compound by Zampella 
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et al.278 Considering that the relative and absolute configurations of the three stereocenters 
contained in the polyketide fragment were established through computational methods, 
Reddy et al. planned to achieve the synthesis of the (3S, 4S)-isomer instead of the initially 
proposed (3R, 4R)-isomer. With this purpose, the authors started from the enantiomer of 
aldehyde ent-583 which was subjected to a Evans aldol reaction to construct the syn-1,2-
amino alcohol system which contains the (3S, 4S)-stereochemistry upon the ADMOA 
fragment. Then, the same synthetic sequence described above was implemented to 
complete the synthesis of targeted compound 580 in a 0.4% over 15 steps from aldehyde 
ent-583. In this case, the spectroscopic data of synthetic 580 matched with those reported 
for the natural solomonamide B, therefore confirming the revised structure of 
solomonamide B (Scheme 72). 
 
 
Scheme 72. Total Synthesis of Revised Structure of Solomonamide B (580) via Intramolecular Heck 
Reaction (Reddy et al. 2016)283 
 
As the structure of solomonamide B was derived from solomonamide A, the 
structure of solomonamide A also needed revision. Due to solomonamide A was 
biogenetically derived from solomonamide B, the three stereocenters (2S, 3S and 4S) 
present in solomonamide B should be contained in solomonamide A, thus leaving one 
stereocenter at the C5 position of the ADMOA fragment whose absolute stereochemistry 
needed to be fixed, initially established as 5R. With this aim, the authors carried out the 
synthesis of the (3S, 4S, 5S)-isomer instead of the initially proposed (3R, 4R, 5R)-
configuration. Thus, macrocyclic compound 589, previously obtained through the 
synthesis of the revised solomonamide B was subjected to an Upjohn dihydroxylation to 
obtain triol 590 in a 74% yield as a single diastereoisomer. The reason for which this last 
reaction proceeded in a stereoselective manner could be explained by the rigid 
conformation of the macrocycle through intramolecular H-bonding. Subsequent selective 
bencylic oxidation by the use of Dess-Martin periodinane (DMP) afforded the -hydroxy 
ketone 591 in a 67% yield. From this ketone 591, compound 579 was obtained in four 
additional steps, and its spectroscopic data were matching with those reported for the 
natural solomonamide A. With the aim to confirm the absolute C5-configuration 
generated during the Upjohn dihydroxylation, the authors employed a QM/NMR 
approach based on comparison of the experimental 13C NMR chemical shift data and the 
predicted values calculated at the density functional theory (DFT) level for all the possible 
theoretical diastereoisomers, concluding the assignment of the C5-configuration as 5S 
(Scheme 73). 
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Scheme 73. Total Synthesis of the Revised Structure of the Solomonamide A (579) (Reddy et al. 2018)284
 
 
4.3. An Olefin Metathesis Approach towards the Solomonamides 
Our ongoing interest in the discovery and development of new potential leads 
based on cyclopeptidic- and cyclodepsipeptidaic-type compounds,286, 250b prompted us to 
initiate a research program directed toward the total synthesis of this novel and 
unexplored class of cyclopeptides. With the aim of establishing a flexible and divergent 
synthetic strategy capable of providing not only the natural products, but also provide an 
entry into a plethora of analogues for biological studies, we sought to explore the ring-
closing metathesis (RCM) reaction as the key step for construction of the macrocycle. 
This cyclisation step would be followed by an oxidation phase, which would incorporate 
the functional groups needed to reach the final oxidation stage found in the natural 
products. From a strategic perspective, we considered that the construction of the 
macrocyclic core at the 4,5-bond would be capable of providing rapid access not only to 
the final products, but also to analogues from late stage intermediates, allowing for the 
facile entry into numerous scaffolds. Furthermore, it is worthy to note that this synthetic 
strategy utilizes simple starting materials, avoiding the construction of the complex 
ADMOA residue, which can be constructed in the later stages of the synthesis through an 
epoxidation of the olefins 596-599, followed by an oxirane-ring opening process to 
introduce the amine group. Accordingly, as detailed in Scheme 74, our delineated strategy 
in retrosynthetic terms begins with the straightforward amide disconnection of the L-
                                                          
286 (a) Sarabia, F.; Chammaa, S.; Sánchez-Ruiz, A.; Martín-Ortiz, L.; López-Herrera, F. J. Curr. Med. Chem. 2004, 11, 13091332. 
(b) Sarabia, F.; Chammaa, S. J. Org. Chem. 2005, 70, 78467857. (c) Sarabia, F.; Chammaa, S.; García-Castro, M.  J. Org. Chem. 
2005, 70, 78587865. (d) Goh, S.; Hohmeier, A.; Stone, T. C.; Offord, V.; Sarabia, F.; García-Ruiz, C.; Good, L. Appl. Environ. 
Microbiol. 2015, 81, 56505659. 
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serine residue, followed by the removal of the functional groups, which would be 
introduced by means of oxidative manipulations (oxidation phase) of the resulting 
metathesis products. In this way, the synthetic strategy would render the corresponding 
macrocyclic alkenes represented by the cis-4,5 derivatives 596-599, which would possess 
or not various functionalities at the benzylic position. All these macrocyclic compounds, 
in turn, could be obtained from the corresponding acyclic precursors 600-603 via a ring-
closing metathesis process (Scheme 74). In addition, during the execution of this 
synthetic work, Reddy et al. published the total synthesis of solomonamide B,283 based 
on an intramolecular Heck reaction as described above in Scheme 71, and led to the 
revision of the initially proposed structure for 578. As the present synthetic studies were 
initiated prior to the Reddy publication, we targeted the initially proposed structures for 
the solomonamides. 
 
 
Scheme 74. Retrosynthetic Analysis for the Solomonamides 
 
4.3.1. Ring-Closing Metathesis at the C4-C5 Bond 
Encouraged by the appealing features of this synthetic strategy, as mentioned 
above, we initiated the synthetic route. Our initial forays toward the solomonamide 
structures were conducted to demonstrate the viability of the olefin metathesis approach, 
based on the disconnection of the 4,5-positions bond, using the model compounds 614 
and 615 (Scheme 75). To this end, the readily accessible dipeptides 612 and 613 were 
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prepared from 2-bromo aniline 604 and the iodonitrobenzene derivative 605, 287 
respectively, according to the synthetic sequence depicted in Scheme 75, entailing a Stille 
reaction for compound 606, and a sequential Stille reaction/reduction, for compound 607. 
Couplings of the resulting anilines 606 and 607 with dipeptide 608283 furnished the 
corresponding dipeptides 609 and 610, which, after Boc deprotection, were coupled with 
commercial acid 611 to yield the targeted ring-closing metathesis precursors 612 and 613. 
Thus, 612 and 613 were treated with 10 mol% of Hoveyda-Grubbs 2nd generation (HG-
II) catalyst in refluxing dichloromethane in the presence of p-benzoquinone288 to obtain 
the expected macrocycles 614 and 615 in excellent 75 and 79% yields, respectively, as 
the sole products of the reaction. The newly formed double bonds (Δ4,5) of 614 and 615 
were determined in both cases to be exclusively in the E-configuration, as evidenced by 
a coupling constant J of 15.9 Hz (Scheme 75). 
 
Scheme 75. Towards the Total Synthesis of Solomonamides: RCM of Model Compounds 614 and 615 
 
Despite this stereochemical outcome, and with the possibility in mind that the 
structural pattern of the acyclic precursor could influence the double bond geometry and 
switch in favour to the desired Z-isomer,289 we proceeded to extend this reaction to the 
desired system. To this aim, olefinic acid 622 was previously prepared from the described 
epoxy alcohol ent-500,249c according to the methodology reported in the literature for 
                                                          
287 Jin-Gim, H.; Li, H.; Lee, E.; Ryu, J.-H.; Jeon, R. Bioorg. Med. Chem. Lett. 2013, 23, 513517. 
288 Hong, S. H.; Sanders, D. P.; Lee, C. W.; Grubbs, R. H. J. Am. Chem. Soc. 2005, 127, 1716017161. 
289 For representative examples of the influence of the structural pattern in the stereochemistry of the ring-closing metathesis, see: (a) 
Nicolaou, K. C.; He, Y.; Vourloumis, D.; Vallberg, H.; Roschangar, F.; Sarabia, F.; Ninkovic, S.; Yang, Z.; Trujillo, J. I. J. Am. Chem. 
Soc. 1997, 119, 79607973. (b) Vassilikogiannakis, G.; Margaros, I.; Tofi, M. Org. Lett. 2004, 6, 205208. (c) Nicolaou, K. C.; 
Montagnon, T.; Vassilikogiannakis, G.; Mathison, C. J. N. J. Am. Chem. Soc. 2005, 127, 88728888. 
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related compounds.290 Thus, after the transformation of ent-500 into the iodide 616, a 
reductive opening process was accomplished by treatment with Zn/NaI to obtain allylic 
alcohol 617. After treatment of 617 with TBAF, all attempts to directly oxidize the 
primary alcohol to the corresponding acid of the resulting diol 618 met with no success. 
These disappointing results forced us to manipulate the primary and secondary hydroxyl 
groups of 618, via selective protection and deprotection steps, to obtain alcohol 621 
without difficulty. Olefinic alcohol 621 was then oxidized in two steps, Dess-Martin 
periodinane (DMP) oxidation followed by final treatment of the aldehyde with sodium 
chlorite under Pinnick conditions to furnish acid 622 in good overall yield (Scheme 76).  
 
 
Scheme 76. Synthesis of the Olefinic Acid 622 
 
The assembly of compounds 610 and 622 was achieved in a similar manner as 
described before for 612, providing 601 in a 74% overall yield. Upon exposure of 601 to 
HG-II catalyst, the expected macrocycle 597 was not obtained, instead recovering starting 
material, together with a significant degree of decomposition. Attributing steric factors to 
this failed cyclisation, the silyl protecting group was removed by treatment of 601 with 
HFpyr to give allylic alcohol 600. Various reports in the literature, describing metathesis 
reactions involving allylic alcohols, indicate that these structural systems may favour the 
closing process,291 although other studies point out that these systems result in detrimental 
effects for the metathesis reaction.292  Nonetheless, when allylic alcohol 600 was treated 
with the HG-II catalyst in dichloromethane at 40 ºC in the presence of p-benzoquinone, 
the E-olefin 623 was obtained exclusively in a gratifying 71% yield, with no formation 
of the required Z-isomer 596, as revealed by the 1H NMR spectra of the crude reaction 
mixture (Scheme 77).  
                                                          
290 Reddy, S. V.; Kumar, K. P.; Ramakrishna, K. V. S.; Sharma, G. V. M.  Tetrahedron Lett. 2015, 56, 2018-2022. 
291 (a) Hoye, T. R.; Zhao, H. Org. Lett. 1999, 1, 11231125. (b) Maishal, T. K.; Sinha-Mahapatra, D. K.; Paranjape, K.; Sarkar, A. 
Tetrahedron Lett. 2002, 43, 22632267. (c) Imahori, T.; Ojima, H.; Tateyama, H.; Mihara, Y.; Takahata, H. Tetrahedron Lett. 2008, 
49, 265268. (d) Imahori, T.; Ojima, H.; Yoshimura, Y.; Takahata, H. Chem. Eur. J. 2008, 14, 1076210771. 
292 (a) Cheng-Sánchez, I.; García-Ruiz, C.; Guerrero-Vásquez, G. A.; Sarabia, F. J. Org. Chem. 2017, 82, 47444757. (b) Paquette, 
L. A.; Efremov, I. J. Am. Chem. Soc. 2001, 123, 44924501. (c) Gurjar, M. K.; Yakambram, P. Tetrahedron Lett. 2001, 42, 
36333636. 
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Scheme 77. Towards the Total Synthesis of Solomonamides: Synthesis of Macrocycle 623 
 
In parallel to these preliminary works, we accomplished related synthetic studies 
extended to more functionalised precursors that would provide for a shortened path 
towards the completion of the synthesis of these natural substances. In this direction, we 
pursued the preparation of the macrocycles 598 and 599 (See Scheme 74) as potential 
advanced precursors. In order to rapidly inspect the validity of this approach, we initially 
worked with a model system represented by the deoxy aromatic derivatives. Thus, the 
readily accessible allylic alcohol 624293 was transformed into the aniline 625 by treatment 
with Zn/NH4Cl. Following the delineated synthesis for previous compounds, 625 was 
coupled with dipeptide 608 to yield the coupled product 626 as a 1:1 mixture of 
diastereoisomers. The assembly of 626 with acid 611 was preceded by Boc deprotection 
under conventional acidic conditions, followed by amide coupling assisted by HATU. 
Disappointingly, the expected coupling product 627 was not detected, instead the 
derivative 628 was obtained as a result of a cationic rearrangement of the labile allylic 
alcohol 626, which probably occurred during the Boc deprotection step under the acidic 
conditions used (Scheme 78). Different attempts for removal the Boc group under mild 
acidic (TMSCl, TMSOTf, Sn(OTf)2, TiCl4, SnCl4), neutral (I2, TBAF, H2O at reflux) or 
basic conditions (Na2CO3, K3PO4, NaO
tBu) 294  resulted similarly unfruitful with the 
formation of rearranged byproducts, recovery of starting material or degradation, 
respectively. As a consequence of these results, we considered a direct coupling between 
aniline 625 and the peptidic fragment 631, which was efficiently prepared by utilising 
solid phase peptide synthesis (SPPS) as described in Scheme 78. Thus, the coupling of 
aniline 625 and acid 631 provided the desired diolefinic precursor 627 in a 77% yield. 
Finally, the ring-closing metathesis of 627 under the same conditions as in previous cases, 
                                                          
293 Carrión, M. D.; Chayah, M.; Entrena, A.; López, A.; Gallo, M. A.; Acuña-Castroviejo, D.; Camacho, M. E. Bioorg. Med. Chem. 
2013, 21, 41324142. 
294 For a comprehensive revision of different methods of Boc cleavage see: (a) Dandepally, S. R.; Williams, A. L. Tetrahedron Lett. 
2009, 50, 1071-1074. (b) Kumar, G. P.; Rambabu, D.; Rao, M. V. B.; Pal, M. J. Chem. 2013, 2013, 916960; Chem. Abstr. 2013, 160, 
723475.   
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afforded the macrocyclic derivative 633 in a 73% yield as the E-isomer, supported by the 
J4,5 coupling constant (14.6 Hz),  and as a 1:1 mixture of diastereoisomers (Scheme 78). 
Interestingly, the protected precursor 632, prepared by silylation of 627 with TBSOTf, 
did not provide the corresponding macrocylic derivative when it was treated with the HG-
II catalyst under the same conditions used for 627, indicating that steric factors may be 
responsible for the failed ring closure. 
 
 
 
Scheme 78. Towards the Total Synthesis of the Solomonamides via Diolefin 627 
 
The extension of this synthetic scheme to the aromatic system contained in the 
natural products was initiated with the aldehyde 635 prepared from commercially 
available 634.295 Subsequent treatment of aldehyde 635 with magnesium vinylbromide 
provided allylic alcohol 636, which required the reduction of the nitro group to the 
corresponding amine to give 637. This seemingly simple operation however proved more 
problematic than expected. For example, treatment of 636 with Zn/NH4Cl did not provide 
                                                          
295 Hengartner, U.; Batcho, A. D.; Blount, J. F.; Leimgruber, W.; Larscheid, M. E.; Scott, J. W. J. Org. Chem. 1979, 44, 37483752. 
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the expected aniline 637, instead a complex mixture of unidentifiable degradation 
products were obtained. We surmised that the benzyloxy group installed in the aromatic 
ring was playing a crucial role in the reactivity of the benzylic alcohol, making it 
especially sensitive even under the weak acidic conditions of the reduction reaction. To 
circumvent this rather disappointing outcome, we decided to protect the hydroxyl group 
as the silyl ether 638. However, the Zn-mediated reduction of the nitro group did not 
provide the expected aniline 639, instead the result again was the formation of a complex 
mixture of degradation products.  
 
Other reduction methods, including LiAlH4 or Ni-Raney, were attempted but they 
also were unsucessful. Finally, the more robust BOM (PhCH2OCH2-) protecting group 
proved to be the solution for this problematic reduction, as the BOM derivative 640 
provided the expected aniline 641 when treated with Zn/NH4Cl in a reasonable and 
reproducible 79% yield. The linkage of aniline 641 and dipeptide 631 was then performed 
as described above for 627 to obtain compound 642, which was subjected to the ring-
closing metathesis to provide macrocycle 643 in an excellent 84% yield as a 1:1 mixture 
of diastereoisomers and the E-olefin as the only detectable double bond isomer. It is 
intriguing that this ring-closing metathesis process proceeded in such good yield, despite 
the presence of a protecting group at the hydroxyl group of the diolefinic precursor 
(Scheme 79). 
 
Scheme 79. Towards the Total Synthesis of the Solomonamides via Diolefin 642  
 
The implementation of this synthetic scheme onto the more functionalised system 
found in the natural products was then confronted by the assembly of acid 644, prepared 
by SPPS (See Experimental Part in Chapter 7) and 641 under conventional conditions 
employed in this work (HATU/DIPEA). However, no desired product 645 was obtained 
despite attempts with an array of coupling reagents such as BOP, PyBOP, DIC/HOBt or 
DIC/HOAt. Reasoning that steric hindrances around the acid 644 could explain this 
failure, we attempted the synthesis of the advanced precursor 645 by sequential couplings 
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of aniline 641 with the amino acid derivatives 629 and 630 and the less sterically 
encumbered acid 622. Unfortunately, the last coupling with acid 622 did not provide the 
expected product 645, instead a complex mixture of HATU derivatives was obtained from 
the starting acid. Intrigued by these failed reactions, we turned our attention to the simple 
aniline 625, in which the hydroxyl group at C6 position was free, in order to determine 
the reasons of the serious hurdles found during this synthetic course. To this end, aniline 
625 and acid 644 were coupled by treatment with HATU/DIPEA and the corresponding 
coupling product 646 was obtained, albeit in a low 36% yield, with the unexpected 
cleavage of the silyl protecting group. Several attempts of this reaction revealed its lack 
of reproducibility, confirming the difficulties of such a coupling. Although obtained in 
low yield, compound 646 was in hand and we were in position to investigate the ring-
closing metathesis reaction for this more complex system. The reaction, undertaken under 
similar conditions as in previous cases, did not give the expected macrocycle 647, thus 
demonstrating the unsuitability of these substrates in the construction of the macrocylic 
core of the solomonamides via RCM. The reason for failure is most likely due to the 
sensitivity of the reaction to steric factors arising from the presence of substituents at both 
allylic and benzylic positions (Scheme 80). 
 
 
 
Scheme 80. Exploration of the RCM in More Complex Systems  
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In yet another attempt to access the macrocyclic solomonamide precursors 
functionalised at the benzylic position, we considered the incorporation of a ketone at this 
position, since this is the functional group present in the natural products. In addition, the 
generation of the ,-unsaturated ketone system, after the macrocyclisation process, 
would allow for the rapid and facile access to an epoxide via oxidation of the double bond. 
Notably, we were skeptical about the success of the metathesis reaction in such a system, 
represented by compound 648, given that the olefin is unactivated as it is conjugated (,-
unsaturated phenylketone). Despite this concern, we opted to experimentally verify the 
chemical reactivity of 648 under the action of the Hoveyda-Grubbs and related catalysts. 
To this aim, we prepared ketone 648 by oxidation of the alcohol 627 with MnO2 and then, 
subjected to the catalytic action of the Hoveyda-Grubbs 2nd generation, keeping in mind 
the difficulty of this reaction due to the inactivated nature of the double bond of the ,-
unsaturated ketone system. Indeed, this reaction did not provide any desired product, even 
when the reaction was forced using drastic conditions (ex. toluene at 60 ºC and 100 ºC), 
instead providing recovered starting material in all cases. In another attempt to obtain 
cyclic ketone 649, cyclic alcohol 633 was treated with MnO2 but the result was similarly 
unsuccessful, with only starting material recovered and no detection of the coveted ketone 
649 (Scheme 81). 
 
 
 
Scheme 81. Exploration of the RCM of the Diolefinic Ketone 648 
 
Although a Z-geometry for the 4,5 double bond was proposed to provide access 
to the syn-1,2-difunctionalized system present at these positions in the natural products, 
the fact that we obtained instead the E-olefinic macrocycles in all cases represented an 
additional difficulty in this study to obtain the final targets. Nonetheless, this synthetic 
strategy was not discarded at this point, as synthetic methods are available to provide the 
required syn isomer from a trans double bond.296 Consequently, we decided to continue 
                                                          
296  (a) Martín-Ortiz, L.; Chammaa, S.; Pino-González, M. S.; Sánchez-Ruiz, A.; García-Castro, M.; Assiego, C.; Sarabia, F. 
Tetrahedron Lett. 2004, 45, 90699072. (b) Miyashita, M.; Mizutani, T.; Tadano, G.; Iwata, Y.; Miyazawa, M.; Tanino, K. Angew. 
Chem. Int. Ed. 2005, 44, 50945097. (c) Yu, X.-Q.; Yoshimura, F.; Ito, F.; Sasaki, M.; Hirai, A.; Tanino, K.; Miyashita, M. Angew. 
Chem. Int. Ed. 2008, 47, 750754. 
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with the present synthetic approach and the next step was to evaluate the feasibility of 
such compounds to provide more oxidized derivatives through an oxidation phase that 
would give access to the final products. In this sense, we studied the oxidation of 
compounds 615, 623 and 643 as representative macrocyclic precursors of the 
solomonamides. Thus, when 615 or 623 were subjected to the oxidative action of m-
CPBA, we found, to our dismay, that these reactions did not yield the expected epoxides 
650 or 651. Instead, starting materials were recovered in both cases. In light of these 
discouraging results, we attempted the epoxidation utilizing the dioxirane derived from 
trifluoromethylketone,297 however the result was similarly frustrating, with no formation 
of any desired oxidation products. Other oxidative reactions were screened, such as a 
dihydroxylation reaction mediated by OsO4, and electrophilic additions, mediated by the 
actions of bromine or NBS, but these did not provide favorable results, not detecting 
formation of any of the possible oxidation products. The poor solubility observed for 
these cyclic compounds in common organic solvents could explain the lack of reactivity 
found for them towards the oxidative reagents. However, the more soluble derivative 643 
also proved to be unreactive when it was subjected to the epoxidation reagents (m-CPBA 
and dioxirane species), resulting in the recovery of starting material and no detection of 
epoxide 652 (Scheme 82).  
 
 
Scheme 82. Attempts of Oxidation of the RCM Products 
 
Theoretical studies were carried out in order to justify the lack of reactivity exerted 
by these macrocyclic compounds. Thus, initial results from DFT calculations carried out 
in solution showed that the HOMO orbital of the molecules is centered around the 
intracyclic phenyl ring with a low electronic density around the alkene moiety.298 This 
result suggests that the main reactive point for the oxidant should not be the alkene, as it 
could be expected, but the aromatic ring. At this stage, no further work was required to 
recognize that oxidation of the previous solomonamide precursors was extremely hard to 
accomplish. Therefore, a new approach was considered. 
                                                          
297 Yang, D.; Wong, M.-K.; Yip, Y.-C. J. Org. Chem. 1995, 60, 38873889. 
298 DFT calculations were carried out using Gaussian 09 at the B3LYP/6-31G’ level of theory using the SMD solvation methodology, 
choosing acetonitrile as solvent.  
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4.3.2. Ring-Closing Metathesis at the C5-C6 Bond 
Given the results obtained during the synthetic studies towards the solomonamides 
utilizing the macrocyclic construction at the C4-C5 bond, we turned our attention to the 
construction of the macrocyclic core of the solomonamides at the C5-C6 bond. In relation 
to the synthetic strategy explored in the previous section, the removal of the functional 
groups, which should be accessible during an oxidation phase, would lead to the relatively 
simple precursor 653. Whereas the styryl double bond could be transformed into a ketone 
or an -hydroxy ketone via Wacker or dihydroxylation oxidations for solomonamides A 
and B, respectively, the introduction of the required amine group at the C4 position was 
initially planned via a C-H activation.  
 
 
Scheme 83. Second Approach to the Solomonamides via RCM: The C5-C6 Disconnection 
 
The syntheses of the key precursor 653 would be performed by a RCM of the 
acyclic derivative 654, whose synthesis would be achieved by simple peptidic-like 
assemblies between the corresponding amine and olefinic acid. As in the previous 
synthetic exploration, we preferred to initiate this study with the model compound 659 to 
test the viability of the new synthetic proposal. The preparation of this RCM precursor 
was successfully achieved from the simple aniline 655299 by sequential couplings with 
dipeptide 608 and hydroxy acid 658, obtained from the known diol 657300 by selective 
                                                          
299  Aoyama, A.; Endo-Umeda, K.; Kishida, K.; Ohgane, K.; Noguchi-Yachide, T.; Aoyama, H.; Ishikawa, M.; Miyachi, H.; 
Makishima, M.; Hashimoto, Y. J. Med. Chem. 2012, 55, 73607377. 
300 Wagner, H.; Harms, K.; Koert, U.; Meder, S.; Boheim, G. Angew. Chem. Int. Ed. 1996, 35, 2643-2646. 
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oxidation with TEMPO/BAIB. With compound 659 in hand, we proceeded with the olefin 
metathesis reaction by use of the HG-II catalyst in refluxing dichloromethane. However, 
it was with much disappointment, that this reaction failed to afford any macrocyclic 
product, leading instead to decomposition and/or polymerization, together with the 
recovery of some starting material (12%). Additional attempts that included more 
forcing conditions (toluene at 65ºC or 100 ºC) and other catalysts (Grubbs 1st and 2nd 
generations, Hoveyda-Grubbs 1st generation) were thwarted, with no detection of the 
desired macrocyclic product 660 (Scheme 83).  
 
Despite these discouraging results, we decided to press forward with the synthetic 
strategy by exploring the ring closing metathesis in the real system represented by the 
product 654. We reasoned that in the case of the metathesis precursor 654, the electronic 
effect of the benzyloxy group at the para position with respect to the styryl double bond 
could exert a favourable effect in terms of reactivity for the unreactive olefin. In order to 
confirm this hypothesis, we prepared the styryl derivative 663 from compound 661 in a 
very good overall yield. We then proceeded to test the construction of the macrocyclic 
ring of the solomonamide model system 666. To this end, compound 663 was coupled 
with commercial acid 664 to obtain the acyclic precursor 665 in a 74% yield. Having 
prepared compound 665, we were primed to test our hypothesis regarding the favourable 
electronic donating effect of the benzyloxy group on the ring-closing metathesis reaction. 
Indeed, we were gratified to discover that cyclic compound 666 was obtained in a 43% 
yield and, exclusively, as the E-isomer, when the acyclic precursor 665 was exposed to 
the HG-II catalyst in refluxing dichloromethane in the presence of 1,4-benzoquinone 
(Scheme 84).  
 
In light of this encouraging result, the ring-closing metathesis was extended to the 
advanced intermediate 654, which was efficiently prepared from the Boc derivative 663 
and acid 658 in 86% overall yield, according to the previously described fragment 
coupling protocol. To our dismay, treatment of 654 with the HG-II catalyst, under the 
same conditions previously employed in earlier cases, did not provide the coveted 
solomonamide precursor 653, providing instead degradation products and recovered 
starting material. A possible explanation for the failure of the metathesis reaction is the 
formation of either the five-membered ring intermediate A, 301  by chelation of the 
ruthenium carbenoid with the hydroxyl group, or the seven-membered ring chelate 
intermediate B,302 in which sequestration of the ruthenium carbenoid species occurred 
through a hydrogen bond of the hydroxyl group with the chlorine atom, which could 
explain the inactivation of the catalyst for the RCM (Scheme 84).  
 
                                                          
301 Engelhardt, F. C.; Schmitt, M. J.; Taylor, R. E. Org. Lett. 2001, 3, 22092212. 
302 Hoveyda, A. H.; Lombardi, P. J.; O’Brien, R. V.; Zhugralin, A. R. J. Am. Chem. Soc. 2009, 131, 83788379. 
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Scheme 84. RCM of the Acyclic Precursors 654 and 665 
 
As support for this mechanistic hypothesis,303 we decided to protect the hydroxyl 
group to avoid the formation of the proposed unproductive intermediates. Therefore, the 
TBS derivative 667 was prepared in a good yield by treatment of 654 with TBSOTf in 
the presence of 2,6-lutidine. The resulting silyl ether 667 was then subjected to the 
exposure of the HG-II catalyst and, to our delight, the macrocyclic product 668 was 
obtained in a reasonable 47% yield. The completion of the synthesis of the natural 
products should require an eventual removal of the TBS protecting group. With this future 
objective in mind, we proceeded with the desilylation reaction by treatment of 668 with 
HFpyr. Surprisingly, the expected hydroxyl derivative 653 was not obtained, instead 
recovered starting material. Other fluoride-based reagents (TBAF, TBAF-AcOH) 
afforded the same frustrating result. Therefore, we decided to replace the TBS group with 
                                                          
303 (a) Lin, Y. A.; Davis, B. G. Beilstein J. Org. Chem. 2010, 6, 12191228. (b) Fuwa, H.; Saito, A.; Sasaki, M. Angew. Chem. Int. 
Ed. 2010, 49, 30413044. (c) Schmidt, B.; Staude, L. J. Org. Chem. 2009, 74, 92379240. (d) Schmidt, B.; Nave, S. Chem. Commun. 
2006, 24892491.  
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a more labile protecting group, choosing TES as a suitable alternative. Then, compound 
669 was prepared by reaction of 654 with TESOTf/2,6-lutidine and its suitability as a 
viable substrate for the preparation of 653 was evaluated. Gratifyingly, the RCM reaction 
of 669 provided 670 in a similar yield as for 668 (53%) and its desilylation, by treatment 
with TBAF, yielded the desired macrocyclic 653 in 85% yield (Scheme 85).  
 
 
 
Scheme 85. RCM of the Acyclic Precursors 667 and 669: Synthesis of 653 
 
4.3.3. Ring-Closing Metathesis at the C3-C4 Bond 
Prior to the completion of the synthetic study towards the natural solomonamides, 
for which meaningful quantities of 653 or precursor 670 were required, we opted to 
complete the exploration of the RCM reaction by exploring the C6-C7 bond as another 
disconnection point to construct the macrocyclic system of the solomonamides. This new 
disconnection strategy would be based on the retrosynthetic analysis depicted in Scheme 
86. Having established the viability of the RCM strategy for the construction of the 
macrocylic core of the solomonamides at two different sites, the C5-C6 and the C4-C5 
bonds, we decided to extend the RCM-based strategy to the C3-C4 position, scanning all 
the options along the six-carbons chain contained in the ADMOA fragment. In this new 
scenario, the removal of the functional groups at the C3 and C4 positions revealed 
compound 671 as a potential precursor for solomonamide B, which could be obtained 
from the acyclic derivative 672 via RCM. Thus, aldehyde 635 was transformed into the 
amine 675 without problems according to the synthetic sequence described in Scheme 
86. Our experience gathered during the synthetic campaign led us to choose BOM as the 
most suitable protecting group for the benzylic alcohol and to introduce sequentially the 
two amino acids (D-Ala and Gly) through the Fmoc derivatives 629 and 630 to obtain 
compound 677. Prior to the preparation of the subtarget RCM precursor 672, we 
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considered the use of the commercially available acid 678 to test the possibilities of this 
new strategy. Having prepared model compound 679, treatment with HG-II catalyst under 
similar reaction conditions as previously used, did not provide the desired result with the 
no formation of the macrocyclic compound 680. In fact, a rational explanation for this 
result could be the formation of a stable 5-membered ring chelate between the ruthenium 
carbene and the carbonyl group of the amide (intermediate A), which renders the 
metallacyclobutane intermediate unreactive toward the retro [2 + 2] cycloaddition304 
(Scheme 86).  
 
Scheme 86. Third Approach to the Solomonamides via RCM: The C3-C4 Disconnection towards 
Macrocycle 680 
 
In parallel with these dissapointing results directed towards the solomonamide B, 
we explored a synthetic pathway towards solomonamide A. In this sense, we decided 
firstly to target a model compound, represented by compound 687 in Scheme 87, as a 
suitable precursor that would allow to a rapid validation of the 3,4-strategy. With this 
                                                          
304 (a) Fürstner, A.; Thiel, O. R.; Lehmann, C. W. Organometallics 2002, 21, 331335. (b) Choi, T.-L.; Chatterjee, A. K.; Grubbs, R. 
H. Angew. Chem. Int. Ed. 2001, 40, 12771279. (c)  Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H. J. Am. Chem. Soc. 
2003, 125, 1136011370. 
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aim, we started the synthetic plan from known alcohol 682,305 which was subjected to a 
Parikh-Doering oxidation followed by a Wittig reaction to obtain nitro derivative 683 in 
53% over 2 steps, which was then reducted to aniline 684 by the action of Zn/NH4Cl in 
60% yield. From aniline 684, we were able to obtain model precursor 687 in a similar 
way than previously described above for 679. To our dismay, the desired macrocycle 688 
was not obtained after treatment of 687 with HG-II catalyst under the same reaction 
conditions as before, thus confirming the formation of the unreactive metallacyclobutane 
intermediate as in the previous case (Scheme 87).  
 
 
 
Scheme 87. Third Approach to the Solomonamides via RCM: The C3-C4 Disconnection towards 
Macrocycle 688 
 
In ligth of these results, we decided to explore the RCM by use of Lewis acids,306 
which are useful additives to promote the ring closure as demonstrated in cross-metathesis 
reactions bearing similar structural motifs. Then, we repeated the RCM reaction of 
dialkenes 679 and 687 under the presence of Ti(OiPr)4. However, in both cases the result 
of the RCM reaction met with no success as in previous cases, detecting a mixture of 
starting material together degradation products. Attempts of these RCM reactions under 
the action of other Lewis acids as La(OTf)3 or Zn(OTf)2 were similar unfruitful, not 
detecting the desired macrocyclic compounds 680 or 689 (Scheme 88). With these 
                                                          
305 Aeluri, M.; Gaddam, J.; Trinath, D. V. K. S.; Chandrasekar, G.; Kitambi, S. S.; Arya, P. Eur. J. Org. Chem. 2013, 39553958. 
306 For representative examples see: (a) Lübbe, C.; Dumrath, A.; Neumann, H.; Beller, M.; Kadyrov, R. ChemCatChem 2014, 6, 
105108. (b) Nagarapu, L.; Gaikwad, H. K.; Bantu, R.; Manikonda, S. R.; Kumar, C. G.; Pombala, S. Tetrahedron Lett. 2012, 53, 
12871291. (c) Pentzer, E. B.; Gadzikwa, T.; Nguyen, S. T. Org. Lett. 2008, 10, 56135615. (d) Vedrenne, E.; Dupont, H.; Oualef, 
S.; Elkaïm, L.; Grimaud, L. Synlett 2005, 670672. 
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dissapointing results, we decided to stop exploration of the 3,4-RCM in favor to the 5,6-
RCM route described before. 
 
 
Scheme 88. Attempts of RCM Reaction Assisted by Lewis Acids:Ti(OiPr)4, La(OTf)3 or Zn(OTf)2 
 
4.4. Biological Activity and Molecular Modelling of Selected Solomonamide 
Precursors.  
At this stage of the synthetic work, with an efficient route defined to obtain the 
final natural products by the 5,6-RCM strategy, we were intrigued with the biological 
properties of the synthesized products, recognizing that the macrocyclic peptides 
represented unprecedented and novel molecular architectures of biological interest. For 
this reason, we decided to explore and investigate their biological activities in 
collaboration with the group of Prof. Ana R. Quesada from the Molecular Biology and 
Biochemistry Department of Málaga University. To this aim, we performed preliminary 
biological evaluations, which consisted of the measurement of the antitumor properties 
of selected compounds against a panel of various tumor cell lines. The chosen 
solomonamide derivatives for this study were 614, 615, 623, 633, 666, 670 and 653 as 
representative compounds of the different scaffolds generated during the synthetic work. 
In addition, compound 690, obtained from 615 by treatment with Na/NH3 (See Figure 
2), was included for this study to evaluate the effect of the protecting group upon 
biological activity.  
 
As a first attempt to characterize the biological activities of the synthetic 
solomonamide analogues, the cytotoxicity profile of the aforementioned compounds was 
examined using nine different cancer cell lines (see Table 2), as well as a primary culture 
of non transformed bovine aorta endothelial (BAEC) cells. The results of these biological 
evaluations, summarized in Table 2, clearly revealed a relevant cytotoxic activity for only 
one compound, 653, which displayed the best values of inhibition of the series in the low 
M range, against all the tumor cell lines. In addition, 653 was also cytotoxic against the 
endothelial cells line (BAEC), which may indicate a putative antiangiogenic effect of this 
compound.270 In contrast, the other compounds were practically devoid of antitumor 
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activity except compounds 623 and 666, which displayed cytotoxicity, particularly 
against the HL60 tumor cell line albeit moderately. From these results, a highlight is the 
notable enhancement of activity observed upon introduction of functional groups in the 
polyketide fragment contained in these compounds, as concluded when biological 
activities of 666 and 653 are compared, or 615 and 623 for the case of the HL60 cell line. 
In addition, the isomeric derivative of 653, compound 623, displayed similar 
antiproliferative activity as 653 against HL60, but, in contrast, was inactive against the 
other cell lines, including BAEC, revealing the importance of the position of the double 
bond of the molecule upon biological activities. This structural effect is also reflected 
when the biological activities of the isomeric compounds 615 and 666 are compared.  
 
 
Figure 13. Synthetic Solomonamide Precursors Submitted to Biological Evaluations 
 
 
Table 2. In vitro Antitumor Activities of Solomonamide Precursors against Various Tumor Cell Lines and 
BAEC (IC50, M)a 
Compd. HL60b KU812Fc U937d HT-1080e MDA- 
MB-231f 
U87MGg HepG2h HT-29i U2OSj BAECk 
614 > 50 > 50 > 50 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
615 > 50 n.d. n.d. > 100 > 100 > 100 > 100 > 100 > 100 43,8   1,2 
690 > 50 > 50 > 50 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
623 17,2  6,6 n.d. n.d. > 50 > 50 n.d. n.d. n.d. n.d. > 100 
633 > 50 > 50 > 50 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
666 20,5  5.2 > 50 > 50 31,1  2,8 > 100 > 100 > 100 > 100 > 100 69,6  12,5 
670 > 50 > 50 > 50 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
653 14,7  4,4 14,0  3.05 7,02  2.32 16,3  2.9 16,5  1,01 34,8  5,1 18,9  1,5 13,3  0,6 12,9  3,1 18,1  2,2 
[a] In vitro cytotoxicities were determined according to the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye 
reduction assay as detailed in experimental part. The IC50 values were obtained from semilogarithmic dose-response plots as the 
concentration of compound yielding a 50% of cell survival. [b] HL60: Human promyelocytic leukemia. [c] KU812F: Chronic 
Myelogenous leukemia. [d] U937: Histiocytic lymphoma. [e] HT1080: Human fibrosarcoma. [f] MDA-MB-231: Human breast 
adenocarcinoma. [g] U87MG: Gioblastoma. [h] HepG2: Hepatocellular carcinoma. [i] HT-29: Colorectal adenocarcinoma. [j] 
U2OS: Osteosarcoma. [k] BAEC: Non transformed bovine aortic endothelial cells. 
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In an attempt to make sense of this result, molecular modelling studies were 
conducted for compounds 615, 623, 666 and 653 to obtain the corresponding minimized 
structures (Figure 14).307 The resulting models revealed a certain structural distorsion 
when 615 and 666, on one side, and 623 and 653, on the other, are compared, respectively. 
Thus, whereas 666 and 653 are almost flat, 615 and 623 displayed considerable twisting. 
These differences in the resulting minimized molecular structures may explain the 
differences observed for the biological activities found for these compounds. 
Additionally, the overall shape of 615 is very similar to 623, and the same is evident also 
for 666 and 653. In this case, despite these conformational similarities, it is clear that the 
functional groups incorporated in 623 and 653, in particular the hydroxy group, may exert 
a key biological interaction through a hydrogen bonding interaction with an acceptor-type 
residue located at the active site of the biological targets. These interactions may justify 
the greater activities displayed by 623 and 653 compared with 615 and 666, respectively. 
In addition, the importance of the hydroxy group can be further deduced from the loss of 
the biological activities of compound 670 with the TES-protected hydroxy group. 
 
 
Figure 14. Computer-generated Minimum-Energy Conformations for Compounds 615, 623, 653 and 666 
 
4.5. In vitro and in vivo Antiangiogenic Potential of Solomonamide Precursors 
The promising in vitro antitumor activity reported above for compound 653 
prompted us to evaluate the antiangiogenic potential of the complete series of 
solomonamide precursors, with the collaboration of the group of Prof. Ana R. Quesada. 
Angiogenesis involves the generation of new capillaries by sprouting of pre-existing 
vessels. Although in a healthy situation this process is tightly regulated by a balance of 
stimulators and inhibitors, being restricted to specific situations such as embryonic 
development, endometrial regulation, reproductive cycle, and wound repair, a persistent 
and deregulated angiogenesis is related to the course of many pathologies308,309 and is 
                                                          
307 Minimum energy conformations were calculated using the PM3 method found in HyperChem 5.0 software. Optimization was 
performed using Polak-Ribiere algorithm until the RMS gradient reached a value below 0.001 kcal/(Å·mol). 
308 Potente, M.; Gerhardt, H.; Carmeliet, P. Cell 2011, 146, 873−887.  
309 Quesada, A.R., Medina, M.Á., Muñoz-Chápuli, R., Ponce, Á.L. Curr. Pharm. Des. 2010, 16, 3932-3957. 
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considered as one of the hallmarks of cancer.310 In consequence, the pharmacological 
regulation of angiogenesis emerges as an attractive strategy for the treatment of cancer 
and other angiogenesis-dependent diseases. 311  Attending to this evidence, the active 
search for new compounds able to modulate angiogenesis is a crucial research strategy in 
order to discover potential antiangiogenic drugs with possible clinical applications.  
 
With the aim to study the antiangiogenic potential of the previously synthesized 
solomonamide precursors 614, 615, 690, 623, 633, 666, 670 and 653, we performed a 
primary screening in vitro based on the analysis of their inhibitory activity in the 
formation of endothelial tubular-like structures, measuring their minimum inhibitory 
concentration (MIC). In this primary screening, we identified compound 653 as the 
solomonamide precursor that showed the best MIC value (1 M) compared to the rest of 
analogues tested (>50 M) (Figure 15, part A). This markedly low MIC value confirmed 
the unique bioactivity of this compound. Current approaches to target tumor vessels 
include two strategies: (a) the inhibition of the formation of new blood vessels following 
the activation of the endothelial cells (antiangiogenic drugs), and (b) the disruption and 
destruction of the pre-existing vasculature (tumor vascular disrupting drugs).312 As shown 
in Figure 15 part B, 653 is not able to disrupt the tubule-like structures already formed, 
discarding a possible vascular disrupting activity of this compound. These results 
prompted us to select compound 653 for further analysis of its antiangiogenic potential. 
 
Figure 15. Compound 653 Exhibits a Strong Inhibitory Effect on Tubulogenesis in vitro, without Affecting 
Already Formed Structures. A) Effect of solomonamide precursors on endothelial tubular-like structures 
formation on Matrigel. BAEC were seeded on Matrigel in presence of the compounds and structures 
formation was evaluated after 5 hours. Vehicle (DMSO) was added to the negative control; staurosporine 
2 µM was used as positive inhibition control. B) Vascular disruption assay in vitro. Compounds were added 
to already formed BAEC tubular-like structures on Matrigel. Effects were evaluated after 90 minutes. 
Combrestatin (CA4P) 0.2 µM was used as a positive control (Scale bar = 1000 µm). Each experimental 
condition was conducted in duplicates, and three independent assays were performed in each case. 
                                                          
310 Hanahan, D.; Weinberg, R. A. Cell 2011, 144, 646−674. 
311 (a) Folkman, J. N. Engl. J. Med. 1971, 285, 1182−1186. (b) Folkman, J. Nat. Rev. Drug Discov. 2007, 6, 273−286. (c) Carmeliet, 
P. Nature 2005, 438, 932−936. 
312 Tozer, G.M., Kanthou C., Baguley B.C. Nat. Rev. Cancer 2005, 5, 423–435. 
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During angiogenesis, migration is an indispensable step by which endothelial cells 
activate their migratory and invasive potential, moving towards the pro-angiogenic signal, 
making the formation of new vessels possible in the tissue. A wound-healing assay was 
performed in order to evaluate the possible effect of the solomonamide precursor on 
endothelial cell migration in vitro. As shown in Figure 16, 653 significantly reduced the 
migratory capabilities of BAEC at not toxic doses (MIC for migration =10 M).  
 
Figure 16. Compound 653 Decreases Endothelial Cell Migration Capability. A) Representative 
photographs of wound healing assay after 7 h of treatment with 653. Vehicle (DMSO) was added to control 
condition. Discontinued lines point the free-cell area at time 0 h in each experimental condition. (Scale bar 
= 500 µm). B) Quantification of the non-recovered area in the wound-healing assay after 7 hours of 
treatment with 653. Data are showed as percentages of the free-cell area at time 0 h and are expressed as 
the mean ±SD of three independent experiments (*p<0.05,**p<0.01). 
 
In addition to the migratory potential, during angiogenesis activated endothelial 
cells must be able to degrade extracellular matrix components in order to allow the 
invasion through the tissue. The possible effect of 653 on the invasive capability of 
endothelial cells was studied. 653 was able to inhibit the invasive potential of BAEC in a 
dose-response manner, reaching a 50% of inhibition at a concentration close to 5 M 
(Figure 17, part A). We studied also the effect of 653 on the capability of endothelial 
cells to degrade the proteins of extracellular matrix (ECM). Our results showed that the 
presence of matrix metalloproteinase-2 (MMP-2), the main MMP expressed in 
endothelial cells, was reduced both in cell extracts and in conditioned media of BAEC 
treated with 653 at 20 M (Figure 17, part C). These results supported the observed 
inhibitory effect of this compound on endothelial cell invasion. In order to study the cell 
specificity of the protease modulation by this compound, the effect of 653 on the 
proteolytic potential of HT1080 tumor cells was examined. While endothelial cells only 
express one gelatin degrading MMP, HT1080 cells express both gelatinases: MMP-2 and 
MMP-9. As shown in Figure 17 part D, both MMP activities were decreased when these 
cells were treated with 653, suggesting that the inhibitory effect of 653 on the ECM 
degrading potential is not specific for endothelial cells. In order to better understand the 
inhibitory effect of 653 on ECM degradation capability, MMP-2 gelatinase activity was 
measured in the gel in absence or presence of the compound. The gelatin degradation 
bands corresponding to MMP-2 in control endothelial conditioned media were unaffected 
when gels were incubated in presence of the compound (Figure 17, part E), indicating 
that 653 was not able to directly inhibit MMP-2.  
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Figure 17. Compound 653 Inhibits Endothelial Cell Invasion and ECM Degradation Capability. A) 
Representative photographs of invading endothelial cells through Matrigel-coated transwells after 16 hours 
of treatment (Scale bar = 500 µμm). B) Quantification of the cell invasion assay. The number of invading 
cells stained in the control stimulated with FBS was considered as 100% of invasion. C) Representative 
gelatin zymography and quantification of MMP-2 presence in conditioned media and cell extracts of BAEC 
treated with 653. D) Representative gelatin zymographies and quantifications of MMP-9 and MMP-2 
presence in conditioned media and cell extracts of HT-1080 treated with 653. E) Representative in situ 
gelatin zymography of untreated BAEC conditioned media, and quantification of MMP-2 activity in 
absence (control) or presence of 653 20 M added to the incubation buffer. For all quantifications, data are 
the mean ±SD of at least three independent experiments (*p<0.05,**p<0.01, ***p<0.001, ****p<0,0001).  
 
The in vitro observed evidences of the inhibitory activity of 653 on key steps of 
angiogenesis observed in vitro prompted us to study the in vivo effect of this compound 
in two different animal models: the chick chorioallantoic membrane (CAM) and the 
zebrafish yolk membrane (ZFYM) assays. In the chick CAM assay, that allowed us to 
evaluate the in vivo effect in a context of physiological angiogenesis which occurs during 
the development of the chick embryo, 653 was able to inhibit angiogenesis in a dose-
dependent manner between 0.1-10 nmol/CAM (Figure 18 part A and Table 3), which is 
a very low concentration range in comparison with those reported for other known 
antiangiogenic compounds (~30 nmol/CAM).313 
 
Then, the in vivo antiangiogenic activity of compound 653 was confirmed by 
using the zebrafish yolk membrane (ZFYM) assay, that allow us to evaluate the in vivo 
effect in a background of induced angiogenesis by the injection of the fibroblast growth 
factor-2 (FGF-2) in the zebrafish embryo, mimicking a pathological situation. As shown 
in Figure 18 part B and Table 4, the treatment of embryos with different doses of 653 
diminished the angiogenic response of subintestinal vessels to exogenous FGF-2 in 
                                                          
313 (a) Castro, M. E.; González-Iriarte, M.; Barrero, A. F.; Salvador-Tormo, N.; Muñoz-Chápuli, R.; Medina, M. Á.; Quesada, A. R. 
Int. J. Cancer 2004, 110, 31–38. (b) Martínez-Poveda, B.; Quesada, A. R.; Medina, M. Á. Int. J. Cancer 2005, 117, 775−780. (c) 
Cárdenas, C.; Quesada, A. R.; Medina, M. Á. PLoS One 2011, 6, e23407. (d) Garcia-Caballero, M.; Mari-Beffa, M.; Medina, M. Á.; 
Quesada, A. R. J. Invest. Dermatol. 2011, 131, 1347−1355. 
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zebrafish, manifested by a decreased number of embryos which presented a strong or mild 
angiogenic response and increased number of embryos unresponsive to FGF-2 stimulus. 
 
 
Figure 18. Compound 653 Shows a Potent Antiangiogenic Effect in vivo. A) Representative photographs 
of CAM assay testing 653. Negative control condition containing vehicle (DMSO) and positive control 
condition containing Apl-1 3 nmol/CAM, were used in the assay. Circles show the locations of the methyl 
cellulose discs. B) Representative photographs of ZFYM assay. The response of subintestinal vessels of 
zebrafish embryos to FGF-2-induced angiogenesis in presence of 653 was evaluated. Zebrafish embryos 
were stained for alkaline phosphatase (AP) activity. Dashes lines delimit subintestinal vessels basket; arrow 
heads points to the FGF-2 injection site, and asterisks marks the angiogenic response to FGF-2. 
  
Table 3. Inhibition of in vivo angiogenesis in the CAM assay by 653. Table summarizes the evaluation of 
the effect of different doses of the compound in the CAM of chicken embryos. When angiogenesis 
inhibition was observed the CAM was scored positive. 
CAM assay 
653 (nmol/CAM) Positive/ total % Inhibition 
0 0/11 0 
0.1 1/7 14 
0.5 2/7 29 
1 6/9 67 
5 9/12 75 
10 10/10 100 
 
  
Table 4. Inhibition of in vivo angiogenesis in the ZFYM assay by 653. Table summarizes the observed 
effect of different doses of the compound in FGF-2-induced angiogenesis on the SIVs of zebrafish embryos. 
Embryos were scored as – (no response to FGF-2), + (mild response) or ++ (strong response). 
ZFYM assay 
FGF-2 
Induction 653 (µM) 
SCORE (%) 
- / total(%) + / total(%) ++ / total(%) 
None 0 20/20 (100) 0/20 (0) 0/20 (0) 
2 ng 0 5/21 (23.8) 10/21 (47.6) 6/21 (28.6) 
2 ng 5 9/19 (47.4) 7/19 (36.8) 3/19 (15.8) 
2 ng 10 13/23 (56.5) 9/23 (39.1) 1/23 (4.3) 
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Cellular processes related to angiogenesis are controlled by a complex network of 
signaling pathways in endothelial cells. The pharmacological interference of this 
signaling system constitutes a very interesting strategy in order to design new therapeutic 
approaches.314 Since PI3K/Akt and ERK-MAPK are two of the main signaling cascades 
implicated in the transduction of pro-angiogenic signals and play an essential role in the 
regulation of many processes such proliferation, migration, differentiation and 
morphogenesis,315 we studied the effect of 653 in the activation of Akt and ERK1/2. Our 
results revealed that 653 prevents Akt and ERK1/2 phosphorylation in response to serum 
induction, therefore inhibiting the activation of both pathway at a concentration of 20 M. 
These results throw some light about the mechanism of action of 653, pointing to 
PI3K/Akt and ERK-MAPK pathway as major targets of the compound (Figure 19).  
 
Figure 19. Compound 653 Inhibits Akt and ERK1/2 Phosphorylation in Endothelial Cells. A) 
Representative Western-blots of phosphorylated Akt, total Akt, phosphorylated ERK1/2, total ERK1/2 and 
tubulin in protein extracts from BAEC induced with serum in absence or presence of 653. B) Western-blots 
were quantified by densitometry, and the pAkt/total Akt and P-ERK1/2 / ERK-1/2 ratios were expressed as 
the percentage of ratio in serum-stimulated BAECs (in presence of serum, in absence of 653). Data are 
means of two independent experiments. 
 
4.6. Towards the Total Synthesis of the Revised Structure of the 
Solomonamides  
In order to complete our synthetic campaign towards the natural solomonamides, 
we planned to carry out the total synthesis of the corrected structure of the solomonamides 
A and B, as Reddy et al. revised.283, 284 In this sense, we envisioned the introduction of 
the amino group via an Overman rearrangement,316 and the cyclisation of the macrocycle 
through a RCM reaction from the key trichloroacetimidate 691, which could be obtained 
by a peptidic coupling of carboxylic acid 693 and amine 692. In turn, acid 693 could be 
achieved by a Bu2BOTf mediated stereoselective Evans aldol reaction, involving Evans 
chiral auxiliary 694 and aldehyde 695 (Scheme 89). 
                                                          
314 Muñoz-Cápuli, R.; Quesada, A. R.; Medina, M. Á. Cell. Mol Life Sci. 2004, 61, 2224−2243. 
315 (a) Shiojima, I. Walsh, K. Circ. Res. 2002, 90, 1243−1250. (b) Somanath, P. R.; Razorenova , O. V.; Chen, J.; Byzova, T. V. Cell 
Cycle 2006, 5, 512−518. 
316 For recent advances in the Overman rearrangement see: Fernandes, R. A.; Kattanguru, P.; Gholap, S. P.; Chaudhari, D. A. Org. 
Biomol. Chem. 2017, 15, 2672−2710. 
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Scheme 89. Retrosynthetic Analysis of the Revised Structures of the Solomonamides 
 
Thus, we started our designed strategy with the Bu2BOTf mediated Evans aldol 
reaction of 694 and 695 to obtain oxazolidinone 696 in 84% yield. Protection of the free 
alcohol as a BOM derivative was achieved using BOMCl and DIPEA in a moderate 47% 
yield. Next, reduction of the oxazolidinone 697 by the use of LiBH4 afforded alcohol 
derivative 698 in quantitative yield. Alcohol 698 was then oxidized to the acid in two 
steps, Dess-Martin periodinane (DMP) oxidation in quantitative yield followed by a final 
treatment of the resulting aldehyde with sodium chlorite under Pinnick conditions to 
furnish acid 693. The obtained acid did not required further purification and was 
subsequently coupled with amine 692 to yield peptide 701 in 45% over two steps. 
Deprotection of the TBS protecting group in 701 by the use of TBAF afforded alcohol 
702 in 74% yield, and was then reacted with CCl3CN in presence of catalytic amount of 
DBU to obtain trichloroacetimidate 691 (Scheme 90). 
 
At this point of the synthesis, we were able to attempt the key Overman 
rearrangement of trichloroacetimidate 691. In a first attempt, we tried the rearrangement 
reaction by the action of PdCl2(PhCN)2 as catalyst in the presence of 1,4-quinone as 
additive317 and refluxing CH2Cl2 for 15 h. However, under these reaction conditions we 
did not observed the desired rearrangement product, instead starting material was 
recovered (Table 5, entry 1). Other reactions conditions were attempted, changing the 
catalyst, by the use of COPCl, temperature, solvent and/or additive, but the reactions met 
with failure, recovering starting material and/or obtaining unidentified degradations 
products in all the cases tested (Table 5, entries 2-5). These discouraging results could be 
explained by a coordination of the palladium catalyst with the styryl double bond during 
the Overman rearrangement. Having in mind this hypothesis, we decided to change the 
styryl group by a iodide to avoid these possible coordination effects.  
                                                          
317 Sutherland, A.; Zaed, A. M. Org. Biomol. Chem. 2010, 8, 4394−4399. 
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Scheme 90. Synthesis of Trichloroacetimidate 691 and Attempts to the Synthesis of Trichloroacetamide 
703 via Overman Rearrangement 
 
With this purpose, we started the synthesis of the required iodo 
trichloroacetimidate 707 from nitro derivative 605 (Scheme 91). Reduction of the nitro 
group by the action of Zn/NH4Cl was followed by a peptide coupling of the resulting 
amine 704 with acid 608 to obtain peptide 585 in 79% yield. Then, a two-steps sequence, 
involving a Boc deprotection and a subsequent peptide coupling with acid 693, yielded 
705 in 33% yield over two steps with the unexpected cleavage of the silyl protecting 
group. The final conversion of 705 into iodo trichloroacetimidate 707 was achieved in 
84% yield by the reaction with CCl3CN in presence of DBU (Scheme 91). Once we had 
in our hands compound 707, we attempted the Overman rearrangement under the same 
reaction conditions employed above (Table 5, entry 6). However, the result of the 
reaction was the same than the previous cases, not detecting the desired 
trichloroacetamide 708, instead recovering starting material. Different attempts to 
optimize this rearrangement reaction by the change of catalyst, temperature, solvent 
and/or additive were unsuccessful, recovering trichloroacetimidate 707 in all cases 
(Table 5, entries 6-10). 
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Scheme 91. Synthesis of Trichloroacetimidate 707 and Attempts to the Synthesis of Trichloroacetamide 
708 via Overman Rearrangement 
 
Table 5. Attempts for Overman Rearrangement of 691 and 707 [a] 
Entry Compd. Catalyst Temperature Solvent Additive Product 
1[b] 691 PdCl2(PhCN)2 45 ºC CH2Cl2
 1,4-quinone Recoverd 691 
2[b] 691 PdCl2(PhCN)2 45 ºC CH2Cl2 none Recoverd 691 
3[b] 691 PdCl2(PhCN)2 80 ºC Toluene 1,4-quinone Degradation  
4[b] 691 (R)-COPCl 80 ºC Toluene 1,4-quinone Recoverd 691 
5[b] 691 none 160 ºC Xylene anh. K2CO3 Degradation 
6[b] 707 PdCl2(PhCN)2 45 ºC CH2Cl2 1,4-quinone Recovered 707 
7[b] 707 (R)-COPCl 25 ºC CH2Cl2 none Recovered 707 
8[c] 707 (R)-COPCl 25 ºC CH2Cl2 1,4-quinone Recovered 707 
9c] 707 (R)-COPCl 45 ºC CH2Cl2 1,4-quinone Recovered 707 
10[c] 707 (R)-COPCl 80 ºC Toluene 1,4-quinone  Recovered 707 
[a] All reactions were carried out with 1.0 equiv of 691 or 707, 10 mol% of catalyst and 50 mol% of 1,4-quinone or 2 mg of 
anhydrous K2CO3/mL solvent. Dry solvents were used in all cases, with a final molar concentration of ~0.03 M. All the 
reactions were stirred overnight. [b] The reaction was carried out with crude trichloroacetimidate in presence of DBU. [c] 
The reaction was carried out with pure trichloroacetimidate previously purified by flash column  chromatography, 30% 
EtOAc in hexanes → 80% EtOAc in hexanes. COP = Di-μ-chlorobis[η5-(R)-(pR)-2-(2′-(4′-methylethyl)oxazolinyl) 
cyclopentadienyl,1-C,3′-N)(η4 tetraphenylcyclobutadiene)cobalt]dipalladium 
 
At this point, no further work was required to recognize that the Overman 
rearrangement in our system was extremely hard to accomplish. Having demonstrated 
that the styryl double bond was not the problem for the failure of the Overman 
rearrangement, a plausible explanation could be the chelation of the palladium with the 
nitrogen groups along the peptide structure found in 691 or 707. Therefore, a new 
approach was considered. Our new approach was based on the introduction of the amino 
group at the early stages of the synthesis in order to avoid the problematic Overman 
rearrangement by the time the peptidic structure is already installed. With this aim, we 
started from the previously synthesized acid 693, which was transformed into hydroxy 
acid 709. Treatment of 709 with CCl3CN in presence of DBU afforded bis-
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trichloroacetimidate 710, which was subjected to the Overman rearrangement by the use 
of PdCl2(PhCN)2 as catalyst in refluxing dichloromethane and in the presence of 1,4-
quinone as additive. However, the expected trichloroacetamide 711 was not detected, 
obtaining instead a separable 1:1 mixture of lactames 712a and 712b in a 40% combined 
yield (Scheme 92).  
 
Scheme 92. Attempts to the Synthesis of Trichloroacetamide 711 
 
Considering that the presence of the second trichloroacetimidate group in 710 
could favour the cyclisation to form the lactame, we decided to start the synthesis from 
allylic alcohol 698 to avoid this undesired cyclisation reaction. As shown in Scheme 93, 
TBS deprotection in 698 yielded diol 713 in 79%, which was then treated with 
CCl3CN/DBU to obtain trichloroacetimidate 714 in 81% yield. Unfortunately, the 
Overman rearrangement of 714 as well as the subsequent steps depicted in Scheme 93 
still remain incomplete due to the lack of time. Thus, the results from this new approach 
towards the solomonamides are not included in the current PhD Thesis, and it will be 
reported in due time. 
 
 
Scheme 93. Planned Strategy Towards the Total Synthesis of the Revised Structures of the Solomonamides  
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4.7. Summary 
 In conclusion, an extensive synthetic exploration directed towards the 
solomonamides was conducted based on a ring-closing metathesis as the key reaction for 
the rapid and efficient access to their macrocyclic cores. The result of this synthetic study 
was the establishment of an efficient ring closure process which proceeded in high yields 
and complete stereoselectivity. During the course of these efforts, unexpected hurdles 
arose along the way, mainly with: 1) the reactivity of the hydroxyl group at the benzylic 
position (compounds 626 and 636); 2) the reactivity of diolefins containing allylic and 
homoallylic alcohols (compounds 600, 601, 627, 642, 654, 659, 667 and 669) or 
containing a ,-unsaturated carbonyl system (case of compounds 679 and 687) toward 
the ruthenium catalysts, and 3) the reactivity of macrocyclic olefins (compounds 615, 623 
and 643) toward oxidative reagents. Although many of these synthetic problems were 
overcome, others remained elusive and represent synthetic challenges for future works. 
In relation to the ring-closing metathesis reactions, many of the described findings 
support the observations and results reported by other authors for this reaction on this 
class of structural systems.  
 
More importantly, not only did we explore the scope and limitations of the ring-
closing metathesis in the synthesis of the macrocyclic core of the solomonamides, but we 
also identified several structurally related solomonamide precursors possessing 
significant cytotoxicities against various tumor cell lines, including endothelial cells, in 
the low M range. In addition, the putative antiangiogenic potential of the solomonamide 
synthetic precursors has been evaluated. Through a preliminary in vitro screening, based 
in the inhibitory activity of endothelial tube formation, the compound 653 was selected 
for a deeper characterization of its antiangiogenic potential, and we found that 653 is able 
to inhibit some key steps of the angiogenic process, including the proliferation, migration 
and invasion of endothelial cells, and to diminish their capability to degrade the 
extracellular matrix proteins. Furthermore, the antiangiogenic potential of 653 was 
confirmed by two different in vivo models, the chorioallantoic membrane (CAM) and the 
zebrafish yolk membrane (ZFYM) assays, respectively. The reduction in ERK1/2 and 
Akt phosphorylation in endothelial cells treated with 653 indicated that the mechanism 
of action of this compound could target the upstream components that are common to 
both pathways. Thus, our results show a new and interesting biological activity of 653 as 
an inhibitor of the persistent and deregulated angiogenesis that characterizes cancer and 
other pathologies. In addition, these results suggest the potential therapeutic application 
of solomonamide derivatives and reinforce the value of marine products as drug 
candidates for the treatment of angiogenesis-related malignances. 
 
In summary, the described chemistry highlights the benefits of the olefin 
metathesis reaction in the field of the total synthesis of natural products, featuring 
convergency and flexibility for structural diversity and has allowed the identification of 
bioactive compounds with interesting antitumor properties. In addition, these biological 
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evaluations of relatively simple compounds, devoid of the functional groups present in 
the natural counterparts, portend promising antitumor properties for the natural products 
and qualify them as new scaffolds of biological and medicinal interest. Finally, several 
synthetic efforts towards the total synthesis of the revised structures of the 
solomonamides have been initiated based on an Overman rearrangement strategy. The 
completion of the synthesis of the natural products, the design of new analogues based 
upon compound 653, and further biological studies to elucidate the mechanism of its 
antiangiogenic activities are currently in progress and they will be reported in due course. 
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5.1. Isolation, Structure and Biology of the Celebesides 
As mentioned before, Nature represents a striking and a huge source of new 
natural products which are key in drug discovery.318 In particular, cyclodepsipeptides286 
are secondary metabolites that comprise a wide variety of cyclic peptides of natural origin 
characterized by the occurrence of at least one ester linkage.319 The wide spectrum of 
biological activities that this class of natural product display, including 
immunosuppressant, antibiotic, antifungi, antiinflammatory or antitumoral activities, 
together with their atractive molecular structures, have elicited great interest to the 
biological, medical and chemical community. 320  As a new demonstration of the 
impressive source of secondary metabolites type-cyclodepsipeptide from marine 
enviroment, three unprecedented cyclic depsipeptides termed celebesides A-C (718-720) 
were isolated by Bewley et al. 321 from the marine sponge Siliquariaspongia mirabilis 
collected from the Sulawesi Island, in Indonesia  (Figure 20).  
 
 
Figure 20. Molecular Structures of Celebesides A-C 
 
The structure of these compounds were elucidated by extensive spectroscopic 
methods. The absolute configurations of the amino acids were determined by Marfey’s 
method322 and chiral HPLC, while the relative configuration of the polyketide moiety was 
resolved by combination of J-based analysis and quantic mechanic (QM) calculations. 
These natural products are unusual [26]-membered cyclic depsipeptides that contain a 
polyketide chain namely 7,9-dihydroxy-8,10-dimethyltrideca-2,4-dienoic acid (Ddtd), 
and a peptide chain comprises by five amino acids residues, including a N-methyl valine, 
a -methyl L-asparagine, a D-isoserine, a 3-carbamoyl D-threonine and a L-serine in 
celebeside C (720), and a phosphoserine residue in celebesides A (718) and B (719). 
Interestingly, the 3-carbamoyl threonine and phosphoserine are uncommon aminoacids 
contained in marine natural products. From the biological standpoint, celebeside A (718) 
                                                          
318 (a) Drug Discovery from Nature; Grabley, S.; Thiericke, R.; Eds.; Springer-Verlag: Berlin, 2000. (b) Samuelsson, G. Drugs of 
Natural Origin; Swedish Pharmaceutical Press: Stockholm, 1992. (c) Nicolaou, K. C.; Chen, J. S.; Dalby, S. M. Bioorg. Med. Chem. 
2009, 17, 2290–2303. 
319 (a)  Faulkner, D. J. Nat. Prod. Rep. 1994, 11, 355–394. (b) Burja, A. M.; Banaigs, B.; Abou-Mansour, E.; Burgess, J. G.; Wright, 
P. C. Tetrahedron, 2001, 57, 9347–9377. (c) Faulkner, D. J. Nat. Prod. Rep. 2002, 19, 1–48. 
320 Ballard, C. E.; Yu, H.; Wang, B. Curr. Med. Chem. 2002, 9, 471–498. 
321 Plaza, A.; Bifulco, G.; Keffer, J. L.; Lloyd, J. R.; Baker, H. L.; Bewley, C. A. J. Org. Chem. 2009, 74, 504–512. 
322 Fujii, K.; Ikai, Y.; Oka, H.; Suzuki, M.; Harada, K.-I.; Anal. Chem. 1997, 69, 5146–5151. 
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showed anti-HIV activity, with an IC50 of 1.9 g/ml. In addition, 718 was cytotoxic 
against a human colon cancer cell line (HTC-116) in the low M range. In contrast, 
celebeside C (720) was inactive, while celebeside B (719) was not biologically evaluated. 
Once again, the scarcity of the isolated cyclodepsipeptides from the natural sources is a 
drawback for further pharmacological assays. This difficulty to access large amounts of 
these compounds makes quite difficult to gain insight into their biological profiles and 
mechanism of biological action and justifies the chemical synthesis of these unexplored 
marine cyclodepsipeptides. 
 
5.2. Chemistry of the Celebesides 
The synthesis of the lipidic chain of celebeside A (718) carried out by our group 
in 2014 represents the only synthetic approach towards the polyketide fragment contained 
in celebesides reported to date.250e Our synthesis was based on the use of a new class of 
sulfonium salts to obtain glycidic amides in a stereoselective fashion (Scheme 94).  
 
 
 
Scheme 94. Synthesis of the Polyketide Chain of the Celebeside A (Sarabia et al. 2014)250e 
 
The oxirane ring-opening reactions of the obtained epoxy amides let to obtain the 
syn,anti,syn dipropionate-acetate stereopentad unit contained in the celebesides, as well 
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as in many other natural products as YM-47522,323 the anti-fungal basiliskamide324 and 
the cyclodepsipeptide langunamide A.325 As depicted in Scheme 94, the oxirane ring 
opening of 721 with Me2CuLi was followed by TBS protection of the resulting alcohol, 
and subsequent amide reduction with NH3.BH3/LDA to obtain alcohol 722 in 60% overall 
yield from 721. Then, Swern oxidation afforded aldehyde 723 which was treated with 
chiral sulfonium salt 457 under basic conditions to afford epoxy amide 724 in 42% yield 
over 2 steps. This reaction was performed with the known non-chiral sulfur ylide 725 to 
gave epoxy amide 726 as the major isomer (ratio 9:1) in 68% yield over 2 steps. The 
efficient stereocontrol during the nucleophilic addition was due to the starting chiral 
aldehyde 723. Reduction of epoxy amide 724 or 726 with Super-H® gave the 
corresponding epoxy alchols wich were treated with Red-Al to obtain diol 727 which 
represent the complete polyketide fragment of celebeside A (718). 
 
5.3. An Olefin Metathesis Approach Towards the Celebesides 
5.3.1. Synthesis of the Peptide Fragment of the Celebesides  
We decided to initiate a research programme towards the total synthesis of the 
celebesides, which is justified by the following reasons: (1) Intriguing biological 
properties displayed by these natural compounds; (2) The need to have and supply enough 
material for further biological evaluations; (3) To confirm their novel structures; (4) To 
pave the synthetic scheme for generation of related compounds as novel scaffolds with 
potential therapeutic applications. In particular, among the three celebesides, we firstly 
focused our efforts on the synthesis of celebeside A (718) due to the attractive biological 
profile displayed.  
 
To this aim, we designed a retrosynthetic analysis of the celebeside A (718) based 
on an olefin ring-closing metathesis reaction as the key step for the construction of the 
macrocycle. Thus, as depicted in Scheme 95, part A, our analysis began with the amide 
and ester disconnections of the L-serine residue and the N-Me-valine residue, 
respectively, to render two key fragments: the peptidic fragment 728 and the polyketide 
fragment 729. For the consecution of the peptide fragment of the celebesides (728), we 
decided to use the solid phase peptide synthesis (SPPS) methodology as a suitable 
technology for rapid and advantageous access to the linear peptide chain. We selected the 
2-chlorotrityl chloride (CTC) resin due to its resistence in the basic media employed in 
peptide coupling conditions. The general strategy is depicted in Scheme 95, part B. 
 
In our first approach towards celebeside A, we initially targeted a more simple 
derivative for a rapid validation of our RCM strategy. In this sense, we planned to produce 
a model peptidic fragment that possessed a -alanine aminoacid intead of the D-isoserine 
residue which is contained in the natural products. In addition, the proposed model did 
                                                          
323 Ermolenko, M. S. Tetrahedron Lett. 1996, 37, 6711–6712. 
324 Barsby, T.; Kelly, M. T.; Andersen, R. J. J. Nat. Prod. 2002, 65, 1447–1451. 
325 Huang, W.; Ren, R.-G.; Dong, H.-Q.; Wei, B.-G.; Lin, G.-Q. J. Org. Chem. 2013, 78, 10747–10762. 
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not contain the methyl group upon the asparagine residue, avoiding the preparation of this 
complex amino acid.  
 
 
 
Scheme 95. Retrosynthetic Analysis of Celebeside A (A) and Solid Phase Peptide Synthesis (SPPS) 
Strategy (B) 
 
With this purpose, we started the solid phase synthesis from the CTC resin which 
was properly derivatized with the Fmoc-L-Ser(Bn)-OH (730) using HOBt and DIPEA in 
dimethylformamide (DMF) for 30 h to produce the resin-bound peptide 735. The Fmoc 
group of 735 was removed by treatment with 20% solution of piperidine in DMF and the 
Fmoc-L-Asn(Trt)-OH (736) was loaded onto the resulting resin using HOBt and DIC in 
DMF. The same sequence to remove the Fmoc groups and to couple amino acids was 
repeated to introduce the Fmoc-D-Thr(tBu)-OH (732). To check the loading of the amino 
acid and to ensure the effectiveness of the chosen coupling procedure, we decided to 
cleave the tripeptide by treatment of 737 with AcOH/CF3CH2OH (TFE)/CH2Cl2 (7:2:1), 
which gave pure tripeptide 738. The synthesis was continued from 737, repeating the 
procedure of coupling and Fmoc deprotection steps for the sequentially introduction of 
Fmoc--Ala-OH (739), and the commercial 2,4-pentadienoic acid 734, to obtain the 
resin-bound peptide 741. At the end of the solid phase peptide synthesis, the resin-bound 
peptide 741 was cleaved from the resin by treatment with a AcOH:TFE:CH2Cl2 (7:2:1) 
mixture to obtain the model peptide chain of the celebesides 742 in 65% overall yield 
from CTC resin  in a high  degree of purity as determined by its NMR spectra and did not 
required further purification (Scheme 96).  
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Scheme 96. Solid Phase Synthesis of 742  
 
 In order to ensure that during the solid phase synthesis of 742 any process of 
epimerization took place,326 we decided to repeat the synthesis via solution phase, and 
then compare the spectroscopic data of both products, which should match. Thus, the 
synthesis of 742 via solution phase began with the protection of the Fmoc-L-Ser(Bn)-OH 
(730) as allyl ester derivative. From protected compound 743, deprotection of the Fmoc 
group by treament with a solution of piperidine in CH2Cl2 afforded the corresponding 
free amine, which was subjected to a peptide coupling with the Fmoc-L-Asn(Trt)-OH 
(736) in presence of HOBt and EDC to obtain peptide 744 in 58% over 2 steps. Then, an 
iterative process to deprotect the Fmoc groups and to couple the Fmoc aminoacids 
derivatives was repeated three times under the same reaction conditions than previously 
employed to introduce sequentially the amino acids Fmoc-D-Thr(tBu)-OH (732) and 
Fmoc--Ala-OH (739) and the 2,4-pentadienoic acid 734 in 60%, 57% and 53% over 2 
steps, respectively (Scheme 97). Final deprotection of the allyl group in presence of 
Pd(PPh3)4 and morpholine gave the model peptidic chain of the celebesides (747) in 
quantitative yield. Spectroscopic properties of 747 obtained from solid phase and from 
solution phase were identical, thus confirming that epimerization process did not occur 
during the solid phase synthesis. Thus, with these results, we have established a solid 
phase synthesis strategy for the construction of the peptide fragment of the celebesides.  
 
                                                          
326 For an example of epimerization process in solid phase peptide synthesis see: Spatola, A. F.; Darlak, K.; Romanovskis Tetrahedron 
Lett. 1996, 37, 591–594. 
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Scheme 97. Synthesis of 742 by Solution Phase 
 
 With the aim to extend the previous established solid phase strategy to a more 
advanced celebeside peptide chain, we decided to include in the peptidie fragment the 
amino acid D-isoserine that is contained in the structure of the natural celebesides. With 
this purpose, we first carried out the synthesis of the required Fmoc-D-isoserine 733. 
Thus, the synthesis of 733 started from D-(+)-malic acid (748), which was transformed 
in three steps into acylc acide 749, as shown in Scheme 98, part A. Then, the Curtius 
rearrangement was used to introduce the isocyanate group through the termal 
decomposition of the carboxylic azide intermediate. The resulting isocyanate 750 was 
reacted with FmocOH to afford carbamate 751, which was subsequent treated with HCl 
at 40 ºC to obtain Fmoc-D-isoserine (733)327 in 26% over 6 steps (Scheme 98, part A). 
With 733 in hand, we proceeded with the solid phase synthesis of the more advanced 
peptidic chain of celebesides, represented by compound 753 in Scheme 98, part B. 
Starting again from the 2-chlorotrityl chloride (CTC) resin, we repeated the same steps 
for the solid phase synthesis of 742, but in this case we included the Fmoc D-isoserine 
733 instead the Fmoc--alanine (739), thus obtaining the corresponding peptide fragment 
753 in 63% overall yield from CTC resin (Scheme 98, part B). 
 
                                                          
327 The synthesis of D-isoserine has been described in the literature according to a slightly modified protocol (a) Kodra, J. T.; 
Jorgensen, A. S.; Andersen, B.; Behrens, C.; Brand, C. L.; Christensen, I. T.; Guldbrandt, M.; Jeppesen, C. B.; Knudsen, L. B.; 
Madsen, P.; Nishimura, E.; Sams, C.; Sidelmann, U. G.; Pedersen, R. A.; Lynn, F. C.; Lau, J. J. Med. Chem. 2008, 51, 5387–5396.(b) 
Böttcher, C.; Burger, K. Tetrahedron Lett. 2003, 44, 4223–4226. 
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Scheme 98. Synthesis of Fmoc-D-Isoserine 733 (A) and Solid Phase Synthesis of 753 (B) 
 
5.3.2. Synthesis of the Polyketide Fragment of Celebeside A 
At this point of the synthesis, where we were able to establish a synthetic strategy 
for the consecution of the peptidic fragment of the celebesides by solid and solution phase, 
we focused on the synthesis of the polyketide fragment of celebeside A. As previously 
showed in Scheme 94, our goup achieved the synthesis of the polyketide fragment of 
celebeside A by oxirane ring-opening reactions of epoxy amides obtained by sulfonium 
ylides. Now, with the aim to explore new strategies, we planned a different approach 
without the use of sulfoniums ylides. In this sense, the new approach was based on the 
combined asymmetric methylation, anti-aldol reaction, and Brown’s asymmetric 
allylation to obtain the required syn,anti,syn dipropionate-acetate stereopentad unit 
(Scheme 99, part A).   
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Scheme 99. Retrosynthetic Analysis (A) and Synthesis of the Polyketide Fragment of the Celebeside A 
(729) (B) 
 
Thus, this new synthetic plan started with the conversion of aldehyde 756 in ,-
unsaturated ester 758 via a Wittig reaction by the use of 
[(Ethoxycarbonyl)methylene]triphenylphosphorane. Reduction of the ester 758 with 
DIBAL-H afforded allylic alcohol 759 in 81% yield. Subsequent Sharpless asymmetric 
epoxidation by the use of (+)-L-DET gave epoxy alcohol 760 in 84% yield, which was 
subjected to the oxirane opening employing Me2CuLi to obtain a 3:1 mixture of opening 
products in 2- and 3- positions, respectively. Therefore, the oxirane opening step was 
followed by a periodic cleavage employing NaIO4 to obtain diol 761 in 62% over two 
steps  (Scheme 99). From 761, a sequence of protection of the diol as silyl ethers and 
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selective deprotection of the primary alcohol was achieved in 60% overall yield to obtain 
alcohol 763, which was subjected to a oxidation reaction with Dess-Martin periodinane 
to obtain aldehyde 764 in 95% yield. Final Brown’s asymmetric allylation of aldehyde 
764 by the use of (-)-Ipc2B(allyl) gave 729 in excellent 92% yield and complete 
stereoselectivity, which represents the complete polyketide fragment of the celebeside A.  
 
 
Scheme 100. Synthesis of Celebeside A Polyketide Fragment Model 766 
 
At this point where we were able to establish a solid strategy to access to the 
polyketide fragment of the celebeside A, we decided to focus on the preparation of a more 
simple derivative for a rapid validation of our RCM strategy, represented by compound 
766 in Scheme 100, avoiding the use of the complex chain 729 contained in the natural 
product which required more steps for its synthesis.  
 
The synthesis of the polyketide chain model 766 started with the known hydrolytic 
kinetic resolution of the corresponding racemic 1,2-epoxyhexane by the action of cobalt 
catalyst 767, to afford enationmeric pure 768 in 33% yield.328 Then, epoxide opening of 
768 by use of homoallylmagnesium bromide gave alohol 770 in 67% yield, which was 
subjected to a Yamaguchi esterification with Fmoc-N-Me-Valine-OH (771) to obtain 
ester 772 in 74% yield. Finally, Fmoc deprotection by treatment of 772 with piperdine 
yielded 766 in quantitative yield (Scheme 100).  
                                                          
328 Haase, B.; Schneider, M. Tetrahedron: Asymmetry 1993, 4, 1017–1026. 
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5.3.3. Towards the Macrocyclic Core of Celebeside A 
 With model amine 766 in our hands, we would be able to complete the last steps 
of towards the celebeside A in order to try our RCM strategy (Scheme 101). However, 
this task still remains incomplete due to the lack of time. Thus, the last steps towards the 
celebesides are not included in the current PhD Thesis, and it will be reported in due time. 
 
 
 
Scheme 101. Planned Strategy towards the Macrocyclic Core of the Celebeside A via RCM 
 
5.4. Summary 
In conclusion, we have envisioned a synthetic strategy directed towards the 
celebesides utilizing an olefin metathesis reaction to form the [26]-membered ring 
contained in these natural products. In our strategy, we have used the solid phase synthesis 
as a suitale technology for a rapid and efficient access to the peptide fragment contained 
in the celebesides (compounds 742 and 753), while the polyketide chain of the celebeside 
A, represented by compound 729, has been achieved in a stereoselective fashion, 
featuring an asymmetric methylation, epoxide opening and Brown’s asymmetric 
allylation as the key steps. The described synthetic strategy for the celebesides would 
allow for access to the natural products, as well as would offer the opportunity for the 
generation of a wide array of celebeside analogues by modifing the amino acids contained 
in the peptide chain during the solid phase-based synthesis in an easy and rapid manner. 
The completion of the synthesis of the celebeside A is currently in progress and will be 
reported in due course.
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6.1. Conclusions 
The conclusions of the current PhD Thesis are summarized as the following: 
1) We have established a new total synthesis of (-)-depudecin (442) utilizing an 
olefin cross-metathesis reaction as the key step, which was successfully achieved 
in a convergent manner to provide (-)-depudecin (442) in only 12 steps and 26% 
overall yield from (+)-methyl-D-lactate. This new convergent approach greatly 
improves upon our previous linear synthesis (17 steps, 19% overall yield) as well 
as the Schreiber synthesis (23 steps, 0.7% overall yield). 
 
2) The developed synthetic route was amenable to stereochemical and functional 
modifications, allowing the preparation of two stereoisomers of (-)-depudecin, the 
10-epi-depudecin (498) and its enantiomer (ent-442), as well as homodepudecin 
(506). In addition, we have complemented the set of analogues with the 
preparation of truncated analogues 540, 541 and 555.  
 
3) The synthesized depudecin analogues were biologically evaluated against several 
tumor cell lines, including endothelial cells and the results led us to complete a 
preliminary structure-activity relationship (SAR) study for this natural product 
concluding that: a) the C-10 stereochemistry of the product is not essential upon 
the biological activity; b) the presence of at least one of the epoxide groups is key 
upon the biological activity, but it is not necessary the simultaneous presence of 
both epoxides; and c) the terminal allylic alcohol system is not essential, and it 
can be substitued by its isomer. 
 
4) An extensive synthetic exploration directed towards the solomonamides was 
conducted based on a ring-closing metathesis as the key reaction for the rapid and 
efficient access to their macrocyclic cores, which proceeded in high yields and 
complete stereoselectivity.  
 
5) We identified several structurally related solomonamide precursors possessing 
significant cytotoxicities against various tumor cell lines, including endothelial 
cells, in the low M range. In particular, we found that compound 653 exhibits a 
potent antiangiogenic effect in vitro and in vivo, and the results suggest the 
potential therapeutic application of solomonamide derivatives as inhibitors of the 
persistent and deregulated angiogenesis that characterizes cancer and other 
pathologies. 
 
6) We envisioned a synthetic strategy directed towards the celebesides utilizing an 
olefin metathesis reaction to form the [26]-membered ring contained in these 
natural products. In our strategy, we used the solid phase synthesis as a suitable 
technology for a rapid and efficient access to the peptide fragment contained in 
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the celebesides, while the polyketide chain of the celebeside A was achieved in a 
stereoselective fashion. 
 
7) The described chemistry highlights the benefits of the olefin metathesis reaction 
in the field of the total synthesis of natural products, featuring convergency and 
flexibility for structural diversity and has allowed the identification of bioactive 
compounds with interesting antitumor properties.  
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7.1. General Techniques 
All reactions were carried out under an argon atmosphere with dry, freshly 
distilled solvents under anhydrous conditions, unless using aqueous reagents or otherwise 
noted. All solvents used in reactions were dried and distilled using standard procedures. 
Tetrahydrofuran (THF) was distilled from sodium benzophenone, methylene chloride 
(CH2Cl2) from calcium hydride, diethyl ether from sodium. Yields refer to 
chromatographically and spectroscopically (1H NMR) homogeneous materials, unless 
otherwise stated. All solutions used in workup procedures were saturated unless otherwise 
noted. All reagents were purchased at highest commercial quality and used without 
further purification unless otherwise stated. All reactions were monitored by thin-layer 
chromatography (TLC) using 0.25 mm silica gel plates (60F-254) using UV light (254 
nm) as visualizing agent and acidic ceric ammonium molybdate/phosphomolybdic acid 
or potassium permanganate solutions and heat as developing agents. Flash column 
chromatography (FCC) was performed using silica gel (60 Å, particle size 230-400 mesh) 
under air pressure. All solvents used for chromatographic purifications were distilled 
prior to use. 1H and 13C NMR spectra were recorded on a Bruker DPX-400 MHz 
instrument and calibrated using residual undeuterated solvent as an internal reference. 
Chemical shifts are reported in ppm with the resonance resulting from incomplete 
deuteration of the solvent as the internal standard (13CDCl3: 7.26 ppm, s and 77.0 ppm, t; 
13CD3OD: 4.87 ppm, s, 3.31 ppm, quin and 49.1 ppm, sep; 
13C2D6OS: 2.49 ppm, quin and 
39.52 ppm, sep). Data are reported as follows: chemical shift /ppm (multiplicity, 
coupling constants J (Hz) and integration (1H only)). The following abbreviations were 
used to explain the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; quin = 
quintet; b = broad; m = multiplet or combination thereof. 13C signals are singles, unless 
otherwise stated. High resolution mass spectrometry (HRMS) was performed on a H-ESI 
and APCI mass spectrometer in positive mode and using an ion trap (Orbitrap) as the 
mass analyzer type. HRMS signals are reported to 4 decimal places and are within  5 
ppm of theoretical values. Specific optical rotations were recorded on a Perkin-Elmer 241 
polarimeter with a sodium halogen lamp (ƛ = 589 nm) and a cell path length of 100 mm 
(c given in g/100 mL). Melting points were collected using a Gallenkamp melting point 
system using a gradient of 0.5 ºC per min.  
 
7.2. Experimental Procedures and Compound Characterization Related to 
Depudecin 
7.2.1. Synthesis of Epoxy Alkene 460 
Epoxy Alkene 460. A solution of epoxy alcohol 464253 (220 mg, 0.95 
mmol, 1.0 equiv) in a 1:1 DMSO:CH2Cl2 mixture (20 mL) was treated 
with Et3N (0.4 mL, 14.20 mmol, 3.0 equiv) and SO3·pyr (375 mg, 2.37 
mmol, 2.5 equiv) at 0 ºC. The mixture was stirred until complete 
conversion of the alcohol ( 3 h). After this time, the reaction mixture was quenched by 
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addition of a buffer solution (pH = 7) and diluted with Et2O. The aqueous phase was 
extracted with Et2O twice and the combined organic layers were washed with brine, dried 
over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure to 
give the crude aldehyde (0.95 mmol) which was used in the next step without further 
purification. To a stirred suspension of methyl triphenylphosphonium bromide (693 mg, 
1.90 mmol, 2.0 equiv) in THF (10 mL) at 0 ºC was added dropwise NaHMDS (0.95 mL, 
2.0 M in THF, 1.87 mmol, 2.0 equiv). The resulting suspension was stirred for 30 min at 
this temperature, and after this time, a solution of the crude aldehyde (0.95 mmol) in 
THF (5 mL) was added dropwise, and the resulting mixture stirred for 1 h. After this time, 
the crude mixture was diluted with Et2O and washed with a saturated aqueous NH4Cl 
solution. The aqueous phase was extracted with Et2O and the combined organic extracts 
were washed with brine, dried over MgSO4, filtered and the solvent evaporated under 
reduced pressure. The crude product was purified by flash column chromatography (silica 
gel, 10% EtOAc in hexanes) to obtain epoxy alkene 460 (100 mg, 50% over two steps) 
as a pale yellow oil: Rf = 0.74 (silica gel, 10% EtOAc in hexanes); [α]25D = + 35.2 (c 0.40, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 5.63–5.53 (m, 1 H), 5.45 (dd, J = 17.2, 1.5 Hz, 
1 H), 5.26 (ddd, J = 10.2, 1.5, 0.5 Hz, 1 H), 3.66–3.58 (m, 1 H), 3.20 (dd, J = 7.5, 2.2 Hz, 
1 H), 2.85 (dd, J = 5.9, 2.2 Hz, 1 H), 1.21 (d, J = 6.4 Hz, 3 H), 0.90 (s, 9 H), 0.10 (s, 3 
H), 0.07 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 135.5, 118.9, 67.5, 63.5, 56.5, 25.8, 
20.8, 18.1, –4.7, –4.9; HRMS (H-ESI) m/e calcd for C12H24O2Si [M + H]+ 229.1624, 
found 229.1618. 
 
7.2.2. Synthesis of Diepoxy Amide 466 
Diepoxy Amide 466. Epoxy alcohol 465254 (640 mg, 2.96 
mmol 1.0 equiv) was dissolved in a CH2Cl2/DMSO (1:1) 
mixture (12 mL) and cooled at 0 ºC. At this temperature, 
Et3N (1.2 mL, 8.88 mmol, 3.0 equiv) was added followed 
by SO3·pyr (840 mg, 5.20 mmol, 1.8 equiv). The reaction 
mixture was allowed to reach room temperature and, after 5 h, was quenched by addition 
of a buffer solution (pH = 7) and diluted with Et2O. The aqueous phase was extracted 
with Et2O (3 x 20 mL) and the combined organic extracts were washed with water and 
brine, then dried over anhydrous MgSO4 and the solvent removed under reduced pressure. 
The resulting crude aldehyde was used in the next step without further purification. To a 
suspension of sulfonium salt 457249, 250 (1.0 g, 3.40 mmol, 1.1 equiv) in t-BuOH (40 mL) 
was added a 5.0 M aqueous NaOH solution (0.6 mL, 3.0 mmol, 1.0 equiv) at 25 ºC. After 
1 h at this temperature, a solution of crude aldehyde in t-BuOH (10 mL) was added and 
the resulting reaction mixture was stirred overnight. The crude mixture was then diluted 
with CH2Cl2 and H2O and, after decantation, the aqueous phase was extracted with 
CH2Cl2 three times. The combined organic extracts were washed with brine, dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude product was purified 
by flash column chromatography (silica gel, 20% EtOAc in hexanes) to obtain diepoxy 
amide 466 (920 mg, 73% over 2 steps) as a pale yellow oil and whose spectroscopic and 
physical properties matched with those described in the literature:250f Rf = 0.20 (Silica 
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gel, 40% EtOAc in hexanes); [α]25D = –17.1 (c 0.34, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ (ppm): 4.27 (ddd, J = 8.8, 4.7, 3.5 Hz, 1 H), 3.97 (ddd, J = 9.1, 5.2, 1.3 Hz, 1 
H), 3.89–3.86 (m, 1 H), 3.85 (d, J = 2.0 Hz, 1 H), 3.69 (dd, J = 12.3, 3.7 Hz, 1 H), 3.54 
(d, J = 2.0 Hz, 1 H), 3.30 (dd, J = 3.4, 2.0 Hz, 1 H), 3.11–3.06 (m, 2 H), 2.59–2.50 (m, 1 
H), 2.48–2.39 (m, 1 H), 2.08 (s, 3 H), 2.05–2.00 (m, 1 H), 1.83–1.73 (m, 1 H), 1.59 (s, 3 
H), 1.48 (s, 3 H), 0.84 (s, 9 H), 0.02 (s, 3 H), 0.00 (s, 3 H); 13C NMR (100 MHz, CDCl3) 
δ (ppm): 162.9, 95.9, 67.0, 61.6, 56.3, 55.9, 55.5, 51.7, 51.2, 34.4, 30.6, 26.2, 25.8, 22.9, 
18.3, 15.7, –5.4, –5.4; HRMS (H-ESI) m/e calcd for C20H37NO5SSi [M + H]+ 432.2240, 
found 432.2239. 
 
7.2.3. Synthesis of Diepoxy Alkene 461 
Diepoxy Alkene 461. To a solution of diepoxy amide 466 (95 
mg, 0.34 mmol, 1.0 equiv) in THF (1.5 mL) was added dropwise 
Red-Al (0.03 mL, 70% w/v in toluene, 0.09 mmol, 0.5 equiv) at 
0 ºC. After 30 min at this temperature, the reaction mixture was quenched by addition of 
a saturated aqueous Na+/K+ tartrate solution and diluted with EtOAc. The resulting 
mixture was vigorously stirred until a clear separation of both oganic and aqueous phases. 
After separation of both layers, the aqueous phase was extracted with EtOAc and the 
combined organic extracts washed with H2O and brine, dried over anhydrous MgSO4, 
and the solvent evaporated under reduced pressure. The resulting crude aldehyde was 
used in the next step without further purification. To a stirred suspension of methyl 
triphenylphosphonium bromide (123 mg, 0.35 mmol, 1.75 equiv) in THF (1.0 mL) at 0 
ºC was added dropwise NaHMDS (0.18 mL, 2.0 M in THF, 0.35 mmol, 1.75 equiv). The 
resulting suspension was stirred for 15 min at this temperature, and after this time, a 
solution of the crude aldehyde (0.20 mmol) in THF (3.0 mL) was added dropwise, and 
the resulting mixture was stirred for 30 min. After this time, the crude mixture was diluted 
with Et2O and washed with a saturated aqueous NH4Cl solution. The aqueous phase was 
extracted with Et2O and the combined organic extracts were washed with brine, dried 
over MgSO4, filtered and the solvent evaporated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) 
to obtain the epoxy alkene 461 (33 mg, 50% over two steps) as a colorless oil: Rf = 0.89 
(silica gel, 40% EtOAc in hexanes); []25D = –20.2 (c 0.39, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 5.59–5.49 (m, 2 H), 5.35–5.30 (m, 1 H), 3.88 (dd, J = 12.2, 2.9 Hz, 1 H), 3.75 
(dd, J = 12.2, 4.0 Hz, 1 H), 3.36 (dd, J = 7.0, 2.1 Hz, 1 H), 3.11 (ddd, J = 4.0, 2.8, 2.2 Hz, 
1 H), 3.00 (dd, J = 4.3, 2.2 Hz, 1 H), 2.92 (dd, J = 4.4, 2.1 Hz, 1 H), 0.89 (s, 9 H), 0.07 
(s, 3 H), 0.07 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 134.5, 128.5, 62.1, 57.7, 56.0, 55.9, 
53.3, 29.7, 25.8, 18.3, –5.4; HRMS (H-ESI) m/z calcd for C13H24O3Si [M + H]+ 257.1573, 
found 257.1567.  
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7.2.4. Synthesis of Aldehyde 467 
Aldehyde 467. To a solution of epoxy alcohol 465 (4.0 g, 18.32 
mmol, 1.0 equiv) in a 1:1 DMSO:CH2Cl2 mixture (36 mL) was 
added Et3N (7.7 mL, 54.95 mmol, 3.0 equiv) followed by 
SO3·pyr (7.3 g, 45.79 mmol, 2.5 equiv) at 0 ºC. The reaction mixture was stirred at this 
temperature until depletion of the starting alcohol as judged by TLC ( 5 h). After this 
time, the reaction mixture was quenched by addition of a buffer solution (pH = 7) and 
diluted with Et2O. The aqueous phase was extracted with Et2O (2 x 30 mL) and the 
combined organic layers were washed with brine, dried over anhydrous MgSO4, filtered 
and the solvent evaporated under reduced pressure to give the crude aldehyde (18 mmol) 
which was used in the next step without further purification. To a solution of the crude 
aldehyde in CH2Cl2 (95 mL) was added (formylmethylene)triphenylphosphorane (7.0 g, 
23.08 mmol, 1.2 equiv) and the mixture was stirred for 12 h. After this time the solvent 
was removed under reduced pressure and the residue purified by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) to obtain aldehyde 467 (3.3 g, 74% 
over two steps) as a pale yellow oil: Rf = 0.51 (silica gel, 30% EtOAc in hexanes); []25D 
= –24.8 (c 0.21, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 9.57 (d, J = 7.7 Hz, 1 H), 6.57 
(dd, J = 15.8, 6.9 Hz, 1 H), 6.40 (ddd, J = 15.8, 7.7, 0.6 Hz, 1 H), 3.94–3.89 (m, 1 H), 
3.81 (dd, J = 12.2, 3.8 Hz, 1 H), 3.55 (dd, J = 6.9, 2.0 Hz, 1 H), 3.12 (ddd, J = 3.8, 3.0, 
2.0 Hz, 1 H), 0.90 (s, 9 H), 0.08 (s, 3 H), 0.07 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
192.4, 152.3, 133.9, 61.9, 61.5, 53.4, 25.8, 18.3, –5.3; HRMS (H-ESI) m/z calcd for 
C12H22O3Si [M + H]
+ 243.1416, found 243.1398. 
 
7.2.5. Synthesis of Allylic Alcohol 468 
Allylic Alcohol 468. A solution of aldehyde 467 (3.3 g, 13.61 
mmol, 1.0 equiv) in CH2Cl2 (120 mL) was cooled at -78 ºC 
and treated with DIBAL-H (13.6 mL, 1.0 M in toluene, 13.61 
mmol, 1.0 equiv). After 20 min, the reaction was quenched by addition of MeOH at -78 
ºC and the mixture was allowed to reach room temperature, treated with a saturated 
aqueous Na+/K+ tartrate solution and diluted with CH2Cl2. The resulting mixture was 
vigorously stirred until a clear separation of both organic and aqueous phases. The organic 
layer was separated and the aqueous phase was extracted with CH2Cl2 three times. The 
combined organic layers were washed with brine, dried over anhydrous MgSO4, filtered 
and the solvent evaporated under reduced pressure. The residue was purified by flash 
column chromatography (silica gel, 15% EtOAc in hexanes) to obtain allylic alcohol 468 
(3.0 g, 90%) as a yellow oil: Rf = 0.35 (silica gel, 30% EtOAc in hexanes); []25D = –31.8 
(c 0.64, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 6.09 (dt, J = 15.7, 5.3 Hz, 1 H), 5.51 
(ddt, J = 15.6, 7.9, 1.7 Hz, 1 H), 4.19 (td, J = 5.7, 1.6 Hz, 2 H), 3.86 (dd, J = 12.0, 3.3 Hz, 
1 H), 3.73 (dd, J = 12.0, 4.4 Hz, 1 H), 3.32 (dd, J = 7.9, 2.1 Hz, 1 H), 3.02 (ddd, J = 4.4, 
3.2, 2.2 Hz, 1 H), 1.39 (t, J = 5.9 Hz, 1 H), 0.90 (s, 9 H), 0.09 (s, 3 H), 0.08 (s, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 132.5, 128.2, 62.9, 62.8, 60.4, 55.3, 25.9, 18.4, –5.3; HRMS 
(H-ESI) m/z calcd for C12H24O3Si [M + H]
+ 245.1573, found 245.1595. 
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7.2.6. Synthesis of Diepoxy Alcohol 469 
Diepoxy Alcohol 469. To a suspension of titanium 
tetraisopropoxide (1.27 mL, 4.29 mmol, 0.35 equiv) and 4Å 
molecular sieves (8.0 g) in CH2Cl2 (85 mL) was added (+)-L-
DET (0.74 mL, 4.29 mmol, 0.35 equiv) at -20 ºC. After 15 min at this temperature, a 
solution of allylic alcohol 468 (3.0 g, 12.27 mmol, 1.0 equiv) in CH2Cl2 (100 mL) was 
added dropwise, followed by the addition, after additional 30 min, of TBHP (5.0 mL, 5.5 
M solution in decane, 24.55 mmol, 2.0 equiv) at the same temperature. After 12 h at this 
temperature, the reaction mixture was quenched with Me2S (4.2 mL, 56.47 mmol, 4.6 
equiv) at 0 ºC, filtered off and the solvent was evaporated under reduced pressure. The 
crude product was purified by flash column chromatography (silica gel, 20% EtOAc in 
hexanes) to obtain diepoxy alcohol 469 (2.49 g, 78%) as a colourless oil: Rf = 0.40 (silica 
gel, 50% EtOAc in hexanes); []25D = –22.4 (c 0.51, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 3.98 (ddd, J = 12.8, 4.9, 2.3 Hz, 1 H), 3.88 (dd, J = 12.2, 2.9 Hz, 1 H), 3.75 (dd, 
J = 12.2, 4.0 Hz, 1 H), 3.73–3.68 (m, 1 H), 3.17–3.15 (m, 1 H), 3.11 (ddd, J = 4.0, 2.9, 
2.2 Hz, 1 H), 3.08 (dd, J = 4.6, 2.2 Hz, 1 H), 2.98 (dd, J = 4.7, 2.2 Hz, 1 H), 0.89 (s, 9 H), 
0.08 (s, 3 H), 0.07 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 62.5, 62.0, 56.1, 55.8, 53.5, 
53.4, 25.8, 18.3, –5.4; HRMS (H-ESI) m/z calcd for C12H24O4Si [M + H]+ 261.1522, 
found 261.1523.  
 
7.2.7. Synthesis of Diepoxy Alkene 461 from Diepoxy Alcohol 469 
Diepoxy Alkene 461 from Diepoxy Alcohol 469. Diepoxy 
alcohol 469 (1.8 g, 6.91 mmol, 1.0 equiv) was converted to 
diepoxy alkene 461 (1.0 g, 60% over two steps) according to the 
procedure described above for 460 by sequential treatments with Et3N (2.9 mL)/SO3·pyr 
(2.8 g) and methyl triphenylphosphonium bromide (5.0 g)/NaHMDS (7.0 mL). The 
spectroscopic properties of the resulting diepoxy alkene were indetical with those 
exhibited by 461 obtained above from 466. 
 
7.2.8. Synthesis of Bis(silyl ether) 470 and Dimer 471. Cross-Metathesis of Olefins 
460 and 461 
Bis(silyl ether) 470 and Dimer 471. Cross-
Metathesis of Olefins 460 and 461. Hoveyda-
Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 0.2 
equiv), diepoxy alkene 461 (23 mg, 0.09 mmol, 1.0 
equiv) and epoxy alkene 460 (60 mg, 0.27 mmol, 3.0 
equiv) were dissolved in degassed CH2Cl2 (8 mL) and 
the reaction mixture was heated at 40 ºC for 12 h. 
After this time, the solvent was removed under reduced pressure and the resulting crude 
product was purified by flash column chromatography (silica gel, 5% EtOAc in hexanes) 
to obtain dimer 471 (23 mg, 60%) and bis(silyl ether) 470 (6 mg, 15%) as a colourless 
and a pale yellow oils, respectively. [470]: Rf = 0.57 (silica gel, 10% EtOAc in hexanes); 
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[]25D = –31.4 (c 0.40, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.72 (dd, J = 15.7, 7.0 Hz, 
1 H), 5.64 (dd, J = 15.6, 7.0 Hz, 1 H), 3.88 (dd, J = 12.2, 2.7 Hz, 1 H), 3.74 (dd, J = 12.2, 
4.0 Hz, 1 H), 3.67–3.60 (m, 1 H), 3.37 (dd, J = 7.0, 2.1 Hz, 1 H), 3.23 (dd, J = 6.9, 2.1 
Hz, 1 H), 3.11–3.07 (m, 1 H), 3.00 (dd, J = 4.2, 2.2 Hz, 1 H), 2.93 (dd, J = 4.2, 2.1 Hz, 1 
H), 2.86 (dd, J = 5.7, 2.1 Hz, 1 H), 1.20 (d, J = 6.4 Hz, 3 H), 0.90 (s, 9 H), 0.89 (s, 9 H), 
0.09 (s, 3 H), 0.07 (s, 3 H), 0.07 (s, 3 H), 0.06 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
132.7, 130.8, 69.2, 64.7, 61.9, 58.1, 56.1, 54.8, 54.8, 53.0, 25.8, 20.3, 18.3, 18.2, –4.8, –
5.4; HRMS (APCI) m/e calcd for C23H44O5Si2 [M + Na]
+ 479.2625, found 479.2621; 
[471]: Rf = 0.77 (silica gel, 10% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 5.68 
(dd, J = 4.4, 2.4 Hz, 2 H), 3.77 (dd, J = 6.2, 4.3 Hz, 2 H), 3.31 (dt, J = 4.4, 2.2 Hz, 2 H), 
2.78 (dd, J = 4.2, 2.1 Hz, 2 H), 1.23 (d, J = 6.3 Hz, 6 H), 0.88 (s, 18 H), 0.05 (s, 6 H), 
0.04 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 131.7, 67.2, 63.9, 55.1, 25.8, 20.8, 18.1, –
4.7, –4.8; HRMS (APCI) m/e calcd for C22H44O4Si2 [M + H]+ 429.2856, found 429.2862. 
 
7.2.9. Synthesis of Epoxy Alcohol 459 
Epoxy Alcohol 459. Silyl derivative 470 (30 mg, 0.07 
mmol, 1.0 equiv) was dissolved in a mixture THF-H2O 
(20:1) (5 mL) and over this solution was added p-TsOH 
(2 mg, 0.01 mmol, 0.1 equiv) at 25 ºC. After stirring for 
40 min at the same temperature, the solvent was removed under vacuum and the crude 
mixture purified by flash column chromatography (silica gel, 40% EtOAc in hexanes) to 
obtain diepoxy alcohol 459 (11 mg, 50%) as a pale colourless oil: Rf = 0.38 (Silica gel, 
60% EtOAc in hexanes); [α]25D = –35.2 (c 0.40, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 
5.73 (dd, J = 15.6, 7.1 Hz, 1 H), 5.64 (dd, J = 15.7, 7.2 Hz, 1 H), 3.72 (dd, J = 13.2, 3.1 
Hz, 1 H), 3.67–3.59 (m, 1 H), 3.39 (dd, J = 7.2, 2.1 Hz, 1 H), 3.24 (dd, J = 7.1, 2.0 Hz, 1 
H), 3.19–3.15 (m, 1 H), 3.10 (dd, J = 4.3, 2.2 Hz, 1 H), 3.05–3.01 (m, 1 H), 2.94 (dd, J = 
4.3, 2.1 Hz, 1 H), 2.87 (dd, J = 5.7, 2.1 Hz, 1 H), 1.60 (bs, 1 H), 1.20 (d, J = 6.4 Hz, 3 H), 
0.90 (s, 9 H), 0.09 (s, 3 H), 0.07 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 132.8, 130.5, 
69.1, 64.7, 61.7, 60.4, 57.9, 55.7, 54.8, 53.0, 25.8, 20.3, 18.2, –4.7, –4.8; HRMS (APCI) 
m/e calcd for C17H30O5Si [M + H]
+ 343.1941, found 343.1936. 
 
7.2.10. Synthesis of Epoxy Alkene 473 
Epoxy Alkene 473. Epoxy olefin 473 was prepared from epoxy alcohol 
472248 (2.7 g, 7.57 mmol, 1.0 equiv) by sequential treatments with 
SO3·pyr and Ph3P=CH2 according to the same procedure described 
above for the preparation of 460, to obtain epoxy alkene 473 (2.2 g, 85% 
over two steps) as a colourless oil: Rf = 0.66 (silica gel, 20% EtOAc in hexanes); []25D 
= + 12.7 (c 0.59, CH2Cl2);
 1H NMR (400 MHz, CDCl3) δ 7.72–7.68 (m, 4 H), 7.44–7.36 
(m, 6 H), 5.56 (ddd, J = 17.3, 10.2, 7.7 Hz, 1 H), 5.44–5.38 (m, 1 H), 5.25 (ddd, J = 10.3, 
1.5, 0.5 Hz, 1 H), 3.76–3.68 (m, 1 H), 3.19 (dd, J = 7.7, 2.2 Hz, 1 H), 2.96 (dd, J = 5.7, 
2.2 Hz, 1 H), 1.10 (d, J = 6.4 Hz, 3 H), 1.08 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 
135.9, 135.8, 135.3, 134.3, 133.7, 129.7, 129.6, 127.6, 127.5, 119.3, 69.9, 64.3, 56.1, 
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26.9, 19.9, 19.3; HRMS (H-ESI) m/z calcd for C22H28O2Si [M + H]
+ 353.1937, found 
353.1933. 
 
7.2.11. Synthesis of Diepoxy Alkene 474 
Diepoxy Alkene 474. To a solution of silyl ether 461 (700 mg, 2.73 
mmol, 1.0 equiv) in THF (70 mL) was added TBAF (5.5 mL, 1.0 
M in THF, 5.45 mmol, 2.0 equiv) at 0 ºC. The reaction mixture was 
stirred at 25 ºC for 1 h and, after this time, diluted with Et2O and washed with a saturated 
aqueous NH4Cl solution. The aqueous phase was then extracted with Et2O twice and the 
organic extracts were washed with brine, dried over MgSO4 and filtered. The solvent was 
removed under vacuum and the crude product was purified by flash column 
chromatography (silica gel, 10% EtOAc in hexanes → 30% EtOAc in hexanes) to obtain 
diepoxy alkene 474 (314 mg, 81%) as a colourless oil: Rf  = 0.33 (silica gel, 40% EtOAc 
in hexanes); []25D = –15.8 (c 0.27, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.47–5.37 
(m, 2 H), 5.24–5.18 (m, 1 H), 3.79 (ddd, J = 11.4, 9.0, 2.5 Hz, 1 H), 3.53 (dd, J = 12.9, 
4.3 Hz, 1 H), 3.29–3.25 (m, 1 H), 3.05 (dd, J = 4.3, 2.3 Hz, 1 H), 2.95–2.90 (m, 1 H), 2.81 
(dd, J = 4.8, 2.1 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 134.2, 120.4, 60.7, 57.9, 56.0, 
55.9, 53.5; HRMS (H-ESI) m/z calcd for C7H10O3 [M + H]
+ 143.0708, found 143.0696. 
 
7.2.12. Synthesis of Triepoxy Alcohol 455. Cross-Metathesis of Olefins 473 and 474 
Triepoxy Alcohol 455. Cross-Metathesis of Olefins 
473 and 474. Hoveyda-Grubbs 2nd generation catalyst 
(35 mg, 0.06 mmol, 0.10 equiv), diepoxy alkene 474 (80 
mg, 0.56 mmol, 1.0 equiv) and epoxy alkene 473 (595 
mg, 1.69 mmol, 3.0 equiv) were dissolved in degassed CH2Cl2 (6 mL) and the reaction 
mixture was heated at 40 ºC for 12 h. After this time, the solvent was removed under 
reduced pressure and the resulting crude product was purified by flash column 
chromatography (silica gel, 20% EtOAc in hexanes → 40% EtOAc in hexanes) to obtain 
triepoxy alcohol 455 (129 mg, 50%) as a colourless oil: Rf  = 0.51 (silica gel, 60% EtOAc 
in hexanes); []25D = –30.3 (c 0.45, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.71–7.66 
(m, 4 H), 7.44–7.35 (m, 6 H), 5.69 (dd, J = 15.7, 7.3 Hz, 1 H), 5.57 (dd, J = 15.6, 7.3 Hz, 
1 H), 3.98 (dd, J = 10.7, 2.2 Hz, 1 H), 3.76–3.68 (m, 2 H), 3.37 (dd, J = 7.3, 2.0 Hz, 1 H), 
3.21–3.16 (m, 2 H), 3.11 (dd, J = 4.3, 2.2 Hz, 1 H), 2.94 (ddd, J = 6.4, 4.9, 2.1 Hz, 2 H), 
1.34 (t, J = 7.1 Hz, 1 H), 1.10 (d, J = 6.4 Hz, 3 H), 1.07 (s, 9 H); 13C NMR (100 MHz, 
CDCl3) δ 135.8, 134.2, 133.6, 132.8, 130.5, 129.7, 127.6, 127.6, 69.7, 64.6, 62.5, 60.4, 
57.9, 55.7, 54.7, 52.9, 26.9, 19.9, 19.3; HRMS (H-ESI) m/z calcd for C27H34O5Si [M + 
Na]+ 489.2073, found 489.2073. 
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7.2.13. Synthesis of Tosyl Derivative 475 
Tosyl Derivative 475. Triepoxy alcohol 455 (57 mg, 
0.12 mmol, 1.0 equiv) was dissolved in CH2Cl2 (7 mL) 
and cooled at 0 ºC. Over this solution was then added 
p-TsCl (28 mg, 0.15 mmol, 1.2 equiv), TEA (30 L, 
0.18 mmol, 1.5 equiv) and 4-DMAP (0.3 mg, 0.002 mmol, 0.02 equiv). After 3 h, the 
reaction mixture was quenched by addition of water and the aqueous phase was extracted 
with CH2Cl2 three times. The organic phase was washed with brine, dried over MgSO4, 
filtered and the solvent removed under reduced pressure to obtain tosyl derivative 475 
(90 mg, 0.12 mmol), which did not require further purification for the next step. For 
analytical purposes, a sample of this crude (5.0 mg, 0.007 mmol) was purified by flash 
column chromatography (silica gel, 20% EtOAc in hexanes) to provide pure tosyl 
derivative 475 (3.8 mg, 87%) as a colourless oil: Rf = 0.33 (silica gel, 40% EtOAc in 
hexanes); [α]25D= –18.6 (c 0.25, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.81–7.78 (m, 2 
H), 7.71–7.65 (m, 4 H), 7.43–7.34 (m, 8 H), 5.67 (dd, J = 15.7, 7.3 Hz, 1 H), 5.54 (dd, J 
= 15.6, 7.6 Hz, 1 H), 4.20 (dd, J = 11.6, 3.7 Hz, 1 H), 4.08 (dd, J = 11.6, 5.2 Hz, 1 H), 
3.76–3.68 (m, 1 H), 3.32 (dd, J = 7.4, 1.9 Hz, 1 H), 3.22–3.17 (m, 2 H), 2.98 (dd, J = 4.0, 
2.0 Hz, 1 H), 2.94 (dd, J = 5.5, 2.2 Hz, 1 H), 2.88 (dd, J = 4.0, 2.0 Hz, 1 H), 2.46 (s, 3 H), 
1.10 (d, J = 6.4 Hz, 3 H), 1.07 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 145.3, 135.9, 
135.8, 134.2, 134.1, 133.6, 133.1, 130.2, 130.0, 129.7, 129.6, 127.9, 127.6, 127.5, 69.7, 
68.5, 64.6, 57.1, 54.8, 54.6, 53.8, 52.3, 26.9, 21.7, 19.9, 19.3; HRMS (H-ESI) m/z calcd 
for C34H40O7SSi [M + Na]
+ 643.2162, found 643.2161. 
 
7.2.14. Synthesis of Iodide Derivative 476 
Iodide Derivative 476. To a solution of crude tosyl 
derivative 475 (85 mg, 0.11 mmol, 1.0 equiv) in dry 
acetone (7 mL) was added dry KI (28 mg, 0.17 mmol, 1.5 
equiv) at room temperature, and the resulting crude 
mixture was refluxed for 5.5 hours. The reaction mixture was then allowed to cool to 
room temperature and the solvent was evaporated under reduced pressure. The resulting 
crude was diluted with H2O and extracted with Et2O. After separation of both phases, the 
organic extracts were washed with brine, dried over MgSO4, filtered and the solvent 
removed under reduced pressure to obtain iodide derivative 476 (80 mg, 0.11 mmol), 
which did not require further purification for the next step. For analytical purposes, a 
sample of this crude (4.5 mg, 0.006 mmol) was purified by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) to afford the iodide derivative 476 
(3.2 mg, 93%) as a colourless oil: Rf = 0.56 (silica gel, 30% EtOAc in hexanes); [α]25D= 
–19.4 (c 0.45 CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.71–7.66 (m, 4 H), 7.44–7.34 (m, 
6 H), 5.69 (dd, J = 15.7, 7.3 Hz, 1 H), 5.56 (dd, J = 15.7, 7.4 Hz, 1 H), 3.76–3.69 (m, 1 
H), 3.35 (d, J = 7.2 Hz, 1 H), 3.28–3.21 (m, 2 H), 3.20 (dd, J = 7.2, 2.1 Hz, 1 H), 3.10 
(dd, J = 12.4, 8.8 Hz, 1 H), 2.96–2.93 (m, 3 H), 1.10 (d, J = 6.4 Hz, 3 H), 1.07 (s, 9 H); 
13C NMR (100 MHz, CDCl3) δ 135.9, 135.8, 134.2, 133.6, 132.9, 130.3, 129.7, 129.6, 
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127.6, 127.5, 69.7, 64.6, 59.4, 57.3, 55.7, 54.8, 54.6, 26.9, 19.9, 19.3, 3.2; HRMS (H-
ESI) m/z calcd for C27H33IO4Si [M + Na]
+ 599.1091, found 599.1088. 
 
7.2.15. Synthesis of Allylic Alcohol 477 
Allylic Alcohol 477. To a solution of the crude iodide 
derivative 476 (80 mg, 0.10 mmol, 1.0 equiv) in THF (10 
mL) was added n-BuLi (0.13 mL, 1.6 M in hexane, 0.20 
mmol, 2.0 equiv) at -78 ºC, and the reaction mixture was 
stirred for 5 min. After this time, the reaction mixture was then quenched at -78 ºC with 
MeOH followed by addition of a saturated aqueous NH4Cl solution at 0 ºC. The resulting 
mixture was extracted with EtOAc (3 x 10 mL) and the organic extracts were washed 
with brine, dried over MgSO4, and filtered. The solvent was then removed under reduced 
pressure and the resulting crude mixture purified by flash column chromatogaphy (silica 
gel, 20% EtOAc in hexanes) to obtain allylic alcohol 477 (41 mg, 90% over 3 steps from 
455) as a colourless oil: Rf = 0.57 (silica gel, 40% EtOAc in hexanes); [α]25D= –20.9 (c 
0.28, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.71–7.66 (m, 4 H), 7.43–7.34 (m, 6 H), 
5.94 (ddd, J = 17.3, 10.6, 5.5 Hz, 1 H), 5.67 (dd, J = 15.7, 7.1 Hz, 1 H), 5.58 (dd, J = 
15.7, 7.2 Hz, 1 H), 5.40 (dt, J = 17.3, 1.3 Hz , 1 H), 5.28 (dt, J = 10.6, 1.3 Hz, 1 H), 4.15–
4.09 (m, 1 H), 3.76–3.70 (m, 1 H), 3.40 (dd, J = 7.1, 2.2 Hz, 1 H), 3.20 (dd, J = 7.0, 2.1 
Hz, 1 H), 2.99 (dd, J = 4.3, 2.2 Hz, 1 H), 2.95 (dd, J = 5.5, 2.1 Hz, 1 H), 1.10 (d, J = 6.4 
Hz, 3 H), 1.07 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 136.2, 135.9, 135.8, 134.2, 133.6, 
132.7, 130.9, 129.7, 129.6, 127.6, 127.5, 117.0, 71.5, 69.7, 64.5, 62.4, 55.0, 54.8, 26.9, 
19.9, 19.3; HRMS (H-ESI) m/z calcd for C27H34O4Si [M + H]
+ 451.2305, found 451.2301. 
 
7.2.16. Synthesis of (-)-Depudecin (442) 
(-)-Depudecin (442). Silyl derivative 477 (11 mg, 0.02 
mmol, 1.0 equiv) was dissolved in THF (3 mL) and over this 
solution was added TBAF (29 µL, 1.0 M in THF, 0.03 mmol, 
1.2 equiv) at 25 ºC. After 90 min, the reaction mixture was 
diluted with EtOAc and washed with a saturated aqueous NH4Cl solution. The aqueous 
phase was then extracted with EtOAc and the organic extracts were washed with H2O, 
brine, dried over MgSO4 and filtered. The solvent was removed under vacuum and the 
crude product was purified by flash column chromatography (silica gel, 20% EtOAc in 
hexanes → 60% EtOAc in hexanes) to afford (-)-depudecin (442) (4.5 mg, 90%) as a 
colourless oil: Rf = 0.52 (silica gel, EtOAc); [α]25D= –31.1 (c 0.17, CH2Cl2) (lit.236 [α]24D= 
–35.8 (c 0.52, MeOH); (lit.245 [α]23D= –31.0 (c 0.08, CHCl3); (lit.248 [α]25D= –29.6 (c 0.12, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 5.94 (ddd, J = 17.3, 10.6, 5.5 Hz, 1 H), 5.72–
5.69 (m, 2 H), 5.40 (dt, J = 17.3, 1.3 Hz, 1 H), 5.28 (dt, J = 10.6, 1.3 Hz, 1 H), 4.13 (d, J 
= 4.4 Hz, 1 H), 3.74 (dd, J = 11.3, 6.2 Hz, 1 H), 3.45–3.42 (m, 1 H), 3.40–3.36 (m, 1 H), 
3.01 (dd, J = 4.3, 2.2 Hz, 1 H), 2.91 (dd, J = 4.5, 2.2 Hz, 1 H), 1.93 (d, J = 6.5 Hz, 1 H), 
1.80 (d, J = 6.1 Hz, 1 H), 1.31 (d, J = 6.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 136.1, 
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132.0, 131.5, 117.1, 71.5, 66.9, 64.1, 62.4, 55.3, 54.9, 20.0; HRMS (H-ESI) m/z calcd for 
C11H16O4 [M + H]
+ 213.1127, found 213.1115. 
 
7.2.17. Synthesis of Diepoxy Iodide 479 and Diiodide 480. Iodination of Diepoxy 
Alcohol 474. 
Diepoxy Iodide 479 and Diiodide 480. Iodination of Diepoxy 
Alcohol 474. To a solution of diepoxy alcohol 474 (50 mg, 0.35 
mmol, 1.0 equiv) in THF (10 mL) at 0 ºC was added imidazole (72 
mg, 1.05 mmol, 3.0 equiv), PPh3 (138 mg, 0.53 mmol, 1.5 equiv) 
and iodine (134 mg, 0.53 mmol, 1.5 equiv) at 25 ºC. The mixture 
was vigorously stirred at 25 ºC for 20 min. After this time, the 
solvent was evaporated under reduced pressure and the crude residue was purified by 
flash column chromatography (silica gel, 5% EtOAc in hexanes→10% EtOAc in 
hexanes) to obtain diepoxy iodide 479 (22 mg, 25%) and diiodide 480 (42 mg, 47%) as 
yellow oils. [479]: Rf = 0.90 (silica gel, 40% EtOAc in hexanes); []25D = –35.8 (c 0.87, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 5.58–5.53 (m, 2 H), 5.35–5.31 (m, 1 H), 3.37–
3.32 (m, 1 H), 3.28–3.22 (m, 2 H), 3.12–3.05 (m, 1 H), 2.96–2.94 (m, 2 H); 13C NMR 
(100 MHz, CDCl3) δ 134.1, 120.5, 60.1, 59.6, 57.1, 55.6, 3.2; HRMS (H-ESI) m/z calcd 
for C7H9IO2 [M + H]
+ 252.9726, found 252.9698. [480]: Rf = 0.81 (silica gel, 40% EtOAc 
in hexanes); []25D = –29.4 (c 0.31, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 6.09 (dtd, J 
= 15.4, 7.9, 1.4 Hz, 1 H), 5.76 (ddt, J = 15.2, 5.7, 1.0 Hz, 1 H), 4.09 (dd, J = 10.2, 4.9 Hz, 
1 H), 3.90–3.86 (m, 2 H), 3.29–3.24 (m, 2 H), 3.10–3.06 (m, 1 H), 2.94 (dd, J = 4.6, 1.9 
Hz, 1 H), 2.23 (d, J = 6.0 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 131.0, 130.8, 70.3, 
64.0, 55.9, 3.7, 3.4; HRMS (H-ESI) m/z calcd for C7H10I2O2 [M + H]
+ 380.8848, found 
380.8856. 
 
7.2.18. Synthesis of Dialkene 478 
Dialkene 478. To a solution of iodide derivative 479 (13 mg, 0.04 
mmol, 1.0 equiv) in THF (3 mL) was added n-BuLi (50.0 µL, 1.6 M in 
hexane, 0.08 mmol, 2.0 equiv) at -78 ºC, and the reaction was stirred for 
5 min. The reaction mixture was then quenched at -78 ºC with MeOH followed by 
addition of a saturated aqueous NH4Cl solution at 0 ºC. The resulting mixture was 
extracted with EtOAc and the organic extracts were washed with brine, dried over 
MgSO4, and filtered. The solvent was then removed under reduced pressure and the 
resulting crude mixture purified by flash column chromatogaphy (silica gel, 25% EtOAc 
in hexanes) to obtain dialkene 478 (6.3 mg, 97%) as a colourless oil: Rf = 0.51 (silica gel, 
40% EtOAc in hexanes); [α]25 D = –12.35 (c 0.15, CH2Cl2); 1H NMR (400 MHz, CDCl3) 
δ 5.95 (ddd, J = 17.3, 10.6, 5.5 Hz, 1 H), 5.58 (dd, J = 9.9, 7.3 Hz, 1 H), 5.53 (d, J = 1.8 
Hz, 1 H), 5.40 (dt, J = 17.3, 1.4 Hz, 1 H), 5.34–5.30 (m, 1 H), 5.27 (dt, J = 10.6, 1.3 Hz, 
1 H), 4.13 (t, J = 4.7 Hz, 1 H), 3.41 (dd, J = 7.1, 2.2 Hz, 1 H), 3.00 (dd, J = 4.4, 2.2 Hz, 
1 H), 2.01 (bs, 1 H); 13C NMR (100 MHz, CDCl3) δ 136.3, 134.5, 120.2, 116.9, 71.6, 
62.2, 56.3; HRMS (H-ESI) m/z calcd for C7H10O2 [M + H]
+ 127.0759, found 127.0780. 
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7.2.19. Synthesis of Epoxy Alkene 481 
Epoxy Alkene 481. Epoxy olefin 481 was prepared from epoxy 
alcohol 465 (700 mg, 3.21 mmol, 1.0 equiv) by sequential treatments 
with SO3·pyr and Ph3P=CH2 according to the same procedure 
described above for the preparation of 460, to obtain epoxy alkene 481 (424 mg, 66% 
over two steps) as a colourless oil: Rf = 0.67 (silica gel, 10% EtOAc in hexanes); [α]25D= 
–29.2 (c 0.56, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.64–5.55 (m, 1 H), 5.47 (dd, J = 
17.2, 1.3 Hz, 1 H), 5.27 (ddd, J = 10.2, 1.6, 0.6 Hz, 1 H), 3.86 (dd, J = 12.0, 3.2 Hz, 1 H), 
3.71 (dd, J = 12.0, 4.5 Hz, 1 H), 3.27 (dd, J = 7.5, 2.1 Hz, 1 H), 2.99 (ddd, J = 4.5, 3.2, 
2.2 Hz, 1 H), 0.89 (s, 9 H), 0.07 (s, 3 H), 0.07 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
135.2, 119.4, 62.96, 60.3, 56.1, 25.9, 18.3, –5.3; HRMS (H-ESI) m/z calcd for C11H22O2Si 
[M + H]+ 215.1467, found 215.1465. 
 
7.2.20. Synthesis of Epoxy Alcohol 482 
Epoxy Alcohol 482. Silyl ether 481 (424 mg, 1.98 mmol, 1.0 equiv) was 
dissolved in THF (40 mL) and to this solution was added TBAF (4.0 
mL, 1.0 M in THF, 3.96 mmol, 2.0 equiv) at 0 ºC. The reaction mixture 
was stirred at 25 ºC for 1 h and, after this time, the reaction mixture was diluted with Et2O 
and washed with a saturated aqueous NH4Cl solution. The aqueous phase was then 
extracted with Et2O and the organic extracts were washed with brine, dried over MgSO4 
and filtered. The solvent was removed under vacuum and the crude product was purified 
by flash column chromatography (silica gel, 20% EtOAc in hexanes) to obtain epoxy 
alcohol 482 (108 mg, 55%) as a colourless oil: Rf = 0.27 (silica gel, 40% EtOAc in 
hexanes); [α]25D= –19.8 (c 0.31, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.60 (ddd, J = 
17.3, 10.0, 7.4 Hz, 1 H), 5.50 (dd, J = 17.2, 1.6 Hz, 1 H), 5.31 (dd, J = 10.4, 1.7 Hz, 1 H), 
3.95 (d, J = 12.7 Hz, 1 H), 3.68 (d, J = 12.6 Hz, 1 H), 3.40 (dd, J = 7.4, 2.2 Hz, 1 H), 3.08 
(dt, J = 4.1, 2.4 Hz, 1 H), 2.01 (bs, 1 H); 13C NMR (100 MHz, CDCl3) δ 134.7, 120.0, 
61.2, 59.9, 55.8; HRMS (H-ESI) m/z calcd for C5H8O2 [M + H]
+ 101.0603, found 
101.0597.  
 
7.2.21. Synthesis of Diepoxy Alcohol 469. Reduction of Diepoxy Amide 466 
Diepoxy Alcohol 469. Reduction of Diepoxy Amide 466. 
Diepoxy amide 466 (700 mg, 1.62 mmol, 1.0 equiv) in THF 
(30 mL) was treated with LiEt3BH (3.2 mL, 3.20 mmol, 1.0 M 
in THF, 2.0 equiv) at 0 ºC. After 1 h at this temperature, the reaction mixture was diluted 
with Et2O and washed with a saturated aqueous NH4Cl solution. The aqueous phase was 
separated, extracted with Et2O twice and the combined organic layers washed with water 
and brine, dried over anhydrous MgSO4 and concentrated under reduced pressure. 
Purification by flash column chromatography (silica gel, 20% EtOAc in hexanes) 
provided diepoxy alcohol 469 (371 mg, 88%) whose physical and spectroscopic 
properties were identical to those obtained from 468. 
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7.2.22. Synthesis of Iodide Derivative 483 
Iodide Derivative 483. To a solution of diepoxy alcohol 469 
(200 mg, 0.768 mmol, 1.0 equiv) in THF (20 mL) at 0 ºC was 
added imidazole (157 mg, 2.30 mmol, 3.0 equiv), PPh3 (302 mg, 
1.15 mmol, 1.5 equiv) and iodine (292 mg, 1.15 mmol, 1.5 equiv) at 25 ºC. The mixture 
was vigorously stirred at 25 ºC for 20 min. After this time, the solvent was evaporated 
under reduced pressure and the crude product was purified by flash column 
chromatography (silica gel, 5% EtOAc in hexanes) to obtain iodide derivative 483 (196 
mg, 69%) as a pale yellow oil: Rf = 0.68 (silica gel, 30% EtOAc in hexanes); [α]25 D = –
24.2 (c 0.62, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 3.88 (dd, J = 12.2, 2.7 Hz, 1 H), 
3.77–3.71 (m, 1 H), 3.29–3.21 (m, 2 H), 3.15–3.06 (m, 2 H), 3.00 (dd, J = 4.2, 2.1 Hz, 1 
H), 2.92 (dd, J = 4.3, 1.7 Hz, 1 H), 0.89 (s, 9 H), 0.08 (s, 3 H), 0.07 (s, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 61.9, 59.9, 56.1, 55.7, 52.8, 25.9, 18.4, 3.5, –5.3; HRMS (H-ESI) 
m/z calcd for C12H23IO3Si [M + H]
+ 371.0539, found 371.0540. 
 
7.2.23. Synthesis of Allylic Alcohol 484 
Allylic Alcohol 484. A solution of diepoxy iodide 483 (196 mg, 
0.53 mmol, 1.0 equiv) in THF (40 mL) was reacted with n-BuLi 
(0.7 mL, 1.6 M in hexane, 1.06 mmol, 2.0 equiv) at -78 ºC, 
according to the same procedure as described above for the preparation of 477, to afford, 
after similar processing, allylic alcohol 484 (116 mg, 90%) as a colourless oil: Rf = 0.47 
(silica gel, 30% EtOAc in hexanes); [α]25D= –33.1 (c 0.87, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 5.95–5.78 (m, 1 H), 5.36 (ddd, J = 17.3, 1.7, 1.2 Hz, 1 H), 5.22 (ddd, J = 10.6, 
1.2, 0.7 Hz, 1 H), 4.08–4.01 (m, 1 H), 3.84 (ddd, J = 12.2, 3.0, 1.6 Hz, 1 H), 3.67 (tdd, J 
= 4.6, 3.8, 1.1 Hz, 1 H), 3.10 (ddd, J = 4.6, 2.0, 0.8 Hz, 1 H), 3.00–2.97 (m, 1 H), 2.41 
(bs, 1 H), 0.87 (s, 9 H), 0.05 (s, 3 H), 0.05 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 136.4, 
116.7, 71.9, 62.7, 58.2, 56.4, 25.8, 18.3, –5.3; HRMS (H-ESI) m/z calcd for C12H24O3Si 
[M + H]+ 245.1573, found 245.1568. 
 
7.2.24. Synthesis of Bis(silyl ether) 485 
Bis(silyl ether) 485. A solution of allylic alcohol 484 in CH2Cl2 
(15 mL) was treated with imidazole (49 mg, 0.71 mmol, 1.5 
equiv) and TBDPSCl (0.15 mL, 0.57 mmol, 1.2 equiv) at 0 ºC. 
The resulting solution was stirred for 12 h and then poured into CH2Cl2, washed with H2O 
and brine, dried over anhydrous MgSO4, filtered and the solvent evaporated under 
reduced pressure. The crude product was purified by flash column chromatography (silica 
gel, 5% EtOAc in hexanes) to obtain bis(silyl ether) derivative 485 (229 mg, quant.) as a 
colourless oil: Rf = 0.89 (silica gel, 30% EtOAc in hexanes); [α]25 D = –9.45 (c 0.12, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.70–7.65 (m, 4 H), 7.43–7.38 (m, 6 H), 5.80 
(ddd, J = 17.2, 10.5, 5.8 Hz, 1 H), 5.19–5.13 (m, 1 H), 5.07 (dt, J = 10.6, 1.4 Hz, 1 H), 
4.09 (t, J = 5.6 Hz, 1 H), 3.75 (dd, J = 11.9, 3.4 Hz, 1 H), 3.64 (dd, J = 11.9, 4.5 Hz, 1 H), 
2.98 (dd, J = 5.5, 2.2 Hz, 1 H), 2.94–2.90 (m, 1 H), 1.16 (s, 9 H), 1.09 (s, 9 H), 0.90 (s, 3 
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H), 0.90 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 135.9, 135.2, 134.8, 132.6, 130.3, 129.7, 
127.9, 127.7, 127.5, 127.5, 74.9, 62.9, 58.8, 55.9, 27.0, 25.9, 20.7, 19.0, –5.3; HRMS (H-
ESI) m/z calcd for C28H42O3Si2 [M + H]
+ 483.2751, found 483.2752. 
 
7.2.25. Synthesis of Epoxy Ether 486 
Epoxy Ether 486. A solution of bis(silyl ether) 485 
(229 mg, 0.48 mmol, 1.0 equiv) in CH2Cl2/MeOH 
mixture (4:1, 10 mL) was treated with CSA (11 mg, 
0.05 mmol, 0.1 equiv) at 0 ºC. The reaction mixture was 
stirred at 0 ºC until depletion of starting material as 
judged by TLC (4.5 h). Then, the reaction was quenched by addition of Et3N (30 µL) and 
the resultant mixture was concentrated under reduced pressure. The residue was purified 
by flash column chromatography (silica gel, 5% EtOAc in hexanes) to obtain epoxy ether 
486 (262 mg, 75%) as a colourless oil: Rf = 0.65 (silica gel, 30% EtOAc in hexanes); [α]25 
D = +28.6 (c 0.52, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.75–7.65 (m, 8 H), 7.47–7.34 
(m, 12 H), 5.97–5.86 (m, 1 H), 5.86–5.76 (m, 1 H), 5.29–4.83 (m, 4 H), 4.57–4.48 (m, 1 
H), 4.11 (t, J = 5.7 Hz, 1 H), 4.04–3.90 (m, 2 H), 3.90–3.76 (m, 2 H), 3.75–3.59 (m, 1 H), 
3.57–3.32 (m, 1 H), 3.08 (dd, J = 5.6, 2.3 Hz, 1 H), 3.04–2.93 (m, 2 H), 2.65–2.45 (m, 
1H), 1.12 (s, 9 H), 1.10 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 137.0, 137.0, 136.1, 
136.1, 136.0, 135.9, 135.9, 135.8, 133.8, 133.7, 130.1, 129.9, 129.8, 129.7, 127.8, 127.8, 
127.6, 127.5, 117.8, 116.7, 75.5, 74.8, 74.5, 73.5, 64.8, 61.2, 58.6, 55.8, 27.2, 26.9, 19.6, 
19.4; HRMS (H-ESI) m/z calcd for C44H56O6Si2 [M + Na]
+ 759.3513, found 759.3506. 
 
7.2.26. Synthesis of Diepoxy Alcohol 487 
Diepoxy Alcohol 487. Silyl derivative 483 (212 mg, 0.57 mmol, 
1.0 equiv) was dissolved in THF (10 mL) and to this solution was 
added TBAF (1.14 mL, 1.0 M in THF, 1.14 mmol, 2.0 equiv) at 0 
ºC. The reaction mixture was stirred at 25 ºC for 1.15 h and, after this time, the reaction 
mixture was diluted with Et2O and washed with a saturated aqueous NH4Cl solution. The 
aqueous phase was then extracted with Et2O three times and the combined organic 
extracts were washed with brine, dried over MgSO4 and filtered. The solvent was 
removed under vacuum and the crude product was purified by flash column 
chromatography (silica gel, 20% EtOAc in hexanes → 30% EtOAc in hexanes) to obtain 
diepoxy alcohol 487 (127 mg, 87%) as a colourless oil: Rf  = 0.33 (silica gel, 60% EtOAc 
in hexanes); []25D = –21.4 (c 0.24, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 3.96 (d, J = 
12.8 Hz, 1 H), 3.69 (d, J = 11.8 Hz, 1 H), 3.27 (dd, J = 2.5, 1.9 Hz, 1 H), 3.25 (dd, J = 
1.6, 1.1 Hz, 1 H), 3.17 (ddd, J = 7.3, 4.4, 2.0 Hz, 1 H), 3.13 (ddd, J = 8.5, 3.5, 1.3 Hz, 1 
H), 3.12–3.06 (m, 1 H), 2.98 (dd, J = 3.6, 1.3 Hz, 1 H), 2.35 (bs, 1 H); 13C NMR (100 
MHz, CDCl3) δ 60.4, 59.8, 55.9, 55.8, 52.8, 3.5; HRMS (H-ESI) m/z calcd for C6H9IO3 
[M + H]+ 256.9675, found 256.9675. 
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7.2.27. Synthesis of Diepoxy Iodide 479. Olefination of Diepoxy Alcohol 487 
Diepoxy Iodide 479. Olefination of Diepoxy Alcohol 487. Diepoxy 
olefin 479 was prepared from diepoxy alcohol 487 (70 mg, 0.27 
mmol, 1.0 equiv) by sequential treatments with SO3·pyr and 
Ph3P=CH2 according to the same procedure described above for the preparation of 460, 
to obtain diepoxy alkene 479 (31 mg, 47% over two steps) whose physical and 
spectroscopic properties were identical to those obtained from 474. 
 
7.2.28. Synthesis of ,-Unsaturated Ester 490 
α,β-Unsaturated Ester 490. To a solution of (-)-ethyl-L-lactate 488 
(3.2 mL, 27.94 mmol, 1.0 equiv) in CH2Cl2 (20 mL) was added TEA 
(8.30 mL, 61.47 mmol, 2.2 equiv), TBDPSCl (7.89 mL, 30.73 mmol, 
1.1 equiv) and 4-DMAP (683 mg, 5.59 mmol, 0.2 equiv) at 0 ºC. The 
mixture was stirred for 12 h and then diluted with brine and the aqueous phase was 
extracted with CH2Cl2 three times. The combined organic layers were dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure to obtain 
silyl derivative 489 (10 g, quant.) as a colourless oil which was used in the next step 
without further purification. A solution of silyl derivative 489 (10.0 g, 28.04 mmol, 1.0 
equiv) in CH2Cl2 (60 mL) was cooled at -78 ºC and then treated with DIBAL-H (28 mL, 
1.0 M in toluene, 28.04 mmol, 1.0 equiv). After 20 min, the reaction was quenched by 
dropwise addition of MeOH at -78 ºC and the mixture was allowed to reach room 
temperature, treated with a saturated aqueous Na+/K+ tartrate solution and diluted with 
CH2Cl2. The resulting mixture was vigorously stirred until a clear separation of both 
organic and aqueous phases. The aqueous phase was then separated, the organic extract 
washed with water and brine, dried over MgSO4 and the solvent evaporated under reduced 
pressure. The resulting crude aldehyde (28 mmol) was used in the next step without 
purification. A solution of tributyl(ethoxycarbonylmethylene)phosphonium bromide 
(11.0 g, 35.0 mmol, 1.25 equiv) in CH2Cl2 (40 mL) was washed twice with a 1.0 M 
aqueous NaOH solution (60 mL), then dried over MgSO4 and diluted with toluene (40 
mL). After removing CH2Cl2 under reduced pressure, the resulting solution was added to 
a stirred solution of the crude aldehyde and benzoic acid (682 mg, 5.60 mmol, 0.2 equiv) 
in toluene (100 mL) at 95 ºC. After 30 min at this temperature, the solvent was evaporated 
under reduced pressure and the resulting residue purified by flash column 
chromatography (silica gel, 10 % EtOAc in hexanes) to provide the corresponding,-
unsaturated ester 490 (9.2 g, 86% over two steps) as a colourless oil and whose 
spectroscopic and physical properties matched with those described in the literature:261 Rf 
= 0.69 (silica gel, 20% EtOAc in hexanes); []25D = +11.2 (c 0.89, CH2Cl2); 1H NMR (400 
MHz, CDCl3) δ 7.76–7.66 (m, 4 H), 7.48–7.37 (m, 6 H), 6.96 (ddd, J = 15.5, 4.5, 2.4 Hz, 
1 H), 6.07 (ddd, J = 15.5, 2.6, 1.7 Hz, 1 H), 4.56–4.48 (m, 1 H), 4.24 (qdd, J = 7.0, 3.1, 
1.0 Hz, 2 H), 1.33 (t, J = 7.1 Hz, 3 H), 1.18 (d, J = 6.5 Hz, 3 H), 1.15 (s, J = 2.2 Hz, 9 H); 
13C NMR (100 MHz, CDCl3) δ 166.8, 151.5, 135.9, 135.8, 134.1, 133.5, 129.1, 128.3, 
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127.7, 127.6, 119.2, 68.7, 60.3, 27.0, 23.4, 19.3, 14.3; HRMS (H-ESI) m/z calcd for 
C23H30O3Si [M + H]
+ 383.2043, found 383.2040. 
 
7.2.29. Synthesis of Allylic Alcohol 491 
Allylic Alcohol 491. A solution of α,β-unsaturated ester 490 (9.0 g, 
23.53 mmol, 1.0 equiv) in CH2Cl2 (50 mL) was cooled at -78 ºC and 
treated with DIBAL-H (70 mL, 1.0 M in toluene, 70.58 mmol, 3.0 
equiv). After 20 min, the reaction was quenched by addition of MeOH 
at -78 ºC and the mixture was allowed to reach room temperature, treated with a saturated 
aqueous Na+/K+ tartrate solution and diluted with CH2Cl2. The resulting mixture was 
vigorously stirred until a clear separation of both organic and aqueous phases. The organic 
layer was separated and the aqueous phase was extracted with CH2Cl2 three times. The 
combined organic layers were washed with brine, dried over anhydrous MgSO4, filtered 
and the solvent evaporated under reduced pressure. The residue was purified by flash 
column chromatography (silica gel, 20% EtOAc in hexanes) to obtain allylic alcohol 491 
(7.2 g, 90%) as a colourless oil and whose spectroscopic and physical properties matched 
with those described in the literature:261 Rf = 0.20 (silica gel, 20% EtOAc in hexanes); 
[]25D = –15.6 (c 0.43, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.70–7.65 (m, 4 H), 7.46–
7.33 (m, 6 H), 5.65 (dd, J = 15.4, 5.6 Hz, 1 H), 5.56 (dt, J = 15.4, 4.9 Hz, 1 H), 4.35 (p, J 
= 5.7 Hz, 1 H), 3.99 (d, J = 4.8 Hz, 2 H), 1.55 (bs, 1 H), 1.17 (d, J = 6.3 Hz, 3 H), 1.07 
(s, 9 H); 13C NMR (100 MHz, CDCl3) δ 136.0, 135.9, 135.8, 134.5, 134.4, 129.6, 129.5, 
127.8, 127.5, 127.4, 69.7, 63.1, 27.0, 24.2, 19.2; HRMS (H-ESI) m/z calcd for C21H28O2Si 
[M + H]+ 341.1937, found 341.1938. 
 
7.2.30. Synthesis of Epoxy Alcohol 492 
Epoxy Alcohol 492. To a suspension of titanium tetraisopropoxide 
(2.4 mL, 8.22 mmol, 0.35 equiv) and 4Å molecular sieves (15.0 g) in 
CH2Cl2 (100 mL) was added (+)-L-DET (1.4 mL, 8.22 mmol, 0.35 
equiv) at -50 ºC. After 15 min at this temperature, a solution of allylic 
alcohol 491 (8.0 g, 23.49 mmol, 1.0 equiv) in CH2Cl2 (80 mL) was added dropwise, 
followed by the addition, after additional 30 min, of TBHP (8.5 mL, 5.5 M solution in 
decane, 46.99 mmol, 2.0 equiv) at the same temperature. After 12 h at this temperature, 
the reaction mixture was quenched with Me2S (6.5 mL, 108 mmol, 4.6 equiv) at 0 ºC, 
filtered off and the solvent was evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) to 
obtain epoxy alcohol 492 (7.4 g, 88%) as a colourless oil: Rf = 0.40 (silica gel, 40% EtOAc 
in hexanes); []25D = –3.7 (c 0.9, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.73–7.67 (m, 
4 H), 7.45–7.37 (m, 6 H), 3.71 (dd, J = 12.8, 1.8 Hz, 1 H), 3.68–3.63 (m, 1 H), 3.41 (dd, 
J = 12.7, 4.3 Hz, 1 H), 2.91 (dd, J = 5.4, 1.9 Hz, 1 H), 2.71–2.67 (m, 1 H), 1.23 (d, J = 
6.2 Hz, 3 H), 1.07 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 135.9, 135.8, 133.9, 133.8, 
129.8, 129.7, 127.7, 127.6, 68.7, 61.3, 58.8, 57.4, 26.9, 20.9, 19.2; HRMS (H-ESI) m/z 
calcd for C21H28O3Si [M + H]
+ 357.1886, found 357.1876. 
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7.2.31. Synthesis of Epoxy Alkene 493 
Epoxy Alkene 493. Epoxy olefin 493 was prepared from epoxy alcohol 
492 (4.6 g, 12.90 mmol, 1.0 equiv) by sequential treatments with 
SO3·pyr and Ph3P=CH2 according to the same procedure described 
above for the preparation of 460, to obtain epoxy alkene 493 (3.6 g, 80% 
over two steps) as a pale yellow oil: Rf = 0.69 (silica gel, 20% EtOAc in hexanes); []25D 
= –11.7 (c 0.67, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.69–7.65 (m, 4 H), 7.43–7.36 
(m, 6 H), 5.56–5.44 (m, 1 H), 5.32 (dd, J = 17.2, 1.5 Hz, 1 H), 5.21 (dd, J = 10.3, 1.5 Hz, 
1 H), 3.60 (p, J = 6.1 Hz, 1 H), 2.90 (dd, J = 7.5, 2.1 Hz, 1 H), 2.81 (dd, J = 5.7, 2.1 Hz, 
1 H), 1.21 (d, J = 6.3 Hz, 3 H), 1.06 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 135.97, 
135.88, 135.2, 134.8, 134.0, 133.7, 129.8, 129.7, 127.7, 119.3, 69.1, 63.5, 57.7, 26.9, 
20.9, 19.2; HRMS (H-ESI) m/z calcd for C22H28O2Si [M + H]
+ 353.1937, found 353.1935. 
 
7.2.32. Synthesis of Triepoxy Alcohol 494 
Triepoxy Alcohol 494. A solution of diepoxy olefin 474 
(100 mg, 0.70 mmol, 1.0 equiv) and epoxy olefin 493 
(744 mg, 2.11 mmol, 3.0 equiv) in degassed CH2Cl2 (7 
mL) was reacted with Hoveyda-Grubbs 2nd generation 
catalyst (44 mg, 0.10 mmol, 0.10 equiv) according to the same procedure as described 
above for the synthesis of 455, to afford triepoxy alcohol 494 (179 mg, 55%) as a 
colourless oil: Rf  = 0.56 (silica gel, 60% EtOAc in hexanes); []25D = +26.5 (c 0.39, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.69–7.64 (m, 4 H), 7.45–7.34 (m, 6 H), 5.60 
(dd, J = 15.6, 7.1 Hz, 1 H), 5.45 (dd, J = 15.6, 7.4 Hz, 1 H), 3.76–3.67 (m, 2 H), 3.66–
3.58 (m, 1 H), 3.34 (dd, J = 7.5, 1.9 Hz, 1 H), 3.19 (dt, J = 3.5, 2.3 Hz, 1 H), 3.11 (dd, J 
= 4.3, 2.2 Hz, 1 H), 2.93–2.89 (m, 2 H), 2.79 (dd, J = 5.6, 2.0 Hz, 1 H), 1.22 (d, J = 6.3 
Hz, 3 H), 1.05 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 135.9, 135.8, 133.8, 133.7, 132.7, 
130.2, 129.8, 129.7, 127.67, 127.6, 68.9, 63.9, 60.5, 57.9, 56.0, 55.8, 54.8, 53.1, 26.8, 
20.8, 19.2; HRMS (H-ESI) m/z calcd for C27H34O5Si [M + Na]
+ 489.2074, found 
489.2073. 
 
7.2.33. Synthesis of Tosyl Derivative 495 
Tosyl Derivative 495. The tosylation of triepoxy 
alcohol 494 (65 mg, 0.14 mmol, 1.0 equiv) was 
achieved in exactly the same way as described above 
fot 475, to obtain tosyl derivative 495 (105 mg, 0.14 
mmol), which did not require further purification for the next step. For analytical 
purposes, a sample of this crude (7.0 mg, 0.009 mmol) was purified by flash column 
chromatography (silica gel, 20% EtOAc in hexanes) to provide pure tosyl derivative 495 
(5.5 mg, 95%) as a colourless oil: Rf = 0.83 (silica gel, 60% EtOAc in hexanes); [α]25D= 
+20.6 (c 0.34, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.82–7.78 (m, 2 H), 7.69–7.64 (m, 
4 H), 7.44–7.40 (m, 2 H), 7.40–7.34 (m, 6 H), 5.61–5.52 (m, 1 H), 5.41 (dd, J = 15.7, 7.5 
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Hz, 1 H), 4.22 (dd, J = 11.7, 3.6 Hz, 1 H), 4.09 (dd, J = 11.6, 5.3 Hz, 1 H), 3.64–3.57 (m, 
1 H), 3.32–3.27 (m, 1 H), 3.23–3.20 (m, 1 H), 3.00 (dd, J = 3.9, 2.0 Hz, 1 H), 2.91–2.86 
(m, 2 H), 2.78 (dd, J = 5.6, 2.0 Hz, 1 H), 2.46 (s, 3 H), 1.21 (d, J = 6.3 Hz, 3 H), 1.05 (s, 
9 H); 13C NMR (100 MHz, CDCl3) δ 145.3, 135.9, 135.8, 133.9, 133.8, 133.7, 133.0, 
132.6, 130.0, 129.8, 129.7, 127.9, 127.7, 127.6, 68.9, 68.5, 63.8, 57.1, 55.9, 54.9, 53.8, 
52.3, 26.9, 21.7, 20.8, 19.2; HRMS (H-ESI) m/z calcd for C34H40O7SSi [M + Na]
+ 
643.2162, found 643.2160. 
 
7.2.34. Synthesis of Iodide Derivative 496 
Iodide Derivative 496. The iodination of crude tosyl 
derivative 495 (98 mg, 0.13 mmol, 1.0 equiv) was 
carried out according to the procedure described above for 
476, to afford iodide derivative 496 (97 mg, 0.13 mmol), 
which did not require further purification for the next step. For analytical purposes, a 
sample of this crude (6.5 mg, 0.009 mmol) was purified by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) to obtain pure iodide 496 (4.5 mg, 
91%) as a colourless oil: Rf = 0.66 (silica gel, 30% EtOAc in hexanes); [α]25D= +12.1 (c 
0.34 CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.69–7.64 (m, 4 H), 7.44–7.34 (m, 6 H), 
5.59 (dd, J = 15.6, 7.1 Hz, 1 H), 5.43 (dd, J = 15.6, 7.9 Hz, 1 H), 3.63–3.57 (m, 1 H), 3.32 
(dd, J = 7.4, 1.7 Hz, 1 H), 3.28–3.24 (m, 2 H), 3.14–3.07 (m, 1 H), 2.98–2.91 (m, 2 H), 
2.90 (dd, J = 7.3, 2.1 Hz, 1 H), 2.79 (dd, J = 5.6, 2.0 Hz, 1 H), 1.22 (d, J = 6.2 Hz, 3 H), 
1.05 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 135.9, 135.8, 133.8, 133.7, 132.9, 130.0, 
129.9, 129.8, 127.7, 127.6, 68.9, 63.9, 59.4, 57.3, 55.9, 55.7, 54.8, 26.9, 20.8, 19.2, 3.1; 
HRMS (H-ESI) m/z calcd for C27H33IO4Si [M + Na]
+ 599.1091, found 599.1090. 
 
7.2.35. Synthesis of Allylic Alcohol 497 
Allylic Alcohol 497. A solution of diepoxy iodide 496 (91 
mg, 0.12 mmol, 1.0 equiv) in THF (10 mL) was reacted 
with n-BuLi (0.15 mL, 1.6 M in hexane, 0.24 mmol, 2.0 
equiv) at -78 ºC, according to the same procedure as 
described above for the preparation of 477, to afford, after similar processing, allylic 
alcohol 497 (50 mg, 91% over 3 steps): Rf = 0.50 (silica gel, 40% EtOAc in hexanes); 
[α]25D= +18.9 (c 0.23, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.69–7.64 (m, 4 H), 7.42–
7.34 (m, 6 H), 5.96 (ddd, J = 17.3, 10.6, 5.5 Hz, 1 H), 5.57 (dd, J = 15.7, 7.2 Hz, 1 H), 
5.45 (dd, J = 12.3, 4.4 Hz, 1 H), 5.29 (dt, J = 10.6, 1.3 Hz, 1 H), 4.15–4.09 (m, 1 H), 3.60 
(p, J = 6.1 Hz, 1 H), 3.38 (dd, J = 7.5, 2.1 Hz, 1 H), 2.97 (dd, J = 4.4, 2.2 Hz, 1 H), 2.90 
(dd, J = 7.2, 1.9 Hz, 1 H), 2.80 (dd, J = 5.7, 2.0 Hz, 1 H), 2.05 (bs, 1 H), 1.22 (d, J = 6.2 
Hz, 3 H), 1.05 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 136.2, 135.9, 135.8, 133.8, 133.7, 
132.6, 130.6, 129.8, 129.7, 127.7, 127.6, 117.0, 71.6, 69.0, 63.8, 62.4, 56.2, 55.1, 26.9, 
20.8, 19.2; HRMS (H-ESI) m/z calcd for C27H34O4Si [M + H]
+ 451.2305, found 451.2315. 
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7.2.36. Synthesis of 10-epi-Depudecin (498) 
10-epi-Depudecin (498). Silyl derivative 497 (16 mg, 0.04 
mmol, 1.0 equiv) was desilylated by the action of TBAF 
(0.04 mL, 1.0 M in THF, 0.04 mmol, 1.2 equiv) in the same 
way as desrcribed above for (-)-depudecin (442) to afford 
10-epi-depudecin (498) (6.0 mg, 85%) as a colourless oil: Rf = 0.52 (silica gel, EtOAc); 
[α]25D= +33.3 (c 0.9, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.94 (ddd, J = 17.3, 10.6, 
5.5 Hz, 1 H), 5.73–5.70 (m, 2 H), 5.39 (dt, J = 17.2, 1.4 Hz, 1 H), 5.27 (dt, J = 10.6, 1.3 
Hz, 1 H), 4.13 (dd, J = 10.3, 5.6 Hz, 1 H), 4.01 (dd, J = 4.4, 1.8 Hz, 1 H), 3.48–3.45 (m, 
1 H), 3.44–3.41 (m, 1 H), 3.01 (dd, J = 4.3, 2.2 Hz, 1 H), 2.94 (dd, J = 3.0, 2.2 Hz, 1 H), 
1.98 (d, J = 6.5 Hz, 1 H), 1.87 (bs, 1 H), 1.27 (d, J = 6.5 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 136.1, 132.2, 131.4, 117.1, 71.5, 64.6, 63.5, 62.4, 54.9, 53.5, 18.7; HRMS (H-
ESI) m/z calcd for C11H16O4 [M + H]
+ 213.1127, found 213.1129. 
 
7.2.37. Synthesis of Diepoxy Amide ent-466 
Diepoxy Amide ent-466. Epoxy alcohol ent-465329 (133 
mg, 0.62 mmol 1.0 equiv) was dissolved in a 
CH2Cl2/DMSO (1:1) mixture (2.5 mL) and cooled at 0 ºC. 
At this temperature, Et3N (0.25 mL, 1.83 mmol, 3.0 equiv) 
was added followed by SO3·pyr (175 mg, 1.08 mmol, 1.8 
equiv). The reaction mixture was allowed to reach 25 ºC 
and, after 5 h, was quenched by addition of a buffer solution (pH = 7) and diluted with 
Et2O. The aqueous phase was extracted with Et2O and the combined organic extracts were 
washed with water and brine, then dried over anhydrous MgSO4 and the solvent removed 
under reduced pressure. The resulting crude aldehyde was used in the next step without 
further purification. The crude aldehyde (1.0 equiv) was reacted with sulfonium salt ent-
457249,250 (221 mg, 0.71 mmol, 1.1 equiv) and NaOH (5.0 M aqueous solution, 0.13 mL, 
0.63 mmol, 1.0 equiv) according to the procedure described above for epoxy amide 466 
to yield diepoxy amide ent-466 (179 mg, 68% over 2 steps) as a pale yellow oil: Flash 
column chromatography (silica gel, 20% EtOAc in hexanes); Rf = 0.21 (Silica gel, 40% 
EtOAc in hexanes); [α]25D = +26.7 (c 0.40, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 4.27 
(ddd, J = 8.4, 4.7, 3.3 Hz, 1 H), 3.96 (ddd, J = 9.2, 5.2, 1.2 Hz, 1 H), 3.88–3.86 (m, 1 H), 
3.85 (d, J = 2.4 Hz, 1 H), 3.68 (dd, J = 12.3, 3.7 Hz, 1 H), 3.54 (d, J = 2.0 Hz, 1 H), 3.29 
(dd, J = 3.4, 2.0 Hz, 1 H), 3.07 (dq, J = 3.5, 2.2 Hz, 2 H), 2.58–2.49 (m, 1 H), 2.47–2.39 
(m, 1 H), 2.07 (s, 3 H), 1.80–1.73 (m, 1 H), 1.58 (s, 3 H), 1.47 (s, 3 H), 0.83 (s, 9 H), 0.01 
(s, 3 H), 0.00 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 162.9, 95.9, 67.0, 61.6, 56.3, 55.9, 
55.5, 51.7, 51.2, 34.4, 30.6, 26.2, 25.6, 22.9, 18.3, 15.7, –3.6, –5.4; HRMS (H-ESI) m/e 
calcd for C20H37NO5SSi [M + H]
+ 432.2240, found 432.2242. 
 
                                                          
329 (a) Shibuya, H.; Kawashima, K.; Narita, N.; Ikeda, M.; Kitagawa Chem. Pharm. Bull. 1992, 40, 1154-1165. (b) Hayashi, Y.; Shoji, 
M.; Mukaiyama, T.; Gotoh, H.; Yamaguchi, S.; Nakata, M.; Kakeya, H.; Osada, H. J. Org. Chem. 2005, 70, 5643-5654. 
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7.2.38. Synthesis of Diepoxy Alkene ent-461 
Diepoxy Alkene ent-461. Diepoxy olefin ent-461 (67 mg, 52% 
over two steps) was prepared from epoxy amide ent-466 (190 mg, 
0.34 mmol, 1.0 equiv) by sequential treatments with Red-Al and 
Ph3P=CH2 according to the same procedure described above for the preparation of 461. 
[ent-461]: colorless oil; Rf = 0.87 (silica gel, 40% EtOAc in hexanes); []25D = +29.9 (c 
0.45, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 5.63–5.47 (m, 2 H), 5.33–5.29 (m, 1 H), 
3.87 (dd, J = 12.2, 2.9 Hz, 1 H), 3.74 (dd, J = 12.2, 4.1 Hz, 1 H), 3.35 (dd, J = 7.1, 2.1 
Hz, 1 H), 3.10 (ddd, J = 4.0, 2.8, 2.2 Hz, 1 H), 2.99 (dd, J = 4.4, 2.1 Hz, 1 H), 2.91 (dd, J 
= 4.4, 2.1 Hz, 1 H), 0.89 (s, 9 H), 0.07 (s, 3 H), 0.06 (s, 3 H);  13C NMR (100 MHz, CDCl3) 
δ 134.4, 120.2, 62.1, 57.9, 56.0, 55.9, 53.3, 25.8, 18.3, –5.4; HRMS (H-ESI) m/z calcd 
for C13H24O3Si [M + H]
+ 257.1573, found 257.1576. 
 
7.2.39. Synthesis of Diepoxy Alcohol ent-474 
Diepoxy alcohol ent-474. Diepoxy alcohol ent-474 (33 mg, 85%) 
was prepared from silyl ether ent-461 (67 mg, 0.26 mmol, 1.0 
equiv) by treatment with TBAF according to the same procedure 
described above for the preparation of 474. [ent-474]: colourless oil; Rf = 0.32 (silica gel, 
40% EtOAc in hexanes); []25D = + 23.3 (c 0.33, CH2Cl2); 1H NMR (400 MHz, CDCl3) 
δ 5.47–5.37 (m, 2 H), 5.24–5.18 (m, 1 H), 3.79 (ddd, J = 11.4, 9.0, 2.5 Hz, 1 H), 3.53 (dd, 
J = 12.9, 4.3 Hz, 1 H), 3.29–3.25 (m, 1 H), 3.05 (dd, J = 4.3, 2.3 Hz, 1 H), 2.95–2.90 (m, 
1 H), 2.81 (dd, J = 4.8, 2.1 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 134.2, 120.4, 60.7, 
57.9, 56.0, 55.9, 53.5; HRMS (H-ESI) m/z calcd for C7H10O3 [M + H]
+ 143.0708, found 
143.0712. 
 
7.2.40. Synthesis of Epoxy Alkene ent-473 
Epoxy Alkene ent-473. Epoxy olefin ent-473 was prepared from epoxy 
alcohol ent-472 (3.8 g, 10.66 mmol, 1.0 equiv) by sequential treatments 
with SO3·pyr and Ph3P=CH2 according to the same procedure described 
above for the preparation of 460, to obtain epoxy alkene ent-473 (3.3 g, 
87% over two steps) whose spectroscopic and physical properties were identical to epoxy 
alkene 473, except for its specific rotation: []25D = –11.5 (c 0.45, CH2Cl2); HRMS (H-
ESI) m/z calcd for C22H28O2Si [M + H]
+ 353.1937, found 353.1936. 
 
7.2.41. Synthesis of Triepoxy Alcohol ent-455 
Triepoxy Alcohol ent-455. A solution of diepoxy olefin 
ent-474 (33 mg, 0.23 mmol, 1.0 equiv) and epoxy olefin 
ent-473 (245 mg, 0.70 mmol, 3.0 equiv) in degassed 
CH2Cl2 (7 mL) was reacted with Hoveyda-Grubbs 2
nd 
generation catalyst (14 mg, 0.03 mmol, 0.10 equiv) according to the same procedure as 
described above for the synthesis of 455, to afford triepoxy alcohol ent-455 (53 mg, 52%) 
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as a colourless oil: Rf  = 0.56 (silica gel, 60% EtOAc in hexanes); [α]25D= +28.7 (c 0.41, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.72–7.65 (m, 4 H), 7.46–7.34 (m, 6 H), 5.70 
(dd, J = 15.7, 7.3 Hz, 1 H), 5.58 (dd, J = 15.7, 7.3 Hz, 1 H), 3.97 (dd, J = 12.9, 2.3 Hz, 1 
H), 3.76–3.68 (m, 2 H), 3.37 (dd, J = 7.3, 2.0 Hz, 1 H), 3.20 (dd, J = 7.3, 2.2 Hz, 1H), 
3.19– 3.17 (m, 1 H), 3.10 (dd, J = 4.3, 2.3 Hz, 1 H), 2.95 (dd, J = 5.5, 2.1 Hz, 1 H), 2.93 
(dd, J = 4.3, 2.1 Hz, 1 H), 1.54–1.49 (bs), 1.11 (d, J = 6.4 Hz, 3 H), 1.08 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 135.9, 135.8, 134.2, 133.6, 132.8, 130.5, 129.7, 129.6, 127.6, 
127.5, 69.7, 64.6, 60.5, 57.9, 55.8, 54.8, 54.6, 53.0, 26.9, 19.9, 19.3; HRMS (H-ESI) m/z 
calcd for C27H34O5Si [M + Na]
+ 489.2073, found 489.2066. 
 
7.2.42. Synthesis of Tosyl Derivative ent-475 
Tosyl Derivative ent-475. The tosylation of triepoxy 
alcohol ent-455 (19 mg, 0.04 mmol, 1.0 equiv) was 
achieved in exactly the same way as described above 
for 475, to obtain tosyl derivative ent-475 (35 mg, 
0.04 mmol), which did not require further purification for the next step. For analytical 
purposes, a sample of this crude (2.5 mg, 0.0029 mmol) was purified by flash column 
chromatography (silica gel, 20% EtOAc in hexanes) to obtain tosyl derivative ent-475 
(1.7 mg, 94%) as a colourless oil: Rf = 0.74 (silica gel, 60% EtOAc in hexanes); [α]25D= 
+11.3 (c 0.20, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.82–7.77 (m, 2 H), 7.72–7.66 (m, 
4 H), 7.45–7.34 (m, 8 H), 5.68 (dd, J = 15.6, 7.3 Hz, 1 H), 5.54 (dd, J = 15.7, 7.5 Hz, 1 
H), 4.21 (dd, J = 11.7, 3.7 Hz, 1 H), 4.08 (dd, J = 11.6, 5.2 Hz, 1 H), 3.76–3.69 (m, 1 H), 
3.32 (dd, J = 7.4, 1.8 Hz, 1 H), 3.23–3.20 (m, 1 H), 3.19 (dd, J = 7.2, 2.1 Hz, 1 H), 2.98 
(dd, J = 4.0, 2.0 Hz, 1 H), 2.95 (dd, J = 5.5, 2.1 Hz, 1 H), 2.89 (dd, J = 4.0, 2.0 Hz, 1 H), 
2.46 (s, 3 H), 1.10 (d, J = 6.4 Hz, 3 H), 1.07 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 
145.3, 135.9, 135.8, 134.2, 133.6, 133.1, 132.6, 130.2, 130.0, 129.7, 129.6, 127.9, 127.6, 
127.5, 69.7, 68.5, 64.6, 57.1, 54.8, 54.6, 53.8, 52.3, 26.9, 26.8, 21.7, 19.9, 19.3; HRMS 
(H-ESI) m/z calcd for C34H40O7SSi [M + Na]
+ 643.2162, found 643.2153. 
 
7.2.43. Synthesis of Iodide Derivative ent-476 
Iodide Derivative ent-476. The iodination of crude tosyl 
derivative ent-475 (32 mg, 0.037 mmol, 1.0 equiv) was 
carried out according to the procedure described above for 
476, to afford iodide derivative ent-476 (30 mg, 0.037 
mmol), which did not require further purification for the next step. For analytical 
purposes, a sample of this crude (3.0 mg, 0.0037 mmol) was purified by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) to obtain pure iodide ent-476 (2.0 
mg, 95%) as a colourless oil: Rf = 0.83 (silica gel, 40% EtOAc in hexanes); [α]25D= +11.1 
(c 0. 30 CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.72–7.66 (m, 4 H), 7.46–7.34 (m, 6 H), 
5.69 (dd, J = 15.7, 7.3 Hz, 1 H), 5.56 (dd, J = 15.7, 7.4 Hz, 1 H), 3.78–3.69 (m, 1 H), 3.35 
(d, J = 7.2 Hz, 1 H), 3.28–3.23 (m, 2 H), 3.20 (dd, J = 7.2, 2.1 Hz, 1 H), 3.14–3.08 (m, 1 
H), 2.97–2.94 (m, 3 H), 1.11 (d, J = 6.4 Hz, 3 H), 1.08 (s, 9 H); 13C NMR (100 MHz, 
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CDCl3) δ 135.88, 135.84, 134.19, 133.64, 132.96, 130.31, 129.69, 129.67, 127.60, 127.6, 
69.7, 64.6, 59.4, 57.3, 55.7, 54.7, 54.6, 26.9, 19.9, 19.3, 3.1; HRMS (H-ESI) m/z calcd 
for C27H33IO4Si [M + H]
+ 577.1271, found 577.1259. 
 
7.2.44. Synthesis of Allylic Alcohol ent-477 
Allylic Alcohol ent-477. A solution of crude iodide ent-476 
(24 mg, 0.033 mmol, 1.0 equiv) in THF (4 mL) was 
reacted with n-BuLi (41.0 µL, 1.6 M in hexane, 0.066 mmol, 
2.0 equiv) at -78 ºC, according to the same procedure as 
described above for the preparation of 477, to afford, after similar processing, allylic 
alcohol ent-477 (13 mg, 89% over 3 steps) as a colourless oil: Rf = 0.48 (silica gel, 40% 
EtOAc in hexanes); [α]25D= +16.9 (c 0.19, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.71– 
7.66 (m, 4 H), 7.46–7.34 (m, 6 H), 5.94 (ddd, J = 17.3, 10.6, 5.5 Hz, 1 H), 5.67 (dd, J = 
15.7, 7.1 Hz, 1 H), 5.59 (dd, J = 15.7, 7.1 Hz, 1 H), 5.43–5.37 (m, 1 H), 5.28 (dt, J = 10.6, 
1.3 Hz, 1 H), 4.17–4.10 (m, 1 H), 3.76– 3.70 (m, 1 H), 3.40 (dd, J = 7.1, 2.2 Hz, 1 H), 
3.20 (dd, J = 7.0, 2.1 Hz, 1 H), 2.99 (dd, J = 4.3, 2.2 Hz, 1 H), 2.95 (dd, J = 5.5, 2.1 Hz, 
1 H), 1.88 (d, J = 6.6 Hz, 1 H), 1.11 (d, J = 6.4 Hz, 3 H), 1.07 (s, 9 H); 13C NMR (100 
MHz, CDCl3) δ 136.2, 135.9, 135.8, 133.1, 133.0, 132.6, 130.9, 129.7, 129.6, 127.6, 
127.5, 117.0, 71.5, 69.7, 64.5, 62.4, 54.9, 54.7, 26.9, 19.9, 19.3; HRMS (H-ESI) m/z calcd 
for C27H34O4Si [M + H]
+ 451.2305, found 451.2315. 
 
7.2.45. Synthesis of (+)-Depudecin (ent-442) 
(+)-Depudecin (ent-442). Silyl derivative ent-477 (8 mg, 
0.02 mmol, 1.0 equiv) was desilylated by the action of TBAF 
(0.02 mL, 1.0 M in THF, 0.02 mmol, 1.2 equiv) in the same 
way as desrcribed above for (-)-depudecin (1) to afford (+)-
depudecin (ent-442) (3.0 mg, 88%) as a colourless oil: Rf = 0.50 (silica gel, EtOAc); 
[α]25D= +35.6 (c 0.38, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.95 (ddd, J = 17.2, 10.6, 
5.5 Hz, 1 H), 5.73–5.71 (m, 2 H), 5.41 (dt, J = 17.3, 1.3 Hz, 1 H), 5.29 (dt, J = 10.6, 1.2 
Hz, 1 H), 4.15 (d, J = 5.4 Hz, 1 H), 3.79–3.74 (m, 1 H), 3.46–3.44 (m, 1 H), 3.41–3.39 
(m, 1 H), 3.03 (dd, J = 4.2, 2.2 Hz, 1 H), 2.92 (dd, J = 4.5, 2.2 Hz, 1 H), 1.90 (d, J = 6.4 
Hz, 1 H), 1.77 (d, J = 6.0 Hz, 1 H), 1.32 (d, J = 6.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) 
δ 136.1, 132.0, 131.5, 117.1, 71.5, 66.9, 64.1, 62.4, 55.3, 54.9, 20.0; HRMS (H-ESI) m/z 
calcd for C11H16O4 [M + H]
+ 213.1127, found 213.1118. 
 
7.2.46. Synthesis of Epoxy Alkene 501 
Epoxy Alkene 501. Epoxy alkene 501 was prepared from epoxy 
alcohol 500249c (400 mg, 1.08 mmol, 1.0 equiv) by sequential 
treatments with SO3·pyr and Ph3P=CH2 according to the same 
procedure described above for the preparation of 460, to obtain 
epoxy alkene 501 (312 mg, 79% over two steps) as a pale yellow oil: Rf = 0.73 (silica gel, 
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20% EtOAc in hexanes); []25D = –35.5 (c 0.40, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 
7.66 – 7.61 (m, 4 H), 7.45 – 7.36 (m, 6 H), 6.03 (dtd, J = 15.6, 5.3, 0.5 Hz, 1 H), 5.50 (dt, 
J = 8.0, 1.6 Hz, 1 H), 5.47 (dt, J = 8.0, 1.6 Hz, 1 H), 3.64 (dd, J = 10.2, 5.2 Hz, 1 H), 3.58 
(dd, J = 10.2, 7.7 Hz, 1 H), 3.29 (dd, J = 7.9, 2.1 Hz, 1 H), 2.79 (dd, J = 7.3, 2.2 Hz, 1 H), 
1.71 – 1.60 (m, 1 H), 1.05 (s, 9 H), 0.99 (d, J = 6.9 Hz, 3 H); 13C NMR (100 MHz, CDCl3) 
δ 136.1, 135.8, 133.7, 129.7, 127.7, 118.9, 65.9, 62.1, 57.2, 38.1, 26.9, 19.4, 12.7; HRMS 
(H-ESI) m/z calcd for C23H31O2Si [M + H]
+ 367.2093, found 367.2090. 
 
7.2.47. Synthesis of Triepoxy Alcohol 502 
Triepoxy Alcohol 502. A solution of epoxy olefin 
501 (158 mg, 0.43 mmol, 1.0 equiv) and diepoxy 
olefin 474 (184 mg, 1.29 mmol, 3.0 equiv) in 
degassed CH2Cl2 (4 mL) was reacted with 
Hoveyda-Grubbs 2nd generation catalyst (54 mg, 0.08 mmol, 0.20 equiv) according to the 
same procedure as described above for the synthesis of 455, to afford triepoxy alcohol 
502 (103 mg, 50%) as a colourless oil: Rf  = 0.60 (silica gel, 60% EtOAc in hexanes); 
[α]25D= –12.9 (c 0.20, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.61 (m, 4 H), 7.46 
– 7.33 (m, 6 H), 5.74 (dd, J = 15.7, 7.2 Hz, 1 H), 5.62 (dd, J = 15.7, 7.4 Hz, 1 H), 3.97 (d, 
J = 12.7 Hz, 1 H), 3.74 – 3.66 (m, 4 H), 3.39 (dd, J = 7.4, 2.0 Hz, 1 H), 3.22 (dd, J = 7.2, 
2.2 Hz, 1 H), 3.10 (dd, J = 4.4, 2.2 Hz, 1 H), 2.91 (ddd, J = 8.8, 5.5, 2.1 Hz, 2 H), 1.75 – 
1.68 (m, 1 H), 1.06 (s, 9 H), 0.99 (d, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
135.6, 133.8, 133.6, 130.2, 129.7, 127.7, 65.8, 62.5, 60.5, 57.9, 55.8, 54.9, 53.1, 38.0, 
29.7, 26.9, 19.3, 12.7; HRMS (H-ESI) m/z calcd for C28H37O5Si [M + H]
+ 481.2410, 
found 481.2408. 
 
7.2.48. Synthesis of Tosyl Derivative 503 
Tosyl Derivative 503. The tosylation of triepoxy 
alcohol 502 (32 mg, 0.07 mmol, 1.0 equiv) was 
achieved in exactly the same way as described 
above for 475, to obtain tosyl derivative 503 (44 
mg, 0.07 mmol), which did not require further purification for the next step. For 
analytical purposes, a sample of this crude (10 mg, 0.01 mmol) was purified by flash 
column chromatography (silica gel, 20% EtOAc in hexanes) to obtain tosyl derivative 
503 (9.6 mg, 96%) as a colourless oil: Rf = 0.76 (silica gel, 60% EtOAc in hexanes); 
[α]25D= –30.5 (c 0.30, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.84 – 7.76 (m, 2 H), 7.69 
– 7.60 (m, 4 H), 7.45 – 7.28 (m, 8 H), 5.73 (dd, J = 15.7, 7.2 Hz, 1 H), 5.58 (dd, J = 15.6, 
7.4 Hz, 1 H), 4.21 (dd, J = 11.7, 3.7 Hz, 1 H), 4.08 (dd, J = 11.6, 5.2 Hz, 1 H), 3.76 – 3.62 
(m, 3 H), 3.35 (dd, J = 7.5, 2.1 Hz, 1 H), 3.25 – 3.19 (m, 2 H), 3.16 – 3.07 (m, 2 H), 2.92 
– 2.85 (m, 1 H), 2.46 (s, 3 H), 1.75 – 1.67 (m, 1 H), 1.06 (s, 9 H), 0.99 (d, J = 7.0 Hz, 3 
H); 13C NMR (100 MHz, CDCl3) δ 135.6, 133.6, 130.0, 129.7, 128.0, 127.7, 68.5, 65.7, 
62.6, 55.7, 52.3, 45.9, 38.0, 29.7, 26.9, 21.7, 19.3, 12.7, 8.6; HRMS (H-ESI) m/z calcd 
for C35H43O7SSi [M + H]
+ 635.2499, found 635.2496. 
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7.2.49. Synthesis of Iodide Derivative 504 
Iodide Derivative 504. The iodination of crude tosyl 
derivative 503 (34 mg, 0.05 mmol, 1.0 equiv) was 
carried out according to the procedure described 
above for 476, to afford iodide derivative 504 (30 mg, 
0.037 mmol), which did not require further purification for the next step. For analytical 
purposes, a sample of this crude (10 mg, 0.02 mmol) was purified by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) to obtain pure iodide 504 (9.4 mg, 
94%) as a colourless oil: Rf = 0.86 (silica gel, 40% EtOAc in hexanes); [α]25D=  –10.2 (c 
0. 20 CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.70 – 7.63 (m, 4 H), 7.45 – 7.34 (m, 6 H), 
5.74 (dd, J = 15.7, 7.4 Hz, 1 H), 5.61 (dd, J = 15.7, 7.5 Hz, 1 H), 3.74 – 3.62 (m, 3 H), 
3.37 (dd, J = 7.2, 3.5 Hz, 1 H), 3.28 – 3.20 (m, 3 H), 2.97 – 2.92 (m, 2 H), 2.90 (dd, J = 
6.6, 2.2 Hz, 1 H), 1.77 – 1.66 (m, 1 H), 1.06 (s, 9 H), 1.00 (d, J = 7.0 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 135.6, 133.9, 133.6, 130.0, 129.7, 127.7, 65.8, 62.5, 59.5, 57.3, 55.7, 
54.9, 38.0, 29.7, 26.9, 19.3, 12.7, 3.2; HRMS (H-ESI) m/z calcd for C28H36IO4Si [M + 
H]+ 591.1428, found 591.1425. 
 
7.2.50. Synthesis of Allylic Alcohol 505 
Allylic Alcohol 505. A solution of crude iodide 504 
(22 mg, 0.037 mmol, 1.0 equiv) in THF (3 mL) was 
reacted with n-BuLi (50 µL, 1.6 M in hexane, 0.074 
mmol, 2.0 equiv) at -78 ºC, according to the same 
procedure as described above for the preparation of 477, to afford, after similar 
processing, allylic alcohol 505 (15 mg, 85% over 3 steps) as a colourless oil: Rf = 0.50 
(silica gel, 40% EtOAc in hexanes); [α]25D= –12.8 (c 0.10, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 7.71 – 7.60 (m, 4 H), 7.45 – 7.32 (m, 6 H), 5.94 (ddd, J = 17.3, 10.6, 5.5 Hz, 1 
H), 5.71 (dd, J = 9.0, 6.7 Hz, 1 H), 5.64 (dd, J = 11.0, 4.7 Hz, 1 H), 5.43 – 5.36 (m, 1 H), 
5.27 (dt, J = 10.6, 1.3 Hz, 1 H), 3.68 (ddd, J = 22.0, 10.0, 5.0 Hz, 3 H), 3.43 (dd, J = 7.2, 
2.2 Hz, 1 H), 3.22 (dd, J = 7.1, 2.0 Hz, 1 H), 3.00 (dd, J = 4.3, 2.2 Hz, 1 H), 2.92 – 2.88 
(m, 1 H), 1.75 – 1.65 (m, 1 H), 1.06 (s, 9 H), 0.99 (d, J = 7.0 Hz, 3 H); 13C NMR (100 
MHz, CDCl3) δ 136.2, 135.6, 133.6, 130.6, 130.0, 129.7, 127.7, 117.0, 71.6, 65.8, 62.4, 
55.1, 38.0, 29.7, 26.9, 19.3, 14.1, 12.6; HRMS (H-ESI) m/z calcd for C28H37O4Si [M + 
H]+ 465.2461, found 465.2460. 
 
7.2.51. Synthesis of Homodepudecin (506) 
Homodepudecin (506). Silyl derivative 505 (15 mg, 0.03 
mmol, 1.0 equiv) was desilylated by the action of TBAF 
(0.04 mL, 1.0 M in THF, 0.04 mmol, 1.2 equiv) in the same 
way as desrcribed above for (-)-depudecin (442) to afford 
homodepudecin (506) (7 mg, 97%) as a colourless oil: Rf = 
0.52 (silica gel, EtOAc); [α]25D= –21.1 (c 0.20, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 
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5.94 (ddd, J = 17.3, 10.6, 5.5 Hz, 1 H), 5.72 – 5.68 (m, 2 H), 5.43 – 5.37 (m, 1 H), 5.28 
(dt, J = 10.6, 1.3 Hz, 1 H), 4.17 – 4.09 (m, 1 H), 3.74 – 3.63 (m, 2 H), 3.43 (dd, J = 7.0, 
2.1 Hz, 1 H), 3.26 – 3.19 (m, 1 H), 3.01 (dd, J = 4.3, 2.2 Hz, 1 H), 2.82 (dd, J = 7.2, 2.2 
Hz, 1 H), 1.92 (d, J = 5.9 Hz, 1 H), 1.73 (bs, 1 H), 1.72 – 1.63 (m, 1 H), 1.02 (d, J = 7.0 
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 136.2, 132.9, 131.0, 117.1, 71.5, 65.9, 63.4, 
62.4, 55.9, 54.9, 38.0, 13.0; HRMS (H-ESI) m/z calcd for C12H19O4 [M + H]
+ 227.1283, 
found 227.1280. 
 
7.2.52. Synthesis of Cyclopropyl Alcohol 514 
Cyclopropyl Alcohol 514. Et2Zn (10.9 mL, 1.0 M in hexane, 10.9 
mmol, 2.2 equiv) was added to a solution of dimethoxyethane (1.1 
mL) in CH2Cl2 (36 mL) at -15 ºC and over the resulting solution 
was added CH2I2 (1.75 mL, 21.74 mmol, 4.4 equiv) dropwise over 20 min. After stirring 
the reaction mixture for 10 min at -15 ºC, a solution of borolane 512 (1.5 mL, 5.93 mmol, 
1.2 equiv) in CH2Cl2 (6 mL) was added dropwise over 5 min followed by the inmediate 
addition of a solution of allylic alcohol 513 (1 g, 4.94 mmol, 1.0 equiv) in CH2Cl2 (5.5 
mL). Then, the reaction mixture was stirred for 15 h at -20 ºC. After this time, the reaction 
was quenched by sequential addition of a saturated NH4Cl solution and an aqueous 1.0 N 
HCl solution, and the aqueous phase was extracted with Et2O. Then, a mixture of a 2 N 
NaOH solution (20 mL)/30% H2O2 (4 mL) was added to the ether phase and the mixture 
was stirred for 5 min at 25 ºC. After this time, the ether layer was separate and was washed 
sequentially with saturated NH4Cl solution, saturated Na2S2O3 solution and brine, dried 
over MgSO4 and filtered. The solvent was removed under vacuum and the crude product 
was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) to 
afford cyclopropyl 514 (952 mg, 89%) as a colorless oil: Rf = 0.76 (silica gel, 50% EtOAc 
in hexanes); []25D = –9.9 (c 0.15, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 3.68 – 3.58 
(m, 2 H), 3.50 – 3.41 (m, 2 H), 1.36 – 1.25 (m, 2 H), 0.89 (s, 9 H), 0.50 (dt, J = 8.3, 5.0 
Hz, 1 H), 0.44 (dt, J = 8.5, 5.0 Hz, 1 H), 0.05 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 
66.6, 65.8, 25.9, 19.4, 19.3, 7.8, -5.2, -5.2; HRMS (H-ESI) m/z calcd for C11H25O2Si [M 
+ H]+ 217.1624, found 217.1622. 
 
7.2.53. Synthesis of Cyclopropyl Alkene 515 
Cyclopropyl Alkene 515. Cyclopropyl alkene 515 was prepared from 
cyclopropyl alcohol 514 (950 mg, 4.39 mmol, 1.0 equiv) by sequential 
treatments with SO3·pyr and Ph3P=CH2 according to the same 
procedure described above for the preparation of 460, to obtain cyclopropyl alkene 515 
(420 mg, 45% over two steps) as a pale yellow oil: Flash column chromatography (silica 
gel, 5% EtOAc in hexanes); Rf = 0.85 (silica gel, 10% EtOAc in hexanes); [α]25D = – 15.9 
(c 0.20, CH2Cl2);
 1H NMR (400 MHz, CDCl3) δ 5.41 (ddd, J = 17.1, 10.2, 8.6 Hz, 1 H), 
5.04 (ddd, J = 17.1, 1.7, 0.6 Hz, 1 H), 4.85 (dd, J = 10.2, 1.8 Hz, 1 H), 3.61 (dd, J = 10.8, 
5.8 Hz, 1 H), 3.54 (dd, J = 5.9, 4.5 Hz, 1 H), 1.33 (ddd, J = 13.2, 8.7, 4.8 Hz, 2 H), 0.89 
(s, 9 H), 0.71 – 0.65 (m, 1 H), 0.60 (dt, J = 8.5, 4.8 Hz, 1 H), 0.05 (s, 6 H); 13C NMR (100 
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MHz, CDCl3) δ 141.2, 111.8, 65.6, 25.9, 22.9, 20.2, 18.4, 11.5, -5.1; HRMS (H-ESI) m/z 
calcd for C12H25OSi [M + H]
+ 213.1675, found 213.1672. 
 
7.2.54. Synthesis of Cyclopropyl Alcohol 516 
Cyclopropyl Alcohol 516. Silyl derivative 515 (420 mg, 1.98 mmol, 1.0 
equiv) was dissolved in THF (15 mL) and to this solution was added 
TBAF (4 mL, 1.0 M in THF, 3.96 mmol, 2.0 equiv) at 25 ºC. After 1 h, 
the reaction mixture was diluted with EtOAc and washed with a saturated aqueous NH4Cl 
solution. The aqueous phase was then extracted with EtOAc and the organic extracts were 
washed with H2O, brine, dried over MgSO4 and filtered. The solvent was removed under 
vacuum and the crude product was purified by flash column chromatography (silica gel, 
15% EtOAc in hexanes) to afford cyclopropyl alcohol 516 (107 mg, 55%) as a pale yellow 
oil: Rf = 0.30 (silica gel, 30% EtOAc in hexanes); [α]25D= –30.2 (c 0.10, CH2Cl2); 1H 
NMR (400 MHz, CDCl3) δ 5.41 (ddd, J = 17.1, 10.2, 8.6 Hz, 1 H), 5.07 (ddd, J = 17.1, 
1.6, 0.5 Hz, 1 H), 4.88 (dd, J = 10.2, 1.6 Hz, 1 H), 3.51 (dd, J = 6.9, 3.2 Hz, 2 H), 1.35 
(ddd, J = 13.4, 8.4, 4.6 Hz, 1 H), 1.21 – 1.12 (m, 1 H), 0.71 – 0.63 (m, 2 H); 13C NMR 
(100 MHz, CDCl3) δ 140.6, 112.4, 66.3, 22.9, 20.6, 11.6; HRMS (H-ESI) m/z calcd for 
C6H11O [M + H]
+ 99.0809, found 99.0808. 
 
7.2.55. Synthesis of Aldehyde 517 
Aldehyde 517. To a solution of cyclopropyl alcohol 516 (105 mg, 
1.07 mmol, 1.0 equiv) in a 1:1 DMSO:CH2Cl2 mixture (2.2 mL) was 
added Et3N (0.45 mL, 3.21 mmol, 3.0 equiv) followed by SO3·pyr 
(426 mg, 2.67 mmol, 2.5 equiv) at 0 ºC. The reaction mixture was stirred at this 
temperature until depletion of the starting alcohol as judged by TLC ( 4 h). After this 
time, the reaction mixture was quenched by addition of a buffer solution (pH = 7) and 
diluted with Et2O. The aqueous phase was extracted with Et2O and the combined organic 
layers were washed with brine, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure to give the crude aldehyde (1.1 mmol) which was 
used in the next step without further purification. To a solution of the crude aldehyde in 
CH2Cl2 (5 mL) was added (formylmethylene) triphenylphosphorane (671 mg, 2.14 mmol, 
2.0 equiv) and the mixture was stirred for 12 h. After this time the solvent was removed 
under reduced pressure at 25 ºC and the residue purified by flash column chromatography 
(silica gel, 5% EtOAc in hexanes) to obtain aldehyde 517 (10 mg, 1% over two steps) as 
a colorless oil: Rf = 0.30 (silica gel, 20% EtOAc in hexanes); []25D = –10.8 (c 0.09, 
CH2Cl2);
 1H NMR (400 MHz, CDCl3) δ 9.43 (d, J = 7.8 Hz, 1 H), 6.38 – 6.29 (m, 1 H), 
6.18 (dd, J = 15.4, 7.8 Hz, 1 H), 5.45 (ddd, J = 17.0, 10.2, 8.3 Hz, 1 H), 5.15 (ddd, J = 
17.0, 1.3, 0.6 Hz, 1 H), 5.03 – 4.96 (m, 1 H), 1.83 – 1.76 (m, 1 H), 1.76 – 1.69 (m, 1 H), 
1.21 – 1.14 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 193.1, 161.1, 138.2, 130.4, 114.5, 
27.5, 24.7, 17.4; HRMS (H-ESI) m/z calcd for C8H11O [M + H]
+ 123.0809, found 
123.0807. 
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7.2.56. Synthesis of Cyclopropyl Alcohol 519 
Cyclopropyl Alcohol 519. Cyclopropyl alcohol 519 was 
prepared from alcohol 518 (2.1 g, 9.19 mmol, 1.0 equiv) 
according to the same procedure described above for the 
preparation of 514 to obtain cyclopropyl alcohol 519 (2.2 g, 98%) as a colorless oil: Flash 
column chromatography (silica gel, 10% EtOAc in hexanes); Rf = 0.70 (silica gel, 50% 
EtOAc in hexanes); []25D = –39.5 (c 0.25, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.65 
– 5.57 (m, 1 H), 5.24 (ddt, J = 15.2, 8.6, 1.5 Hz, 1 H), 4.10 (dd, J = 5.5, 1.5 Hz, 2 H), 3.53 
– 3.46 (m, 1 H), 3.47 – 3.40 (m, 1 H), 1.37 – 1.25 (m, 2 H), 0.90 (s, 9 H), 0.69 – 0.61 (m, 
2 H), 0.06 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 133.1, 127.6, 66.4, 63.8, 26.0, 22.9, 
19.2, 18.5, 11.6, -5.1; HRMS (H-ESI) m/z calcd for C13H27O2Si [M + H]
+ 243.1780, found 
243.1781. 
 
7.2.57. Synthesis of Cyclopropyl Alkene 520 
Cyclopropyl Alkene 520. Cyclopropyl alkene 520 was prepared 
from cyclopropyl alcohol 519 (2.2 g, 9.08 mmol, 1.0 equiv)  by 
sequential treatments with SO3·pyr and Ph3P=CH2 according to 
the same procedure described above for the preparation of 460, to obtain cyclopropyl 
alkene 520 (1 g, 46% over two steps) as a colorless oil: Flash column chromatography 
(silica gel, 100% hexanes) to obtain cyclopropyl alkene 520 (1 g, 46% over two steps) as 
a colorless oil: Rf = 0.95 (silica gel, 5% EtOAc in hexanes); [α]25D = – 25.1 (c 0.30, 
CH2Cl2);
 1H NMR (400 MHz, CDCl3) δ 5.61 (dt, J = 15.2, 5.4 Hz, 1 H), 5.46 – 5.34 (m, 
1 H), 5.25 (ddt, J = 15.2, 8.3, 1.5 Hz, 1 H), 5.05 (dd, J = 17.1, 1.7 Hz, 1 H), 4.87 (dd, J = 
10.2, 1.6 Hz, 1 H), 4.11 (dd, J = 5.4, 1.5 Hz, 2 H), 1.48 – 1.37 (m, 2 H), 0.91 (s, 9 H), 
0.49 (ddd, J = 8.4, 5.6, 2.6 Hz, 1 H), 0.36 – 0.30 (m, 1 H), 0.07 (s, 6 H); 13C NMR (100 
MHz, CDCl3) δ 140.5, 132.9, 127.6, 112.2, 63.8, 26.0, 24.4, 23.3, 18.5, 14.9, -5.1; HRMS 
(H-ESI) m/z calcd for C14H27OSi [M + H]
+ 239.1831, found 239.1830. 
 
7.2.58. Synthesis of Allylic Alcohol 521 
Allylic Alcohol 521. Silyl derivative 520 (1 g, 4.19 mmol, 1.0 
equiv)  was desilylated by the action of TBAF (8.4 mL, 1.0 M in 
THF, 8.40 mmol, 2.0 equiv) in the same way as desrcribed above 
for 516 to afford 521 (513mg, 98%) as a pale yellow oil: Flash column chromatography 
(silica gel, 2.5% EtOAc in hexanes → 10% EtOAc in hexanes); Rf = 0.20 (silica gel, 20% 
EtOAc in hexanes); [α]25D= –26.3 (c 0.15, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.75 
– 5.67 (m, 1 H), 5.46 – 5.34 (m, 1 H), 5.34 – 5.23 (m, 1 H), 5.10 – 5.03 (m, 1 H), 4.89 
(dd, J = 10.2, 1.6 Hz, 1 H), 4.11 – 4.04 (m, 2 H), 1.49 – 1.41 (m, 2 H), 0.91 – 0.83 (m, 2 
H); 13C NMR (100 MHz, CDCl3) δ 140.2, 135.1, 127.2, 112.5, 63.6, 24.6, 23.3, 15.0; 
HRMS (H-ESI) m/z calcd for C8H13O [M + H]
+ 125.0966, found 125.0964. 
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7.2.59. Synthesis of Epoxy Cyclopropyl Alkene 511 
Epoxy Cyclopropyl Alkene 511. To a suspension of titanium 
tetraisopropoxide (0.28 mL, 0.95 mmol, 0.23 equiv) and 4Å 
molecular sieves (5.0 g) in CH2Cl2 (50 mL) was added (+)-L-DET 
(0.18 mL, 1.03 mmol, 0.25 equiv) at -50 ºC. After 15 min at this temperature, a solution 
of allylic alcohol 521 (513 mg, 4.13 mmol, 1.0 equiv) in CH2Cl2 (2 mL) was added 
dropwise, followed by the addition, after additional 30 min, of TBHP (1.13 mL, 5.5 M 
solution in decane, 6.19 mmol, 1.5 equiv) at the same temperature. After 15 h at -20 ºC, 
the reaction mixture was quenched with Me2S (1.4 mL, 19.00 mmol, 4.6 equiv) at 0 ºC, 
filtered off and the solvent was evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) to 
obtain epoxy alcohol 511 (603 mg, 71%) as a colourless oil: Rf = 0.40 (silica gel, 50% 
EtOAc in hexanes); []25D = –18.6 (c 0.15, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.36 
(ddd, J = 17.1, 10.2, 8.6 Hz, 1 H), 5.01 (ddd, J = 17.0, 1.7, 0.6 Hz, 1 H), 4.83 (ddd, J = 
10.2, 1.7, 0.4 Hz, 1 H), 3.43 (dd, J = 7.0, 3.3 Hz, 2 H), 1.23 – 1.14 (m, 1 H), 0.91 – 0.84 
(m, 2 H), 0.82 – 0.74 (m, 1 H), 0.41 – 0.35 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 
141.6, 111.54, 66.9, 21.9, 21.2, 18.2, 12.3, 8.7; HRMS (H-ESI) m/z calcd for C8H13O2 [M 
+ H]+ 141.0916, found 141.0913. 
 
7.2.60. Synthesis of Cyclopropyl Alcohol 523 
Cyclopropyl Alcohol 523. Cyclopropyl alcohol 523 was prepared 
from allylic alcohol 522 (1 g, 2.94 mmol, 1.0 equiv) according to the 
same procedure described above for the preparation of 514 to obtain 
cyclopropyl alcohol 523 (1 g, 96%) as a yellow oil: Flash column 
chromatography (silica gel, 15% EtOAc in hexanes); Rf = 0.50 (silica gel, 30% EtOAc in 
hexanes); []25D = –12.1 (c 0.45, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.65 (m, 
4 H), 7.44 – 7.33 (m, 6 H), 3.64 (t, J = 6.0 Hz, 1 H), 3.39 – 3.33 (m, 1 H), 3.32 – 3.22 (m, 
1 H), 1.35 – 1.31 (m, 2 H), 1.17 (d, J = 6.1 Hz, 3 H), 1.04 (s, 9 H), 0.92 – 0.86 (m, 1 H), 
0.34 – 0.27 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 135.9, 135.9, 134.5, 134.4, 129.6, 
129.6, 127.6, 127.5, 72.4, 66.6, 26.9, 25.3, 19.8, 7.3; HRMS (H-ESI) m/z calcd for 
C22H31O2Si [M + H]
+ 355.2093, found 355.2091. 
 
7.2.61. Synthesis of Cyclopropyl Alkene 510 
Cyclopropyl Alkene 510. Cyclopropyl alkene 510 was prepared from 
cyclopropyl alcohol 523 (1 g, 2.82 mmol, 1.0 equiv) by sequential 
treatments with SO3·pyr and Ph3P=CH2 according to the same procedure 
described above for the preparation of 460, to obtain cyclopropyl alkene 
510 (380 mg, 40% over two steps) as a yellow oil: Flash column chromatography (silica 
gel, 100% hexanes); Rf = 0.92 (silica gel, 10% EtOAc in hexanes); [α]25D = – 36.2 (c 0.20, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.72 – 7.64 (m, 4 H), 7.47 – 7.32 (m, 6 H), 5.40 
– 5.28 (m, 1 H), 4.94 (ddd, J = 17.1, 1.8, 0.6 Hz, 1 H), 4.84 – 4.78 (m, 1 H), 3.29 (dq, J 
= 12.4, 6.2 Hz, 1 H), 1.30 – 1.22 (m, 2 H), 1.15 (d, J = 6.1 Hz, 3 H), 1.05 (s, 9 H), 0.52 – 
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0.45 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 141.3, 136.0, 135.9, 129.5, 129.5, 127.5, 
127.5, 111.6, 72.5, 28.8, 27.0, 23.5, 21.0, 19.2, 10.8; HRMS (H-ESI) m/z calcd for 
C23H31OSi [M + H]
+ 351.2144, found 351.2142. 
 
7.2.62. Synthesis of Epoxy Ester 533 
Epoxy Ester 533. To a solution of epoxy alcohol 473 (1.2 
g, 3.37 mmol, 1.0 equiv) in a 1:1 DMSO:CH2Cl2 mixture (7 
mL) was added Et3N (1.4 mL, 10.10 mmol, 3.0 equiv) 
followed by SO3·pyr (1.3 g, 8.41 mmol, 2.5 equiv) at 0 ºC. 
The reaction mixture was stirred at this temperature until depletion of the starting alcohol 
as judged by TLC ( 5 h). After this time, the reaction mixture was quenched by addition 
of a buffer solution (pH = 7) and diluted with Et2O. The aqueous phase was extracted 
with Et2O and the combined organic layers were washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure to give the crude 
aldehyde (3.4 mmol) which was used in the next step without further purification. The 
crude aldehyde (3.4 mmol, 1.0 equiv), triethyl 4-phosphonocrotonate (532) (1.0 g, 4.76 
mmol, 1.4 equiv), LiOH (113 mg, 4.71 mmol, 1.4 equiv) and 4 Å molecular sieves (5 g) 
were dissolved in THF (15 mL) and refluxed for 15 h. After this time, the mixture was 
filtered through a pad of SiO2 and washed with Et2O. The organic solvent was removed 
under reduced pressure and the residue was purified by flash column chromatography 
(silica gel, 5% EtOAc in hexanes) to obtain ester 533 (707 mg, 47% over two steps) as a 
pale yellow oil: Rf = 0.54 (silica gel, 20% EtOAc in hexanes); []25D = – 10.8 (c 0.71, 
CH2Cl2);
 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.66 (m, 4 H), 7.44 – 7.36 (m, 6 H), 7.25 
– 7.19 (m, 1 H), 6.41 (dd, J = 15.3, 11.2 Hz, 1 H), 5.89 (d, J = 15.4 Hz, 1 H), 5.78 (dd, J 
= 15.3, 7.7 Hz, 1 H), 4.21 (q, J = 7.1 Hz, 2 H), 3.77 (dd, J = 6.3, 5.5 Hz, 1 H), 3.26 (dd, 
J = 7.6, 2.1 Hz, 1 H), 2.98 (dd, J = 5.4, 2.1 Hz, 1 H), 1.30 (t, J = 7.1 Hz, 3 H), 1.12 (d, J 
= 6.5 Hz, 3 H), 1.08 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 166.8, 142.7, 138.4, 135.9, 
135.9, 134.1, 133.6, 131.3, 129.7, 129.7, 127.6, 127.6, 122.3, 69.6, 65.0, 60.5, 55.0, 26.9, 
19.9, 19.3, 14.3; HRMS (H-ESI) m/z calcd for C27H34O4Si [M + H]
+ 451.2305, found 
451.2303. 
 
7.2.63. Synthesis of Cyclopropyl Ester 535 
Cyclopropyl Ester 535. Cyclopropyl ester 535 was prepared 
from cyclopropyl alcohol 523 (500 mg, 1.40 mmol, 1.0 
equiv) according to the same procedure described above for 
the preparation of 533, to obtain cyclopropyl ester 535 (320 
mg, 51% over two steps) as a pale yellow oil: Flash column chromatography (silica gel, 
5% EtOAc in hexanes); Rf = 0.85 (silica gel, 20% EtOAc in hexanes); []25D = – 18.66 (c 
0.10, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.71 – 7.63 (m, 4 H), 7.45 – 7.33 (m, 6 H), 
7.25 – 7.16 (m, 1  H), 6.03 (dd, J = 19.0, 7.2 Hz, 1 H), 5.74 (d, J = 15.3 Hz, 1 H), 5.56 
(dd, J = 15.0, 9.3 Hz, 1 H), 4.21 (q, J = 7.2 Hz, 3 H), 3.36 – 3.28 (m, 1 H), 1.34 – 1.28 
(m, 2 H), 1.21 – 1.16 (m, 4 H), 1.08 (d, J = 5.6 Hz, 3 H), 1.04 (s, 9 H), 0.71 – 0.60 (m, 2 
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H); 13C NMR (100 MHz, CDCl3) δ 167.5, 147.6, 145.0, 135.9, 135.9, 135.9, 134.3, 134.2, 
129.6, 129.6, 127.6, 117.9, 72.3, 69.6, 60.1, 30.4, 27.0, 21.2, 19.3, 14.4, 12.6; HRMS (H-
ESI) m/z calcd for C28H37O3Si [M + H]
+ 449.2512, found 449.2511. 
 
7.2.64. Synthesis of Allylic Alcohol 531 
Allylic Alcohol 531. A solution of ester 535 (100 mg, 0.22 
mmol, 1.0 equiv) in CH2Cl2 (10 mL) was cooled at -78 ºC 
and treated with DIBAL-H (0.6 mL, 1.0 M in toluene, 0.56 
mmol, 2.5 equiv). After 20 min, the reaction was quenched 
by addition of MeOH at -78 ºC and the mixture was allowed to reach room temperature, 
treated with a saturated aqueous Na+/K+ tartrate solution and diluted with CH2Cl2. The 
resulting mixture was vigorously stirred until a clear separation of both organic and 
aqueous phases. The organic layer was separated and the aqueous phase was extracted 
with CH2Cl2 three times. The combined organic layers were washed with brine, dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
residue was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) 
to obtain allylic alcohol 531 (70 mg, 77%) as a colorless oil: Rf = 0.75 (silica gel, 50% 
EtOAc in hexanes); [α]25D = – 15.7 (c 0.15, CH2Cl2);1H NMR (400 MHz, CDCl3) δ 7.72 
– 7.64 (m, 4 H), 7.44 – 7.34 (m, 6 H), 6.17 (dd, J = 15.1, 10.5 Hz, 1 H), 5.96 (dd, J = 
15.1, 10.5 Hz, 1 H), 5.70 (ddd, J = 15.1, 10.5, 4.3 Hz, 1 H), 5.22 (dd, J = 15.1, 8.9 Hz, 1 
H), 4.17 (d, J = 6.0 Hz, 2 H), 3.35 – 3.28 (m, 1 H), 1.19 – 1.15 (m, 2 H), 1.07 (d, J = 4.2 
Hz, 3 H), 1.05 (s, 9 H), 0.59 – 0.49 (m, 1 H), 0.36 – 0.27 (m, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 138.2, 136.0, 135.9, 135.9, 134.5, 134.3, 132.1, 129.6, 129.5, 128.5, 127.5, 
127.1, 72.4, 66.6, 63.7, 29.4, 27.0, 23.6, 19.3, 11.6; HRMS (H-ESI) m/z calcd for 
C26H35O2Si [M + H]
+ 407.2406, found 407.2404. 
 
7.2.65. Synthesis of Ester 545 
Ester 545. Ester 545 was prepared from allylic alcohol 522 (500 
mg, 1.47 mmol, 1.0 equiv) according to the same procedure 
described above for the preparation of 533, to obtain ester 545 (525 
mg, 88% over two steps) as a colorless oil: Flash column 
chromatography (silica gel, 10% EtOAc in hexanes); Rf = 0.60 (silica gel, 10% EtOAc in 
hexanes); []25D = –10.1 (c 0.93, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.61 (m, 
4 H), 7.44 – 7.33 (m, 6 H), 7.22 (dd, J = 15.4, 10.8 Hz, 1 H), 6.19 (dd, J = 15.4, 10.6 Hz, 
1 H), 6.07 (dd, J = 15.2, 5.2 Hz, 1 H), 5.79 (d, J = 15.4 Hz, 1 H), 4.42 – 4.35 (m, 1 H), 
4.20 (q, J = 7.1 Hz, 2 H), 1.30 (t, J = 7.1 Hz, 3 H), 1.16 (d, J = 6.4 Hz, 3 H), 1.07 (s, 9 
H); 13C NMR (100 MHz, CDCl3) δ 167.1, 146.5, 144.3, 135.8, 134.2, 133.7, 129.7, 129.7, 
127.6, 126.2, 120.9, 69.4, 60.3, 26.9, 23.8, 19.3, 14.3; HRMS (H-ESI) m/z calcd for 
C25H32O3Si [M + H]
+ 409.2199, found 409.2197. 
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7.2.66. Synthesis of Allylic Alcohol 546 
Allylic Alcohol 546. A solution of ester 545 (525 mg, 2.29 mmol, 
1.0 equiv) in CH2Cl2 (15 mL) was cooled at -78 ºC and treated 
with DIBAL-H (5.7 mL, 1.0 M in toluene, 5.72 mmol, 2.5 equiv). 
After 20 min, the reaction was quenched by addition of MeOH at 
-78 ºC and the mixture was allowed to reach room temperature, treated with a saturated 
aqueous Na+/K+ tartrate solution and diluted with CH2Cl2. The resulting mixture was 
vigorously stirred until a clear separation of both organic and aqueous phases. The organic 
layer was separated and the aqueous phase was extracted with CH2Cl2 three times. The 
combined organic layers were washed with brine, dried over anhydrous MgSO4, filtered 
and the solvent evaporated under reduced pressure. The residue was purified by flash 
column chromatography (silica gel, 5% EtOAc in hexanes) to obtain allylic alcohol 546 
(423 mg, 90%) as a pale colorless oil: Rf = 0.20 (silica gel, 10% EtOAc in hexanes); []25D 
= + 21.5 (c 0.66, CH2Cl2);
 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.63 (m, 4 H), 7.44 – 
7.33 (m, 6 H), 6.19 (ddt, J = 15.1, 10.5, 1.3 Hz, 1 H), 6.03 (dd, J = 15.4, 10.7 Hz, 1 H), 
5.72 (ddd, J = 13.6, 10.0, 5.9 Hz, 2 H), 4.38 – 4.30 (m, 1 H), 4.17 (t, J = 5.0 Hz, 2 H), 
1.14 (d, J = 6.3 Hz, 3 H), 1.07 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 138.3, 135.9, 
135.9, 134.5, 134.1, 131.3, 131.2, 129.6, 129.5, 127.7, 127.5, 127.5, 69.7, 63.5, 27.0, 
24.2, 19.3; HRMS (H-ESI) m/z calcd for C23H30O2Si [M + H]
+ 367.2093, found 367.2096. 
 
7.2.67. Synthesis of Epoxy Alcohol 548 
Epoxy Alcohol 548. To a solution of allylic alcohol 546 (1.1 g, 
3.14 mmol, 1.0 equiv) and NaHCO3 (600 mg, 7.22 mmol, 2.3 
equiv) in CH2Cl2 (100 mL) was added m-CPBA (914 mg, 4.08 
mmol, 1.3 equiv) at -15 ºC, and the resulting mixture was stirred 
at this temperature for 4 h. After this time the reaction was quenched by addition of Me2S 
(0.23 mL, 3.14 mmol, 1.0 equiv) at 0 ºC. The mixture was stirred for 5 minutes at the 
same temperature. Then, a saturated aqueous NaHCO3 solution was added and the 
aqueous phase was extracted with Et2O. The organic layer was washed with brine, dried 
over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
residue was purified by flash column chromatography (silica gel, 10% EtOAc in hexanes) 
to obtain epoxy alcohol 548 (1.0 g, 88%) as a colorless oil: Rf = 0.68 (silica gel, 50% 
EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ 7.71 – 7.64 (m, 8 H), 7.45 – 7.34 (m, 
12 H), 5.95 (dd, J = 11.2, 4.4 Hz, 1 H), 5.91 (dd, J = 11.1, 4.4 Hz, 1 H), 5.32 (ddd, J = 
15.5, 8.0, 1.3 Hz, 1 H), 5.20 (ddd, J = 15.5, 8.1, 1.2 Hz, 1 H), 4.39 – 4.31 (m, 2 H), 3.95 
(dd, J = 5.0, 2.3 Hz, 1 H), 3.92 (dd, J = 4.9, 2.3 Hz, 1 H), 3.70 – 3.61 (m, 1 H), 3.34 (ddd, 
J = 13.2, 8.1, 2.2 Hz, 1 H), 2.98 (dt, J = 4.4, 2.4 Hz, 1 H), 2.94 (dt, J = 4.4, 2.3 Hz, 1 H), 
1.18 – 1.14 (m, 6 H), 1.09 – 1.07 (m, 18 H); 13C NMR (100 MHz, CDCl3) δ 140.3, 140.2, 
135.9, 135.9, 135.9, 134.3, 134.3, 133.9, 133.9, 129.7, 129.6, 127.6, 127.5, 125.3, 125.0, 
69.4, 69.2, 61.2, 60.1, 60.1, 55.3, 55.2, 27.0, 23.9, 23.9, 19.3, 19.3; HRMS (H-ESI) m/z 
calcd for C23H30O3Si [M + H]
+ 383.2043, found 383.2046. 
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7.2.68. Synthesis of Aldehyde 549 
Aldehyde 549. Aldehyde 549 was prepared from epoxy 
alcohol 548 (574 mg, 1.50 mmol, 1.0 equiv) by sequential 
treatments with SO3·pyr and Ph3P=CHCHO according to the 
same procedure described above for the preparation of 467, to 
obtain aldehyde 549 (387 mg, 63% over two steps) as a pale yellow oil: Flash column 
chromatography (silica gel, 5% EtOAc in hexanes); Rf = 0.75 (silica gel, 40% EtOAc in 
hexanes); 1H NMR (400 MHz, CDCl3) δ 9.59 (d, J = 3.6 Hz, 1 H), 9.57 (d, J = 3.6 Hz, 1 
H), 7.69 – 7.64 (m, 8 H), 7.44 – 7.33 (m, 12 H), 6.57 (dd, J = 6.6, 1.1 Hz, 1 H), 6.53 (dd, 
J = 6.6, 1.1 Hz, 1 H), 6.41 (ddd, J = 7.7, 3.8, 0.5 Hz, 1 H), 6.38 – 6.35 (m, 1 H), 5.97 (dd, 
J = 8.5, 5.4 Hz, 1 H), 5.93 (dd, J = 8.7, 5.6 Hz, 1 H), 5.32 (ddd, J = 15.5, 7.4, 1.4 Hz, 1 
H), 5.24 (ddd, J = 15.5, 7.7, 1.4 Hz, 1 H), 4.40 – 4.32 (m, 2 H), 3.33 – 3.27 (m, 4 H), 1.18 
– 1.15 (m, 6 H), 1.07 (s, 9 H), 1.07 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 192.5, 152.1, 
141.1, 140.9, 135.9, 135.9, 134.2, 133.9, 133.6, 133.6, 129.7, 129.7, 127.6, 127.5, 124.3, 
124.1, 69.2, 69.2, 61.1, 60.9, 58.1, 57.9, 26.9, 23.9, 19.3; HRMS (H-ESI) m/z calcd for 
C25H30O3Si [M + H]
+ 407.2044, found 407.2041. 
 
7.2.69. Synthesis of Allylic Alcohol 550 
Allylic Alcohol 550. A solution of aldehyde 549 (387 mg, 
0.95 mmol, 1.0 equiv) in CH2Cl2 (20 mL) was cooled at -78 
ºC and treated with DIBAL-H (1.0 mL, 1.0 M in toluene, 
0.95 mmol, 1.0 equiv). After 20 min, the reaction was 
quenched by addition of MeOH at -78 ºC and the mixture was allowed to reach room 
temperature, treated with a saturated aqueous Na+/K+ tartrate solution and diluted with 
CH2Cl2. The resulting mixture was vigorously stirred until a clear separation of both 
organic and aqueous phases. The organic layer was separated and the aqueous phase was 
extracted with CH2Cl2 three times. The combined organic layers were washed with brine, 
dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. 
The residue was purified by flash column chromatography (silica gel, 20% EtOAc in 
hexanes) to obtain allylic alcohol 550 (265 mg, 68%) as a yellow oil: Rf = 0.25 (silica gel, 
40% EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.63 (m, 8 H), 7.45 – 7.32 
(m, 12 H), 6.09 (ddd, J = 5.6, 5.0, 3.7 Hz, 1 H), 6.05 (ddd, J = 5.7, 5.0, 3.4 Hz, 1 H), 5.91 
(dd, J = 10.2, 5.4 Hz, 1 H), 5.87 (dd, J = 10.3, 5.5 Hz, 1 H), 5.52 (dt, J = 7.7, 1.6 Hz, 1 
H), 5.31 (ddd, J = 15.5, 7.6, 1.4 Hz, 1 H), 5.20 (ddd, J = 15.5, 7.8, 1.3 Hz, 1 H), 4.38 – 
4.29 (m, 2 H), 4.23 – 4.15 (m, 4 H), 3.16 (dtd, J = 18.0, 8.0, 2.0 Hz, 4 H), 1.18 – 1.12 (m, 
6 H), 1.10 – 1.05 (m, 19 H); 13C NMR (100 MHz, CDCl3) δ 139.8, 139.6, 135.9, 135.9, 
135.9, 134.3, 134.3, 133.9, 133.9, 129.6, 129.6, 128.2, 128.1, 127.5, 127.5, 125.5, 125.2, 
69.4, 69.3, 62.7, 62.7, 59.9, 59.8, 59.6, 59.6, 27.0, 23.9, 19.3; HRMS (H-ESI) m/z calcd 
for C25H32O3Si [M + H]
+ 409.2199, found 409.2195. 
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7.2.70. Synthesis of Tosyl Derivative 552 
Tosyl Derivative 552. To a suspension of titanium 
tetraisopropoxide (0.04 mL, 0.15 mmol, 0.23 equiv) and 4Å 
molecular sieves (1.0 g) in CH2Cl2 (10 mL) was added (+)-
L-DET (0.03 mL, 0.16 mmol, 0.25 equiv) at -50 ºC. After 
15 min at this temperature, a solution of allylic alcohol 550 (265 mg, 0.65 mmol, 1.0 
equiv) in CH2Cl2 (5 mL) was added dropwise, followed by the addition, after additional 
30 min, of TBHP (0.2 mL, 5.5 M solution in decane, 0.97 mmol, 1.5 equiv) at the same 
temperature. After 15 h at -20 ºC, the reaction mixture was quenched with Me2S (0.2 mL, 
2.96 mmol, 4.6 equiv) at 0 ºC, filtered off and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (silica gel, 
30% EtOAc in hexanes) to obtain diepoxy alcohol 551 (300 mg, ~72%,  impurified with 
~100 mg of (+)-DET) as a colourless oil which was used in the next steps without further 
purification. Diepoxy alcohol 551 obtained above (300 mg, 0.71 mmol, 1.0 equiv) was 
dissolved in CH2Cl2 (20 mL) and cooled at 0 ºC. Over this solution was then added p-
TsCl (162 mg, 0.85 mmol, 1.2 equiv), TEA (0.15 mL, 1.06 mmol, 1.5 equiv) and 4-
DMAP (2 mg, 0.01 mmol, 0.02 equiv). After 3 h, the reaction mixture was quenched by 
addition of water and the aqueous phase was extracted with CH2Cl2 three times. The 
organic phase was washed with brine, dried over MgSO4, filtered and the solvent removed 
under reduced pressure to obtain tosyl derivative 552 (245 mg, 0.42 mmol), which did 
not require further purification for the next step. For analytical purposes, a sample of this 
crude (35 mg, 0.06 mmol) was purified by flash column chromatography (silica gel, 
20% EtOAc in hexanes) to provide pure tosyl derivative 552 (33 mg, 95%) as a colourless 
oil: Rf = 0.80 (silica gel, 60% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 7.87 – 
7.77 (m, 4 H), 7.68 – 7.60 (m, 8 H), 7.45 – 7.32 (m, 16 H), 5.90 (td, J = 15.0, 5.4 Hz, 2 
H), 5.22 (ddd, J = 15.6, 7.9, 1.4 Hz, 1 H), 5.12 (ddd, J = 15.4, 7.9, 1.3 Hz, 1 H), 4.32 (dd, 
J = 11.9, 6.6 Hz, 2 H), 4.22 – 4.12 (m, 2 H), 4.06 (dd, J = 11.6, 5.3 Hz, 1 H), 4.00 (dd, J 
= 11.6, 5.6 Hz, 1 H), 3.24 (dd, J = 7.9, 1.9 Hz, 1 H), 3.22 – 3.14 (m, 3 H), 2.93 (dd, J = 
4.1, 2.0 Hz, 1 H), 2.89 (dd, J = 4.4, 2.0 Hz, 1 H), 2.72 (ddd, J = 9.8, 4.3, 2.1 Hz, 2 H), 
2.46 (s, 6 H), 1.16 – 1.12 (m, 6 H), 1.07 – 1.04 (m, 18 H); 13C NMR (100 MHz, CDCl3) 
δ 145.2, 140.9, 140.7, 135.9, 135.9, 134.2, 134.2, 133.9, 132.6, 130.0, 129.7, 128.6, 128.0, 
128.0, 127.5, 127.5, 124.3, 124.2, 69.2, 69.2, 68.8, 68.7, 62.8, 61.6, 57.2, 57.0, 56.4, 55.4, 
54.6, 54.1, 52.8, 52.3, 29.7, 26.9, 23.9, 21.8, 19.2, 1.0; HRMS (H-ESI) m/z calcd for 
C32H38O6SSi [M + H]
+ 579.2237, found 579.2235. 
 
7.2.71. Synthesis of Iodide Derivative 553 
Iodide Derivative 553. The iodination of crude tosyl 
derivative 552 (200 mg, 0.34 mmol, 1.0 equiv) was carried 
out according to the procedure described above for 476, to 
afford iodide derivative 553 (130 mg, 0.24 mmol), which did 
not require further purification for the next step. For analytical purposes, a sample of this 
crude (65 mg, 0.12 mmol) was purified by flash column chromatography (silica gel, 
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10% EtOAc in hexanes) to afford pure iodide derivative 553 (59 mg, 93%) as a colourless 
oil: Rf = 0.60 (silica gel, 30% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 7.68 – 
7.62 (m, 8 H), 7.44 – 7.35 (m, 12 H), 5.92 (dddd, J = 15.5, 11.6, 5.4, 0.5 Hz, 2 H), 5.24 
(ddd, J = 15.5, 7.8, 1.5 Hz, 1 H), 5.14 (ddd, J = 15.5, 8.0, 1.3 Hz, 1 H), 4.36 – 4.29 (m, 2 
H), 4.16 (dq, J = 15.6, 7.2 Hz, 2 H), 3.29 – 3.18 (m, 4 H), 3.13 – 3.04 (m, 2 H), 2.94 – 
2.90 (m, 2 H), 2.80 (ddd, J = 8.9, 4.0, 2.1 Hz, 2 H), 1.17 – 1.13 (m, 6 H), 1.08 – 1.04 (m, 
18 H); 13C NMR (100 MHz, CDCl3) δ 140.8, 140.6, 135.9, 135.9, 134.2, 134.2, 133.9, 
129.7, 127.6, 127.5, 124.5, 124.4, 69.3, 69.2, 60.1, 59.7, 57.4, 57.2, 56.5, 56.1, 55.6, 55.4, 
26.9, 23.9, 19.2, 1.0; HRMS (H-ESI) m/z calcd for C25H31IO3Si [M + H]
+ 535.1165, found 
535.1163. 
 
7.2.72. Synthesis of Allylic Alcohol 554 
Allylic Alcohol 554. A solution of iodide 553 (65 mg, 0.12 
mmol, 1.0 equiv) in THF (9 mL) was reacted with n-BuLi (0.15 
mL, 1.6 M in hexane, 0.24 mmol, 2.0 equiv) at -78 ºC, according 
to the same procedure as described above for the preparation of 
477, to afford, after similar processing, allylic alcohol 554 (41 mg, 85% over 3 steps from 
10) as a colourless oil: Flash column chromatogaphy (silica gel, 15% EtOAc in hexanes); 
Rf = 0.60 (silica gel, 30% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 7.69 – 7.62 
(m, 8 H), 7.44 – 7.32 (m, 12 H), 5.98 – 5.79 (m, 4 H), 5.44 – 5.35 (m, 2 H), 5.33 – 5.25 
(m, 3 H), 5.17 (ddd, J = 15.4, 8.1, 1.3 Hz, 1 H), 4.36 – 4.29 (m, 3 H), 4.13 – 4.06 (m, 1 
H), 3.38 – 3.32 (m, 2 H), 2.90 – 2.84 (m, 2 H), 1.17 – 1.14 (m, 6 H), 1.07 – 1.05 (m, 18 
H); 13C NMR (100 MHz, CDCl3) δ 140.5, 140.3, 136.4, 135.9, 135.9, 135.4, 134.3, 133.9, 
129.6, 129.6, 127.5, 127.5, 125.2, 124.8, 117.8, 116.8, 71.6, 70.1, 69.4, 69.2, 62.3, 61.6, 
55.6, 54.5, 26.9, 23.9, 19.2; HRMS (H-ESI) m/z calcd for C25H32O3Si [M + H]
+ 409.2199, 
found 409.2196. 
 
7.2.73. Synthesis of Depudecin Analogue 555 
Depudecin Analogue 555. Silyl derivative 554 (25 mg, 0.06 
mmol, 1.0 equiv) was desilylated by the action of TBAF (70 µL, 
1.0 M in THF, 0.07 mmol, 1.2 equiv) in the same way as 
desrcribed above for (-)-depudecin (442) to afford depudecin 
analogue 555 (8.0 mg, 78%) as a colourless oil: Flash column chromatography (silica gel, 
30% EtOAc in hexanes → 100% EtOAc); Rf = 0.56 (silica gel, EtOAc); 1H NMR (400 
MHz, CDCl3) δ 6.05 – 5.99 (m, 1 H), 5.86 (ddd, J = 17.2, 10.5, 6.3 Hz, 1 H), 5.41 (dt, J 
= 17.3, 1.4 Hz, 2 H), 5.28 (dt, J = 10.5, 1.3 Hz, 1 H), 4.41 – 4.30 (m, 2 H), 3.46 (dd, J = 
8.0, 2.3 Hz, 1 H), 3.04 (dd, J = 3.2, 2.3 Hz, 1 H), 1.98 (bs, 1 H), 1.52 (bs, 1 H), 1.29 (d, J 
= 6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 140.2, 140.2, 136.2, 135.3, 126.1, 125.9, 
117.9, 116.9, 71.6, 70.0, 67.9, 62.3, 61.7, 55.5, 54.3, 54.2, 23.2, 23.1; HRMS (H-ESI) m/z 
calcd for C9H14O3 [M + H]
+ 171.1021, found 171.1023. 
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7.2.74. Synthesis of Aldehyde 556 
Aldehyde 556. Aldehyde 556 was prepared from epoxy alcohol 
472 (2.1 g, 5.89 mmol, 1.0 equiv) by sequential treatments with 
SO3·pyr and Ph3P=CHCHO according to the same procedure 
described above for the preparation of 467, to obtain aldehyde 556 
(1.7 g, 76% over two steps) as a pale yellow oil: Flash column chromatography (silica 
gel, 5% EtOAc in hexanes); Rf = 0.80 (silica gel, 30% EtOAc in hexanes); []25D = – 18.1 
(c 0.82, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 9.54 (d, J = 7.7 Hz, 1 H), 7.71 – 7.65 
(m, 4 H), 7.46 – 7.35 (m, 6 H), 6.47 (dd, J = 15.8, 7.1 Hz, 1 H), 6.31 (dd, J = 15.8, 7.7 
Hz, 1 H), 3.87 – 3.80 (m, 1 H), 3.43 (dd, J = 7.1, 2.0 Hz, 1 H), 3.05 (dd, J = 5.2, 2.0 Hz, 
1 H), 1.15 (d, J = 6.4 Hz, 3 H), 1.08 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 192.5, 152.3, 
135.8, 133.9, 133.8, 133.4, 129.9, 129.8, 127.8, 127.7, 127.7, 69.2, 65.3, 53.7, 26.8, 19.9, 
19.3; HRMS (H-ESI) m/z calcd for C23H28O3Si [M + H]
+ 381.1886, found 381.18861. 
 
7.2.75. Synthesis of Allylic Alcohol 557 
Allylic Alcohol 557. A solution of aldehyde 556 (1.7 g, 4.47 
mmol, 1.0 equiv) in CH2Cl2 (100 mL) was cooled at -78 ºC and 
treated with DIBAL-H (4.5 mL, 1.0 M in toluene, 4.47 mmol, 1.0 
equiv). After 20 min, the reaction was quenched by addition of 
MeOH at -78 ºC and the mixture was allowed to reach room temperature, treated with a 
saturated aqueous Na+/K+ tartrate solution and diluted with CH2Cl2. The resulting mixture 
was vigorously stirred until a clear separation of both organic and aqueous phases. The 
organic layer was separated and the aqueous phase was extracted with CH2Cl2 three times. 
The combined organic layers were washed with brine, dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure. The residue was purified by 
flash column chromatography (silica gel, 10% EtOAc in hexanes) to obtain allylic alcohol 
557 (1.69 g, 98%) as a pale yellow oil: Rf = 0.30 (silica gel, 30% EtOAc in hexanes); 
[]25D = – 31.5 (c 0.65, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.67 (m, 4 H), 7.43 
– 7.34 (m, 6 H), 6.01 (ddd, J = 15.6, 5.5, 5.1 Hz, 1 H), 5.46 (ddt, J = 15.6, 8.0, 1.6 Hz, 1 
H), 4.17 (td, J = 5.7, 1.6 Hz, 2 H), 3.76 – 3.68 (m, 1 H), 3.22 (dd, J = 8.0, 2.1 Hz, 1 H), 
2.97 (dd, J = 5.6, 2.2 Hz, 1 H), 1.11 (d, J = 6.4 Hz, 3 H), 1.08 (s, 9 H); 13C NMR (100 
MHz, CDCl3) δ 135.9, 135.9, 134.4, 133.6, 129.7, 129.7, 128.3, 127.6, 127.6, 125.3, 69.9, 
64.4, 62.7, 55.3, 26.9, 19.9, 19.3; HRMS (H-ESI) m/z calcd for C23H30O3Si [M + H]
+ 
383.2043, found 383.2047. 
 
7.2.76. Synthesis of Diepoxy Alcohol 558 
Diepoxy Alcohol 558. To a suspension of titanium 
tetraisopropoxide (0.3 mL, 1.02 mmol, 0.23 equiv) and 4Å 
molecular sieves (3.0 g) in CH2Cl2 (40 mL) was added (+)-L-DET 
(0.19 mL, 1.10 mmol, 0.25 equiv) at -50 ºC. After 15 min at this 
temperature, a solution of allylic alcohol 557 (1.69 g, 4.42 mmol, 1.0 equiv) in CH2Cl2 
(20 mL) was added dropwise, followed by the addition, after additional 30 min, of TBHP 
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(1.2 mL, 5.5 M solution in decane, 6.63 mmol, 1.5 equiv) at the same temperature. After 
15 h at -20 ºC, the reaction mixture was quenched with Me2S (1.5 mL, 20.32 mmol, 4.6 
equiv) at 0 ºC, filtered off and the solvent was evaporated under reduced pressure. The 
crude product was purified by flash column chromatography (silica gel, 20% EtOAc in 
hexanes) to obtain diepoxy alcohol 558 (1 g, 57% impurified with (+)-DET) as a 
colourless oil: Rf = 0.40 (silica gel, 50% EtOAc in hexanes); []25D = –11.3 (c 0.45, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.72 – 7.64 (m, 4 H), 7.46 – 7.34 (m, 6 H), 3.95 
(ddd, J = 12.8, 4.7, 2.1 Hz, 1 H), 3.84 – 3.77 (m, 1 H), 3.67 (ddd, J = 12.8, 7.9, 3.5 Hz, 1 
H), 3.07 (dt, J = 3.6, 2.3 Hz, 1 H), 3.03 (dd, J = 5.1, 2.2 Hz, 1 H), 2.99 (dd, J = 4.6, 2.3 
Hz, 1 H), 2.87 (dd, J = 4.7, 2.2 Hz, 1 H), 1.11 (d, J = 6.4 Hz, 3 H), 1.06 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 135.9, 135.8, 133.6, 133.6, 129.8, 129.7, 127.7, 127.6, 71.9, 62.5, 
59.9, 55.7, 53.4, 26.9, 19.9, 19.3, 14.2; HRMS (H-ESI) m/z calcd for C23H30O4Si [M + 
H]+ 399.1992, found 399.1994. 
 
7.2.77. Synthesis of Aldehyde 559 
Aldehyde 559. To a solution of epoxy alcohol 558 
obtained above (1 g, 2.51 mmol, 1.0 equiv) in a 1:1 
DMSO:CH2Cl2 mixture (5 mL) was added Et3N (1 mL, 
7.53 mmol, 3.0 equiv) followed by SO3·pyr (1 g, 6.27 
mmol, 2.5 equiv) at 0 ºC. The reaction mixture was stirred at this temperature until 
depletion of the starting alcohol as judged by TLC ( 5 h). After this time, the reaction 
mixture was quenched by addition of a buffer solution (pH = 7) and diluted with Et2O. 
The aqueous phase was extracted with Et2O and the combined organic layers were washed 
with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated under 
reduced pressure to give the crude aldehyde (2.51 mmol) which was used in the next 
step without further purification. To a solution of the crude aldehyde in CH2Cl2 (10 mL) 
was added (formylmethylene)triphenylphosphorane (1.98 g, 6.52 mmol, 2.5 equiv) and 
the mixture was stirred for 15 h. After this time the solvent was removed under reduced 
pressure and the residue purified by flash column chromatography (silica gel, 5% EtOAc 
in hexanes) to obtain aldehyde 559 (163 mg, 31% over two steps) as a pale yellow oil: Rf 
= 0.65 (silica gel, 50% EtOAc in hexanes); []25D = –15.6 (c 0.49, CH2Cl2); 1H NMR (400 
MHz, CDCl3) δ 9.59 (d, J = 7.9 Hz, 1 H), 7.73 – 7.64 (m, 4 H), 7.47 – 7.34 (m, 6 H), 7.08 
(dd, J = 15.3, 11.0 Hz, 1 H), 6.64 (dd, J = 15.3, 11.0 Hz, 1 H), 6.19 (dd, J = 15.4, 7.9 Hz, 
1 H), 5.94 (dd, J = 15.3, 7.5 Hz, 1 H), 3.83 (dd, J = 6.4, 5.0 Hz, 1 H), 3.38 (dd, J = 7.5, 
1.4 Hz, 1 H), 3.04 (dd, J = 5.0, 1.8 Hz, 1 H), 2.95 – 2.93 (m, 2 H), 1.13 (d, J = 6.4 Hz, 3 
H), 1.07 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 193.5, 149.4, 139.5, 135.8, 134.8, 134.1, 
133.5, 132.6, 131.9, 129.8, 129.8, 127.7, 127.6, 68.8, 60.1, 58.5, 54.7, 53.1, 26.9, 19.9, 
19.3; HRMS (H-ESI) m/z calcd for C27H32O4Si [M + H]
+ 449.2148, found 449.2145. 
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7.2.78. Synthesis of Allylic Alcohol 565 
Allylic Alcohol 565. To a solution of diepoxy amide 564 
(350 mg, 0.58 mmol, 1.0 equiv) in THF (7 mL) was added 
dropwise Red-Al (0.36 mL, 70% w/v in toluene, 1.17 mmol, 
2.0 equiv) at 0 ºC. After 1 h at this temperature, the reaction 
mixture was quenched by addition of a saturated aqueous NH4Cl solution. After 
separation of both layers, the aqueous phase was extracted twice with EtOAc and the 
combined organic extracts washed with H2O and brine, dried over anhydrous MgSO4, 
and the solvent evaporated under reduced pressure. The resulting crude diepoxy aldehyde 
(~0.58 mmol) was used in the next step without further purification. The crude aldehyde 
was dissolved in MeOH (10 mL) and reacted with NaBH4 (44 mg, 1.16 mmol, 2.0 equiv) 
at 0 ºC. After 1 h, the reaction mixture was quenched by addition of H2O and the solvent 
was removed under reduced pressure. The crude was then dissolved in EtOAc and washed 
with H2O and brine. Removal of the solvent under reduced pressure followed by 
purification of the resiude by flash column chromatography (silica gel, 20% EtOAc in 
hexanes) provided diepoxy alcohol 565 (70 mg, 28% over 2 steps) as a colorless oil: Rf = 
0.30 (silica gel, 50% EtOAc in hexanes); []25D = +13.8 (c 0.34, CH2Cl2); 1H NMR (400 
MHz, CDCl3) δ 7.73 – 7.66 (m, 4 H), 7.46 – 7.36 (m, 6 H), 5.64 (qd, J = 15.7, 7.0 Hz, 2 
H), 3.95 (d, J = 12.8 Hz, 1 H), 3.77 – 3.67 (m, 2 H), 3.42 (dd, J = 7.0, 2.2 Hz, 1 H), 3.21 
(dd, J = 6.9, 2.1 Hz, 1 H), 3.07 (dt, J = 3.8, 2.4 Hz, 1 H), 2.96 (dd, J = 5.6, 2.1 Hz, 1 H), 
1.11 (d, J = 6.4 Hz, 3 H), 1.08 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 135.9, 135.9, 
134.2, 133.6, 132.5, 131.2, 129.7, 129.7, 127.6, 127.6, 69.8, 67.4, 64.5, 60.9, 60.1, 54.8, 
54.5, 26.9, 19.9, 19.3; HRMS (H-ESI) m/z calcd for C27H34O4Si [M + H]
+ 451.2305, 
found 451.2303. 
 
7.2.79. Synthesis of Tosyl Derivative 566 
Tosyl Derivative 566. The tosylation of diepoxy alcohol 
565 (70 mg, 0.16 mmol, 1.0 equiv) was achieved in exactly 
the same way as described above for 475, to obtain tosyl 
derivative 566 (80 mg, 86%) as a colorless oil: Flash column 
chromatography (silica gel, 20% EtOAc in hexanes); Rf = 0.77 (silica gel, 50% EtOAc in 
hexanes); []25D = +15.6 (c 0.16, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.82 – 7.79 (m, 
2 H), 7.71 – 7.66 (m, 4 H), 7.44 – 7.34 (m, 8H), 5.65 (dd, J = 15.7, 7.4 Hz, 1 H), 5.50 (dd, 
J = 15.7, 7.4 Hz, 1 H), 4.21 (dd, J = 11.5, 3.8 Hz, 1 H), 4.04 (dd, J = 11.5, 5.5 Hz, 1 H), 
3.76 – 3.69 (m, 1 H), 3.24 (dd, J = 7.4, 2.0 Hz, 1 H), 3.18 (dd, J = 7.4, 2.0 Hz, 1 H), 3.10 
(ddd, J = 5.7, 3.8, 2.0 Hz, 1 H), 2.93 (dd, J = 5.5, 2.1 Hz, 1 H), 2.46 (s, 3 H), 1.10 (d, J = 
6.4 Hz, 3 H), 1.07 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 145.2, 135.9, 135.8, 134.2, 
133.3, 129.9, 129.9, 129.7, 129.7, 128.0, 127.6, 127.6, 69.7, 69.2, 64.5, 60.4, 56.5, 55.4, 
54.6, 29.7, 26.9, 21.7, 19.9, 19.3; HRMS (H-ESI) m/z calcd for C32H38O6SSi [M + H]
+ 
579.2237, found 579.2236. 
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7.2.80. Synthesis of Iodide Derivative 567 
Iodide Derivative 567. The iodination of tosyl derivative 566 
(30 mg, 0.05 mmol, 1.0 equiv) was carried out according to the 
procedure described above for 476, to afford iodide derivative 
567 (25 mg, 90%) as a colorless oil: Flash column 
chromatography (silica gel, 10% EtOAc in hexanes); Rf = 0.58 (silica gel, 30% EtOAc in 
hexanes); [α]25D= +12.7 (c 0.35 CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.66 (m, 
4 H), 7.44 – 7.35 (m, 6 H), 5.67 (dd, J = 15.7, 7.2 Hz, 1 H), 5.57 (dd, J = 15.7, 7.0 Hz, 1 
H), 3.77 – 3.70 (m, 1 H), 3.27 – 3.21 (m, 2 H), 3.20 (dd, J = 7.2, 2.1 Hz, 1 H), 3.17 – 3.08 
(m, 2 H), 2.95 (dd, J = 5.5, 2.1 Hz, 1 H), 1.11 (d, J = 6.4 Hz, 3 H), 1.07 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 135.9, 135.9, 135.8, 132.8, 130.5, 129.8, 129.7, 129.7, 127.6, 127.6, 
69.7, 64.5, 61.1, 60.1, 54.7, 29.7, 26.9, 19.9, 19.3, 3.8; HRMS (H-ESI) m/z calcd for 
C25H31IO3Si [M + H]
+ 535.1165, found 535.1167. 
 
7.2.81. Synthesis of Allylic Alcohol 568 
Allylic Alcohol 568. A solution of iodide 567 (20 mg, 0.04 mmol, 
1.0 equiv) in THF (3 mL) was reacted with n-BuLi (0.05 mL, 1.6 
M in hexane, 0.08 mmol, 2.0 equiv) at -78 ºC, according to the 
same procedure as described above for the preparation of 477, to 
afford, after similar processing, allylic alcohol 568 (13 mg, 87%) as a colorless oil: Flash 
column chromatogaphy (silica gel, 15% EtOAc in hexanes); Rf = 0.20 (silica gel, 30% 
EtOAc in hexanes); [α]25D= +19.1 (c 0.39, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.73 
– 7.67 (m, 4 H), 7.44 – 7.34 (m, 6 H), 5.89 (dddd, J = 17.2, 16.3, 8.1, 3.3 Hz, 2 H), 5.46 
(ddd, J = 15.6, 7.9, 1.4 Hz, 1 H), 5.28 (dt, J = 17.2, 1.3 Hz, 1 H), 5.18 (dt, J = 10.4, 1.3 
Hz, 1 H), 4.65 (t, J = 6.1 Hz, 1 H), 4.27 – 4.17 (m, 1 H), 3.76 – 3.69 (m, 1 H), 3.21 (dd, J 
= 8.0, 2.1 Hz, 1 H), 2.96 (dd, J = 5.6, 2.2 Hz, 1 H), 1.10 (d, J = 6.4 Hz,3 ), 1.07 (s, 9 H); 
13C NMR (100 MHz, CDCl3) δ 138.7, 136.1, 135.9, 135.9, 132.5, 129.7, 129.6, 128.8, 
128.3, 127.6, 127.6, 115.8, 72.9, 69.9, 68.2, 64.4, 55.2, 38.8, 26.9, 19.9, 19.3; HRMS (H-
ESI) m/z calcd for C25H32O3Si [M + H]
+ 409.2199, found 409.2197. 
 
7.2.82. Synthesis of Ester 570 
Ester 570. To a solution of diepoxy amide 564 (175 mg, 
0.29 mmol, 1.0 equiv) in THF (5 mL) was added 
dropwise with Red-Al (0.20 mL, 70% w/v in toluene, 
0.65 mmol, 2.2 equiv) at 0 ºC. After 1 h at this 
temperature, the reaction mixture was quenched by addition of a saturated aqueous NH4Cl 
solution. After separation of both layers, the aqueous phase was extracted twice with 
EtOAc and the combined organic extracts washed with H2O and brine, dried over 
anhydrous MgSO4, and the solvent evaporated under reduced pressure. The resulting 
crude diepoxy aldehyde (~0.29 mmol) was used in the next step without further 
purification. A solution of tributyl(ethoxycarbonylmethylene)phosphonium bromide (134 
mg, 0.36 mmol, 1.25 equiv) in CH2Cl2 (3 mL) was washed twice with a 1.0 M aqueous 
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NaOH solution (1 mL), dried and diluted with toluene (3 mL). After removing CH2Cl2, 
the resulting solution was then added to a stirred solution of crude aldehyde and benzoic 
acid (13 mg, 0.10 mmol, 0.2 equiv) in toluene (5 mL) at 95 ºC. After 30 min the solvent 
was evaporated and the resulting residue was purified by flash column chromatography 
(silica gel, 20% EtOAc in hexanes) to provide the corresponding ,-unsaturated ester 
570 (40 mg, 28% over 2 steps) as a colourless oil: Rf = 0.44 (silica gel, 30% EtOAc in 
hexanes); [α]25D= +10.5 (c 0.62, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.66 (m, 
4 H), 7.44 – 7.35 (m, 6 H), 6.70 (dd, J = 15.7, 6.9 Hz, 1 H), 6.15 (d, J = 15.7 Hz, 1 H), 
5.66 (qd, J = 15.7, 6.9 Hz, 2 H), 4.22 (q, J = 7.1 Hz, 2 H), 3.79 – 3.70 (m, 1 H), 3.36 (dd, 
J = 6.9, 1.8 Hz, 1 H), 3.32 (dd, J = 6.7, 1.9 Hz, 1 H), 3.21 (dd, J = 6.9, 2.1 Hz, 1 H), 2.96 
(dd, J = 5.5, 2.1 Hz, 1 H), 1.30 (t, J = 7.1 Hz, 3 H), 1.11 (d, J = 6.4 Hz, 3 H), 1.08 (s, 9 
H); 13C NMR (100 MHz, CDCl3) δ 165.5, 143.3, 135.9, 135.9, 135.7, 132.9, 130.4, 129.7, 
129.7, 127.8, 127.6, 127.6, 124.2, 69.7, 64.6, 60.7, 59.9, 58.3, 54.6, 26.9, 19.9, 19.3, 14.2; 
HRMS (H-ESI) m/z calcd for C29H36O5Si [M + H]
+ 493.2410, found 493.2413. 
 
7.2.83. Synthesis of Allylic Alcohol 571 
Allylic Alcohol 571. A solution of ester 570 (40 mg, 
0.08 mmol, 1.0 equiv) in CH2Cl2 (5 mL) was cooled at 
-78 ºC and treated with DIBAL-H (0.2 mL, 1.0 M in 
toluene, 0.20 mmol, 2.5 equiv). After 20 min, the 
reaction was quenched by addition of MeOH at -78 ºC and the mixture was allowed to 
reach room temperature, treated with a saturated aqueous Na+/K+ tartrate solution and 
diluted with CH2Cl2. The resulting mixture was vigorously stirred until a clear separation 
of both organic and aqueous phases. The organic layer was separated and the aqueous 
phase was extracted with CH2Cl2 three times. The combined organic layers were washed 
with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated under 
reduced pressure. The residue was purified by flash column chromatography (silica gel, 
5% EtOAc in hexanes) to obtain allylic alcohol 571 (8.0 mg, 22%) as a pale colorless oil: 
Rf = 0.10 (silica gel, 30% EtOAc in hexanes); []25D =  +20.3 (c 0.51, CH2Cl2); 1H NMR 
(400 MHz, CDCl3) δ 7.72 – 7.65 (m, 4 H), 7.44 – 7.35 (m, 6 H), 6.09 (ddd, J = 15.3, 7.7, 
2.8 Hz, 1 H), 5.65 – 5.61 (m, 2 H), 5.51 (ddt, J = 15.6, 7.5, 1.7 Hz, 1 H), 4.19 (dd, J = 
5.0, 1.3 Hz, 2 H), 3.78 – 3.67 (m, 1 H), 3.30 – 3.23 (m, 2 H), 3.23 – 3.18 (m, 1 H), 2.95 
(dd, J = 5.6, 2.2 Hz, 1 H), 1.10 (d, J = 6.4 Hz, 3 H), 1.07 (s, J = 2.6 Hz, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 135.9, 135.9, 134.7, 134.2, 133.7, 133.6, 131.9, 131.4, 129.7, 129.7, 
127.6, 127.6, 69.8, 64.6, 62.6, 59.8, 59.2, 54.8, 30.9, 26.9, 19.3; HRMS (H-ESI) m/z calcd 
for C27H34O4Si [M + H]
+ 451.2305, found 451.2302. 
 
7.2.84. Synthesis of Depudecin Analogue 540 
Depudecin Analogue 540. Silyl derivative 571 (8 mg, 
0.02 mmol, 1.0 equiv) was desilylated by the action of 
TBAF (30 µL, 1.0 M in THF, 0.03 mmol, 1.2 equiv) in 
the same way as desrcribed above for (-)-depudecin 
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(442) to afford depudecin analogue 540 (1.5 mg, 40%) as a colorless oil: Flash column 
chromatography (silica gel, 2% MeOH in CH2Cl2); Rf = 0.51 (silica gel, 2% MeOH in 
CH2Cl2); [α]25D= +15.9 (c 0.47, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 6.10 (dtd, J = 
15.6, 5.1, 0.5 Hz, 1 H), 5.78 – 5.65 (m, 2 H), 5.52 (ddt, J = 15.6, 7.5, 1.7 Hz, 1 H), 4.20 
(d, J = 3.6 Hz, 2 H), 3.75 (dd, J = 10.3, 5.2 Hz, 1 H), 3.39 (dd, J = 6.9, 2.2 Hz, 1 H), 3.33 
– 3.26 (m, 2 H), 2.90 (dd, J = 4.6, 2.2 Hz, 1 H), 1.31 (d, J = 6.5 Hz, 3 H); 13C NMR (100 
MHz, CDCl3) δ 134.8, 131.9, 131.3, 127.5, 66.9, 64.1, 62.6, 59.9, 59.1, 55.4, 20.0; HRMS 
(H-ESI) m/z calcd for C11H16O4 [M + H]
+ 213.1127, found 213.1125. 
 
7.2.85. Synthesis of Epoxy Amide 572 
Epoxy Amide 572. (COCl)2 (0.23 mL, 2.60 mmol, 2.0 equiv) 
was dissolved in CH2Cl2 (7 mL) and cooled at -78 ºC. DMSO 
(0.38 mL, 5.30 mmol, 4.0 equiv) was then added dropwise 
and the mixture stirred for 10 min at the same temperature. 
Then, a solution of epoxy alcohol ent-522 (450 mg, 1.32 
mmol, 1.0 equiv) was added and the reaction mixture was stirred for 40 min at -78 ºC and 
quenched by addition of Et3N (1.1 mL, 7.90 mmol, 6.0 equiv). The resulting mixture was 
vigorously stirred and diluted with H2O and Et2O. The aqueous and organic phases were 
then separated, the organic extract washed with water and brine, dried over MgSO4 and 
the solvent evaporated under reduced pressure to afford the crude aldehyde (~1.30 mmol) 
that was used in the next step without further purification. The crude aldehyde (~1.30 
mmol 1.0 equiv) was reacted with sulfonium salt ent-457249,250 (460 mg, 1.45 mmol, 1.1 
equiv) and NaOH (3.0 M aqueous solution, 0.44 mL, 1.32 mmol, 1.0 equiv) according to 
the procedure described above for epoxy amide 466 to yield epoxy amide 572 (420 mg, 
57% over two steps) as a colourless oil: Flash column chromatography (silica gel, 20% 
EtOAc in hexanes); Rf = 0.30 (silica gel, 20% EtOAc in hexanes); []25D = +9.9 (c 0.30, 
CH2Cl2);
 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.62 (m, 4 H), 7.43 – 7.33 (m, 6 H), 6.04 
(dd, J = 15.5, 5.3 Hz, 1 H), 5.31 (ddd, J = 15.5, 8.0, 1.4 Hz, 1 H), 4.38 – 4.30 (m, 1 H), 
4.29 – 4.22 (m, 1 H), 4.04 – 3.95 (m, 2 H), 3.53 (dd, J = 8.0, 1.8 Hz, 1 H), 3.42 (d, J = 
2.0 Hz, 1 H), 2.56 – 2.47 (m, 1 H), 2.45 – 2.38 (m, 1 H), 2.01 (s, 3 H), 1.85 – 1.78 (m, 1 
H), 1.75 – 1.68 (m, 1 H), 1.65 (s, 3 H), 1.54 (s, 3 H), 1.13 (d, J = 6.4 Hz, 3 H), 1.05 (s, 9 
H); 13C NMR (100 MHz, CDCl3) δ 163.4, 141.9, 135.8, 135.8, 134.2, 133.8, 129.7, 127.6, 
127.6, 127.6, 123.8, 95.9, 69.2, 67.1, 57.8, 55.9, 55.5, 34.4, 30.8, 27.0, 26.2, 23.0, 19.3, 
15.9; HRMS (H-ESI) m/z calcd for C31H43NO4SSi [M + H]
+ 554.2760, found 554.2762. 
 
7.2.86. Synthesis of Diepoxy Amide 573 
Diepoxy Amide 573. To a solution of diepoxy amide 
572 (210 mg, 0.38 mmol, 1.0 equiv) in THF (5 mL) was 
added dropwise with Red-Al (0.23 mL, 70% w/v in 
toluene, 0.76 mmol, 2.0 equiv) at 0 ºC. After 1 h at this 
temperature, the reaction mixture was quenched by 
addition of a saturated aqueous NH4Cl solution. After separation of both layers, the 
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aqueous phase was extracted twice with EtOAc and the combined organic extracts 
washed with H2O and brine, dried over anhydrous MgSO4, and the solvent evaporated 
under reduced pressure. The resulting crude diepoxy aldehyde (~0.38 mmol) was used in 
the next step without further purification. The crude aldehyde (~0.38 mmol, 1.0 equiv) 
was reacted with sulfonium salt ent-457249,250 (132 mg, 0.42 mmol, 1.1 equiv) and NaOH 
(3.0 M aqueous solution, 0.08 mL, 1.0 equiv) according to the procedure described above 
for epoxy amide 466 to yield diepoxy amide 573 (85 mg, 38% over 2 steps) as a colorless 
oil: Rf = 0.40 (silica gel, 40% EtOAc in hexanes); [α]25D= +23.1 (c 0.54, CH2Cl2); 1H 
NMR (400 MHz, CDCl3) δ 7.68 – 7.62 (m, 4 H), 7.45 – 7.32 (m, 6 H), 5.96 (ddd, J = 
15.5, 5.3, 0.5 Hz, 1 H), 5.26 (ddd, J = 15.5, 7.9, 1.5 Hz, 1 H), 4.36 – 4.27 (m, 2 H), 4.02 
(ddd, J = 9.1, 5.2, 1.2 Hz, 1 H), 3.91 (dd, J = 9.2, 0.5 Hz, 1 H), 3.58 (d, J = 1.9 Hz, 1 H), 
3.37 – 3.34 (m, 2 H), 2.91 (dd, J = 3.3, 2.1 Hz, 1 H), 2.59 (ddd, J = 13.0, 7.7, 5.1 Hz, 1 
H), 2.48 (ddd, J = 13.2, 8.3, 7.4 Hz, 1 H), 2.11 (s, J = 3.1 Hz, 3 H), 1.86 – 1.80 (m, 1 H), 
1.75 (d, J = 2.5 Hz, 1 H), 1.66 (s, J = 6.6 Hz, 3 H), 1.54 (s, 3 H), 1.14 (d, J = 6.3 Hz, 3 
H), 1.06 (s, J = 3.6 Hz, 9 H); 13C NMR (100 MHz, CDCl3) δ 162.9, 140.9, 135.9, 135.8, 
134.2, 133.9, 129.7, 129.6, 127.5, 127.5, 124.3, 95.9, 69.2, 67.1, 56.5, 56.0, 55.6, 55.4, 
51.3, 34.5, 30.7, 26.9, 26.2, 23.9, 19.2, 15.9; HRMS (H-ESI) m/z calcd for C33H45NO5SSi 
[M + H]+ 596.2866, found 596.2869. 
 
7.2.87. Synthesis of Tosyl Derivative 574 
Tosyl Derivative 574. To a solution of diepoxy amide 573 
(84 mg, 0.14 mmol, 1.0 equiv) in THF (3 mL) was added 
dropwise Red-Al (0.1 mL, 70% w/v in toluene, 0.31 mmol, 
2.2 equiv) at 0 ºC. After 1 h at 0 ºC, the reaction mixture 
was quenched by addition of a saturated aqueous NH4Cl solution. After separation of both 
layers, the aqueous phase was extracted with EtOAc, the organic extracts were washed 
with brine and dried over MgSO4 and the solvent evaporated under reduced pressure. The 
resulting crude aldehyde was dissolved in MeOH (3 mL) and reacted with NaBH4 (11 
mg, 0.28 mmol, 2.0 equiv) at 0 ºC. After 1 h, the reaction mixture was quenched by 
addition of H2O and the solvent was removed under reduced pressure. The crude was then 
dissolved in EtOAc and washed with H2O and brine. Removal of the solvent under 
reduced pressure provided crude diepoxy alcohol (~0.26 mmol) which was used in the 
next step without purification. Crude diepoxy alcohol obtained above (~0.26 mmol, 1.0 
equiv) was dissolved in CH2Cl2 (5 mL) and cooled at 0 ºC. Over this solution was then 
added p-TsCl (59 mg, 0.31 mmol, 1.2 equiv), TEA (0.05 mL, 1.5 mmol, 1.5 equiv) and 
4-DMAP (1 mg, 0.01 mmol, 0.02 equiv). After 3 h, the reaction mixture was quenched 
by addition of water and the aqueous phase was extracted with CH2Cl2 three times. The 
organic phase was washed with brine, dried over MgSO4, filtered and the solvent removed 
under reduced pressure. The resiude was purified by flash column chromatography (silica 
gel, 20% EtOAc in hexanes) to provide pure tosyl derivative 574 (40 mg, 27% over 3 
steps) as a colourless oil: Rf = 0.83 (silica gel, 60% EtOAc in hexanes); [α]25D= +26.6 (c 
0.38, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.83 – 7.77 (m, 2 H), 7.75 – 7.71 (m, 2 H), 
7.69 – 7.63 (m, 4 H), 7.43 – 7.30 (m, 6 H), 5.93 (dd, J = 15.5, 5.3 Hz, 1 H), 5.23 (ddd, J 
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= 15.5, 7.8, 1.4 Hz, 1 H), 4.38 – 4.28 (m, 1 H), 4.22 (dd, J = 11.6, 3.6 Hz, 1 H), 4.07 (dd, 
J = 11.6, 5.3 Hz, 1 H), 3.25 (dd, J = 7.7, 2.1 Hz, 1 H), 3.20 (ddd, J = 5.6, 3.6, 2.1 Hz, 1 
H), 2.93 (dd, J = 4.1, 2.0 Hz, 1 H), 2.74 (dd, J = 4.1, 2.1 Hz, 1 H), 2.46 (s, 3 H), 1.15 (d, 
J = 6.4 Hz, 3 H), 1.06 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 135.9, 135.8, 134.8, 129.9, 
129.7, 128.0, 127.8, 127.7, 127.5, 124.3, 69.2, 68.7, 57.0, 55.3, 54.1, 52.3, 26.9, 23.9, 
21.7, 19.2; HRMS (H-ESI) m/z calcd for C32H38O6SSi [M + H]
+ 579.2237, found 
579.2234. 
 
7.2.88. Synthesis of Iodide Derivative 575 
Iodide Derivative 575. The iodination of tosyl derivative 574 
(40 mg, 0.07 mmol, 1.0 equiv) was carried out according to the 
procedure described above for 476, to afford iodide derivative 
575 (32 mg, 87%) as a colourless oil: Flash column 
chromatography (silica gel, 10% EtOAc in hexanes); Rf = 0.60 (silica gel, 30% EtOAc in 
hexanes); [α]25D= +19.8 (c 0.43 CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.74 – 7.62 (m, 
4 H), 7.46 – 7.33 (m, 6 H), 5.94 (dd, J = 15.5, 5.3 Hz, 1 H), 5.25 (ddd, J = 15.5, 7.8, 1.4 
Hz, 1 H), 4.34 (ddd, J = 11.4, 6.2, 4.9 Hz, 1 H), 3.30 – 3.26 (m, 1 H), 3.26 – 3.22 (m, 2 
H), 3.15 – 3.09 (m, 1 H), 2.92 (dd, J = 3.9, 1.6 Hz, 1 H), 2.81 (dd, J = 3.9, 2.1 Hz, 1 H), 
1.15 (d, J = 6.3 Hz, 3 H), 1.06 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 140.6, 135.9, 
135.9, 134.8, 133.9, 129.7, 127.8, 127.7, 127.5, 124.4, 69.2, 59.7, 57.2, 55.6, 55.3, 26.9, 
23.9, 19.2, 3.3; HRMS (H-ESI) m/z calcd for C25H31IO3Si [M + H]
+ 535.1165, found 
535.1167. 
 
7.2.89. Synthesis of Allylic Alcohol 576 
Allylic Alcohol 576. A solution of iodide 575 (20 mg, 0.04 
mmol, 1.0 equiv) in THF (3 mL) was reacted with n-BuLi (0.05 
mL, 1.6 M in hexane, 0.08 mmol, 2.0 equiv)  at -78 ºC, according 
to the same procedure as described above for the preparation of 
477, to afford, after similar processing, allylic alcohol 576 (13 mg, 90%) as a colorless 
oil: Flash column chromatogaphy (silica gel, 15% EtOAc in hexanes); Rf = 0.60 (silica 
gel, 30% EtOAc in hexanes); [α]25D= +26.9 (c 0.36 CH2Cl2); 1H NMR (400 MHz, CDCl3) 
δ 7.75 – 7.62 (m, 4 H), 7.46 – 7.31 (m, 6 H), 5.93 (dddd, J = 8.5, 6.2, 5.4, 4.3 Hz, 2 H), 
5.42 – 5.35 (m, 1 H), 5.33 – 5.29 (m, 1 H), 5.29 – 5.25 (m, 1 H), 4.38 – 4.30 (m, 1 H), 
3.33 (dd, J = 7.8, 2.1 Hz, 1 H), 2.87 (dd, J = 4.3, 2.2 Hz, 1 H), 1.15 (d, J = 6.3 Hz, 3 H), 
1.06 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 140.2, 136.4, 135.9, 135.9, 135.9, 134.8, 
129.6, 129.6, 127.7, 127.5, 124.8, 116.7, 71.6, 69.2, 62.2, 60.4, 29.7, 26.9, 14.2; HRMS 
(H-ESI) m/z calcd for C25H32O3Si [M + H]
+ 409.2199, found 409.2196. 
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7.2.90. Synthesis of Depudecin Analogue 541 
Depudecin Analogue 541. Silyl derivative 576 (11 mg, 0.03 
mmol, 1.0 equiv) was desilylated by the action of TBAF (50 µL, 
1.0 M in THF, 0.06 mmol, 2.0 equiv) in the same way as 
desrcribed above for (-)-depudecin (442) to afford depudecin 
analogue 541 (1 mg, 20%) as a colorless oil: Flash column chromatography (silica gel, 
30% EtOAc in hexanes → 100% EtOAc); Rf = 0.56 (silica gel, EtOAc); [α]25D= +27.5 (c 
0.42 CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 5.99 (dddd, J = 17.3, 16.1, 8.2, 2.9 Hz, 2 
H), 5.48 – 5.43 (m, 1 H), 5.43 – 5.37 (m, 1 H), 5.27 (dt, J = 10.6, 1.3 Hz, 1 H), 4.40 – 
4.30 (m, 1 H), 4.17 – 4.08 (m, 1 H), 3.42 (dd, J = 8.0, 2.2 Hz, 1 H), 3.01 (dd, J = 4.4, 2.2 
Hz, 1 H), 1.96 (d, J = 6.3 Hz, 1 H), 1.30 (d, J = 6.5 Hz, 3 H), 1.26 (bs, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 140.1, 136.3, 125.9, 116.9, 71.6, 67.9, 62.3, 55.5, 23.1; HRMS (H-
ESI) m/z calcd for C9H14O3 [M + H]
+ 171.1021, found 171.1023. 
 
7.3. Experimental Procedures and Compound Characterization Related to the 
Solomonamides 
7.3.1. Synthesis of Aniline 606 
Aniline 606. To a solution of bromoaniline 604 (1.0 g, 5.81 mmol, 1.0 equiv) 
and Pd[PPh3]4 (336 mg, 0.29 mmol, 0.05 equiv) in DMF (15 mL) was added 
dropwise allyltri-n-butyltin (2.2 mL, 6.97 mmol, 1.2 equiv). The solution 
was then heated at 80 ºC for 12 h. After this time, the mixture was diluted 
with diethyl ether and washed with water. The organic layer was separated 
and washed with water four times, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The crude product was purified by flash column 
chromatography (silica gel, 5% EtOAc in hexanes) to obtain aniline 606 (596 mg, 77%) 
as a yellow oil: Rf = 0.60 (silica gel, 20% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) 
δ (ppm) 7.13 – 7.05 (m, 2 H), 6.78 (td, J = 7.4, 1.1 Hz, 1 H), 6.72 – 6.69 (m, 1 H), 6.04 – 
5.92 (m, 1 H), 5.18 – 5.09 (m, 2 H), 3.64 (bs, 2 H), 3.33 (d, J = 6.1 Hz, 2 H); 13C NMR 
(100 MHz, CDCl3) δ (ppm) 144.8, 136.0, 130.2, 127.6, 124.0, 118.9, 116.1, 115.9, 36.5; 
HRMS (H-ESI) m/z: [M + H]+ calcd for C9H12N 134.0970; found 134.0967. 
 
7.3.2. Synthesis of Aniline 607 
Aniline 607. To a solution of iodonitrobenzene 605287 (6.0 g, 16.90 
mmol, 1.0 equiv) and Pd[PPh3]4 (3.0 g, 3.40 mmol, 0.15 equiv) in 
DMF (30 mL) was added dropwise allyltri-n-butyltin (6.4 mL, 20.30 
mmol, 1.2 equiv). The solution was then heated at 60 ºC for 15 h. After 
this time, the mixture was diluted with Et2O and water. The organic 
layer was separated and washed with water four times, dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure. The crude product was 
purified by flash column chromatography (silica gel, 100% Hexanes) to obtain the 
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corresponding allyl derivative (3.3 g, 73%) as a yellow oil: Rf = 0.56 (silica gel, 20% 
EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ (ppm) 7.54 (d, J = 2.7 Hz, 1 H), 7.46 
– 7.33 (m, 5 H), 7.28 – 7.25 (m, 1 H), 7.16 (dd, J = 8.5, 2.7 Hz, 1 H), 5.96 (ddt, J = 16.6, 
10.1, 6.4 Hz, 1 H), 5.11 (s, 2 H), 5.09 – 5.07 (m, 1 H), 5.05 – 5.03 (m, 1 H),  3.62 (dt, J = 
6.4, 1.4 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 157.4, 135.8, 135.4, 132.8, 128.7, 
128.3, 127.5, 127.1, 120.4, 116.7, 110.3, 70.6, 36.3; HRMS (H-ESI) m/z: [M + H]+ calcd 
for C16H16NO3 270.1130; found 270.1129. To a solution of the allyl derivative obtained 
above (1.5 g, 5.60 mmol, 1.0 equiv) in acetic acid (15 mL) was added Zn dust (1.0 g, 
16.20 mmol, 3.0 equiv) in ten portions of 100 mg each over 30 min at 25 ºC. The reaction 
mixture was stirred at this temperature until completion monitoring by TLC (1 h) and 
then, quenched by addition of 10% NaOH solution at 0 ºC. The mixture was extracted 
with CH2Cl2, and the organic phase washed with water, dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure. The resulting residue was 
purified by flash column chromatography (silica gel, 5% EtOAc in hexanes) to obtain 607 
(773 mg, 65%) as an orange oil: Rf = 0.38 (silica gel, 20% EtOAc in hexanes); 
1H NMR 
(400 MHz, CDCl3) δ (ppm) 7.46 – 7.37 (m, 4 H), 7.35 – 7.30 (m, 1 H), 6.95 (d, J = 8.3 
Hz, 1 H), 6.41 (dd, J = 8.2, 2.5 Hz, 1 H), 6.35 (d, J = 2.5 Hz, 1 H), 5.95 (ddt, J = 16.6, 
10.5, 6.1 Hz, 1 H), 5.14 – 5.11 (m, 1 H), 5.11 – 5.08 (m, 1 H), 5.03 (s, 2 H), 3.67 (bs, 2 
H), 3.26 (dt, J = 6.1, 1.5 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 158.6, 145.8, 
137.3, 136.4, 130.9, 128.5, 127.8, 127.4, 116.9, 115.8, 104.9, 102.6, 69.9, 35.8; HRMS 
(H-ESI) m/z: [M + H]+ calcd for C16H18NO 240.1388; found 240.1392. 
 
7.3.3. Synthesis of Dipeptide 609 
Dipeptide 609. To a solution of aniline 606 (700 mg, 5.25 mmol, 
1.0 equiv) and Boc-Gly-D-Ala-OH (608)283 (1.3 g, 5.25 mmol, 1.0 
equiv) in DMF (15 mL) was added HATU (3.0 g, 7.88 mmol, 1.5 
equiv) and DIPEA (1.0 mL, 5.25 mmol, 1.0 equiv) at 0 ºC and the 
mixture was stirred for 12 h at 25 ºC. After this time, a saturated 
aqueous NH4Cl solution was added and the organic layer was 
separated. The aqueous phase was extracted with EtOAc, and the combined organic layers 
were washed with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated 
under reduced pressure. The crude product was purified by flash column chromatography 
(silica gel, 20% EtOAc in hexanes → 50% EtOAc in hexanes) to obtain dipeptide 609 
(1.5 g, 81%) as a white foam: Rf  = 0.60 (silica gel, 100% EtOAc); [α]25 D = – 6.23 (c 0.45, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.96 (bs, 1 H), 7.79 (d, J = 8.0 Hz, 1 H), 
7.23 (dd, J = 8.1, 1.7 Hz, 1 H), 7.18 (dd, J = 7.5, 1.5 Hz, 1 H), 7.15 – 7.10 (m, 1 H), 6.87 
(s, 1 H), 5.97 (ddt, J = 16.2, 10.2, 6.0 Hz, 1 H), 5.15 (dd, J = 10.2, 1.6 Hz, 1 H), 5.06 (dd, 
J = 17.2, 1.6 Hz, 1 H), 4.64 – 4.55 (m, 1 H), 3.88 – 3.80 (m, 2 H), 3.41 – 3.33 (m, 2 H), 
1.47 (d, J = 7.0 Hz, 3 H), 1.44 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 170.4, 
170.0, 156.2, 135.9, 135.4, 131.1, 130.2, 127.1, 125.8, 123.9, 116.5, 49.5, 38.7, 36.1, 
31.3, 28.3, 17.8; HRMS (H-ESI) m/z: [M + H]+ calcd for C19H28N3O4 362.2080; found 
362.2079. 
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7.3.4. Synthesis of Dipeptide 610 
Dipeptide 610. To a solution of aniline 607 (730 mg, 3.10 
mmol, 1.0 equiv) and Boc-Gly-D-Ala-OH (21) (752 mg, 3.10 
mmol, 1.0 equiv) in CH2Cl2 (15 mL) was added HATU (1.7 
g, 4.60 mmol, 1.5 equiv) and DIPEA (0.5 mL, 3.10 mmol, 
1.0 equiv) and the mixture was stirred for 12 h at 25 ºC. After 
this time, the reaction mixture was diluted with CH2Cl2 and 
washed sequentially with 1 N HCl and a saturated aqueous 
NaHCO3 solution. The organic layer was separated, washed with brine, dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) 
to obtain dipeptide 610 (1.15 g, 81%) as a pale brown solid: Rf = 0.69 (silica gel, 100% 
EtOAc); [α]25 D = – 3.41 (c 0.10, CH2Cl2); mp = 83-84 ºC; 1H NMR (400 MHz, CDCl3) δ 
(ppm) 8.07 (bs, 1 H), 7.62 (d, J = 2.3 Hz, 1 H), 7.44 – 7.27 (m, 6 H), 7.05 (d, J = 8.5 Hz, 
1 H), 6.94 (d, J = 7.3 Hz, 1 H), 6.73 (dd, J = 8.4, 2.6 Hz, 1 H), 5.94 (ddt, J = 16.2, 10.2, 
5.9 Hz, 1 H), 5.14 – 5.04 (m, 2 H), 5.02 (s, 2 H), 4.59 (p, J = 7.0 Hz, 1 H), 3.91 – 3.77 
(m, 2 H), 3.37 – 3.23 (m, 2 H), 1.46 (d, J = 7.0 Hz, 3 H), 1.44 (s, 9 H); 13C NMR (100 
MHz, CDCl3) δ (ppm) 170.1, 169.9, 157.9, 156.0, 136.9, 136.3, 130.8, 128.5, 127.9, 
127.7, 127.5, 122.3, 116.2, 112.2, 109.4, 80.6, 70.0, 49.6, 39.2, 36.5, 28.2, 17.6; HRMS 
(H-ESI) m/z: [M + H]+ calcd for C26H34N3O5 468.2498; found 468.2487.  
 
7.3.5. Synthesis of Diolefin 612 
Diolefin 612. TFA (5.0 mL) was added to a solution of dipeptide 
609 (360 mg, 0.99 mmol, 1.0 equiv) in CH2Cl2 (60 mL) at 0 ºC 
and the reaction mixture was stirred at 25 ºC until depletion of 
starting material as judged by TLC (3 h). Then, the TFA excess 
was removed under reduced pressure to obtain the corresponding 
ammonium trifluoroacetate salt as a brown solid which was 
dissolved in DMF (10 mL). To this solution, Kosher acid 611 (0.1 
mL, 0.99 mmol, 1.0 equiv), HATU (379 mg, 0.99 mmol, 1.0 equiv) and DIPEA (0.52 
mL, 2.99 mmol, 3.0 equiv) were added and the resulting solution was stirred at 25 ºC for 
12 h. After this time, a saturated aqueous NH4Cl solution was added and the organic layer 
was separated. The aqueous phase was extracted with EtOAc, and the combined organic 
layers were washed with brine, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The resulting residue was purified by flash column 
chromatography (silica gel, 30% EtOAc in hexanes) to obtain diolefin 612 (205 mg, 60% 
over two steps) as a white solid: Rf  = 0.23 (silica gel, 100% EtOAc); [α]25 D = – 8.50 (c 
0.51, CH2Cl2); mp = 80-81 ºC ; 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.82 (bs, 1 H), 7.29 
– 7.27 (m, 1 H), 7.25 – 7.23 (m, 1 H), 7.21 – 7.17 (m, 1 H), 7.16 – 7.11 (m, 1 H), 6.64 (d, 
J = 6.4 Hz, 1 H), 6.17 (bs, 1 H), 5.98 (dt, J = 16.4, 6.3 Hz, 1 H), 5.83 (dt, J = 16.9, 5.8 
Hz, 1 H), 5.19 – 5.14 (m, 1 H), 5.12 – 5.09 (m, 1 H), 5.08 – 5.01 (m, 2 H), 4.60 – 4.51 
(m, 1 H), 3.98 (d, J = 5.4 Hz, 2 H), 3.41 – 3.35 (m, 2 H), 2.44 – 2.33 (m, 4 H), 1.48 (d, J 
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= 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 173.1, 169.9, 169.1, 136.7, 136.0, 
135.3, 130.4, 130.3, 127.4, 125.7, 123.6, 116.6, 115.9, 49.7, 43.1, 36.4, 35.4, 29.4, 17.9; 
HRMS (H-ESI) m/z: [M + H]+ calcd for C19H26N3O3 344.1974; found 344.1965. 
 
7.3.6. Synthesis of Diolefin 613 
Diolefin 613. Dipeptide 610 (150 mg, 0.32 mmol, 1.0 equiv) 
in CH2Cl2 (20 mL) was treated with TFA (1.6 mL) in exactly 
the same manner as previously described for synthesis of 
612. A solution of the ammonium salt and Kosher acid 611 
(30 L, 0.32 mmol, 1.0 equiv), in CH2Cl2 (10 mL) was 
treated with HATU (122 mg, 0.32 mmol, 1.0 equiv) and 
DIPEA (0.17 mL, 0.96 mmol, 3.0 equiv) and the resulting 
solution was stirred at 25 ºC for 12 h. After this time, a saturated aqueous NH4Cl solution 
was added and the organic layer was separated. The aqueous phase was extracted with 
EtOAc, and the combined organic layers were washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The resulting residue 
was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes → 80% 
EtOAc in hexanes) to obtain diolefin 613 (140 mg, 97% over two steps) as a white solid: 
Rf = 0.24 (silica gel, 100%); [α]25 D = – 6.37 (c 0.06, CH2Cl2); mp = 87-88 ºC; 1H NMR 
(400 MHz, CDCl3) δ (ppm) 8.02 (bs, 1 H), 7.63 (bs, 1 H), 7.45 – 7.28 (m, 6 H), 7.05 (d, 
J = 8.5 Hz, 1 H), 6.74 (dd, J = 8.4, 2.6 Hz, 1 H), 6.43 (bs, 1 H), 5.94 (ddd, J = 16.5, 11.1, 
5.8 Hz, 1 H), 5.81 (ddd, J = 17.0, 11.2, 6.2 Hz, 1 H), 5.15 – 5.04 (m, 4 H), 5.03 (s, 2 H), 
4.60 – 4.52 (m, 1 H), 4.04 – 3.93 (m, 2 H), 3.37 – 3.24 (m, 2 H), 2.43 – 2.31 (m, 4 H), 
1.46 (d, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 173.5, 170.8, 169.5, 
157.7, 136.9, 136.7, 136.3, 136.0, 130.7, 128.5, 127.9, 127.5, 123.6, 116.1, 115.6, 112.2, 
110.4, 70.0, 49.8, 43.1, 38.6, 36.2, 36.1, 29.3, 17.7; HRMS (H-ESI) m/z: [M + H]+ calcd 
for C26H32N3O4 450.2393; found 450.2390. 
 
7.3.7. Synthesis of Cyclopeptide 614 
Cyclopeptide 614. Diolefin 612 (45 mg, 0.13 mmol, 1.0 equiv), 
Hoveyda-Grubbs 2nd generation catalyst (8 mg, 0.01 mmol, 0.10 
equiv) and p-benzoquinone (1 mg, 0.01 mmol, 0.10 equiv) were 
dissolved in degassed CH2Cl2 (7 mL, 0.02 M) and the reaction 
mixture was heated at 40 ºC for 12 h. After this time, the solvent 
was removed under reduced pressure and the resulting crude 
product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes 
→ 2% MeOH in CH2Cl2) to obtain macrocycle 614 (31 mg, 75%) as a white solid: Rf  = 
0.56 (silica gel, 10% MeOH in CH2Cl2); [α]25 D = – 6.11 (c 0.08, MeOH); mp = 188-189 
ºC; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.50 (bs, 1 H), 8.45 (d, J = 7.3 Hz, 1 H), 8.37 
(t, J = 5.9 Hz, 1 H), 7.46 (dd, J = 7.8, 0.9 Hz, 1 H), 7.23 – 7.09 (m, 3 H), 5.44 (dt, J = 
15.9, 5.4 Hz, 1 H), 5.08 (dt, J = 15.9, 6.4 Hz, 1 H), 4.35 (p, J = 7.1 Hz, 1 H), 3.85 (dd, J 
= 14.7, 6.4 Hz, 1 H), 3.44 (dd, J = 14.7, 5.7 Hz, 1 H), 3.26 (dd, J = 15.8, 3.6 Hz, 1 H), 
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3.08 (dd, J = 15.5, 5.1 Hz, 1 H), 2.28 – 2.08 (m, 4 H), 1.31 (d, J = 7.2 Hz, 3 H); 13C NMR 
(100 MHz, DMSO-d6) δ (ppm) 173.1, 171.3, 170.8, 136.5, 134.4, 130.9, 130.3, 128.5, 
127.1, 126.0, 125.9, 49.7, 43.7, 34.8, 31.1, 27.9, 17.1; HRMS (H-ESI) m/z: [M + H]+ 
calcd for C17H22N3O3 316.1661; found 316.1655. 
 
7.3.8. Synthesis of Cyclopeptide 615 
Cyclopeptide 615. Diolefin 613 (135 mg, 0.30 mmol, 1.0 
equiv), Hoveyda-Grubbs 2nd generation catalyst (20 mg, 0.03 
mmol, 0.10 equiv) and p-benzoquinone (4.0 mg, 0.03 mmol, 
0.10 equiv) were dissolved in degassed CH2Cl2 (16 mL, 0.02 
M) and the reaction mixture was heated at 40 ºC for 12 h. 
After this time, the solvent was removed under reduced 
pressure and the resulting crude product was purified by flash column chromatography 
(silica gel, 30% EtOAc in hexanes → 3% MeOH in CH2Cl2) to obtain macrocycle 615 
(100 mg, 79%) as a white solid: Rf  = 0.5 (silica gel, 10% MeOH in CH2Cl2); [α]25 D = – 
4.97 (c 0.07, MeOH); mp =198-199 ºC; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.54 (bs, 
1 H), 8.52 (d, J = 7.3 Hz, 1 H), 8.37 (t, J = 6.0 Hz, 1 H), 7.46 – 7.31 (m, 5 H), 7.29 (d, J 
= 2.6 Hz, 1 H), 7.06 (d, J = 8.4 Hz, 1 H), 6.77 (dd, J = 8.4, 2.7 Hz, 1 H), 5.41 (dt, J = 
15.9, 5.4 Hz, 1 H), 5.13 – 5.05 (m, 1 H), 5.04 (s, 2 H), 4.36 (p, J = 7.1 Hz, 1 H), 3.86 (dd, 
J = 14.8, 6.5 Hz, 1 H), 3.43 (dd, J = 14.7, 5.6 Hz, 1 H), 3.20 (dd, J = 16.4, 3.9 Hz, 1 H), 
3.03 (dd, J = 16.2, 5.0 Hz, 1 H), 2.28 – 2.03 (m, 4 H), 1.30 (d, J = 7.2 Hz, 3 H); 13C NMR 
(100 MHz, DMSO-d6) δ (ppm) 173.1, 171.2, 171.0, 157.4, 137.6, 137.3, 131.5, 130.7, 
128.8, 128.2, 128.1, 128.1, 128.0, 125.8, 111.8, 69.7, 49.7, 43.4, 34.7, 33.7, 27.9, 16.8; 
HRMS (H-ESI) m/z: [M + H]+ calcd for C24H28N3O4 422.2080; found 422.2074. 
 
7.3.9. Synthesis of Epoxy Iodide 616 
Epoxy Iodide 616. To a solution of ent-500249c (2.0 g, 5.39 mmol, 
1.0 equiv) in THF (10 mL) at 0 ºC was added imidazole (1.1 g, 
16.19 mmol, 3.0 equiv), PPh3 (2.1 g, 8.09 mmol, 1.5 equiv) and 
iodine (2.0 g, 8.09 mmol, 1.5 equiv) at 25 ºC. The mixture was 
vigorously stirred at 25 ºC for 20 min. After this time the solvent was evaporated under 
reduced pressure and the crude residue was purified by flash column chromatography 
(silica gel, 5% EtOAc in hexanes) to obtain 616 (2.1 g, 84%) as pale yellow oil: Rf = 0.90 
(silica gel, 40% EtOAc in hexanes); [α]25 D = – 18.2 (c 0.15, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ (ppm) 7.69 – 7.64 (m, 4 H), 7.40 (tdd, J = 8.5, 6.2, 2.5 Hz, 6 H), 3.72 – 3.62 
(m, 2 H), 3.28 (dd, J = 9.5, 5.4 Hz, 1 H), 3.12 – 3.06 (m, 1 H), 3.03 (dd, J = 9.5, 7.0 Hz, 
1 H), 2.85 (dd, J = 7.1, 2.0 Hz, 1 H), 1.07 (s, 9 H), 1.04 (d, J = 7.0 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ (ppm) 136.6, 133.5, 129.6, 127.6, 66.7, 64.1, 57.2, 38.1, 26.8, 19.3, 
13.1, 5.1; HRMS (ESI-TOF) m/z calcd for C22H29IO2Si [M + H]
+ 481,1059, found 
481.1058. 
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7.3.10. Synthesis of Alcohol 617 
Alcohol 617. To a solution of 616 (1.7 g, 3.54 mmol, 1.0 equiv) in 
MeOH (40 mL) was added NaI (795 mg, 5.31 mmol, 1.5 equiv) and 
Zn dust (925 mg, 14.15 mmol, 4.0 equiv) and the reaction was heated 
at reflux for 2 h. After this time the reaction mixture was cooled to 25 
ºC and filtered through a pad of celite. The solvent was evaporated 
under reduced pressure and the crude residue was purified by flash column 
chromatography (silica gel, 15% EtOAc in hexanes) to obtain 617 (1.1 g, 88%) as a 
colorless oil and whose spectroscopic and physical properties matched with those 
reported in the literature330: Rf = 0.76 (silica gel, 40% EtOAc in hexanes); [α]25 D = – 17.90 
(c 0.16, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.71 – 7.66 (m, 4 H), 7.48 – 7.38 
(m, 6 H), 5.87 (ddd, J = 17.0, 10.4, 6.5 Hz, 1 H), 5.35 – 5.28 (m, 1 H), 5.18 (ddd, J = 
10.4, 1.8, 1.1 Hz, 1 H), 4.15 – 4.09 (m, 1 H), 3.80 (dd, J = 10.2, 4.0 Hz, 1 H), 3.62 (dd, J 
= 10.2, 7.3 Hz, 1 H), 1.84 (ddd, J = 14.1, 7.1, 4.0 Hz, 1 H), 1.06 (s, 9 H), 0.85 (d, J = 7.0 
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 139.6, 136.5, 134.8, 129.8, 127.7, 115.7, 
68.3, 40.1, 40.0, 26.8, 26.5, 13.3; HRMS (ESI-TOF) m/z calcd for C22H30O2Si [M + H]
+ 
355.2093, found 355.2095. 
 
7.3.11. Synthesis of Diol 618 
Diol 618. Silyl ether 617 (2.7 g, 7.62 mmol, 1.0 equiv) was dissolved in 
THF (20 mL) and to this solution was added TBAF (15 mL, 1.0 M in THF, 
15.23 mmol, 2.0 equiv) at 0 ºC. The reaction mixture was stirred at 25 ºC 
for 3 h and, after this time, the solvent was evaporated under reduced 
pressure and the residue purified by flash column chromatography (silica 
gel, 10% EtOAc in hexanes → 30% EtOAc in hexanes) to obtain diol 618 (800 mg, 90%) 
as a colourless oil whose spectroscopic and physical properties matched with those 
reported in the literature331: Rf  = 0.22 (silica gel, 50% EtOAc in hexanes); [α]25 D = – 
19.77 (c 0.12, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ (ppm) 5.90 (ddd, J = 17.2, 10.3, 
6.9 Hz, 1 H), 5.30 – 5.17 (m, 2 H), 4.03 (dd, J = 16.6, 9.4 Hz, 1 H), 3.77 (dd, J = 10.9, 
3.6 Hz, 1 H), 3.66 (dd, J = 10.9, 7.4 Hz, 1 H), 1.80 (dtd, J = 14.7, 7.2, 3.8 Hz, 1 H), 0.88 
(d, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 139.5, 116.2, 78.7, 67.2, 39.7, 
13.4; HRMS (ESI-TOF) m/z calcd for C6H12O2 [M + H]
+ 117.0916, found 117.0915. 
 
7.3.12. Synthesis of Pivaloyl Silyl Ether 620 
Pivaloyl Silyl Ether 620. To a solution of diol 618 (200 mg, 1.72 mmol, 
1.0 equiv) in CH2Cl2 (10 mL) was added pyridine (2.8 mL, 34.40 mmol, 
20 equiv) and PivCl (0.3 mL, 2.24 mmol, 1.3 equiv) at -30 ºC. The 
reaction mixture was stirred at this temperature until depletion of starting 
material (30 min). After this time a saturated aqueous NaHCO3 solution was added to the 
reaction mixture and the organic layer was separated. The aqueous phase was extracted 
                                                          
330 Habashita, H.; Kawasaki, T.; Takemoto, Y.; Fujii, N.; Ibuka, T. J. Org. Chem. 1998, 63, 2392-2396. 
331 Heathcock, C. H.; Finkelstein, B. L.; Jarvi, E. T.; Radel, P. A.; Hadley, C. R. J. Org. Chem. 1988, 53, 1922-1942. 
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with CH2Cl2 and the combined organic layers were washed with brine, dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
resulting crude pivaloate (1.71 mmol) was used in the next step without further 
purification. A solution of the crude pivaloate in DMF (10 mL) was treated with imidazole 
(235 mg, 3.44 mmol, 2.0 equiv) and TBSCl (389 mg, 2.58 mmol, 1.5 equiv). The resulting 
solution was stirred for 12 h and then poured into Et2O, washed with a saturated aqueous 
NH4Cl solution and brine, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (silica gel, 5% EtOAc in hexanes) to obtain 620 (542 mg, quant. over 
two steps) as a colourless oil: Rf = 0.89 (silica gel, 50% EtOAc in hexanes); [α]25 D = – 
2.45 (c 0.05, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ (ppm) 5.77 (ddd, J = 17.2, 10.4, 6.8 
Hz, 1 H), 5.19 – 5.10 (m, 2 H), 4.09 (dd, J = 10.9, 5.8 Hz, 1 H), 4.06 (dd, J = 6.8, 5.9 Hz, 
1 H), 3.97 (dd, J = 10.9, 6.3 Hz, 1 H), 1.93 (qd, J = 6.8, 0.7 Hz, 1 H), 1.21 (s, J = 1.9 Hz, 
9 H), 0.91 – 0.89 (m, 12 H), 0.04 (s, 3 H), 0.03 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
(ppm) 178.4, 134.8, 127.4, 75.2, 65.8, 36.4, 31.4, 27.2, 26.6, 19.0, 12.6; HRMS (ESI-
TOF) m/z calcd for C17H34O3Si [M + H]
+ 315.2356, found 315.2354. 
 
7.3.13. Synthesis of Acid 622 
Acid 622. A solution of 620 (542 mg, 1.72 mmol, 1.0 equiv) in CH2Cl2 
(40 mL) was cooled at -78 ºC and treated with DIBAL-H (3.5 mL, 1.0 
M in toluene, 3.45 mmol, 2.0 equiv). After 1 h, the reaction was 
quenched by addition of MeOH at -78 ºC and the mixture was allowed 
to reach room temperature, treated with a saturated aqueous Na+/K+ tartrate solution and 
diluted with CH2Cl2. The resulting mixture was vigorously stirred until a clear separation 
of both organic and aqueous phases. The organic layer was separated and the aqueous 
phase was extracted with CH2Cl2 three times. The combined organic layers were washed 
with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated under 
reduced pressure. The resulting crude alcohol (1.30 mmol) was used in the next step 
without further purification.  To a solution of the crude alcohol in CH2Cl2 (10 mL) was 
added a solution of Dess-Martin periodinane (2.8 g, 6.51 mmol, 5.0 equiv) in CH2Cl2 (10 
mL) at 0 ºC. The reaction mixture was stirred at 25 ºC for 12 h and, after this time, the 
reaction mixture was quenched with a 1:1 mixture of a saturated aqueous NaHCO3 
solution / Na2S2O3 1 M. The solution was stirred for 20 min and then, the organic layer 
was separated. The aqueous phase was extracted with CH2Cl2 and the combined organic 
extracts were washed with brine, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The resulting crude aldehyde (1.30 mmol) was used 
in the next step without further purification. A solution of crude aldehyde in tBuOH/H2O 
(4:1, 30 mL) was treated with 2-methyl-2-butene (0.3 mL, 2.60 mmol, 2.0 equiv), 
NaHPO4 (1.1 g, 9.11 mmol, 7.0 equiv) and NaClO2 (825 mg, 9.11 mmol, 7.0 equiv). The 
reaction mixture was stirred for 12 h, then diluted with EtOAc and washed with brine. 
The organic layer was separated, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure to give the crude acid 622 (171 mg, 43% over three 
steps) as a colourless oil which did not require purification: Rf = 0.20 (silica gel, 70% 
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EtOAc in hexanes); [α]25 D = – 3.59 (c 0.04, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 
(ppm) 5.76 (ddd, J = 13.4, 10.2, 5.0 Hz, 1 H), 5.23 (dd, J = 17.0, 14.5 Hz, 2 H), 4.29 – 
4.24 (m, 1 H), 2.67 – 2.54 (m, 1 H), 0.96 – 0.89 (m, 12 H), 0.10 (s, 3 H), 0.07 (s, 3 H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 170.5, 138.3, 116.9, 69.4, 46.6, 18.0, 12.9, -4.2, -
5.2; HRMS (ESI-TOF) m/z calcd for C12H24O3Si [M + H]
+ 245.1573, found 245.1574. 
 
7.3.14. Synthesis of Diolefin 601 
Diolefin 601. Dipeptide 610 (328 mg, 0.70 mmol, 1.0 equiv) 
in CH2Cl2 (20 mL) was treated with TFA (3.5 mL) in exactly 
the same manner as previously described for synthesis of 
612. A solution of the ammonium salt and acid 622 (171 mg, 
0.70 mmol, 1.0 equiv), in CH2Cl2 (15 mL) was treated with 
HATU (400 mg, 1.05 mmol, 1.0 equiv) and DIPEA (0.35 
mL, 2.10 mmol, 3.0 equiv) and the resulting solution was 
stirred at 25 ºC for 12 h. After this time, a saturated aqueous 
NH4Cl solution was added and the organic layer was separated. The aqueous phase was 
extracted with EtOAc, and the combined organic layers were washed with brine, dried 
over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
crude product was purified by flash column chromatography (silica gel, 20% EtOAc in 
hexanes) to obtain diolefin 601 (250 mg, 74% over two steps) as a white solid: Rf  = 0.73 
(silica gel, 100% EtOAc); [α]25 D = –6.06 (c 0.05, CH2Cl2); mp = 98-99 ºC; 1H NMR (400 
MHz, CDCl3) δ (ppm) 8.12 (bs, 1 H), 7.68 (d, J = 7.3 Hz, 1 H), 7.54 (d, J = 2.6 Hz, 1 H), 
7.44 – 7.27 (m, 5 H), 7.06 (m, 1 H), 6.78 – 6.71 (m, 1 H), 6.70 – 6.63 (m, 1 H), 5.92 (ddt, 
J = 16.5, 10.2, 6.1 Hz, 1 H), 5.79 (ddd, J = 17.3, 10.3, 7.2 Hz, 1 H), 5.27 (m, 1 H), 5.10 
(m, 1 H), 5.01 (s, 2 H), 4.60 – 4.51 (m, 1 H), 4.33 (dd, J = 17.1, 7.4 Hz, 1 H), 4.15 – 4.04 
(m, 2 H), 3.62 (dd, J = 17.1, 4.6 Hz, 1 H), 3.36 – 3.22 (m, 1 H), 2.32 (dq, J = 13.7, 6.8 
Hz, 1 H), 1.42 (d, J = 7.0 Hz, 3 H), 1.10 (d, J = 6.9 Hz, 3 H), 0.94 (s, 9 H), 0.19 (s, 3 H), 
0.17 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 175.5, 170.8, 169.8, 157.8, 138.2, 
136.8, 136.3, 136.1, 130.9, 128.5, 127.9, 127.5, 122.7, 117.9, 116.3, 112.2, 109.9, 70.1, 
49.8, 46.6, 43.1, 38.9, 38.5, 25.2, 18.1, 17.4, 16.2, 13.6, 2.9, -4.5, -4.7; HRMS (H-ESI) 
m/z: [M + H]+ calcd for C33H48N3O5Si 594.3363; found 594.3365. 
 
7.3.15. Synthesis of Diolefin 600 
Diolefin 600. To a solution of diolefin 601 (90 mg, 0.15 
mmol, 1.0 equiv) in THF (10 mL) was added HFpyr (0.6 
mL) at 0 ºC and the mixture was stirred for 12 h. The reaction 
mixture was quenched with a saturated aqueous NaHCO3 
solution and diluted with EtOAc. The organic layer was 
separated and the aqueous phase was extracted with EtOAc. 
The combined organic layers were washed with brine, dried 
over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
residue was purified by flash column chromatography (silica gel, 2% MeOH in CH2Cl2) 
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to obtain diolefin 600 (60 mg, 83%) as a white solid: Rf  = 0.66 (silica gel, 10% MeOH in 
CH2Cl2); [α]25 D = – 4.91 (c 0.08, CH2Cl2); mp = 90-91 ºC; 1H NMR (400 MHz, CDCl3) 
δ (ppm) 8.16 (bs, 1 H), 7.69 (d, J = 7.1 Hz, 1 H), 7.56 (d, J = 2.6 Hz, 1 H), 7.43 – 7.28 
(m, 5 H), 7.05 (d, J = 8.4 Hz, 1 H), 6.88 – 6.81 (m, 1 H), 6.73 (dd, J = 8.4, 2.6 Hz, 1 H), 
5.93 (ddd, J = 16.3, 11.1, 6.0 Hz, 1 H), 5.80 (ddd, J = 17.3, 10.3, 7.2 Hz, 1 H), 5.28 (dd, 
J = 16.0, 2.2 Hz, 1 H), 5.20 (d, J = 10.3 Hz, 1 H); 5.14 – 5.04 (m, 2 H), 5.01 (s, 2 H), 4.59 
– 4.48 (m, 1 H), 4.31 (dd, J = 17.2, 7.5 Hz, 1 H), 3.62 (dd, J = 17.1, 4.8 Hz, 1 H), 3.33 – 
3.26 (m, 2 H), 2.35 (dq, J = 13.6, 6.8 Hz, 1 H), 1.41 (d, J = 7.1 Hz, 3 H), 1.09 (d, J = 6.8 
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 175.5, 170.7, 169.9, 157.8, 138.4, 136.9, 
136.3, 136.2, 130.8, 128.5, 127.9, 127.5, 122.8, 117.7, 116.3, 111.9, 109.9, 70.1, 49.8, 
43.2, 36.4, 23.8, 19.6, 17.3, 13.5; HRMS (H-ESI) m/z: [M + H]+ calcd for C27H34N3O5 
480.2498; found 480.2502. 
 
7.3.16. Synthesis of Cyclopeptide 623 
Cyclopeptide 623. Diolefin 600 (30 mg, 0.06 mmol, 1.0 
equiv), Hoveyda-Grubbs 2nd generation catalyst (4.0 mg, 
0.01 mmol, 0.10 equiv) and p-benzoquinone (1.0 mg, 0.01 
mmol, 0.10 equiv) were dissolved in degassed CH2Cl2 (3 
mL, 0.02 M) and the reaction mixture was heated at 40 ºC 
for 12 h. After this time, the solvent was removed under 
reduced pressure and the resulting crude product was 
purified by flash column chromatography (silica gel, CH2Cl2 → 5% MeOH in CH2Cl2) 
to obtain 623 (20 mg, 71%) as a white solid: Rf  = 0.44 (silica gel, 10% MeOH in CH2Cl2); 
[α]25 D = – 8.4 (c 0.05, MeOH); mp = 203-204 ºC; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 
8.67 (bs, 1 H), 8.49 (t, J = 5.5 Hz, 1 H), 7.46 – 7.29 (m, 6 H), 7.07 (d, J = 2.7 Hz, 1 H), 
6.82 (dd, J = 8.3, 2.7 Hz, 1 H), 5.62 (dt, J = 15.9, 5.11 Hz, 1 H), 5.05 (s, 2 H), 4.98 (dd, 
J = 15.9, 7.0 Hz, 1 H), 4.32 – 4.23 (m, 1 H), 4.13 (dd, J = 6.6, 4.7 Hz, 1 H), 3.85 (dd, J = 
14.3, 5.8 Hz, 1 H), 3.19 – 2.99 (m, 3 H), 2.68 – 2.64 (m, 1 H), 1.30 (d, J = 7.3 Hz, 3 H), 
0.85 (d, J = 6.9 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ (ppm) 174.9, 171.5, 170.6, 
157.5, 137.6, 137.5, 131.6, 131.0, 130.2, 128.8, 128.2, 128.1, 127.6, 113.3, 112.3, 72.7, 
69.7, 49.6, 44.9, 43.6, 33.8, 16.9, 11.0; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C25H30N3O5 452.2186; found 452.2188. 
 
7.3.17. Synthesis of Aniline 625 
Aniline 625. To a solution of allylic alcohol 624293 (1.9 g, 10.60 mmol, 
1.0 equiv) in EtOH (60 mL) was added a solution of NH4Cl (2.8 g, 53.02 
mmol, 5.0 equiv) in water (40 mL) followed by Zn dust (10 g, 159.06 
mmol, 15.0 equiv) in ten portions of 1 g each over 30 min at 25 ºC. The 
mixture was stirred at this temperature for 12 h and then the reaction 
mixture was diluted with CH2Cl2 and water, then filtered and rinsed with CH2Cl2. The 
filtrate was diluted with water and extracted with CH2Cl2, and the organic phase washed 
with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated under 
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reduced pressure. The resulting residue was purified by flash column chromatography 
(silica gel, 10% EtOAc in hexanes) to obtain aniline 625 (1.4 g, 85%) as a yellow oil: Rf  
= 0.48 (silica gel, 40% EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ (ppm) 7.13 – 
7.06 (m, 2 H), 6.75 (td, J = 7.5, 1.2 Hz, 1 H), 6.65 (dd, J = 7.9, 0.9 Hz, 1 H), 6.15 (ddd, J 
= 17.0, 10.4, 5.3 Hz, 1 H), 5.34 (dt, J = 17.2, 1.4 Hz, 1 H), 5.25 (dt, J = 10.4, 1.5 Hz, 1 
H), 5.15 (d, J = 5.2 Hz, 1 H), 3.75 (bs, 2 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 144.8, 
138.3, 128.9, 128.0, 126.4, 118.6, 117.1, 115.4, 74.2; HRMS (H-ESI) m/z: [M + H]+ calcd 
for C9H12NO 150.0919; found 150.0907. 
 
7.3.18. Synthesis of Dipeptide 626 
Dipeptide 626. To a solution of aniline 625 (1.3 g, 8.71 mmol, 1.0 
equiv) and Boc-Gly-D-Ala-OH (608) (2.1 g, 8.71 mmol, 1.0 equiv) 
in CH2Cl2 (15 mL) was added HATU (3.6 g, 13.07 mmol, 1.5 
equiv) and DIPEA (1.5 mL, 8.71 mmol, 1.0 equiv) and the mixture 
was stirred for 12 h at 25 ºC. After this time, a saturated aqueous 
NH4Cl solution was added and the organic layer was separated. 
The aqueous phase was extracted with EtOAc, and the combined 
organic layers were washed with brine, dried over anhydrous MgSO4, filtered and the 
solvent evaporated under reduced pressure. The crude product was purified by flash 
column chromatography (silica gel, 20% EtOAc in hexanes → 40% EtOAc in hexanes) 
to obtain dipeptide 626 (2.5 g, 76%, 1:1 mixture of diastereoisomers) as a white foam. 
Data assigned for the mixture of diastereoisomers: Rf  = 0.56 (silica gel, 100% EtOAc); 
1H NMR (400 MHz, CDCl3) δ (ppm)  9.75 (d, J = 8.6 Hz, 1 H), 7.96 (t, J = 8.2 Hz, 1 H), 
7.39 – 7.28 (m, 1 H), 7.25 – 7.15 (m, 1 H), 7.10 (m, 1 H), 7.06 – 6.98 (m, 1 H), 6.08 – 
5.92 (m, 1 H), 5.85 – 5.64 (m, 1 H), 5.20 (d, J = 5.7 Hz, 1 H), 5.16 – 5.07 (m, 1 H), 4.54 
– 4.35 (m, 1 H), 3.89 – 3.62 (m, 2 H), 1.37 (s, 9 H), 1.33 (d, J = 7.2 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ (ppm) 170.5, 170.4, 170.4, 170.1, 170.1, 138.1, 138.1, 136.3, 128.6, 
128.5, 128.1, 127.9, 124.4, 122.4, 122.3, 116.0, 115.9, 80.9, 60.4, 50.3, 50.1, 44.1, 44.0, 
28.3, 28.3, 17.8, 17.8; HRMS (H-ESI) m/z: [M + H]+ calcd for C19H28N3O5 378.2029; 
found 378.2034. 
 
7.3.19. Synthesis of Trifluoroacetate Derivative 628 
Trifluoroacetate Derivative 628. Dipeptide 626 (1.0 g, 2.65 
mmol, 1.0 equiv) in CH2Cl2 (20 mL) was treated with TFA 
(13 mL) in exactly the same manner as previously described 
for synthesis of 612. A solution of the ammonium salt and 
Kosher acid 611 (0.27 mL, 2.65 mmol, 1.0 equiv), in CH2Cl2 
(35 mL) was treated with HATU (1.0 g, 2.65 mmol, 1.0 equiv) 
and DIPEA (1.4 mL, 7.95 mmol, 3.0 equiv) and the resulting 
solution was stirred at 25 ºC for 12 h. After this time, a 
saturated aqueous NH4Cl solution was added and the organic layer was separated. The 
aqueous phase was extracted with EtOAc, and the combined organic layers were washed 
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with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated under 
reduced pressure. The resulting residue was purified by flash column chromatography 
(silica gel, 30% EtOAc in hexanes) to obtain trifluoroacetate derivative 628 (784 mg, 
65%) as a white solid: Rf  = 0.18 (silica gel, 100% EtOAc); [α]25 D = – 9.14 (c 0.12, 
CH2Cl2); mp = 109-110 ºC; 
1H NMR (400 MHz, CDCl3) δ (ppm) 8.62 (bs, 1 H), 7.55 – 
7.35 (m, 2 H), 7.25 – 7.20 (m, 1 H), 7.18 – 7.12 (m, 1 H), 6.85 (d, J = 15.4 Hz, 1 H), 6.15 
(dt, J = 15.4, 6.6 Hz, 1 H), 5.77 – 5.66 (m, 1 H), 5.01 – 4.90 (m, 4 H), 4.69 – 4.58 (m, 1 
H), 4.01 – 3.90 (m, 2 H), 2.37 – 2.22 (m, 4 H), 1.42 (d, J = 5.4 Hz, 3 H); 13C NMR (100 
MHz, CDCl3) δ (ppm) 173.8, 171.2, 169.9, 157.7, 136.7, 134.3, 132.0, 129.7, 129.1, 
126.7, 126.3, 125.1, 123.1, 115.7, 113.1, 68.5, 49.8, 43.3, 35.1, 29.3, 17.4; HRMS (H-
ESI) m/z: [M + H]+ calcd for C21H25F3N3O5 456.1746; found 456.1752. 
 
7.3.20. Synthesis of Acid 631 
Acid 631. A 5 mL polypropylene syringe fitted with 
polyethylene porous disk charged with 2-chlorotrityl chloride 
(CTC) resin (300 mg, L=1.3 mmol/g, 1.0 equiv), was loaded 
with a solution of Fmoc-D-Ala-OH (629) (364 mg, 1.17 mmol, 
3.0 equiv) and DIPEA (0.23 mL, 1.36 mmol, 3.5 equiv) in dry 
DMF (3 mL). The resulting suspension was shaken at 280 rpm 
for 30 h, then the solution was unloaded and the resin was washed by shaking with dry 
DMF (5 x 3 mL). The resulting yellow resin was used in the next step. The polypropylene 
syringe loaded with the yellow resin was treated with a solution of 20% piperidine in 
DMF (3 x 3 mL x 10 min at 280 rpm). After the last run, the resin was washed with dry 
DMF (5 x 3 mL) and loaded with a solution of Fmoc-Gly-OH (630) (232 mg, 0.78 mmol, 
2.0 equiv), HOBt (105 mg, 0.78 mmol, 2.0 equiv) and DIC (0.15 mL, 0.97 mmol, 2.5 
equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for 24 h, and 
then the solution was unloaded and the resin washed with dry DMF (5 x 3 mL). The 
resulting yellow resin was used in the next step. To a 5 mL polypropylene syringe fitted 
with polyethylene porus disk and loaded with the resulting Fmoc protected dipeptide was 
added a solution of 20% piperidine in DMF (3 x 3 mL x 10 min at 280 rpm). After the 
last run, the resin was washed with dry DMF (5 x 3 mL) and treated with a solution of 
Kosher acid 611 (80 µL, 0.78 mmol, 2.0 equiv) HOBt (105 mg, 0.78 mmol, 2.0 equiv) 
and DIC (0.2 mL, 0.97 mmol, 2.5 equiv) in dry DMF (3 mL). The resulting suspension 
was shaken at 280 rpm for 24 h, and then the solution was unloaded and the resinwashed 
with dry DMF (5 x 3 mL). The resulting yellow resin was treated with a solution of 
CH2Cl2/AcOH/TFE (7:2:1, 3 mL) for 30 min. After that, the solution was collected and 
the resin washed with CH2Cl2 (2 x 3 mL). All the collected organic solvents were 
evaporated under reduced pressure and the resulting acid 631 (71 mg, 81 % overall yield 
from CTC resin) was obtained as a white solid which not required further purification: Rf  
= 0.21  (silica gel, 100% EtOAc); [α]25 D = – 5.21 (c 0.07, CH2Cl2); mp = 89-90 ºC; 1H 
NMR (400 MHz, CDCl3) δ (ppm) 6.91 (bs, 1 H), 6.62 (bs, 1 H), 5.84 (ddd, J = 16.2, 11.1, 
5.9 Hz, 1 H), 5.10 (dd, J = 17.1, 1.5 Hz, 1 H), 5.04 (dd, J = 10.3, 1.0 Hz, 1 H), 4.63 – 4.53 
(m, 1 H), 4.10 (dd, J = 16.4, 5.5 Hz, 1 H), 3.94 (dd, J = 17.0, 4.9 Hz, 1 H), 2.46 – 2.35 
                                                                                                Chapter 7  
225 
 
(m, 4 H), 1.48 (d, J = 6.9 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 175.4, 175.3, 
162.9, 136.7, 115.8, 42.5, 36.7, 31.6, 29.4, 23.3; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C10H17N2O4 229.1188; found 229.1194. 
 
7.3.21. Synthesis of Diolefin 627 
Diolefin 627. A solution of the aniline 625 (31 mg, 0.20 mmol, 1.0 
equiv) and acid 631 (46 mg, 0.20 mmol, 1.0 equiv) in dry DMF (8 
mL) was treated with HATU (76 mg, 0.20 mmol, 1.0 equiv) and 
DIPEA (40 µL, 0.20 mmol, 1.0 equiv) and the resulting solution 
was stirred at 25 ºC for 12 h. After this time, a saturated aqueous 
NH4Cl solution was added and the organic layer was separated. 
The aqueous phase was extracted with EtOAc, and the combined 
organic layers were washed with brine, dried over anhydrous MgSO4, filtered and the 
solvent evaporated under reduced pressure. The crude product was purified by flash 
column chromatography (silica gel, 20% EtOAc in hexanes → 80% EtOAc in hexanes) 
to obtain diolefin 627 (55 mg, 77%, 1:1 mixture of diastereoisomers) as a white foam. 
Data assigned for the mixture of diastereoisomers: Rf  = 0.37 (silica gel, 100% EtOAc); 
1H NMR (400 MHz, CDCl3) δ (ppm) 9.83 (bs, 1 H), 9.66 (bs, 1 H), 8.16 (d, J = 8.1 Hz, 1 
H), 8.11 (d, J = 8.1 Hz, 1 H), 7.32 – 7.23 (m, 4 H), 7.16 – 7.10 (m, 2 H), 7.06 (td, J = 7.5, 
0.7 Hz, 2 H), 6.80 – 6.66 (m, 2 H), 6.14 – 5.99 (m, 2 H), 5.82 (dd, J = 11.6, 5.2 Hz, 1 H), 
5.76 (dd, J = 10.3, 6.2 Hz, 1 H), 5.35 – 5.25 (m, 2 H), 5.24 – 5.22 (m, 2 H), 5.20 – 5.12 
(m, 2 H), 5.07 (dd, J = 18.3, 2.9 Hz, 2 H), 5.04 – 4.99 (m, 2 H), 4.84 (bs, 2 H), 4.56 (dd, 
J = 14.7, 7.4 Hz, 1 H), 4.48 (dd, J = 14.1, 6.9 Hz, 1 H), 4.14 (dd, J = 6.6, 2.7 Hz, 1 H), 
4.10 (dd, J = 6.2, 3.2 Hz, 1 H), 3.82 (d, J = 4.8 Hz, 1 H), 3.79 – 3.75 (m, 1 H), 2.40 – 2.29 
(m, 8 H), 1.46 (d, J = 7.8 Hz, 3 H), 1.44 (d, J = 7.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ (ppm) 174.0, 173.9, 170.5, 170.4, 169.4, 169.3, 138.4, 138.2, 136.8, 136.5, 131.0, 130.8, 
128.5, 128.4, 128.4, 128.3, 128.1, 127.8, 124.3, 124.2, 122.2, 122.1, 115.8, 115.7, 115.7, 
115.6, 50.6, 50.2, 42.9, 42.8, 35.3, 35.2, 31.9, 31.4, 29.6, 29.3, 17.7, 17.6; HRMS (H-
ESI) m/z: [M + H]+ calcd for C19H26N3O4 360.1923; found 360.1917. 
 
7.3.22. Synthesis of Silyl Ether 632 
Silyl Ether 632. To a solution of 627 (45 mg, 0.14 mmol, 1.0 
equiv) in CH2Cl2 (5 mL) was added 2,6-lutidine (30 µL, 0.25 
mmol, 2.0 equiv) at 0 ºC and the mixture was stirred 10 min at this 
temperature. After this time TBSOTf (60 µL, 0.25 mmol, 2.0 
equiv) was added at 0 ºC and the mixture was stirred 12 h at 25 ºC. 
Then, the reaction was quenched by addition of H2O. After 
decantation of the organic layer, the aqueous phase was extracted 
with EtOAc, and the combined organic layers were washed with brine, dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes 
→ 100% EtOAc) to obtain silyl ether 632 (50 mg, 85%, 1:1 mixture of diastereoisomers) 
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as a white solid. Data assigned for the mixture of diastereoisomers: Rf  = 0.80 (silica gel, 
100% EtOAc); mp = 121-122 ºC; 1H NMR (400 MHz, CDCl3) δ (ppm) 8.16 (dd, J = 8.1, 
7.9 Hz, 1 H), 7.31 – 7.27 (m, 1 H), 7.12 – 7.03 (m, 2 H), 7.01 – 6.95 (m, 1 H), 6.42 (d, J 
= 5.2 Hz, 1 H), 6.03 – 5.91 (m, 1 H), 5.88 – 5.76 (m, 1 H), 5.33 – 5.10 (m, 3 H), 5.10 – 
4.98 (m, 2 H), 4.47 (p, J = 6.9 Hz, 1 H), 4.02 – 3.96 (m, 2 H), 2.44 – 2.36 (m, 2 H), 2.37 
– 2.31 (m, 2 H), 1.50 – 1.42 (m, 3 H), 0.91 (s, 9 H), 0.14 (s, 3 H), 0.00 (s, 3 H); 13C NMR 
(100 MHz, CDCl3) δ (ppm) 172.7, 169.7, 169.7, 168.3, 168.2, 138.9, 138.7, 136.9, 136.4, 
136.3, 130.5, 130.2, 128.7, 128.6, 127.9, 127.9, 124.4, 124.3, 122.3, 122.3, 115.7, 114.5, 
114.4, 50.1, 49.9, 42.9, 38.6, 35.5, 29.4, 25.7, 19.1, 19.1, 18.3, 18.3, -4.9, -5.0, -5.1, -5.1; 
HRMS (H-ESI) m/z: [M + H]+ calcd for C25H40N3O4Si
 474.2788; found 474.2775. 
 
7.3.23. Synthesis of Cyclopeptide 633 
Cyclopeptide 633. Diolefin 627 (30 mg, 0.08 mmol, 1.0 equiv), 
Hoveyda-Grubbs 2nd generation catalyst (5.0 mg, 0.01 mmol, 0.10 
equiv) and p-benzoquinone (1.0 mg, 0.01 mmol, 0.10 equiv) were 
dissolved in degassed CH2Cl2 (4 mL, 0.02 M) and the reaction 
mixture was heated at 40 ºC for 15 h. After this time, the solvent 
was removed under reduced pressure and the resulting crude 
product was purified by flash column chromatography (silica gel, 
CH2Cl2 → 5% MeOH in CH2Cl2) to obtain macrocycle 633 (21 mg, 73%, 1:1 mixture of 
diastereoisomers) as a white solid. Data assigned for the mixture of diastereoisomers: Rf  
= 0.46 (silica gel, 10% MeOH in CH2Cl2); mp = 153-154 ºC; 
1H NMR (400 MHz, CDCl3) 
δ (ppm) 7.58 (dd, J = 14.1, 8.0 Hz, 2 H), 7.45 – 7.38 (m, 2 H), 7.30 – 7.20 (m, 4 H), 5.78 
– 5.68 (m, 1 H), 5.58 – 5.51 (m, 1 H), 5.35 (dt, J = 14.6, 6.9 Hz, 1 H), 5.15 (d, J = 6.5 Hz, 
1 H), 5.10 (d, J = 6.9 Hz, 1 H), 4.53 (q, J = 7.1 Hz, 1 H), 4.31 (q, J = 7.3 Hz, 1 H), 4.15 
(d, J = 14.8 Hz, 1 H), 3.89 (d, J = 15.6 Hz, 1 H), 3.75 (d, J = 15.4 Hz, 1 H), 3.52 (d, J = 
14.8 Hz, 1 H), 2.53 – 2.44 (m, 4 H), 2.41 – 2.26 (m, 4 H), 1.48 (d, J = 7.4 Hz, 3 H), 1.46 
(d, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 175.1, 174.9, 172.7, 171.7, 
171.2, 171.2, 136.9, 136.7, 134.3, 133.9, 133.8, 133.5, 130.9, 129.9, 127.4, 127.3, 126.9, 
126.4, 125.9, 125.8, 125.8, 125.3, 71.9, 71.6, 50.9, 49.6, 43.6, 42.7, 34.9, 33.5, 28.5, 26.8, 
15.8, 15.5; HRMS (H-ESI) m/z: [M + H]+ calcd for C17H22N3O4 332.1610; found 
332.1588. 
 
7.3.24. Synthesis of Allylic Alcohol 636 
Allylic Alcohol 636. To a solution of nitrobenzaldehyde derivative 
635295 (1.8 g, 6.99 mmol, 1.0 equiv) in THF (25 mL) was added 
vinylmagnesium bromide (10 mL, 1.0 M in THF, 9.79 mmol, 1.4 
equiv) at -78 ºC. After being stirred for 3.5 h, the mixture was 
quenched with 25 mL of 0.01 N HCl, diluted and extracted with 
EtOAc three times. The combined organic layers were washed with brine, dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, 5% EtOAc in hexanes) 
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to obtain allylic alcohol 636 (1.8 g, 90%) as a yellow oil: Rf  = 0.79 (silica gel, 40% EtOAc 
in hexanes); 1H NMR (400 MHz, CDCl3) δ (ppm) 7.66 (d, J = 8.7 Hz, 1 H), 7.53 (d, J = 
2.7 Hz, 1 H), 7.47 – 7.36 (m, 6 H), 7.25 (dd, J = 8.7, 2.7 Hz, 1 H), 6.08 (ddd, J = 17.2, 
10.5, 5.1 Hz, 1 H), 5.75 – 5.70 (m, 1 H), 5.43 (dt, J = 17.2, 1.4 Hz, 1 H), 5.27 (dt, J = 
10.5, 1.4 Hz, 1 H), 5.14 (s, 2 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 158.3, 148.9, 
138.1, 135.7, 130.2, 129.8, 128.8, 128.5, 127.6, 120.7, 115.9, 110.3, 70.67, 69.7; HRMS 
(H-ESI) m/z: [M + H]+ calcd for C16H16NO4 286.1079; found 286.1080. 
 
7.3.25. Synthesis of Silyl Ether 638 
Silyl Ether 638. A solution of allylic alcohol 636 (800 mg, 4.47 
mmol, 1.0 equiv) in CH2Cl2 (40 mL) was treated with imidazole (395 
mg, 5.80 mmol, 1.3 equiv) and TBSCl (875 mg, 5.80 mmol, 1.3 
equiv) at 0 ºC. The resulting solution was stirred for 12 h at 25 ºC 
and then diluted with CH2Cl2, washed with a saturated aqueous 
NH4Cl solution and brine, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography (silica gel, 5% EtOAc in hexanes) to obtain silyl ether 638 (1.2 g, 95%) 
as a colourless oil: Rf = 0.88 (silica gel, 40% EtOAc in hexanes); 
1H NMR (400 MHz, 
CDCl3) δ (ppm) 7.74 (d, J = 8.8 Hz, 1 H), 7.50 (d, J = 2.6 Hz, 1 H), 7.47 – 7.38 (m, 5 H), 
7.25 (dd, J = 8.8, 2.7 Hz, 1 H), 5.98 (ddd, J = 17.0, 10.3, 5.0 Hz, 1 H), 5.84 (dt, J = 5.0, 
1.4 Hz, 1 H), 5.35 (dt, J = 17.0, 1.6 Hz, 1 H), 5.13 (s, 2 H), 5.09 (dt, J = 10.3, 1.6 Hz, 1 
H), 0.92 (s, 9 H), 0.13 (s, 3 H), 0.09 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 157.8, 
147.7, 139.7, 135.8, 131.6, 129.8, 128.8, 128.4, 127.6, 120.9, 113.9, 109.3, 70.6, 69.9, 
25.8, 18.3, -3.5; HRMS (H-ESI) m/z: [M + H]+ calcd for C22H30NO4Si 400.1944; found 
400.1958. 
 
7.3.26. Synthesis of Benzyloxymethyl Acetal 640 
Benzyloxymethyl Acetal 640. To a solution of allylic alcohol 636 
(460 mg, 1.61 mmol, 1.0 equiv) in CH2Cl2 (15 mL) was added 
DIPEA (1.12 mL, 6.45 mmol, 4.0 equiv) and BOMCl (1.2 mL, 6.45 
mmol, 4.0 equiv) at 0 ºC and the mixture was stirred at 25 ºC for 15 
h. After this time, the reaction was quenched by addition of a 
saturated aqueous Na2CO3 solution and the crude mixture was stirred for 30 min. Then, 
the aqueous phase was extracted with CH2Cl2 and the organic phase washed with brine, 
dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. 
The resulting residue was purified by flash column chromatography (silica gel, 5% 
EtOAc in hexanes) to obtain benzyloxymethyl acetal 640 (528 mg, 88%) as a pale yellow 
oil: Rf  = 0.56 (silica gel, 20% EtOAc in hexanes);
1H NMR (400 MHz, CDCl3) δ (ppm) 
7.65 (d, J = 8.8 Hz, 1 H), 7.49 (d, J = 2.7 Hz, 1 H), 7.43 – 7.28 (m, 10 H), 7.22 (dd, J = 
8.8, 2.7 Hz, 1 H), 5.95 (ddd, J = 17.1, 10.3, 6.0 Hz, 1 H), 5.79 (d, J = 6.1 Hz, 1 H), 5.35 
(dt, J = 17.2, 1.4 Hz, 1 H), 5.23 (dt, J = 10.4, 1.3 Hz, 1 H), 5.11 (s, 2 H), 4.91 – 4.77 (m, 
2 H), 4.71 (d, J = 6.9 Hz, 1 H), 4.62 – 4.51 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 
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(ppm) 158.2, 148.9, 137.6, 136.8, 135.8, 129.9, 128.8, 128.5, 128.4, 128.4, 127.9, 127.7, 
127.5, 120.6, 117.0, 109.8, 92.6, 73.4, 70.7, 69.8; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C24H24NO5 406.1655; found 406.1651. 
 
7.3.27. Synthesis of Aniline 641 
Aniline 641. To a solution of benzyloxymethyl acetal 640 (480 mg, 
1.18 mmol, 1.0 equiv) in EtOH (10 mL) was added a solution of 
NH4Cl (317 mg, 5.92 mmol, 5.0 equiv) in water (7.5 mL) followed 
by Zn dust (1.2 g, 17.76 mmol, 15.0 equiv) in twelve portions of 
100 mg each over 30 min at 25 ºC. The mixture was stirred at this 
temperature for 12 h and then the reaction mixture was diluted with CH2Cl2 and water, 
filtered and rinsed with CH2Cl2. The filtrate was diluted with water and extracted with 
CH2Cl2, and the organic phase washed with brine, dried over anhydrous MgSO4, filtered 
and the solvent evaporated under reduced pressure. The resulting residue was purified by 
flash column chromatography (silica gel, 15% EtOAc in hexanes) to obtain aniline 641 
(351 mg, 79%) as a pale yellow oil: Rf  = 0.35 (silica gel, 30% EtOAc in hexanes); 
1H 
NMR (400 MHz, CDCl3) δ (ppm) 7.42 – 7.29 (m, 10 H), 7.01 (d, J = 8.4 Hz, 1 H), 6.35 
(dd, J = 8.3, 2.5 Hz, 1 H), 6.29 (d, J = 2.5 Hz, 1 H), 6.12 (ddd, J = 17.2, 10.4, 5.7 Hz, 1 
H), 5.33 (dt, J = 17.3, 1.6 Hz, 1 H), 5.25 (dt, J = 10.4, 1.6 Hz, 1 H), 5.16 (dt, J = 5.7, 1.5 
Hz, 1 H), 5.02 (s, 2 H), 4.84 – 4.76 (m, 2 H), 4.67 – 4.62 (m, 2 H), 4.16 (bs, 2 H); 13C 
NMR (100 MHz, CDCl3) δ (ppm) 159.8, 146.7, 137.8, 137.2, 136.5, 130.6, 128.5, 128.4, 
127.9, 127.9, 127.7, 127.4, 116.3, 104.2, 102.9, 91.9, 78.1, 77.2, 69.9, 69.8; HRMS (H-
ESI) m/z: [M + H]+ calcd for C24H26NO3 376.1913; found 376.1901. 
 
7.3.28. Synthesis of Diolefin 642 
Diolefin 642. A solution of the aniline 641 (50 mg, 0.13 
mmol, 1.0 equiv) and acid 631 (30 mg, 0.13 mmol, 1.0 equiv) 
in dry DMF (7 mL) was treated with HATU (50 mg, 0.13 
mmol, 1.0 equiv) and DIPEA (22 µL, 0.13 mmol, 1.0 equiv) 
and the resulting solution was stirred at 25 ºC for 12 h. After 
this time, a saturated aqueous NH4Cl solution was added and 
the organic layer was separated. The aqueous phase was 
extracted with EtOAc, and the combined organic layers were washed with brine, dried 
over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
crude product was purified by flash column chromatography (silica gel, 30% EtOAc in 
hexanes) to obtain diolefin 642 (57 mg, 75%, 1:1 mixture of diastereoisomers) as a white 
solid. Data assigned for the mixture of diastereoisomers: Rf  = 0.81 (silica gel, 80% EtOAc 
in hexanes); mp = 90-91 ºC; 1H NMR (400 MHz, CDCl3) δ (ppm) 8.89 (d, J = 16.4 Hz, 1 
H), 7.98 (d, J = 2.5 Hz, 1 H), 7.47 – 7.27 (m, 11 H), 7.08 (dd, J = 8.5, 1.8 Hz, 1 H), 6.70 
(ddd, J = 8.5, 2.6, 1.2 Hz, 1 H), 6.00 (ddd, J = 18.5, 9.3, 4.1 Hz, 1 H), 5.83 (dddd, J = 
12.6, 8.8, 6.1, 4.7 Hz, 1 H), 5.30 – 5.20 (m, 3 H), 5.12 – 4.99 (m, 5 H), 4.80 (ddd, J = 
15.5, 11.0, 6.7 Hz, 2 H), 4.67 (dd, J = 14.2, 12.2 Hz, 1 H), 4.59 – 4.54 (m, 2 H), 2.44 – 
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2.37 (m, 2 H), 2.36 – 2.29 (m, 2 H), 1.45 – 1.38 (m, 3 H); 13C NMR (100 MHz, CDCl3) 
δ (ppm) 176.3, 171.9, 171.9, 170.5, 170.4, 159.4, 137.5, 137.4, 137.2, 136.9, 136.8, 136.4, 
136.4, 130.4, 128.6, 128.6, 128.5, 128.1, 128.1, 128.0, 127.6, 120.2, 120.2, 116.8, 116.8, 
115.8, 115.7, 115.6, 111.1, 111.0, 108.6, 108.5, 92.2, 92.0, 78.2, 78.2, 70.2, 70.1, 49.8, 
49.7, 38.6, 35.7, 33.0, 29.4, 28.7, 19.1, 18.9; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C34H40N3O6 586.2917; found 586.2921. 
7.3.29. Synthesis of Cyclopeptide 643 
Cyclopeptide 643. Diolefin 642 (15 mg, 0.03 mmol, 1.0 
equiv), Hoveyda-Grubbs 2nd generation catalyst (1.6 mg, 
0.003 mmol, 0.10 equiv) and p-benzoquinone (1.0 mg, 0.003 
mmol, 0.10 equiv) were dissolved in degassed CH2Cl2 (2 mL, 
0.02 M) and the reaction mixture was heated at 40 ºC for 15 
h. After this time, the solvent was removed under reduced
pressure and the resulting crude product was purified by flash
column chromatography (silica gel, 20% EtOAc in hexanes → 60% EtOAc in hexanes) 
to obtain macrocycle 643 (12 mg, 84%, 1:1 mixture of diastereoisomers) as a white solid. 
Data assigned for the mixture of diastereoisomers: Rf  = 0.21 (silica gel, 80% EtOAc in 
hexanes); mp = 207-208 ºC; 1H NMR (400 MHz, CDCl3) δ (ppm) 8.81 (bs, 1 H), 8.53 (bs, 
1 H), 8.51 (d, J = 2.6 Hz, 1 H), 8.35 (d, J = 2.6 Hz, 1 H), 7.46 – 7.28 (m, 23 H), 7.04 (d, 
J = 8.4 Hz, 1 H), 6.70 (dd, J = 8.5, 2.6 Hz, 1 H), 6.61 (dd, J = 8.3, 2.6 Hz, 1 H), 6.20 – 
6.11 (m, 1 H), 6.08 – 5.98 (m, 2 H), 5.82 – 5.72 (m, 2 H), 5.60 (dd, J = 15.4, 5.7 Hz, 1 
H), 5.20 – 5.16 (m, 1 H), 5.15 – 5.10 (m, 1 H), 5.07 (s, 4 H), 4.91 – 4.74 (m, 4 H), 4.71 – 
4.63 (m, 4 H), 4.60 (d, J = 7.5 Hz, 2 H), 4.52 – 4.43 (m, 2 H), 2.51 (dd, J = 9.1, 4.1 Hz, 4 
H), 2.39 – 2.20 (m, 4 H), 1.54 (d, J = 7.2 Hz, 3 H), 1.49 (d, J = 7.4 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ (ppm) 172.7, 172.7, 172.2, 170.4, 170.3, 169.5, 159.8, 159.2, 138.7, 
138.1, 137.7, 136.9, 136.9, 132.4, 132.3, 132.0, 131.6, 128.7, 128.6, 128.5, 128.5, 128.5, 
128.1, 127.9, 127.9, 127.9, 127.9, 127.8, 127.7, 127.6, 127.6, 127.5, 119.8, 118.3, 110.7, 
109.9, 106.9, 106.7, 91.5, 90.9, 75.9, 74.5, 69.9, 69.9, 69.7, 69.5, 51.8, 51.5, 50.9, 36.9, 
36.4, 30.2, 29.7, 29.6, 17.9, 16.5; HRMS (H-ESI) m/z: [M + H]+ calcd for C32H36N3O6 
558.2604; found 558.2615. 
7.3.30. Synthesis of Acid 644 
Acid 644. A 5 mL polypropylene syringe fitted with 
polyethylene porous disk charged with 2-chlorotrityl 
chloride (CTC) resin (363 mg, L=1.3 mmol/g, 1.0 equiv), 
was loaded with a solution of Fmoc-D-Ala-OH (629) (441 
mg, 1.42 mmol, 3.0 equiv) and DIPEA (0.29 mL, 1.65 
mmol, 3.5 equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm 
for 30 h, then the solution was unloaded and the resin was washed by shaking with dry 
DMF (5 x 3 mL). The resulting yellow resin was used in the subsequent step. The 
polypropylene syringe loaded with the yellow resin was treated with a solution of 20% 
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piperidine in DMF (3 x 3 mL x 10 min at 280 rpm). After the last run, the resin was 
washed with dry DMF (5 x 3 mL) and loaded with a solution of Fmoc-Gly-OH (630) (281 
mg, 0.94 mmol, 2.0 equiv), HOBt (128 mg, 0.94 mmol, 2.0 equiv) and DIC (0.18 mL, 
1.18 mmol, 2.5 equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 
rpm for 24 h, and then the solution was unloaded and the resin washed with dry DMF (5 
x 3 mL). The resulting yellow resin was used in the next step. To a 5 mL polypropylene 
syringe fitted with polyethylene porous disk and loaded with the Fmoc protected 
dipeptide resin was added a solution of 20% piperidine in DMF (3 x 3 mL x 10 min at 
280 rpm). After the last run, the resin was washed with dry DMF (5 x 3 mL) and treated 
with a solution of the acid 622 (231 mg, 0.94 mmol, 2.0 equiv), HOBt (127 mg, 0.94 
mmol, 2.0 equiv) and DIC (0.18 mL, 1.18 mmol, 2.5 equiv) in dry DMF (3 mL). The 
resulting suspension was shaken at 280 rpm for 24 h, and then the solution was unloaded 
and the resin washed with dry DMF (5 x 3 mL). The resulting yellow resin was treated 
with a solution of CH2Cl2/AcOH/TFE (7:2:1, 3 mL) for 30 min. After that, the solution 
was collected and the resin washed with CH2Cl2 (2 x 3 mL). All the collected organic 
solvents were evaporated under reduced pressure and the resulting acid 644 (90 mg, 84% 
overall yield from CTC resin) was obtained as a colorless solid which not required further 
purification: Rf  = 0.30  (silica gel, 10% MeOH in CH2Cl2); [α]25 D = – 5.44 (c 0.08, 
CH2Cl2); mp = 92-93 ºC; 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.20 (d, J = 5.7 Hz, 1 H), 
5.76 (ddd, J = 17.2, 10.4, 6.8 Hz, 1 H), 5.20 (d, J = 17.1 Hz, 1 H), 5.15 (d, J = 10.5 Hz, 1 
H), 4.61 – 4.47 (m, 1 H), 4.17 (d, J = 6.5 Hz, 1 H), 4.08 (dd, J = 16.6, 5.7 Hz, 1 H), 3.86 
(dd, J = 16.6, 4.8 Hz, 1 H), 2.41 (p, J = 6.9 Hz, 1 H), 1.42 (d, J = 7.0 Hz, 3 H), 1.11 (d, J 
= 7.1 Hz, 3 H), 0.86 (s, 9 H), 0.03 (s, 3 H), 0.02 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
(ppm) 175.9, 168.8, 163.2, 138.8, 116.6, 76.0, 47.8, 42.9, 36.8, 25.8, 18.1, 18.0, 14.7, -
4.3, -5.1; HRMS (H-ESI) m/z: [M + H]+calcd for C17H33N2O5Si 373.2159; found 
373.2164. 
7.3.31. Synthesis of Diolefin 646 
Diolefin 646. To a solution of aniline 625 (64 mg, 0.43 mmol, 1.0 
equiv) and acid 644 (160 mg, 043 mmol, 1.3 equiv) in DMF (10 
mL) was added HATU (163 mg, 0.43 mmol, 1.0 equiv) and 
DIPEA (0.10 mL, 0.43 mmol, 1.0 equiv) at 0 ºC and the mixture 
was stirred for 12 h at 25 ºC. After this time, a saturated aqueous 
NH4Cl solution was added and the organic layer was separated. 
The aqueous phase was extracted with EtOAc, and the combined 
organic layers were washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica gel, 25% EtOAc in hexanes → 
100% EtOAc) to obtain diolefin 646 (60 mg, 36%, 1:1 mixture of diastereoisomers) as a 
white foam. Data assigned for the mixture of diastereoisomers: Rf  = 0.23 (silica gel, 100% 
EtOAc); 1H NMR (400 MHz, CDCl3) δ (ppm) 7.28 – 7.19 (m, 2 H), 7.17 – 7.10 (m, 1 H), 
7.05 (t, J = 7.3 Hz, 1 H), 6.14 – 5.96 (m, 1 H), 5.78 – 5.61 (m, 1 H), 5.32 – 5.06 (m, 5 H), 
4.43 – 4.25 (m, 1 H), 4.18 – 4.07 (m, 1 H), 3.99 (s, 1 H), 3.69 – 3.55 (m, 1 H), 2.44 (s, 1 
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H), 2.35 – 2.22 (m, 1 H), 1.36 (d, J = 5.7 Hz, 3 H), 1.00 – 0.94 (m, 3 H); 13C NMR (100 
MHz, CDCl3) δ (ppm) 176.9, 176.5, 171.6, 171.2, 170.7, 170.5, 138.1, 137.9, 137.8, 
136.1, 131.4, 131.1, 128.6, 128.5, 128.2, 128.1, 124.8, 124.8, 122.6, 122.3, 118.4, 118.0, 
116.7, 116.2, 74.9, 74.3, 60.5, 50.5, 49.5, 46.8, 46.8, 30.7, 29.7, 17.4, 17.3, 13.8, 13.5; 
HRMS (H-ESI) m/z: [M + H]+ calcd for C20H28N3O5
 390.2029; found 390.2037. 
 
7.3.32. Synthesis of Ketone 648 
Ketone 648. To a solution of diolefin 627 (27 mg, 0.08 mmol, 1.0 
equiv) in CH2Cl2 (15 mL) was added MnO2 (131 mg, 1.50 mmol, 
20.0 equiv) and the dark solution was stirred at 25 ºC for 48 h. The 
mixture was filtered through a pad of celite and rinsed with 
CH2Cl2. The solvent was evaporated under reduced pressure to 
obtain ketone 648 (20 mg, 75%) as a white solid which did not 
require purification: Rf  = 0.43 (silica gel, 100% EtOAc); [α]25 D = 
– 6.98 (c 0.09, CH2Cl2); mp = 111-112 ºC; 1H NMR (400 MHz, CDCl3) δ (ppm) 11.91 
(bs, 1 H), 8.72 (dd, J = 8.5, 1.0 Hz, 1 H), 7.90 (dd, J = 8.0, 1.6 Hz, 1 H), 7.59 (ddd, J = 
8.6, 7.5, 1.4 Hz, 1 H), 7.26 – 7.15 (m, 2 H), 7.04 (d, J = 7.2 Hz, 1 H), 6.73 (t, J = 4.9 Hz, 
1 H), 6.42 (dd, J = 16.9, 1.6 Hz, 1 H), 5.98 (dd, J = 10.6, 1.6 Hz, 1 H), 5.91 – 5.77 (m, 1 
H), 5.08 (ddd, J = 17.1, 3.2, 1.6 Hz, 1 H), 5.01 (ddd, J = 2.9, 2.4, 1.2 Hz, 1 H), 4.67 (p, J 
= 7.2 Hz, 1 H), 4.32 (dd, J = 16.8, 5.8 Hz, 1 H), 4.06 (dd, J = 16.8, 4.8 Hz, 1 H), 2.45 – 
2.35 (m, 4 H), 1.54 (d, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 194.2, 
172.9, 171.3, 169.2, 140.7, 136.9, 135.3, 133.0, 131.3, 131.0, 122.9, 122.5, 121.0, 115.8, 
50.4, 43.3, 35.5, 29.4, 18.2; HRMS (H-ESI) m/z: [M + H]+ calcd for C19H24N3O4 
358.1767; found 358.1789. 
 
7.3.33. Synthesis of Dipeptide 656 
Dipeptide 656. To a solution of aniline 655299 (200 mg, 
1.68 mmol, 1.0 equiv) and Boc-Gly-D-Ala-OH (608) (413 
mg, 1.68 mmol, 1.0 equiv) in DMF (10 mL) was added 
HATU (960 mg, 2.52 mmol, 1.5 equiv) and DIPEA (0.30 
mL, 1.68 mmol, 1.0 equiv) and the mixture was stirred for 
12 h at 25 ºC. After this time, the reaction mixture was 
diluted with CH2Cl2 and washed sequentially with 1 N HCl and saturated aqueous 
NaHCO3 solution. The organic layer was separated, washed with brine and dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes) 
to obtain dipeptide 656 (455 mg, 78%) as a white solid: Rf = 0.52 (silica gel, 100% 
EtOAc); [α]25 D = – 6.36 (c 0.06, CH2Cl2); mp = 84-85 ºC; 1H NMR (400 MHz, CDCl3) δ 
(ppm) 8.13 (bs, 1 H), 7.78 (d, J = 8.1 Hz, 1 H), 7.45 (d, J = 7.8 Hz, 1 H), 7.15 (t, J = 7.5 
Hz, 1 H), 6.85 – 6.79 (m, 1 H), 6.76 (d, J = 9.1 Hz, 1 H), 5.68 (dd, J = 17.4, 1.2 Hz, 1 H), 
5.43 (dd, J = 11.0, 1.2 Hz, 1 H), 5.12 (bs, 1 H), 4.66 (q, J = 7.1 Hz, 1 H), 3.92 – 3.77 (m, 
2 H), 1.50 (d, J = 7.0 Hz, 3 H), 1.44 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 170.4, 
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170.0, 156.1, 136.9, 136.2, 131.1, 130.1, 127.2, 125.7, 123.9, 116.5, 49.5, 38.6, 36.1, 
28.2, 17.7; HRMS (H-ESI) m/z: [M + H]+ calcd for C18H26N3O4 348.1923; found 
348.1921. 
 
7.3.34. Synthesis of Acid 658 
Acid 658. To a solution of diol 657300 (300 mg, 2.30 mmol, 1.0 equiv) 
in a 1:1 mixture CH3CN/H2O (50 mL) was added TEMPO (180 mg, 
1.15 mmol, 0.5 equiv) and BAIB (3.7 g, 11.52 mmol, 5 equiv) at 25 ºC. 
The mixture was stirred until complete conversion of the alcohol (7 h). 
After this time, the reaction was diluted with EtOAc and quenched with a saturated 
aqueous Na2S2O3 solution. The organic layer was separated and the aqueous phase was 
then extracted with EtOAc and the combined organic layers were washed with brine and 
dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. 
The resulting residue was purified by flash column chromatography (silica gel, 40% 
EtOAc in hexanes) to obtain 658 (171 mg, 65%) as a colourless oil: Rf  = 0.20 (silica gel, 
50% EtOAc in hexanes); [α]25 D = – 3.12 (c 0.05, CH2Cl2); 1H NMR (400 MHz, CDCl3) 
δ (ppm) 6.59 (bs, 2 H), 5.90 – 5.75 (m, 1 H), 5.19 – 5.11 (m, 2 H), 4.05 (ddd , J = 7.7, 
5.8, 3.9 Hz, 1 H), 3.79 (td, J = 7.4, 4.2 Hz, 1 H), 2.65 – 2.54 (m, 1 H), 2.44 – 2.36 (m, 1 
H), 2.31 – 2.19 (m, 1 H), 1.24 (d, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 
180.7, 133.7, 118.5, 72.3, 44.6, 38.6, 13.9; HRMS (ESI-TOF) m/z calcd for C7H12O3 [M 
+ H]+ 145.0865, found 145.0864.  
 
7.3.35. Synthesis of Diolefin 659 
Diolefin 659. Dipeptide 656 (152 mg, 0.44 mmol, 1.0 equiv) in 
CH2Cl2 (25 mL) was treated with TFA (2.2 mL) in exactly the 
same manner as previously described for synthesis of 612. A 
solution of the ammonium salt and acid 658 (50 mg, 0.44 mmol, 
1.0 equiv), in DMF (15 mL) was treated with HATU (167 mg, 0.44 
mmol, 1.0 equiv) and DIPEA (0.23 mL, 1.31 mmol, 3.0 equiv) and 
the resulting reaction mixture was stirred at 25 ºC for 12 h. After 
this time, a saturated aqueous NH4Cl solution was added and the organic layer was 
separated. The aqueous phase was extracted with EtOAc, and the combined organic layers 
were washed with brine and dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The crude product was purified by flash column 
chromatography (silica gel, CH2Cl2 → 2% MeOH in CH2Cl2) to obtain diolefin 659 (150 
mg, 92% over two steps) as a white solid: Rf = 0.60 (silica gel, 10% MeOH in CH2Cl2);
 
[α]25 D = – 5.43 (c 0.07, CH2Cl2); mp = 104-105 ºC; 1H NMR (400 MHz, CDCl3) δ (ppm) 
8.34 (bs, 1 H), 7.67 – 7.57 (m, 1 H), 7.46 (d, J = 7.6 Hz, 1 H), 7.26 – 7.13 (m, 2 H), 6.82 
– 6.71 (m, 1 H), 6.68 (t, J = 7.6 Hz, 1 H), 6.46 (bs, 1 H), 5.81 (td, J = 16.9, 7.7 Hz, 1 H), 
5.67 (dd, J = 17.4, 1.1 Hz, 1 H), 5.42 – 5.34 (m, 2 H), 5.18 – 5.12 (m, 1 H), 4.67 – 4.51 
(m, 1 H), 4.25 (dd, J = 16.7, 7.3 Hz, 1 H), 3.79 – 3.62 (m, 2 H), 3.14 (qd, J = 7.3, 4.4 Hz, 
2 H), 2.17 (dd, J = 13.7, 8.2 Hz, 1 H), 1.42 (d, J = 6.7 Hz, 3 H), 1.39 (d, J = 6.6 Hz, 3 H); 
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13C NMR (100 MHz, CDCl3) δ (ppm) 176.1, 171.2, 170.2, 133.5, 131.8, 128.3, 126.4, 
126.1, 126.0, 124.5, 124.1, 119.0, 117.5, 73.3, 55.6, 43.5, 39.2, 18.6, 17.2, 12.4. HRMS 
(H-ESI) m/z: [M + H]+ calcd for C20H28N3O4 374.2080; found 374.2072. 
 
7.3.36. Synthesis of Styryl 661 
Styryl 661. To a solution of iodonitrobenzene 605 (2.7 g, 7.60 mmol, 
1.0 equiv) and Pd[PPh3]4 (1.3 g, 1.14 mmol, 0.15 equiv) in DMF (10 
mL) was added dropwise tri-n-butyl(vinyl)tin (2.7 mL, 9.12 mmol, 1.2 
equiv). The solution was then heated at 60 ºC for 48 h. After this time, 
the mixture was diluted with Et2O and water. The organic layer was separated and washed 
with water four times, dried over anhydrous MgSO4, filtered and the solvent evaporated 
under reduced pressure. The crude product was purified by flash column chromatography 
(silica gel, 2% EtOAc in Hexanes) to obtain styryl 661 (1.4 g, 74%) as a yellow oil: Rf  = 
0.51 (silica gel, 20% EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ (ppm) 7.54 (dd, 
J = 10.3, 5.7 Hz, 2 H), 7.46 – 7.34 (m, 5 H), 7.20 (ddd, J = 8.7, 2.7, 0.6 Hz, 1 H), 7.11 
(ddd, J = 11.5, 10.9, 5.5 Hz, 1 H), 5.65 (dd, J = 17.3, 1.0 Hz, 1 H), 5.40 (dd, J = 11.0, 1.0 
Hz, 1 H), 5.13 (s, 2 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 158.4, 135.7, 132.0, 129.5, 
128.8, 128.7, 128.5, 127.6, 126.1, 120.8, 117.4, 109.8, 70.7; HRMS (H-ESI) m/z: [M + 
H]+ calcd for C15H14NO3 256.0974; found 256.0981. 
 
7.3.37. Synthesis of Aniline 662 
Aniline 662. To a solution of styryl 661 (550 mg, 2.16 mmol, 1.0 
equiv) in EtOH (20 mL) was added a solution of NH4Cl (576 mg, 
10.77 mmol, 5.0 equiv) in water (14 mL) followed by Zn dust (2.1 g, 
32.32 mmol, 15.0 equiv) in ten portions of 200 mg each over 30 min 
at 25 ºC. The mixture was stirred at this temperature for 12 h and then the reaction mixture 
was diluted with CH2Cl2 and water, filtered and rinsed with CH2Cl2. The filtrate was 
diluted with water and extracted with CH2Cl2, and the organic phase washed with brine, 
dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. 
The resulting residue was purified by flash column chromatography (silica gel, 10% 
EtOAc in hexanes) to obtain aniline 662 (413 mg, 85%) as a yellow oil: Rf  = 0.47 (silica 
gel, 30% EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ (ppm) 7.45 – 7.31 (m, 5 H), 
7.27 – 7.21 (m, 1 H), 6.71 (dd, J = 17.4, 11.1 Hz, 1 H), 6.44 (dd, J = 8.5, 2.4 Hz, 1 H), 
6.32 (d, J = 2.5 Hz, 1 H), 5.54 (dd, J = 17.4, 1.5 Hz, 1 H), 5.22 (dd, J = 11.0, 1.5 Hz, 1 
H), 5.04 (s, 2 H), 3.78 (bs, 2 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 159.6, 144.9, 
137.2, 132.2, 128.6, 128.5, 127.9, 127.4, 117.5, 113.8, 105.7, 102.3, 69.9; HRMS (H-
ESI) m/z: [M + H]+ calcd for C15H16NO 226.1232; found 226.1229. 
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7.3.38. Synthesis of Dipeptide 663 
Dipeptide 663. To a solution of aniline 662 (340 mg, 1.51 
mmol, 1.0 equiv) and Boc-Gly-D-Ala-OH (608) (483 mg, 
1.962 mmol, 1.0 equiv) in DMF (5 mL) was added HATU 
(861 mg, 2.26 mmol, 1.5 equiv) and DIPEA (0.5 mL, 3.02 
mmol, 1.0 equiv) and the mixture was stirred for 12 h at 25 
ºC. After this time, a saturated aqueous NH4Cl solution was 
added and the organic layer was separated. The aqueous phase was extracted with EtOAc, 
and the combined organic layers were washed with brine, dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure. The crude product was 
purified by flash column chromatography (silica gel, 15% EtOAc in hexanes → 35% 
EtOAc in hexanes) to obtain dipeptide 663 (554 mg, 81%) as a yellow foam: Rf  = 0.64 
(silica gel, 100% EtOAc); [α]25 D = – 3.96 (c 0.15, CH2Cl2); 1H NMR (400 MHz, CDCl3) 
δ (ppm) 8.30 (d, J = 13.1 Hz, 1 H), 7.60 (bs, 1 H), 7.46 – 7.30 (m, 7 H), 6.78 (d, J = 2.7 
Hz, 1 H), 6.76 – 6.69 (m, 1 H), 5.56 (d, J = 17.3 Hz, 1 H), 5.31 (d, J = 11.6 Hz, 1 H), 5.18 
(bs, 1 H), 5.04 (s, 2 H), 4.68 (p, J = 7.1 Hz, 1 H), 3.88 – 3.79 (m, 2 H), 1.47 (d, J = 6.3 
Hz, 3 H), 1.43 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 170.2, 170.1, 158.8, 156.2, 
136.8, 135.1, 131.4, 128.5, 127.9, 127.6, 123.2, 120.4, 116.0, 112.8, 109.1, 80.7, 70.1, 
49.6, 44.4, 28.3, 17.5; HRMS (H-ESI) m/z: [M + H]+ calcd for C25H32N3O5 454.2342; 
found 454.2340. 
 
7.3.39. Synthesis of Diolefin 665 
Diolefin 665. Dipeptide 663 (70 mg, 0.15 mmol, 1.0 equiv) 
in CH2Cl2 (10 mL) was treated with TFA (2.2 mL) in exactly 
the same manner as previously described for synthesis of 
612. A solution of the resulting ammonium salt and hexenoic 
acid 664 (18 µL, 0.15 mmol, 1.0 equiv), in CH2Cl2 (15 mL) 
was treated with BOP (66 mg, 0.15 mmol, 1.0 equiv) and 
DIPEA (77 µL, 0.45 mmol, 3.0 equiv) and the resulting 
solution was stirred at 25 ºC for 12 h. After this time, a saturated aqueous NH4Cl solution 
was added and the organic layer was separated. The aqueous phase was extracted with 
EtOAc, and the combined organic layers were washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The resulting residue 
was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes) to 
obtain diolefin 665 (51 mg, 74% over two steps) as a white solid: Rf  = 0.45 (silica gel, 
100% EtOAc); [α]25 D = – 9.02 (c 0.11, CH2Cl2); mp = 82-83 ºC ; 1H NMR (400 MHz, 
CDCl3) δ (ppm) 8.24 (bs, 1 H), 7.58 (bs, 1 H), 7.44 – 7.30 (m, 6 H), 7.06 (s, 1 H), 6.80 – 
6.75 (m, 1 H), 6.72 (dd, J = 16.1, 9.7 Hz, 1 H), 6.34 (s, 1 H), 5.74 (ddt, J = 17.0, 10.0, 6.8 
Hz, 1 H), 5.56 (d, J = 17.3 Hz, 1 H), 5.29 (d, J = 11.0 Hz, 1 H), 5.05 – 5.00 (m, 3 H), 5.00 
– 4.93 (m, 1 H), 4.71 – 4.61 (m, 1 H), 4.06 – 3.93 (m, 2 H), 2.23 (td, J = 7.8, 1.7 Hz, 2 
H), 2.10 – 2.02 (m, 2 H), 1.77 – 1.68 (m, 2 H), 1.48 (d, J = 7.0 Hz, 3 H); 13C NMR (100 
MHz, CDCl3) δ (ppm) 173.8, 170.1, 169.4, 158.9, 137.7, 136.7, 135.1, 131.4, 128.6, 
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128.0, 127.6, 127.6, 123.0, 116.1, 115.5, 112.7, 109.0, 70.1, 49.8, 43.3, 35.4, 33.1, 24.5, 
17.6; HRMS (H-ESI) m/z: [M + H]+ calcd for C26H32N3O4 450.2393; found 450.2391. 
 
7.3.40. Synthesis of Cyclopeptide 666 
Cyclopeptide 666. Diolefin 665 (19 mg, 0.08 mmol, 1.0 
equiv), Hoveyda-Grubbs 2nd generation catalyst (3 mg, 0.004 
mmol, 0.10 equiv) and p-benzoquinone (1.0 mg, 0.004 
mmol, 0.10 equiv) were dissolved in degassed CH2Cl2 (2 mL, 
0.02 M) and the reaction mixture was heated at 40 ºC for 12 
h. After this time, the solvent was removed under reduced 
pressure and the resulting crude product was purified by 
flash column chromatography (silica gel, CH2Cl2 → 3% MeOH in CH2Cl2) to obtain 
macrocycle 666 (6.1 mg, 43%) as a white solid: Rf  = 0.76 (silica gel, 10% MeOH in 
CH2Cl2); [α]25 D = – 5.32 (c 0.09, MeOH); mp = 196-197 ; 1H NMR (400 MHz, DMSO-
d6) δ (ppm) 8.54 (bs, 1 H), 8.40 (t, J = 5.9 Hz, 1 H), 7.46 – 7.35 (m, 5 H), 7.32 (d, J = 7.0 
Hz, 1 H), 7.29 (d, J = 2.5 Hz, 1 H), 7.06 (d, J = 8.5 Hz, 1 H), 6.77 (dd, J = 8.4, 2.6 Hz, 1 
H), 5.42 (dt, J = 15.8, 5.2 Hz, 1 H), 5.04 (s, 2 H), 4.40 – 4.31 (m, 1 H), 3.85 (dd, J = 14.8, 
6.3 Hz, 1 H), 3.45 (dd, J = 14.8, 5.6 Hz, 1 H), 3.20 (dd, J = 15.5, 5.1 Hz, 1 H), 3.03 (dd, 
J = 15.5, 5.2 Hz, 1 H), 2.34 – 2.04 (m, 4 H), 1.30 (d, J = 7.1 Hz, 3 H); 13C NMR (100 
MHz, DMSO-d6) δ (ppm) 173.1, 171.4, 171.1, 157.4, 137.6, 137.3, 131.6, 130.7, 128.9, 
128.2, 128.1, 128.09, 128.0, 125.8, 111.8, 69.7, 49.7, 43.4, 34.7, 33.7, 27.9, 16.8; HRMS 
(H-ESI) m/z: [M + H]+ calcd for C24H28N3O4 422.2079; found 422.2073. 
 
7.3.41. Synthesis of Diolefin 654 
Diolefin 654. Dipeptide 663 (420 mg, 0.93 mmol, 1.0 equiv) 
in CH2Cl2 (10 mL) was treated with TFA (4.6 mL) in exactly 
the same manner as previously described for synthesis of 
612. A solution of the corresponding ammonium salt and 
acid 658 (174 mg, 1.20 mmol, 1.3 equiv), in CH2Cl2 (15 mL) 
was treated with HATU (528 mg, 1.39 mmol, 1.0 equiv) and 
DIPEA (0.5 mL, 2.78 mmol, 3.0 equiv) and the resulting 
solution was stirred at 25 ºC for 12 h. After this time, a saturated aqueous NH4Cl solution 
was added and the organic layer was separated. The aqueous phase was extracted with 
EtOAc, and the combined organic layers were washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The resulting residue 
was purified by flash column chromatography (silica gel, 50% EtOAc in hexanes → 
100% EtOAc) to obtain diolefin 654 (67 mg, 86% over two steps) as a white solid: Rf  = 
0.46 (silica gel, 10% MeOH in CH2Cl2); [α]25 D = – 3.98 (c 0.07, MeOH); mp = 88-89 ºC; 
1H NMR (400 MHz, MeOD) δ (ppm) 7.53 (d, J = 8.7 Hz, 1 H), 7.44 – 7.27 (m, 6 H), 7.04 
(d, J = 2.6 Hz, 1 H), 6.89 (dd, J = 8.7, 2.6 Hz, 1 H), 6.80 (dd, J = 17.5, 11.1 Hz, 1 H), 
5.98 – 5.82 (m, 1 H), 5.62 (dd, J = 17.4, 1.2 Hz, 1 H), 5.20 (dd, J = 11.0, 1.3 Hz, 1 H), 
5.11 (dd, J = 18.9, 1.7 Hz, 1 H), 5.07 (s, 2 H), 5.07 – 5.03 (m, 1 H), 4.55 – 4.47 (m, 1 H), 
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4.02 (d, J = 16.9 Hz, 1 H), 3.79 (d, J = 16.9 Hz, 1 H), 3.71 (td, J = 7.3, 4.0 Hz, 1 H), 2.48 
– 2.38 (m, 2 H), 2.27 – 2.18 (m, 1 H), 1.46 (d, J = 7.2 Hz, 3 H), 1.11 (d, J = 6.9 Hz, 3 H); 
13C NMR (100 MHz, MeOD) δ (ppm) 177.3, 172.7, 170.5, 163.5, 158.7, 137.1, 134.9, 
134.2, 131.6, 128.1, 127.6, 127.2, 126.4, 116.5, 113.5, 112.9, 112.1, 73.1, 69.7, 42.3, 
38.6, 35.6, 30.3, 16.5, 12.9; HRMS (H-ESI) m/z: [M + H]+ calcd for C27H34N3O5  
480.2499; found 480.2501. 
 
7.3.42. Synthesis of Diolefin 667 
Diolefin 667. To a solution of diolefin 654 (35 mg, 0.07 
mmol, 1.0 equiv) in CH2Cl2 (5 mL) was added 2,6-lutidine 
(20 µL, 0.15 mmol, 2.0 equiv) at 0 ºC and the mixture was 
stirred 10 min at this temperature. After this time TBSOTf 
(0.03 mL, 0.15 mmol, 2.0 equiv) was added at 0 ºC and the 
mixture was stirred for 12 h at 25 ºC. Then, the reaction was 
quenched by addition of H2O. After decantation of the 
organic layer, the aqueous phase was extracted with EtOAc, 
and the combined organic layers were washed with brine, 
dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. 
The crude product was purified by flash column chromatography (silica gel, 20% EtOAc 
in hexanes → 100% EtOAc) to obtain diolefin 667 (31 mg, 72%) as a white solid: Rf  = 
0.80 (silica gel, 100% EtOAc); [α]25 D = – 6.98 (c 0.06, MeOH); mp = 96-97 ºC; 1H NMR 
(400 MHz, MeOD) δ (ppm) 7.52 (d, J = 8.7 Hz, 1 H), 7.44 – 7.40 (m, 2 H), 7.39 – 7.33 
(m, 2 H), 7.33 – 7.27 (m, 1 H), 7.06 (d, J = 2.6 Hz, 1 H), 6.89 (dd, J = 8.7, 2.7 Hz, 1 H), 
6.79 (dd, J = 17.5, 11.1 Hz, 1 H), 5.89 (dddd, J = 16.5, 10.4, 8.2, 6.0 Hz, 1 H), 5.62 (dd, 
J = 17.5, 1.3 Hz, 1 H), 5.19 (dd, J = 11.0, 1.3 Hz, 1 H), 5.11 – 5.07 (m, 1 H), 5.07 (s, 2 
H), 5.06 – 5.03 (m, 1 H), 4.56 – 4.49 (m, 1 H), 4.07 (d, J = 16.5 Hz, 1 H), 3.98 – 3.89 (m, 
1 H), 3.70 (d, J = 16.6 Hz, 1 H), 2.58 – 2.46 (m, 1 H), 2.40 – 2.22 (m, 2 H), 1.47 (d, J = 
7.1 Hz, 3 H), 1.08 (d, J = 7.0 Hz, 3 H), 0.87 (s, 9 H), 0.08 (s, 3 H), 0.03 (s, 3 H); 13C NMR 
(100 MHz, MeOD) δ (ppm) 176.9, 172.6, 169.9, 158.7, 137.1, 134.9, 133.7, 131.6, 128.1, 
127.5, 127.2, 126.4, 125.9, 116.6, 113.4, 112.9, 112.0, 73.3, 69.7, 49.4, 45.9, 42.0, 38.1, 
24.9, 17.5, 16.8, 12.7, -5.6, -6.1; HRMS (H-ESI) m/z: [M + H]+ calcd for C33H48N3O5Si 
594.3363; found 594.3367. 
 
7.3.43. Synthesis of Cyclopeptide 668 
Cyclopeptide 668. Diolefin 667 (20 mg, 0.03 mmol, 1.0 
equiv), Hoveyda-Grubbs 2nd generation catalyst (2 mg, 0.003 
mmol, 0.10 equiv) and p-benzoquinone (1.0 mg, 0.003 
mmol, 0.10 equiv) were dissolved in degassed CH2Cl2 (2 mL, 
0.02 M) and the reaction mixture was heated at 40 ºC for 12 
h. After this time, the solvent was removed under reduced 
pressure and the resulting crude product was purified by 
flash column chromatography (silica gel, 20% EtOAc in hexanes → 60% EtOAc in 
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hexanes) to obtain macrocycle 668 (9.0 mg, 47%) as a white solid: Rf  = 0.51 (silica gel, 
70% EtOAc in hexanes); [α]25 D = – 9.21 (c 0.08, MeOH); mp = 205-206 ºC; 1H NMR 
(400 MHz, MeOD) δ (ppm) 7.44 – 7.27 (m, 6 H), 7.08 (d, J = 2.6 Hz, 1 H), 6.85 (dd, J = 
8.7, 2.8 Hz, 1 H), 6.45 (d, J = 15.8 Hz, 1 H), 5.98 (ddd, J = 15.4, 7.5, 3.1 Hz, 1 H), 5.07 
(s, 2 H), 4.25 (q, J = 7.2 Hz, 1 H), 4.13 (td, J = 6.6, 3.7 Hz, 1 H), 3.96 (d, J = 14.6 Hz, 1 
H), 3.74 (d, J = 14.6 Hz, 1 H), 2.59 – 2.49 (m, 3 H), 1.54 (d, J = 7.2 Hz, 3 H), 1.15 (d, J 
= 7.2 Hz, 3 H), 0.95 (s, 9 H), 0.15 (overlap two singlets, 6 H); 13C NMR (100 MHz, 
MeOD) δ (ppm) 176.8, 171.6, 171.3, 158.2, 137.2, 134.5, 128.6, 128.1, 127.5, 127.2, 
126.3, 126.2, 125.4, 113.3, 112.3, 73.4, 69.7, 50.9, 46.3, 43.3, 38.9, 24.9, 17.5, 14.6, 12.0, 
-5.7, -6.1; HRMS (H-ESI) m/z: [M + Na]+ calcd for C31H43N3O5SiNa 588.2870; found 
588.2868. 
 
7.3.44. Synthesis of Diolefin 669 
Diolefin 669. To a solution of diolefin 654 (53 mg, 0.11 
mmol, 1.0 equiv) in CH2Cl2 (10 mL) was added 2,6-lutidine 
(30 µL, 0.28 mmol, 2.5 equiv) at 0 ºC and the mixture was 
stirred 10 min at this temperature. After this time TESOTf 
(0.06 mL, 0.30 mmol, 2.5 equiv) was added at 0 ºC and the 
mixture was stirred for 12 h at 25 ºC. Then, the reaction was 
quenched by addition of H2O. After decantation of the 
organic layer, the aqueous phase was extracted with EtOAc, 
and the combined organic layers were washed with brine, 
dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. 
The crude product was purified by flash column chromatography (silica gel, 15% EtOAc 
in hexanes → 60% EtOAc) to obtain diolefin 669 (45 mg, 68%) as a white solid: Rf  = 
0.80 (silica gel, 100% EtOAc); [α]25 D = – 9.41 (c 0.08, MeOH); mp = 92-93 ºC; 1H NMR 
(400 MHz, CDCl3) δ (ppm) 7.53 (d, J = 8.7 Hz, 1 H), 7.45 – 7.40 (m, 2 H), 7.39 – 7.33 
(m, 2 H), 7.31 (dt, J = 5.3, 2.1 Hz, 1 H), 7.06 (d, J = 2.6 Hz, 1 H), 6.89 (dd, J = 8.5, 2.4 
Hz, 1 H), 6.80 (dd, J = 17.5, 11.0 Hz, 1 H), 5.89 (dddd, J = 16.5, 10.3, 8.1, 6.1 Hz, 1 H), 
5.62 (dd, J = 17.5, 1.3 Hz, 1 H), 5.20 (dd, J = 11.0, 1.3 Hz, 1 H), 5.13 – 5.03 (m, 4 H), 
4.53 (q, J = 7.0 Hz, 1 H), 4.06 (d, J = 16.6 Hz, 1 H), 3.97 – 3.91 (m, 1 H), 3.74 (d, J = 
16.5 Hz, 1 H), 2.54 – 2.44 (m, 1 H), 2.40 – 2.22 (m, 2 H), 1.47 (d, J = 7.1 Hz, 3 H), 1.09 
(d, J = 7.0 Hz, 3 H), 0.95 (t, J = 7.9 Hz, 9 H), 0.61 (q, J = 7.6 Hz, 6 H); 13C NMR (100 
MHz, CDCl3) δ (ppm) 176.9, 172.7, 169.9, 158.7, 137.1, 134.9, 133.9, 131.6, 128.1, 
127.5, 127.2, 126.4, 125.9, 116.6, 113.4, 112.9, 112.0, 73.4, 69.7, 49.4, 46.1, 41.9, 38.5, 
16.7, 12.9, 5.9, 4.5; HRMS (H-ESI) m/z: [M + H]+ calcd for C33H48N3O5Si 594.3363; 
found 594.3359. 
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7.3.45. Synthesis of Cyclopeptide 670 
Cyclopeptide 670. Diolefin 669 (22 mg, 0.04 mmol, 1.0 
equiv), Hoveyda-Grubbs 2nd generation catalyst (2 mg, 0.004 
mmol, 0.10 equiv) and p-benzoquinone (1.0 mg, 0.004 mmol, 
0.10 equiv) were dissolved in degassed CH2Cl2 (2 mL, 0.02 
M) and the reaction mixture was heated at 40 ºC for 12 h. 
After this time, the solvent was removed under reduced 
pressure and the resulting crude product was purified by flash 
column chromatography (silica gel, 30% EtOAc in hexanes 
→ 60% EtOAc in hexanes) to obtain macrocycle 670 (11 mg, 53%) as a white solid: Rf  
= 0.28 (silica gel, 70% EtOAc in hexanes); [α]25 D = – 11.08 (c 0.09, MeOH); mp = 198-
199 ºC; 1H NMR (400 MHz, MeOD) δ (ppm) 7.44 – 7.40 (m, 2 H), 7.39 – 7.33 (m, 3 H), 
7.33 – 7.27 (m, 2 H), 7.08 (d, J = 2.6 Hz, 1 H), 6.85 (dd, J = 8.6, 2.5 Hz, 1 H), 6.46 (d, J 
= 15.7 Hz, 1 H), 6.02 – 5.93 (m, 1 H), 5.07 (s, 2 H), 4.24 (q, J = 7.1 Hz, 1 H), 4.14 (dd, J 
= 10.2, 6.6 Hz, 1 H), 3.95 (d, J = 14.6 Hz, 1 H), 3.74 (d, J = 14.4 Hz, 1 H), 2.65 – 2.46 
(m, 3 H), 1.54 (d, J = 7.2 Hz, 3 H), 1.17 (d, J = 7.2 Hz, 3 H), 1.02 (t, J = 7.9 Hz, 9 H), 
0.70 (q, J = 7.5 Hz, 6 H); 13C NMR (100 MHz, MeOD) δ (ppm) 176.8, 171.6, 171.3, 
158.1, 137.2, 134.5, 128.7, 128.1, 127.5, 127.2, 126.3, 126.0, 125.4, 113.3, 112.3, 73.2, 
69.9, 50.9, 46.3, 39.1, 29.3, 14.6, 12.2, 5.9, 4.4; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C31H44N3O5Si 566.3050; found 566.3067. 
 
7.3.46. Synthesis of Cyclopeptide 653 
Cyclopeptide 653. To a solution of macrocycle 670 (5.0 mg, 
0.01 mmol, 1.0 equiv) in THF (3 mL) was added at 0 ºC 
TBAF (18 µL, 1.0 M in THF, 0.018 mmol, 2.0 equiv). After 
95 min the solvent was removed under reduced pressure and 
the crude mixture was purified by preparative TLC (silica gel 
60 F254, 1 mm, 100% EtOAc) to obtain macrocycle 653 (3.4 
mg, 85%) as a white solid: Rf  = 0.27 (silica gel, 100% 
EtOAc); [α]25 D = – 7.72 (c 0.04, MeOH); mp = 201-202 ºC; 
1H NMR (400 MHz, MeOD) δ (ppm) 7.44 – 7.40 (m, 2 H), 7.38 – 7.32 (m, 3 H), 7.32 – 
7.27 (m, 1 H), 7.19 (d, J = 2.6 Hz, 1 H), 6.85 (dd, J = 8.6, 2.6 Hz, 1 H), 6.41 (d, J = 15.4 
Hz, 1 H), 6.00 (dt, J = 15.4, 7.4 Hz, 1 H), 5.08 (s, 2 H), 4.55 (s, 1 H), 4.45 (q, J = 7.1 Hz, 
1 H), 4.06 (d, J = 14.9 Hz, 1 H), 3.87 (td, J = 6.8, 2.9 Hz, 1 H), 3.72 (d, J = 14.9 Hz, 1 
H), 2.56 – 2.50 (m, 3 H), 1.47 (d, J = 7.2 Hz, 3 H), 1.25 (d, J = 7.2 Hz, 3 H); 13C NMR 
(100 MHz, MeOD) δ (ppm) 176.7, 171.6, 170.7, 158.3, 137.1, 134.5, 128.9, 128.1, 127.6, 
127.5, 127.2, 126.7, 125.1, 113.0, 111.3, 72.3, 69.8, 50.1, 44.9, 42.9, 39.2, 15.3, 13.5; 
HRMS (H-ESI) m/z: [M + H]+ calcd for C25H30N3O5 452.2186; found 452.2170. 
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7.3.47. Synthesis of Homoallylic Alcohol 673 
Homoallylic Alcohol 673. A solution of aldehyde 635 (395 mg, 
1.54 mmol, 1.0 equiv) in CH2Cl2 (15 mL) was cooled to 0 ºC and 
SnCl4 (0.8 mL, 0.77 mmol, 0.5 equiv, 1.0 M in CH2Cl2) was added 
slowly over 10 min at this temperature and then stirred for 10 min 
at 25 ºC. Allyl trimethylsilane (0.35 mL, 2.30 mmol, 1.5 equiv) 
was added quickly and the reaction was stirred for 15 min, poured into Et2O and after 
decantation the organic phase was washed with brine, dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure. The crude product was 
purified by flash column chromatography (silica gel, 5% EtOAc in Hexanes) to obtain 
the homoallylic alcohol 673 (340 mg, 74%) as a yellow solid: Rf  = 0.67 (silica gel, 40% 
EtOAc in hexanes); mp = 74-75 ºC; 1H NMR (400 MHz, CDCl3) δ (ppm) 7.71 (d, J = 8.8 
Hz, 1 H), 7.52 (d, J = 2.7 Hz, 1 H), 7.46 – 7.34 (m, 5 H), 7.26 – 7.23 (m, 1 H), 5.88 (dddd, 
J = 16.9, 10.5, 7.8, 6.4 Hz, 1 H), 5.26 – 5.19 (m, 2 H), 5.17 (t, J = 1.1 Hz, 1 H), 5.12 (s, 
2 H), 2.67 (dddt, J = 14.0, 6.4, 3.8, 1.3 Hz, 1 H), 2.47 – 2.34 (m, 2 H); 13C NMR (100 
MHz, CDCl3) δ (ppm) 158.0, 148.4, 135.8, 134.2, 131.5, 129.3, 128.8, 128.4, 127.6, 
120.8, 118.9, 109.9, 70.7, 68.2, 42.8; HRMS (H-ESI) m/z: [M + H]+ calcd for C17H18NO4 
300.1236; found 300.1238.  
 
7.3.48. Synthesis of Benzyloxymethyl Acetal 674 
Benzyloxymethyl Acetal 674. To a solution of the homoallylic 
alcohol 673 (226 mg, 0.76 mmol, 1.0 equiv) in CH2Cl2 (10 mL) 
was added DIPEA (0.52 mL, 3.02 mmol, 4.0 equiv) and BOMCl 
(0.56 mL, 3.02 mmol, 4.0 equiv) at 0 ºC and the mixture was 
stirred at 25 ºC for 15 h. After this time, the reaction was quenched 
by addition of saturated aqueous Na2CO3 solution and the crude mixture was stirred for 
30 min. Then, the aqueous phase was extracted with CH2Cl2 and the organic phase 
washed with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated 
under reduced pressure. The resulting residue was purified by flash column 
chromatography (silica gel, 3% EtOAc in hexanes) to obtain benzyloxymethyl acetal 674 
(280 mg, 88%) as a pale yellow oil: Rf  = 0.50 (silica gel, 20% EtOAc in hexanes); 
1H 
NMR (400 MHz, CDCl3) δ (ppm) 7.67 (d, J = 8.7 Hz, 1 H), 7.53 (d, J = 2.6 Hz, 1 H), 
7.46 – 7.22 (m, 11 H), 5.94 (ddt, J = 17.1, 10.1, 7.0 Hz, 1 H), 5.35 (dd, J = 8.0, 4.2 Hz, 1 
H), 5.15 (dd, J = 17.0, 1.7 Hz, 2 H), 5.11 (s, 2 H), 4.91 (d, J = 9.0 Hz, 1 H), 4.71 (dd, J = 
21.3, 5.5 Hz, 2 H), 4.66 (s, 1 H), 4.59 (d, J = 6.9 Hz, 1 H), 4.47 (d, J = 11.8 Hz, 1 H), 
2.67 – 2.59 (m, 1 H), 2.57 – 2.48 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 158.1, 
148.9, 137.6, 135.8, 134.3, 130.3, 129.7, 128.8, 128.4, 128.4, 127.8, 127.7, 127.6, 120.8, 
117.8, 109.7, 93.1, 73.3, 70.7, 69.8, 42.0; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C25H26NO5 420.1811; found 420.1815. 
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7.3.49. Synthesis of Aniline 675 
Aniline 675. To a solution of benzyloxymethyl acetal 674 (280 
mg, 0.67 mmol, 1.0 equiv) in EtOH (6 mL) was added a solution 
of NH4Cl (179 mg, 3.34 mmol, 5.0 equiv) in water (4 mL) 
followed by Zn dust (655 mg, 10.01 mmol, 15.0 equiv) in seven 
portions of 100 mg each over 30 min at 25 ºC. The mixture was 
stirred at this temperature for 15 h and then the reaction mixture was diluted with CH2Cl2 
and water, filtered and rinsed with CH2Cl2. The filtrate was diluted with water and 
extracted with CH2Cl2, and the organic phase washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The resulting residue 
was purified by flash column chromatography (silica gel, 10% EtOAc in hexanes) to 
obtain aniline 675 (217 mg, 87%) as a yellow oil: Rf  = 0.60 (silica gel, 30% EtOAc in 
hexanes); 1H NMR (400 MHz, CDCl3) δ (ppm) 7.41 – 7.30 (m, 10 H), 6.94 (d, J = 8.4 
Hz, 1 H), 6.34 (dd, J = 8.3, 2.5 Hz, 1 H), 6.28 (d, J = 2.5 Hz, 1 H), 5.81 (ddt, J = 17.2, 
10.1, 7.0 Hz, 1 H), 5.12 (ddd, J = 17.1, 3.4, 1.4 Hz, 1 H), 5.05 (ddt, J = 10.2, 2.1, 1.0 Hz, 
1 H), 5.01 (s, 2 H), 4.90 (d, J = 9.1 Hz, 1 H), 4.73 – 4.71 (m, 2 H), 4.67 – 4.63 (m, 1 H), 
4.52 (d, J = 11.7 Hz, 1 H), 4.20 (bs, 2 H), 2.83 – 2.74 (m, 1 H), 2.62 – 2.53 (m, 1 H); 13C 
NMR (100 MHz, CDCl3) δ (ppm) 159.5, 146.5, 137.8, 137.2, 135.3, 130.6, 128.6, 128.4, 
128.0, 127.9, 127.7, 127.5, 117.1, 116.9, 104.1, 102.9, 91.9, 77.9, 69.8, 69.7, 38.7; HRMS 
(H-ESI) m/z: [M + H]+ calcd for C25H28NO3 390.2069; found 390.2071. 
 
7.3.50. Synthesis of Peptide 676 
Peptide 676. To a solution of aniline 675 (217 mg, 0.56 
mmol, 1.0 equiv) and Fmoc-D-Ala-OH (629) (225 mg, 0.72 
mmol, 1.3 equiv) in CH2Cl2 (10 mL) was added PyBOP (435 
mg, 0.84 mmol, 1.5 equiv) and DIPEA (0.2 mL, 1.11 mmol, 
2.0 equiv) at 0 ºC and the mixture was stirred for 15 h at 25 
ºC. After this time, a saturated aqueous NH4Cl solution was 
added and the organic layer was separated. The aqueous phase was extracted with EtOAc, 
and the combined organic layers were washed with brine, dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure. The crude product was 
purified by flash column chromatography (silica gel, 30% EtOAc in hexanes) to obtain 
peptide 676 (247 mg, 65%, 1:1 mixture of diastereoisomers) as a white foam. Data 
assigned for the mixture of diastereoisomers: Rf  = 0.20 (silica gel, 30% EtOAc in 
hexanes); 1H NMR (400 MHz, CDCl3) δ (ppm) 9.32 (d, J = 11.0 Hz, 1 H), 8.03 (d, J = 
8.7 Hz, 1 H), 7.77 (d, J = 7.4 Hz, 2 H), 7.61 (d, J = 6.0 Hz, 2 H), 7.47 – 7.27 (m, 13 H), 
7.21 (dd, J = 7.2, 5.5 Hz, 2 H), 7.02 (d, J = 8.4 Hz, 1 H), 6.69 (dd, J = 8.4, 2.5 Hz, 1 H), 
5.72 (td, J = 16.8, 6.9 Hz, 1 H), 5.40 (d, J = 6.5 Hz, 1 H), 5.13 – 5.01 (m, 4 H), 4.77 – 
4.64 (m, 3 H), 4.64 – 4.56 (m, J = 11.4, 8.2 Hz, 1 H), 4.54 – 4.45 (m, 1 H), 4.43 – 4.32 
(m, 2 H), 4.23 (dd, J = 14.3, 7.2 Hz, 1 H), 2.73 – 2.61 (m, 1 H), 2.53 – 2.40 (m, 1 H), 1.51 
– 1.42 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 170.3, 159.1, 159.0, 155.8, 143.8, 
141.3, 137.3, 137.2, 136.8, 134.2, 134.1, 129.9, 129.9, 128.5, 128.5, 128.4, 127.9, 127.9, 
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127.9, 127.9, 127.9, 127.8, 127.6, 127.1, 125.2, 125.0, 120.0, 117.9, 117.8, 111.1, 108.3, 
108.1, 92.4, 78.6, 70.1, 70.0, 67.1, 51.6, 47.1, 39.9, 39.9, 18.9, 18.9; HRMS (H-ESI) m/z: 
[M + H]+ calcd for C43H43N2O6 683.3121; found 683.3115. 
 
7.3.51. Synthesis of Dipeptide 677 
Dipeptide 677. To a solution of peptide 676 (176 mg, 0.26 
mmol, 1.0 equiv) in CH2Cl2 (5 mL) was added piperidine 
(0.13 mL, 1.29 mmol, 5.0 equiv) and the reaction mixture 
was stirred at 25 ºC for 5 h. After this time, the organic 
solvent was removed under redued pressure and the 
resulting crude product was purified by fash column 
chromatography (silica gel, 30% EtOAc in hexanes → 60% 
EtOAc in hexanes) to obtain the corresponding amine (110 mg, 93%, 1:1 mixture of 
diastereoisomers) as a white solid. Data assigned for the mixture of diastereoisomers: Rf  
= 0.18 (silica gel, 80% EtOAc in hexanes); mp = 82-83 ºC; 1H NMR (400 MHz, CDCl3) 
δ (ppm) 8.15 – 8.01 (m, 1 H), 7.48 – 7.21 (m, 12 H), 7.12 – 6.99 (m, 1 H), 6.74 – 6.62 
(m, 1 H), 5.84 – 5.67 (m, 1 H), 5.13 – 4.99 (m, 5 H), 4.83 – 4.64 (m, 4 H), 4.58 – 4.45 
(m, 1 H), 3.76 (bs, 1 H), 2.71 (dt, J = 14.8, 8.0 Hz, 1 H), 2.50 (dt, J = 13.6, 6.6 Hz, 1 H), 
1.53 – 1.25 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ (ppm) 172.3, 171.9, 159.1, 159.0, 
137.6, 137.5, 137.5, 137.5, 137.4, 137.3, 137.3, 137.3, 136.9, 136.9, 134.5, 134.4, 128.5, 
128.5, 128.5, 128.5, 128.1, 128.0, 127.9, 127.9, 127.6, 121.4, 121.2, 117.8, 117.7, 110.8, 
110.6, 108.5, 108.2, 92.3, 92.3, 70.1, 70.0, 69.9, 61.4, 61.2, 51.4, 51.3, 40.1, 39.9, 16.4, 
15.8. To a solution of the amine obtained above (105 mg, 0.23 mmol, 1.0 equiv) and 
Fmoc-Gly-OH (630) (88 mg, 0.30 mmol, 1.3 equiv) in CH2Cl2 (5 mL) was added HATU 
(130 mg, 0.34 mmol, 1.5 equiv) and DIPEA (0.1 mL, 0.46 mmol, 2.0 equiv) at 0 ºC and 
the mixture was stirred for 15 h at 25 ºC. After this time, a saturated aqueous NH4Cl 
solution was added and the organic layer was separated. The aqueous phase was extracted 
with EtOAc, and the combined organic layers were washed with brine, dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, 15% EtOAc in hexanes 
→ 40% EtOAc in hexanes) to obtain peptide 677 (123 mg, 73%, 1:1 mixture of 
diastereoisomers) as a white foam. Data assigned for the mixture of diastereoisomers: Rf  
= 0.27 (silica gel, 50% EtOAc in hexanes); 1H NMR (400 MHz, CDCl3) δ (ppm) 7.99 – 
7.96 (m, 1 H), 7.75 (dd, J = 7.5, 3.4 Hz, 2 H), 7.59 (d, J = 7.3 Hz, 2 H), 7.45 – 7.23 (m, 
16 H), 7.03 (t, J = 8.9 Hz, 1 H), 6.71 – 6.66 (m, 1 H), 5.72 (ttd, J = 13.7, 7.0, 3.3 Hz, 1 
H), 5.53 (bs, 1 H), 5.13 – 5.06 (m, 2 H), 5.04 (s, 2 H), 4.77 – 4.55 (m, 6 H), 4.44 (d, J = 
6.8 Hz, 2 H), 4.22 (t, J = 6.9 Hz, 1 H), 3.97 – 3.78 (m, 2 H), 2.64 (dt, J = 16.3, 7.0 Hz, 1 
H), 2.44 (ddd, J = 20.6, 13.8, 6.5 Hz, 1 H), 1.49 – 1.44 (m, 3 H); 13C NMR (100 MHz, 
CDCl3) δ (ppm) 174.6, 170.1, 170.0, 165.6, 159.1, 159.1, 156.8, 156.7, 143.7, 143.7, 
141.3, 141.3, 137.2, 136.8, 134.2, 134.2, 130.0, 129.9, 128.6, 128.1, 128.1, 128.0, 127.8, 
127.7, 127.6, 127.1, 127.0, 125.1, 125.0, 121.3, 121.2, 120.0, 119.9, 117.9, 117.9, 111.2, 
111.2, 108.5, 108.3, 92.6, 92.5, 78.3, 77.8, 70.3, 70.2, 70.1, 65.4, 49.9, 47.1, 44.5, 38.7, 
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18.4, 18.3; HRMS (H-ESI) m/z: [M + H]+ calcd for C45H46N3O7 740.3336; found 
740.3327. 
 
7.3.52. Synthesis of Diolefin 679 
Diolefin 679. To a solution of peptide 677 (63 mg, 0.09 
mmol, 1.0 equiv) in CH2Cl2 (5 mL) was added piperidine 
(0.04 mL, 0.43 mmol, 5.0 equiv) and the reaction mixture 
was stirred at 25 ºC 5 h. After this time, the organic solvent 
was removed under reduced pressure and the resulting crude 
amine was used in the next step without purification. To a 
solution of the crude amine (0.09 mmol) and acid 678 (10 
µL, 0.11 mmol, 1.3 equiv) in CH2Cl2 (5 mL) was added HATU (49 mg, 0.13 mmol, 1.5 
equiv) and DIPEA (30 µL, 0.17 mmol, 2.0 equiv) at 0 ºC and the mixture was stirred for 
12 h at 25 ºC. After this time, a saturated aqueous NH4Cl solution was added and the 
organic layer was separated. The aqueous phase was extracted with EtOAc, and the 
combined organic layers were washed with brine, dried over anhydrous MgSO4, filtered 
and the solvent evaporated under reduced pressure. The crude product was purified by 
flash column chromatography (silica gel, 30% EtOAc in hexanes → 100% EtOAc) to 
obtain diolefin 679 (32 mg, 64% over 2 steps, 1:1 mixture of diastereoisomers) as a white 
solid. Data assigned for the mixture of diastereoisomers: Rf = 0.62 (silica gel, 100% 
EtOAc); mp = 95-96 ºC; 1H NMR (400 MHz, CDCl3) δ (ppm) 7.95 (t, J = 2.6 Hz, 1 H), 
7.46 – 7.27 (m, 12 H), 7.03 (t, J = 8.6 Hz, 1 H), 6.85 (s, 1 H), 6.69 (dt, J = 8.4, 2.8 Hz, 1 
H), 5.99 – 5.84 (m, 1 H), 5.80 – 5.65 (m, 1 H), 5.27 – 5.19 (m, 2 H), 5.16 – 5.06 (m, 2 
H), 5.05 (s, 2 H), 4.76 – 4.63 (m, 4 H), 4.56 – 4.46 (m, 2 H), 4.03 – 3.95 (m, 2 H), 3.07 – 
3.00 (m, 2 H), 2.65 (ddd, J = 15.3, 13.9, 7.7 Hz, 1 H), 2.44 (ddd, J = 20.9, 13.1, 6.4 Hz, 
1 H), 1.49 – 1.43 (m, 3 H);  13C NMR (100 MHz, CDCl3) δ (ppm) 174.5, 171.8, 171.4, 
170.1, 168.8, 165.7, 160.2, 159.1, 140.9, 137.2, 137.1, 136.8, 136.8, 134.3, 134.2, 130.7, 
129.9, 129.9, 128.8, 128.6, 128.1, 128.1, 128.0, 127.7, 127.7, 127.6, 127.0, 120.2, 120.1, 
117.9, 117.8, 111.2, 111.1, 108.6, 108.4, 92.7, 92.5, 78.8, 70.3, 70.3, 70.2, 70.1, 50.1, 
50.1, 43.1, 43.0, 41.2, 41.2, 38.7, 18.3, 18.2; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C34H40N3O6 586.2917; found 586.2905. 
 
7.3.53. Synthesis of Alkene 683 
Alkene 683. Alkene 683 was prepared from alcohol 682305 (1.6 g, 4.46 
mmol, 1.0 equiv) by sequential treatments with SO3·pyr and 
Ph3P=CH2 according to the same procedure described above for the 
preparation of 460, to obtain alkene 683 (840 mg, 53% over two steps) 
as a pale yellow oil: Flash column chromatography (silica gel, 5% 
EtOAc in hexanes); Rf = 0.20 (silica gel, 40% EtOAc in hexanes);
 [α]25 
D = + 18.51 (c 0.20, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.86 (ddd, J = 7.4, 5.9, 1.3 
Hz, 2 H), 7.70 – 7.64 (m, 1 H), 7.49 – 7.44 (m, 1 H), 6.02 – 5.90 (m, 1 H), 5.50 (d, J = 
8.2 Hz, 1 H), 5.24 (s, 1 H), 5.22 – 5.18 (m, 1 H), 4.17 (t, J = 8.0 Hz, 1 H), 1.60 (s, 3 H), 
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1.55 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 133.7, 133.2, 132.4, 128.8, 128.5, 124.5, 
119.7, 109.8, 85.6, 77.2, 77.2, 27.2, 26.9; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C20H22NO5 356.1498; found 356.1497. 
 
7.3.54. Synthesis of Aniline 684 
Aniline 684. To a solution of nitro derivative 683 (532 mg, 2.14 mmol, 
1.0 equiv) in EtOH (18 mL) was added a solution of NH4Cl (570 mg, 
10.68 mmol, 5.0 equiv) in water (13 mL) followed by Zn dust (2.0 g, 
32.0 mmol, 15.0 equiv) in ten portions of 200 mg each over 30 min 
at 25 ºC. The mixture was stirred at this temperature for 16 h and then 
the reaction mixture was diluted with CH2Cl2 and water, filtered and 
rinsed with CH2Cl2. The filtrate was diluted with water and extracted with CH2Cl2, and 
the organic phase washed with brine, dried over anhydrous MgSO4, filtered and the 
solvent evaporated under reduced pressure. The resulting residue was purified by flash 
column chromatography (silica gel, 10% EtOAc in hexanes) to obtain aniline 684 (417 
mg, 60%) as a colorless oil: Rf  = 0.55 (silica gel, 30% EtOAc in hexanes); [α]25 D = + 9.43 
(c 0.15, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.19 – 7.11 (m, 1 H), 7.12 – 7.06 (m, 1 
H), 6.84 – 6.74 (m, 2 H), 5.88 (ddd, J = 17.1, 10.4, 6.7 Hz, 1 H), 5.34 (dt, J = 17.2, 1.2 
Hz, 1 H), 5.26 (dd, J = 10.4, 0.9 Hz, 1 H), 4.74 (d, J = 8.7 Hz, 1 H), 4.65 – 4.59 (m, 1 H), 
1.60 (s, 3 H), 1.53 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 134.5, 129.4, 129.0, 120.1, 
119.3, 117.7, 109.2, 82.8, 80.4, 77.2, 27.3, 26.8; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C20H24NO3 326.1756; found 326.1755. 
 
7.3.55. Synthesis of Peptide 685 
Peptide 685. Amine 684 (260 mg, 1.19 mmol, 1.0 equiv), Fmoc-
D-Ala-OH (629) (480 mg, 1.54 mmol, 1.3 equiv), HATU (676 
mg, 1.78 mmol, 1.5 equiv) were dissolved in CH2Cl2 (15 mL) 
and to the resulting solution was added DIPEA (0.41 mL, 2.37 
mmol, 2.0 equiv). The reaction mixture was stirred at 25 ºC for 
12 h. Then, a saturated aqueous NH4Cl solution was added and 
the aqueous phase was extracted with EtOAc, and the combined 
organic layers were washed with brine, dried over anhydrous MgSO4, filtered and the 
solvent evaporated under reduced pressure. The crude product was purified by flash 
column chromatography (silica gel, 10% EtOAc in hexanes → 20% EtOAc in hexanes) 
to obtain peptide 685 (490 mg, 81%) as a white foam: Rf  = 0.50 (silica gel, 40% EtOAc); 
[α]25 D = + 16.79 (c 0.15, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 9.09 (bs, 1 H), 8.16 (d, 
J = 8.3 Hz, 1 H), 7.76 (d, J = 7.5 Hz, 2 H), 7.59 (d, J = 4.0 Hz, 2 H), 7.45 – 7.27 (m, 6 
H), 7.20 (d, J = 7.4 Hz, 1 H), 7.12 (dd, J = 11.2, 4.7 Hz, 1 H), 5.94 – 5.79 (m, 1 H), 5.68 
– 5.54 (m, 1 H), 5.38 – 5.24 (m, 2 H), 4.78 (d, J = 8.8 Hz, 1 H), 4.53 – 4.28 (m, 5 H), 1.65 
(s, 3 H), 1.57 – 1.49 (m, 6 H); 13C NMR (100 MHz, CDCl3) δ 170.4, 155.8, 143.8, 141.3, 
141.3, 136.4, 133.8, 129.2, 128.3, 127.8, 127.8, 127.1, 125.1, 125.0, 124.5, 124.5, 122.8, 
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120.0, 109.5, 82.2, 81.8, 67.1, 51.5, 47.2, 30.9, 27.3, 26.7, 19.3; HRMS (H-ESI) m/z: [M 
+ H]+ calcd for C31H33N2O5 513.2389; found 513.2387. 
 
7.3.56. Synthesis of Dipeptide 686 
Dipeptide 686. Piperidine (0.5 mL, 4.78 mmol, 5.0 equiv) was 
added to a solution of peptide 685 (490 mg, 0.96 mmol, 1.0 
equiv) in CH2Cl2 (15 mL) and the reaction mixture was stirred 
at 25 ºC for 4 h. After this time, the organic solvent was 
removed under reduced pressure to obtain the corresponding 
crude amine (~0.90 mmol) which was used in the next step 
without further purification. The crude amine obtained above 
(~0.90 mmol), Fmoc-Gly-OH (630) (347 mg, 1.17 mmol, 1.3 equiv), HATU (513 mg, 
1.35 mmol, 1.5 equiv) were dissolved in CH2Cl2 (20 mL) and to the resulting solution 
was added DIPEA (0.31 mL, 1.80 mmol, 2.0 equiv). The reaction mixture was stirred at 
25 ºC for 12 h. Then, a saturated aqueous NH4Cl solution was added and the aqueous 
phase was extracted with EtOAc, and the combined organic layers were washed with 
brine, dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (silica gel, 
30% EtOAc in hexanes → 60% EtOAc in hexanes) to obtain dipeptide 686 (426 mg, 78% 
over 2 steps) as a white foam: Rf  = 0.55 (silica gel, 80% EtOAc); [α]25 D = + 9.13 (c 0.20, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 9.12 (bs, 1 H), 8.12 (d, J = 8.1 Hz, 1 H), 7.76 (d, 
J = 7.5 Hz, 2 H), 7.59 (d, J = 7.3 Hz, 2 H), 7.39 (t, J = 7.4 Hz, 2 H), 7.32 (dt, J = 10.9, 
4.5 Hz, 3 H), 7.19 (d, J = 7.1 Hz, 1 H), 7.11 (t, J = 7.1 Hz, 1 H), 6.87 (d, J = 6.8 Hz, 1 H), 
5.87 (ddd, J = 17.2, 10.4, 6.8 Hz, 1 H), 5.54 (bs, 1 H), 5.30 (t, J = 14.7 Hz, 2 H), 4.79 (d, 
J = 8.7 Hz, 1 H), 4.56 (p, J = 6.9 Hz, 1 H), 4.41 (d, J = 7.1 Hz, 3 H), 4.22 (t, J = 7.0 Hz, 
1 H), 3.94 (p, J = 11.5 Hz, 2 H), 1.66 (s, 3 H), 1.56 (s, 3 H), 1.51 (d, J = 7.0 Hz, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 170.0, 168.5, 165.8, 156.6, 143.8, 141.3, 136.3, 133.7, 129.2, 
128.4, 127.8, 127.1, 125.1, 124.7, 124.5, 122.8, 120.0, 119.9, 109.5, 82.3, 81.9, 67.3, 
49.9, 47.1, 44.4, 38.6, 27.3, 26.7, 18.9; HRMS (H-ESI) m/z: [M + H]+ calcd for 
C33H36N3O6 570.2604; found 570.2602. 
 
7.3.57. Synthesis of Dialkene 687 
Dialkene 687. Piperidine (0.34 mL, 3.50 mmol, 5.0 equiv) was 
added to a solution of peptide 686 (400 mg, 0.70 mmol, 1.0 
equiv) in CH2Cl2 (15 mL) and the reaction mixture was stirred at 
25 ºC for 4.5 h. After this time, the organic solvent was removed 
under reduced pressure to obtain the corresponding crude amine 
(~0.70 mmol) which was used in the next step without further 
purification. The crude amine obtained above (~0.70 mmol), 
vinyl acetic acid 678 (0.1 mL, 0.91 mmol, 1.3 equiv), HATU (400 mg, 1.05 mmol, 1.5 
equiv) were dissolved in CH2Cl2 (15 mL) and to the resulting solution was added DIPEA 
(0.28 mL, 1.40 mmol, 2.0 equiv). The reaction mixture was stirred at 25 ºC for 15 h. Then, 
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a saturated aqueous NH4Cl solution was added and the aqueous phase was extracted with 
EtOAc, and the combined organic layers were washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes → 
100% EtOAc in hexanes) to obtain peptide 687 (174 mg, 60% over 2 steps) as a white 
foam: Rf  = 0.30 (silica gel, 100% EtOAc); [α]25 D = + 13.48 (c 0.10, CH2Cl2); 1H NMR 
(400 MHz, CDCl3) δ 9.12 (bs, 1 H), 8.10 (d, J = 8.0 Hz, 1 H), 7.37 – 7.30 (m, 1 H), 7.20 
(d, J = 6.5 Hz, 1 H), 7.11 (t, J = 7.5 Hz, 1 H), 6.93 (d, J = 6.7 Hz, 1 H), 6.44 (t, J = 4.9 
Hz, 1 H), 6.00 – 5.81 (m, 2 H), 5.37 – 5.19 (m, 4 H), 4.79 (d, J = 8.7 Hz, 1 H), 4.53 (p, J 
= 7.0 Hz, 1 H), 4.47 – 4.37 (m, 1 H), 3.99 (dd, J = 5.1, 1.3 Hz, 2 H), 3.06 (d, J = 7.1 Hz, 
2 H), 1.66 (s, 3 H), 1.56 (s, 3 H), 1.50 (d, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) 
δ 171.1, 170.1, 168.4, 136.3, 133.7, 130.8, 129.2, 128.4, 124.7, 124.6, 122.9, 120.2, 119.9, 
109.5, 82.2, 81.9, 49.9, 43.0, 41.2, 27.3, 26.7, 18.8; HRMS (H-ESI) m/z: [M + H]+ calcd 
for C22H30N3O5 416.2186; found 416.2184. 
 
7.3.58. Synthesis of Cyclopeptide 690 
Cyclopeptide 690. To a stirred solution of macrocycle 615 
(28 mg, 0.07 mmol, 1.0 equiv) in THF (10 mL) at -78 ºC was 
added condensed liquid NH3 (8 mL) via cannula. Then, 
small pieces of Na (130 mg, 5.61 mmol, 85 equiv) were added 
to the mixture until the formation of a deep blue solution. The 
reaction was stirred at -78 ºC for 2 h and after this time it was 
quenched by slowly addition of MeOH at the same temperature. The mixture was allowed 
to reach room temperature and concentrated under reduced pressure to a volume of 10 
mL. The reaction was neutralized with Dowex-H+, washed with MeOH and concentrated 
under reduced pressure. The crude product was purified by flash column chromatography 
(silica gel, 7% MeOH in CH2Cl2) to obtain macrocycle 690 (18 mg, 85%) as a white solid: 
Rf  = 0.34 (silica gel, 10% MeOH in CH2Cl2); [α]25 D = – 6.77 (c 0.09, MeOH);  mp = 125-
126 ºC; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 9.30 (bs, 1 H), 8.51 (d, J = 7.2 Hz, 1 H), 
8.38 (bs, 1 H), 7.03 (d, J = 2.4 Hz, 1 H), 6.91 (d, J = 8.2 Hz, 1 H), 6.49 (dd, J = 8.2, 2.5 
Hz, 1 H), 5.40 (dt, J = 15.1, 5.0 Hz, 1 H), 5.07 (dt, J = 15.1, 5.7 Hz, 1 H), 4.32 (p, J = 7.0 
Hz, 1 H), 4.11 (bs, 1 H), 3.84 (dd, J = 14.8, 6.4 Hz, 1 H), 3.43 (dd, J = 14.8, 5.6 Hz, 1 H), 
3.16 – 3.09 (m, 1 H), 2.96 (dd, J = 16.4, 5.2 Hz, 1 H), 2.28 – 2.08 (m, 4 H), 1.29 (d, J = 
7.1 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ 173.1, 171.2, 170.9, 156.3, 136.9, 131.4, 
131.0, 127.8, 123.7, 112.7, 112.4, 49.7, 49.1, 43.4, 33.8, 27.9, 16.9; HRMS (H-ESI) m/z: 
[M + H]+ calcd for C17H22N3O4 332.1610; found 332.1618. 
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7.3.59. Synthesis of Oxazolidinone 696 
Oxazolidinone 696. n-Bu2BOTf (11.6 mL, 1.0 M in 
CH2Cl2, 11.63 mmol, 1.25 equiv) and freshly dry DIPEA 
(2.25 mL, 13.02 mmol, 1.4 equiv) was added sequentially 
over 15 min to a solution of oxazolidinone 694 (2.2 g, 9.30 
mmol, 1.0 equiv) in CH2Cl2 (15 mL) at 0 ºC. The solution 
was cooled to -78 ºC and aldehyde 695 (2.2 g, 11.18 mmol, 
1.2 equiv) was added slowly. After 30 min at -78 ºC, the reaction mixture was stirred at -
20 ºC for 12 h. After this time, the system was placed in an ice bath at 0 ºC and quenched 
with pH 7 phosphate buffer (8 mL) followed by MeOH (20 mL). Then, a mixture of 
MeOH/30% H2O2 (3:1, 20 mL) was added over 30 min and the mixture was stirred for 
30 min maintaining the temperature at 0 ºC. The organic solvent was removed under 
vaccum and the residue was extracted with CH2Cl2 three times. The combined organic 
layers were washed successively with 1 N HCl solution twice (14 mL), saturated aqueous 
NaHCO3 solution (14 mL) and brine, then dried over MgSO4, filtered and concentrated. 
The crude product was purified by flash column chromatography (silica gel, 5% EtOAc 
in hexanes → 10% EtOAc in hexanes) to obtain to obtain 696 (3.4 g, 84%) as a colorless 
oil: Rf  = 0.30 (silica gel, 30% EtOAc in hexanes); [α]25 D = + 12.9 (c 0.85, CH2Cl2); 1H 
NMR (400 MHz, CDCl3) δ 7.37 – 7.28 (m, 3 H), 7.23 – 7.19 (m, 2 H), 5.87 (dtd, J = 15.4, 
4.5, 1.4 Hz, 1 H), 5.72 (ddt, J = 15.4, 5.6, 1.6 Hz, 1 H), 4.70 (ddt, J = 9.4, 7.3, 3.2 Hz, 1 
H), 4.56 – 4.51 (m, 1 H), 4.27 – 4.17 (m, 4 H), 3.86 (qd, J = 7.0, 3.5 Hz, 1 H), 3.26 (dd, 
J = 13.4, 3.4 Hz, 1 H), 2.80 (dd, J = 13.3, 9.4 Hz, 1 H), 1.26 (d, J = 7.1 Hz, 3 H), 0.91 (s, 
9 H), 0.07 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 176.7, 153.1, 135.1, 131.8, 129.5, 
129.0, 128.7, 127.5, 72.0, 66.2, 63.1, 55.2, 42.8, 37.8, 25.9, 18.4, 11.1, -5.2; HRMS (H-
ESI) m/z: [M + H]+ calcd for C23H36NO5Si 434.2363; found 434.2364. 
 
7.3.60. Synthesis of Oxazolidinone 697 
Oxazolidinone 697. To a solution of oxazolidinone 696 
(580 mg, 1.34 mmol, 1.0 equiv) in CH2Cl2 (15 mL) was 
added DIPEA (0.93 mL, 5.35 mmol, 4.0 equiv) and BOMCl 
(1.0 mL, 5.35 mmol, 4.0 equiv) at 0 ºC and the mixture was 
stirred at 25 ºC for 15 h. After this time, the reaction was 
quenched by addition of saturated aqueous Na2CO3 solution 
and the crude mixture was stirred for 30 min. Then, the aqueous phase was extracted with 
CH2Cl2 and the organic phase washed with brine, dried over anhydrous MgSO4, filtered 
and the solvent evaporated under reduced pressure. The resulting residue was purified by 
flash column chromatography (silica gel, 10% EtOAc in hexanes) to obtain oxazolidinone 
697 (346 mg, 47%) as a pale yellow oil: Rf  = 0.60 (silica gel, 30% EtOAc in hexanes); 
[α]25 D = + 22.1 (c 0.31, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.27 (m, 8 H), 
7.20 – 7.16 (m, 2 H), 5.83 (ddd, J = 16.0, 4.7, 4.0 Hz, 1 H), 5.67 (ddt, J = 15.5, 7.7, 1.7 
Hz, 1 H), 4.78 – 4.67 (m, 3 H), 4.52 – 4.38 (m, 3 H), 4.18 (dd, J = 4.3, 1.7 Hz, 2 H), 4.06 
(ddd, J = 11.2, 7.9, 4.1 Hz, 2 H), 3.94 – 3.87 (m, 1 H), 3.26 (dd, J = 13.3, 3.2 Hz, 1 H), 
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2.72 (dd, J = 13.3, 9.8 Hz, 1 H), 1.30 (d, J = 6.9 Hz, 3 H), 0.89 (s, 9 H), 0.05 (s, 3 H), 
0.05 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 174.3, 153.3, 137.9, 135.4, 134.5, 129.4, 
128.9, 128.4, 127.6, 127.6, 127.3, 126.7, 91.9, 77.5, 69.4, 65.9, 62.9, 55.6, 42.6, 37.8, 
25.9, 18.4, 12.4, -5.2; HRMS (H-ESI) m/z: [M + H]+ calcd for C31H44NO6Si 554.2938; 
found 554.2937. 
 
7.3.61. Synthesis of Alcohol 698 
Alcohol 698. LiBH4 (1.25 mL, 2.0 M THF, 2.50 mmol, 4.0 equiv) 
was added to a solution of oxazolidinone 697 (346 mg, 0.63 
mmol, 1.0 equiv) in Et2O (15 mL) at 0 ºC followed by MeOH 
(0.1 mL, 2.50 mmol, 4.0 equiv). The resulting reaction mixture 
was stirred for 1 h at 0 ºC. After this time, a saturated aqueous NaHCO3 solution was 
added, and the residue was extracted with Et2O three times. The combined organic phases 
were washed with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated 
under reduced pressure to obtain alcohol 698 (237 mg, quantitative) as a colorless oil 
which did not required further purification: Rf  = 0.33 (silica gel, 30% EtOAc in hexanes); 
[α]25 D = + 18.9 (c 0.45, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.34 (m, 4 H), 
7.32 – 7.28 (m, 1 H), 5.79 (dtd, J = 15.5, 4.2, 0.6 Hz, 1 H), 5.66 (ddt, J = 15.4, 7.7, 1.7 
Hz, 1 H), 4.79 – 4.69 (m, 3 H), 4.57 – 4.51 (m, 1 H), 4.28 (dd, J = 7.6, 4.4 Hz, 1 H), 4.20 
(dd, J = 4.2, 1.6 Hz, 2 H), 3.69 (dd, J = 11.0, 8.0 Hz, 1 H), 3.54 (dd, J = 11.0, 4.8 Hz, 1 
H), 2.03 – 1.94 (m, 1 H), 0.93 – 0.87 (m, 12 H), 0.07 (s, 6 H); 13C NMR (100 MHz, 
CDCl3) δ 137.7, 134.0, 128.5, 127.9, 127.8, 126.4, 91.9, 79.1, 69.8, 65.5, 62.9, 39.9, 25.9, 
18.4, 12.1, -5.2; HRMS (H-ESI) m/z: [M + H]+ calcd for C21H37O4Si 381.2461; found 
381.2460. 
  
7.3.62. Synthesis of Aldehyde 699 
Aldehyde 699. To a solution of alchol 698 (235 mg, 0.62 mmol, 
1.0 equiv) in CH2Cl2 (10 mL) was added Dess-Martin 
periodinane (528 mg, 1.25 mmol, 2.0 equiv) at 0 ºC and the 
reaction mixture was stirred at this temperature for 2.5 h. Then 
the reaction was quenched by the addition of a 1:1 mixture of 
saturated aqueous NaHCO3 solution and saturated aqueous Na2S2O3 solution. The 
aqueous phase was extracted with EtOAc twice and the combined organic phases were 
washed with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated 
under reduced pressure. The resulting residue was purified by flash column 
chromatography (silica gel, 5% EtOAc in hexanes → 20% EtOAc in hexanes) to obtain 
aldehyde 699 (235 mg, quantitative) as a pale yellow oil: Rf  = 0.50 (silica gel, 30% EtOAc 
in hexanes); [α]25 D = + 32.7 (c 0.80, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 9.78 (d, J = 
1.1 Hz, 1 H), 7.36 – 7.34 (m, 5 H), 5.85 (dtd, J = 15.4, 4.2, 0.8 Hz, 1 H), 5.64 (ddt, J = 
15.4, 8.0, 1.9 Hz, 1 H), 4.82 – 4.78 (m, 1 H), 4.71 – 4.66 (m, 2 H), 4.57 (dd, J = 7.9, 4.5 
Hz, 1 H), 4.52 – 4.46 (m, 1 H), 4.22 – 4.19 (m, 2 H), 2.60 – 2.53 (m, 1 H), 1.14 (d, J = 
7.0 Hz, 3 H), 0.91 (s, 9 H), 0.06 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 203.8, 137.7, 
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134.9, 128.5, 127.9, 127.8, 125.7, 91.7, 75.8, 69.8, 62.8, 51.1, 25.9, 18.3, 8.7, -5.3; HRMS 
(H-ESI) m/z: [M + H]+ calcd for C21H35O4Si 379.2305; found 379.2303. 
 
7.3.63. Synthesis of Acid 693 
Acid 693. 2-methyl-2-butene (0.04 mL, 0.40 mmol, 2.0 equiv) 
was added to a solution of aldehyde 699 (75 mg, 0.20 mmol, 1.0 
equiv) in a 4:1 mixture of tBuOH : H2O (10 mL) followed by the  
addition of NaH2PO4 (166 mg, 1.40 mmol, 7.0 equiv)) and 
NaClO2 (125 mg, 1.40 mmol, 7.0 equiv). The reaction mixture 
was stirred a 25 ºC for 4 h. After this time brine was added and the aqueous phase was 
extracted with EtOAc. The organic phase was washed with dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure to obtain acid 693 (78 mg, 
quantitative) as a colorless oil which did not required further purification: Rf  = 0.20 (silica 
gel, 30% EtOAc in hexanes); [α]25 D = + 29.4 (c 0.35, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 7.36 – 7.32 (m, 5 H), 5.85 (dd, J = 15.4, 4.3 Hz, 1 H), 5.64 (dd, J = 15.4, 8.2 
Hz, 1 H), 4.74 – 4.63 (m, 3 H), 4.56 – 4.42 (m, 2 H), 4.22 – 4.16 (m, 2 H), 2.72 – 2.63 
(m, 1 H), 1.23 (d, J = 7.1 Hz, 3 H), 0.90 (s, 9 H), 0.06 (s, 3 H), 0.06 (s, 3 H). 13C NMR 
(100 MHz, CDCl3) δ 178.5, 137.7, 135.5, 128.4, 127.9, 127.8, 125.6, 91.7, 69.8, 62.7, 
44.5, 25.9, 25.7, 18.3, 11.9, -5.3; HRMS (H-ESI) m/z: [M + H]+ calcd for C21H35O5Si 
395.2254; found 395.2252. 
 
7.3.64. Synthesis of Peptide 701 
Peptide 701. To a solution of peptide 700 (111 mg, 0.25 
mmol, 1.0 equiv) in CH2Cl2 (10 mL) was added piperidine 
(0.12 mL, 1.25 mmol, 5.0 equiv) and the reaction mixture 
was stirred at 25 ºC 3 h. After this time, the organic solvent 
was removed under reduced pressure and the resulting 
crude amine (~0.25 mmol) was used in the next step 
without purification. DIPEA (0.1 mL, 0.62 mmol, 2.5 
equiv) was added to a solution of crude amine 692 (~0.25 
mmol), acid 693 (146 mg, 0.37 mmol, 1.5 equiv), HATU 
(234 mg, 0.62 mmol, 2.5 equiv) in CH2Cl2 (10 mL). The reaction mixture was stirred for 
15 h and after this time, the reaction was diluted with CH2Cl2 and a saturated aqueous 
NH4Cl solution was added. Ater decantation of the organic phase, the aqueous phase was 
extractes with EtOAc and the organic phases were washed with brine, dried over 
anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
resulting residue was purified by flash column chromatography (silica gel, 30% EtOAc 
in hexanes → 60% EtOAc in hexanes) to obtain peptide 701 (80 mg, 45% over 2 steps) 
as a pale yellow oil: Rf  = 0.55 (silica gel, 80% EtOAc in hexanes); [α]25 D = – 9.8 (c 0.18, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 8.39 (bs, 1 H), 7.72 (d, J = 2.5 Hz, 1 H), 7.44 – 
7.27 (m, 12 H), 7.09 (d, J = 7.5 Hz, 1 H), 6.83 – 6.73 (m, 2 H), 6.21 (t, J = 5.5 Hz, 1 H), 
5.78 (dt, J = 15.6, 4.6 Hz, 1 H), 5.62 – 5.48 (m, 3 H), 5.34 (dd, J = 11.1, 1.0 Hz, 1 H), 
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4.84 (s, 2 H), 4.65 – 4.58 (m, 3 H), 4.22 – 4.14 (m, 3 H), 3.67 (dd, J = 17.1, 4.8 Hz, 1 H), 
2.48 – 2.36 (m, 1 H), 1.40 (d, J = 7.0 Hz, 3 H), 1.04 (d, J = 7.1 Hz, 3 H), 0.88 (s, 9 H), 
0.04 (s, 3 H), 0.04 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 173.6, 170.1, 169.9, 158.9, 
138.3, 136.7, 136.4, 135.4, 131.3, 128.6, 128.5, 128.0, 127.9, 127.6, 124.4, 122.6, 116.2, 
112.5, 108.5, 92.8, 71.2, 70.1, 62.8, 49.6, 44.3, 38.6, 29.7, 25.8, 18.4, 12.8, -3.6, -5.3; 
HRMS (H-ESI) m/z: [M + H]+ calcd for C41H56N3O7Si 730.3888; found 730.3886. 
 
7.3.65. Synthesis of Allylic Alcohol 702 
Allylic Alcohol 702. TBAF (0.2 mL, 1.0 M in THF, 0.20 
mmol, 2.0 equiv) was added to a solution of silyl derivative 
701 (75 mg, 0.10 mmol, 1.0 equiv) in THF (5 mL) at 25 ºC 
and the resulting reaction mixture was stirred at this 
temperature for 5 h. After this time, the organic solvent was 
removed under reduce pressure and the resulting residue 
was purified by flash column chromatography (silica gel, 
8% MeOH in CH2Cl2) to obtain alcohol derivative 702 (47 
mg, 74%) as a white solid: Rf  = 0.15 (silica gel, 100% 
EtOAc); [α]25 D = – 15.1 (c 0.20, MeOH); 1H NMR (400 MHz, MeOD) δ 7.53 (d, J = 8.7 
Hz, 1 H), 7.44 – 7.39 (m, 2 H), 7.38 – 7.23 (m, 8 H), 7.06 (d, J = 2.6 Hz, 1 H), 6.89 (dd, 
J = 8.7, 2.6 Hz, 1 H), 6.79 (dd, J = 17.5, 11.0 Hz, 1 H), 5.82 (dddd, J = 8.5, 7.9, 4.0, 1.7 
Hz, 1 H), 5.65 – 5.56 (m, 2 H), 5.19 (dd, J = 11.1, 1.3 Hz, 1 H), 5.06 (s, 2 H), 4.81 – 4.64 
(m, 3 H), 4.61 – 4.48 (m, 2 H), 4.26 – 4.19 (m, 1 H), 4.04 (dd, J = 5.0, 1.4 Hz, 2 H), 3.87 
(dt, J = 26.8, 16.6 Hz, 2 H), 2.63 (p, J = 6.9 Hz, 1 H), 1.45 (d, J = 7.2 Hz, 3 H), 1.17 (d, 
J = 6.9 Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 175.4, 172.6, 170.1, 158.7, 138.0, 137.1, 
134.9, 131.6, 128.1, 127.9, 127.6, 127.5, 127.3, 127.2, 126.9, 126.4, 125.9, 113.4, 112.9, 
112.1, 91.5, 78.1, 69.7, 69.4, 61.4, 45.2, 42.2, 23.4, 16.9, 12.3; HRMS (H-ESI) m/z: [M 
+ H]+ calcd for C35H42N3O7 616.3023; found 616.3021. 
 
7.3.66. Synthesis of Aniline 704 
Aniline 704. To a solution of nitro derivative 605 (3.0 g, 8.45 mmol, 
1.0 equiv) in EtOH (72 mL) was added a solution of NH4Cl (2.3 g, 
42.24 mmol, 5.0 equiv) in water (48 mL) followed by Zn dust (8.3 g, 
126.7 mmol, 15.0 equiv) in ten portions of 800 mg each over 30 min 
at 25 ºC. The mixture was stirred at this temperature for 12 h and then the reaction mixture 
was diluted with CH2Cl2 and water, filtered and rinsed with CH2Cl2. The filtrate was 
diluted with water and extracted with CH2Cl2, and the organic phase washed with brine, 
dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. 
The resulting residue was purified by flash column chromatography (silica gel, 5% 
EtOAc in hexanes) to obtain aniline 704 (2.4 g, 86%) as a yellow oil: Rf  = 0.40 (silica 
gel, 30% EtOAc in hexanes);1H NMR (400 MHz, CDCl3) δ 7.45 – 7.28 (m, 5 H), 7.06 (t, 
J = 8.0 Hz, 1 H), 6.40 (dd, J = 8.0, 1.5 Hz, 1 H), 6.34 – 6.28 (m, 1 H), 5.03 (s, 2 H), 3.65 
(s, 2 H); 13C NMR (100 MHz, CDCl3) δ 160.0, 146.4, 137.2, 130.2, 128.6, 127.9, 127.5, 
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108.8, 105.8, 102.7, 69.9; HRMS (H-ESI) m/z: [M + H]+ calcd for C13H13INO 326.0042; 
found 326.0041. 
 
7.3.67. Synthesis of Dipeptide 585 
Dipeptide 585. To a solution of aniline 704 (1.7 g, 5.44 
mmol, 1.0 equiv) and Boc-Gly-D-Ala-OH (608) (1.7 mg, 
7.08 mmol, 1.3 equiv) in DMF (5 mL) was added HATU 
(3.1 g, 8.17 mmol, 1.5 equiv) and DIPEA (1.88 mL, 10.89 
mmol, 2.0 equiv) and the mixture was stirred for 15 h at 
25 ºC. After this time, the reaction mixture was diluted 
with CH2Cl2 and washed sequentially with 1 N HCl and saturated aqueous NaHCO3 
solution. The organic layer was separated, washed with brine and dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes) to 
obtain dipeptide 585 (2.3 g, 79%) as a white solid: Rf = 0.82 (silica gel, 100% EtOAc);
 
[α]25 D = + 18.44 (c 0.85, CH2Cl2); mp = 104-105 ºC; 1H NMR (400 MHz, CDCl3) δ 8.64 
(bs, 1 H), 7.48 – 7.32 (m, 5 H), 7.20 (t, J = 8.1 Hz, 1 H), 7.09 (d, J = 7.4 Hz, 1 H), 6.86 
(bs, 1 H), 6.74 (dd, J = 8.2, 1.7 Hz, 1 H), 5.26 (t, J = 5.6 Hz, 1 H), 5.05 (s, 2 H), 4.67 (p, 
J = 7.2 Hz, 1 H), 3.85 (d, J = 5.5 Hz, 2 H), 1.48 (d, J = 7.0 Hz, 3 H), 1.46 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 170.2, 163.6, 159.3, 156.4, 138.9, 136.9, 129.7, 128.6, 127.9, 
127.5, 112.5, 111.3, 106.6, 69.9, 49.8, 34.5, 28.3, 24.1, 17.5; HRMS (H-ESI) m/z: [M + 
H]+ calcd for C23H29IN3O5 554.1152; found 554.1151. 
 
7.3.68. Synthesis of Peptide 705 
Peptide 705. Dipeptide 585 (560 mg, 1.01 mmol, 1.0 equiv) 
in CH2Cl2 (20 mL) was treated with TFA (5.0 mL) in exactly 
the same manner as previously described for synthesis of 
612. A solution of the ammonium salt and acid 693 (559 mg, 
1.42 mmol, 1.0 equiv), in CH2Cl2 (15 mL) was treated with 
HATU (962 mg, 2.53 mmol, 2.5 equiv) and DIPEA (0.4 mL, 
4.05 mmol, 4.0 equiv) and the resulting reaction mixture was 
stirred at 25 ºC for 15 h. After this time, a saturated aqueous 
NH4Cl solution was added and the organic layer was 
separated. The aqueous phase was extracted with EtOAc, and the combined organic layers 
were washed with brine and dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The crude product was purified by flash column 
chromatography (silica gel 5% MeOH in CH2Cl2) to obtain 705 (238 mg, 33% over two 
steps) as a white foam: Rf = 0.20 (silica gel, 100% EtOAc);
 [α]25 D = + 9.73 (c 0.25, 
CH2Cl2); 
1H NMR (400 MHz, MeOD) δ 7.44 – 7.39 (m, 3 H), 7.37 – 7.24 (m, 7 H), 7.21 
– 7.14 (m, 2 H), 6.73 (dt, J = 7.1, 2.3 Hz, 1 H), 5.75 (dt, J = 15.5, 5.0 Hz, 1 H), 5.60 
(dddd, J = 15.5, 8.3, 3.4, 1.8 Hz, 1 H), 5.05 (s, 2 H), 4.81 – 4.67 (m, 3 H), 4.57 – 4.46 (m, 
2 H), 4.26 – 4.20 (m, 1 H), 4.01 (dd, J = 5.0, 1.4 Hz, 2 H), 3.93 (d, J = 16.4 Hz, 1 H), 3.76 
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(d, J = 16.4 Hz, 1 H), 2.64 (p, J = 6.9 Hz, 1 H), 1.41 (d, J = 7.2 Hz, 3 H), 1.19 (d, J = 6.9 
Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 175.5, 171.7, 170.1, 159.2, 139.3, 138.0, 137.2, 
135.0, 129.2, 128.1, 127.9, 127.7, 127.6, 127.5, 127.3, 127.2, 126.8, 112.4, 110.5, 106.8, 
91.4, 78.1, 69.6, 69.4, 61.4, 49.6, 45.2, 42.4, 16.9, 12.4; HRMS (H-ESI) m/z: [M + H]+ 
calcd for C33H39IN3O7 716.1833; found 716.1832. 
 
7.3.69. Synthesis of Acid 709 
Acid 709. TBAF (2.4 mL, 1.0 M in THF, 1.20 mmol, 2.0 equiv) 
was added to a solution of silyl derivative 693 (470 mg, 1.20 mmol, 
1.0 equiv) in THF (10 mL) at 0 ºC. The reaction mixture was stirred 
at 25 ºC for 6 h. After this time, the organic solvent was removed 
under reduced pressure and the resulting crude residue was purified by flash column 
chromatography (silica gel, 5% MeOH in CH2Cl2) to obtain acid 709 (336 mg, 
quantitative) as a yellow oil: Rf  = 0.12 (silica gel, 100% EtOAc); [α]25 D = + 23.2 (c 0.46, 
MeOD); 1H NMR (400 MHz, MeOD) δ 7.38 – 7.24 (m, 5 H), 5.87 (dtd, J = 15.6, 5.0, 0.7 
Hz, 1 H), 5.66 (ddt, J = 15.5, 7.9, 1.6 Hz, 1 H), 4.78 (d, J = 6.9 Hz, 1 H), 4.71 – 4.66 (m, 
2 H), 4.54 – 4.43 (m, 2 H), 4.13 – 4.06 (m, 2 H), 2.60 (qd, J = 7.1, 5.8 Hz, 1 H), 1.21 (d, 
J = 7.0 Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 176.6, 137.9, 134.3, 127.9, 127.8, 127.5, 
127.3, 91.3, 77.1, 69.2, 61.4, 23.4, 12.5; HRMS (H-ESI) m/z: [M + H]+ calcd for C15H21O5 
281.1389; found 281.1388. 
 
7.3.70. Synthesis of Lactames 712a and 712b 
Lactames 712a and 712b. CCl3CN (0.3 mL, 2.99 
mmol, 2.5 equiv) and DBU (0.09 mL, 0.60 mmol, 
0.5 equiv) were added to a solution of acid 709 (336 
mg, 1.20 mmol, 1.0 equiv) in CH2Cl2 (15 mL) at 0 
ºC. The reaction mixture was stirred at 25 ºC for 3 
h. After this time, the organic solvent was removed under reduced pressure to obtain the 
corresponding crude bistrichloroacetoimidate 710 (~1.2 mmol) as a dark brown oil which 
was used in the next step without purification. Crude bistrichloroacetoimidate 710 
obtained above (~26 mg, ~0.05 mmol, 1.0 equiv), PdCl2(PhCN)2 (2 mg, 0.005 mmol, 0.1 
equiv) and p-benzoquinone (2.5 mg, 0.02 mmol, 0.5 equiv) were dissolved in CH2Cl2 (2 
mL) and the reaction mixture was stirred at 45 ºC for 15 h. Then, the organic solvent was 
removed under reduced pressure and the obtained crude residue was purified by flash 
column chromatography (silica gel, 15% EtOAc in hexanes) to obtain lactames 712a (60 
mg, 20% over two steps) and 712b (60 mg, 20% over two steps) as a colorless oils. Data 
for 712a: Rf = 0.57 (30% EtOAc in hexanes); [α]25 D = – 22.56 (c 0.35, CH2Cl2); 1H NMR 
(400 MHz, MeOD) δ 7.36 – 7.25 (m, 5 H), 5.98 (ddd, J = 17.2, 10.5, 6.7 Hz, 1 H), 5.45 
(dt, J = 17.2, 1.3 Hz, 1 H), 5.31 (dt, J = 10.5, 1.2 Hz, 1 H), 4.84 (d, J = 3.3 Hz, 2 H), 4.69 
(tt, J = 6.6, 1.2 Hz, 1 H), 4.63 (d, J = 3.3 Hz, 2 H), 3.95 (dd, J = 7.7, 6.6 Hz, 1 H), 2.77 
(p, J = 7.3 Hz, 1 H), 1.29 (d, J = 7.3 Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 177.3, 
137.6, 134.3, 128.0, 127.6, 127.4, 118.1, 94.2, 84.1, 83.1, 69.5, 41.9, 12.5; Data for 712b: 
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Rf = 0.55 (30% EtOAc in hexanes); [α]25 D = + 9.7 (c 0.15, CH2Cl2); 1H NMR (400 MHz, 
MeOD) δ 7.37 – 7.25 (m, 5 H), 6.05 (ddd, J = 17.3, 10.6, 6.9 Hz, 1 H), 5.42 (dt, J = 17.3, 
1.4 Hz, 1 H), 5.37 (dt, J = 10.6, 1.3 Hz, 1 H), 5.11 – 5.06 (m, 1 H), 4.81 (d, J = 3.1 Hz, 2 
H), 4.61 (s, 2 H), 4.26 (t, J = 5.7 Hz, 1 H), 2.71 (qd, J = 7.5, 5.7 Hz, 1 H), 1.27 (d, J = 7.5 
Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 178.3, 137.7, 131.9, 128.1, 127.5, 127.4, 118.5, 
93.9, 81.3, 80.4, 69.7, 40.7, 11.9; HRMS (H-ESI) m/z: [M + H]+ calcd for C15H20NO3 
262.1443; found 262.1441. 
 
7.3.71. Synthesis of Diol 713 
Diol 713. Silyl eter 698 (197 mg, 0.52 mmol, 1.0 equiv) was 
dissolved in THF (10 mL) and to this solution was added TBAF 
(1.0 mL, 1.0 M in THF, 1.04 mmol, 2.0 equiv) at 0 ºC. The reaction 
mixture was stirred at 25 ºC for 5.5 h and then the organic solvent 
was removed under reduced pressure to obtain a crude residue which was purified by 
flash column chromatography (70% EtOAc in hexanes) to obtain diol 713 (109 mg, 79%) 
as a colorless oil: Rf = 0.45 (100% EtOAc); [α]25 D = + 27.7 (c 0.11, CH2Cl2); 1H NMR 
(400 MHz, MeOD) δ 7.36 – 7.24 (m, 5 H), 5.82 (dt, J = 15.6, 5.1 Hz, 1 H), 5.63 (dd, J = 
15.6, 7.9 Hz, 1 H), 4.78 (d, J = 6.8 Hz, 1 H), 4.69 (dd, J = 9.2, 2.4 Hz, 2 H), 4.53 (d, J = 
11.7 Hz, 1 H), 4.19 (dd, J = 7.8, 5.1 Hz, 1 H), 4.08 (d, J = 5.1 Hz, 2 H), 3.64 (dd, J = 10.6, 
6.0 Hz, 1 H), 3.42 (dd, J = 10.6, 6.7 Hz, 1 H), 3.31 (dt, J = 3.2, 1.6 Hz, 1 H), 1.84 – 1.73 
(m, 1 H), 1.00 (d, J = 6.9 Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 137.9, 133.4, 128.6, 
127.9, 127.7, 127.3, 91.6, 77.3, 69.2, 63.8, 61.5, 40.7, 11.1; HRMS (H-ESI) m/z: [M + 
H]+ calcd for C15H23O4 267.1596; found 267.1595. 
 
7.3.72. Synthesis of Bis(trichloroacetimidate) 714 
Bis(trichloroacetimidate) 714. CCl3CN (0.10 mL, 0.92 mmol, 
2.5 equiv) and DBU (0.03 mL, 0.18 mmol, 0.5 equiv) were 
added to a solution of diol 713 (98 mg, 0.37 mmol, 1.0 equiv) 
in CH2Cl2 (5 mL) at 0 ºC. The reaction mixture was stirred at 0 
ºC for 30 min and then at 25 ºC for 3.5 h. After this time, the 
solvent was removed under reduced pressure and the resulting 
crude mixture was purified by flash column chromatography (silica gel, 10% EtOAc in 
hexanes) to obtain bis(trichloroacetimidate) 714 (166 mg, 81%) as a pale yellow oil: Rf  = 
0.88 (silica gel, 50% EtOAc in hexanes); [α]25 D = + 6.44 (c 0.35, CH2Cl2); 1H NMR (400 
MHz, CDCl3) δ 8.32 (bs, 1 H), 8.25 (bs, 1 H), 7.37 – 7.27 (m, 5 H), 5.93 (dt, J = 15.7, 5.4 
Hz, 1 H), 5.82 (dd, J = 15.7, 7.4 Hz, 1 H), 4.85 – 4.78 (m, 3 H), 4.75 – 4.67 (m, 2 H), 4.54 
(d, J = 11.7 Hz, 1 H), 4.31 (ddd, J = 12.7, 8.9, 5.8 Hz, 2 H), 4.21 (dd, J = 10.6, 5.7 Hz, 1 
H), 2.24 – 2.12 (m, 1 H), 1.11 (d, J = 6.9 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 162.9, 
162.4, 137.8, 132.8, 128.5, 127.9, 127.7, 127.4, 92.3, 91.5, 91.4, 76.9, 70.9, 69.8, 68.5, 
37.6, 12.3; HRMS (H-ESI) m/z: [M + H]+ calcd for C19H23Cl6N2O4 552.9789; found 
552.9788. 
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7.4. Experimental Procedures and Compound Characterization Related to the 
Celebesides 
7.4.1. Synthesis of Peptide 738 
Peptide 738. Release of a small amount of peptide from 
resin 737 (19 mg) by treatment with CH2Cl2/AcOH/TFE 
(3.0 mL, 7:2:1) gave the N-Fmoc protected tripeptide 738 
(10 mg), which revealed a load of 0.55 mmol/g of resin 
737: white foam; [α]25 D = – 5.69 (c 0.12, CH2Cl2); 1H 
NMR (400 MHz, MeOD) δ 8.55 (bs, 1 H), 8.14 (d, J = 
8.0 Hz, 1 H), 7.78 (d, J = 7.5 Hz, 2 H), 7.61 (dd, J = 13.1, 7.5 Hz, 2 H), 7.37 (t, J = 7.5 
Hz, 2 H), 7.31 – 7.15 (m, 20 H), 6.81 (d, J = 7.7 Hz, 1 H), 4.81 (dt, J = 8.0, 4.0 Hz, 1 H), 
4.58 (t, J = 3.9 Hz, 1 H), 4.50 – 4.34 (m, 4 H), 4.29 (dd, J = 10.5, 6.5 Hz, 1 H), 4.21 – 
4.08 (m, 2 H), 4.03 (dd, J = 6.2, 3.9 Hz, 1 H), 3.85 (dd, J = 9.7, 4.5 Hz, 1 H), 3.65 (dd, J 
= 9.7, 3.6 Hz, 1 H), 2.94 – 2.87 (m, 2 H), 2.83 – 2.75 (m, 1 H), 1.14 (s, 9 H), 1.06 (d, J = 
6.3 Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 171.6, 171.1, 170.7, 170.2, 156.8, 74.5, 
72.8, 70.4, 69.1, 67.1, 66.6, 59.9, 52.9, 49.8, 38.2, 29.4, 27.3, 22.3, 18.1; HRMS (ESI-
TOF) m/z calcd for C56H59N4O9 [M + H]
+ 931.4282 found 931.4280. 
 
7.4.2. Synthesis of Peptide 742 from Solid Phase Synthesis 
Peptide 742 from Solid Phase Synthesis. A 10 mL 
polypropylene syringe fitted with polyethylene porous 
disk charged with 2-chlorotrityl chloride (CTC) resin 
(200 mg, L=1.22 mmol/g, 1.0 equiv), was loaded with a 
solution of Fmoc-L-Ser(Bn)-OH 730 (200 mg, 0.48 
mmol, 2.0 equiv) and DIPEA (0.10 mL, 0.60 mmol, 2.5 
equiv) in dry DMF (3 mL). The resulting suspension 
was shaken at 280 rpm for 24 h, then the solution was 
unloaded and the resin was washed by shaking with dry DMF (5 x 3 mL). The resulting 
yellow resin was used in the next step. The polypropylene syringe loaded with the yellow 
resin was treated with a solution of 20% piperidine in DMF (3 x 3 mL x 10 min at 280 
rpm). After the last run, the resin was washed with dry DMF (5 x 3 mL) and loaded with 
a solution of Fmoc-L-Asn(Trt)-OH 736 (286 mg, 0.48 mmol, 2.0 equiv), HOBt (65 mg, 
0.48 mmol, 2.0 equiv) and DIC (0.10 mL, 0.60 mmol, 2.5 equiv) in dry DMF (3 mL). The 
resulting suspension was shaken at 280 rpm for 24 h, and then the solution was unloaded 
and the resin washed with dry DMF (5 x 3 mL). The resulting yellow resin was used in 
the next step. To a 10 mL polypropylene syringe fitted with polyethylene porus disk and 
loaded with the resulting Fmoc protected dipeptide was added a solution of 20% 
piperidine in DMF (3 x 3 mL x 10 min at 280 rpm). After the last run, the resin was 
washed with dry DMF (5 x 3 mL) and treated with a solution of Fmoc-D-Thr(tBu)-OH 
732 (191 mg, 0.48 mmol, 2.0 equiv), HOBt (65 mg, 0.48 mmol, 2.0 equiv) and DIC (0.10 
mL, 0.60 mmol, 2.5 equiv) in dry DMF (3 mL). The resulting suspension was shaken at 
280 rpm for 24 h, and then the solution was unloaded and the resin washed with dry DMF 
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(5 x 3 mL). To the same polypropylene syringe was added a solution of 20% piperidine 
in DMF (3 x 3 mL x 10 min at 280 rpm). After the last run, the resin was washed with 
dry DMF (5 x 3 mL) and treated with a solution of -Ala-OH (739) (149 mg, 0.48 mmol, 
2.0 equiv), HOBt (65 mg, 0.48 mmol, 2.0 equiv) and DIC (0.10 mL, 0.60 mmol, 2.5 
equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for 24 h, and 
then the solution was unloaded and the resin washed with dry DMF (5 x 3 mL). Then, to 
the same polypropylene syringe was added a solution of 20% piperidine in DMF (3 x 3 
mL x 10 min at 280 rpm). After the last run, the resin was washed with dry DMF (5 x 3 
mL) and treated with a solution of 2,4-pentadienoic acid 734 (47 mg, 0.48 mmol, 2.0 
equiv), HOBt (65 mg, 0.48 mmol, 2.0 equiv) and DIC (0.10 mL, 0.60 mmol, 2.5 equiv) 
in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for 24 h, and then 
the solution was unloaded and the resin washed with dry DMF (5 x 3 mL). The resulting 
yellow resin was treated with a solution of CH2Cl2/AcOH/TFE (7:2:1, 3 mL) for 30 min. 
After that, the solution was collected and the resin washed with CH2Cl2 (2 x 3 mL). All 
the collected organic solvents were evaporated under reduced pressure and the resulting 
peptide 742 (134 mg, 65 % overall yield from CTC resin) was obtained as a pale yellow 
foam which not required further purification: Rf  = 0.25 (silica gel, 10% MeOH in 
CH2Cl2); [α]25 D = – 15.2 (c 0.23, CH2Cl2); 1H NMR (400 MHz, MeOD) δ 8.60 (bs, 1 H), 
8.11 (d, J = 8.0 Hz, 1 H), 7.80 (d, J = 7.6 Hz, 1 H), 7.29 – 7.17 (m, 20 H), 7.08 (dd, J = 
15.2, 11.0 Hz, 1 H), 6.40 (dt, J = 16.9, 10.5 Hz, 1 H), 5.89 (d, J = 15.2 Hz, 1 H), 5.57 – 
5.50 (m, 1 H), 5.43 – 5.38 (m, 1 H), 4.80 (dt, J = 11.0, 4.0 Hz, 1 H), 4.60 (t, J = 4.0 Hz, 
1 H), 4.38 – 4.33 (m, 1 H), 4.10 (dd, J = 6.4, 3.4 Hz, 1 H), 3.87 (dd, J = 9.7, 4.4 Hz, 1 H), 
3.67 (dd, J = 9.7, 3.6 Hz, 1 H), 3.49 (dt, J = 9.6, 6.3 Hz, 1 H), 3.37 – 3.32 (m, 2 H), 3.04 
– 2.97 (m, 1 H), 2.77 (dd, J = 16.1, 5.0 Hz, 1 H), 2.44 (t, J = 6.4 Hz, 2 H), 1.14 (s, 9 H), 
1.08 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 172.6, 171.7, 171.4, 170.5, 
170.4, 167.2, 144.5, 140.5, 137.8, 135.1, 128.7, 127.9, 127.4, 127.3, 127.3, 126.4, 124.7, 
123.1, 74.5, 72.8, 70.4, 69.3, 66.6, 58.7, 53.1, 49.6, 37.9, 35.6, 35.2, 27.3, 18.5; HRMS 
(ESI-TOF) m/z calcd for C49H58N5O9 [M + H]
+ 860.4235, found 860.4233. 
 
7.4.3. Synthesis of Fmoc-L-Ser(Bn)-OAllyl 743 
Fmoc-L-Ser(Bn)-OAllyl 743. To a solution of Fmoc-L-
Ser(Bn)-OH 730 (2.5 g, 5.99 mmol, 1.0 equiv) and allylic alcohol 
(0.53 mL, 7.79 mmol, 1.3 equiv) in CH2Cl2 (120 mL) at 0 ºC was 
added sequentially HOBt.H2O (1.6 g, 11.98 mmol, 2.0 equiv) and 
DIC (2.32 mL, 14.97 mmol, 2.5 equiv) and the mixture was stirred for 15 h at 25 ºC. After 
this time, the reaction was diluted with H2O and the aqueous phase was extracted twice 
with CH2Cl2. The combined organic layers were washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica gel, 5% EtOAc in hexanes → 10% 
EtOAc in hexanes) to obtain 743 (2.2 g , 79%) as a white foam: Rf  = 0.25 (silica gel, 30% 
EtOAc in hexanes); [α]25 D = – 9.1 (c 0.07, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ (ppm) 
7.78 (d, J = 7.5 Hz, 1 H), 7.63 (d, J = 6.6 Hz, 1 H), 7.41 (t, J = 7.5 Hz, 1 H), 7.36 – 7.27 
(m, 4 H), 5.90 (ddd, J = 22.7, 10.9, 5.7 Hz, 1 H), 5.72 (d, J = 8.7 Hz, 1 H), 5.34 (dd, J = 
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17.2, 1.0 Hz, 1 H), 5.25 (dd, J = 10.4, 0.9 Hz, 1 H), 4.68 (d, J = 5.6 Hz, 1 H), 4.55 (d, J = 
13.8 Hz, 1 H), 4.44 (dd, J = 10.5, 7.3 Hz, 1 H), 4.37 (dd, J = 10.4, 7.4 Hz, 1 H), 4.26 (t, J 
= 7.1 Hz, 1 H), 3.96 (dd, J = 9.4, 3.0 Hz, 1 H), 3.75 (dd, J = 9.4, 3.1 Hz, 1 H); 13C NMR 
(100 MHz, CDCl3) δ (ppm) 170.0, 156.1, 143.8, 141.3, 137.5, 131.6, 128.5, 127.9, 127.7, 
127.7, 127.1, 125.2, 120.0, 118.7, 73.4, 69.9, 67.3, 66.2, 54.5, 47.2; HRMS (ESI-TOF) 
m/z calcd for C28H28NO5 [M + H]
+ 458.1968, found 458.11966.  
 
7.4.4. Synthesis of Fmoc-L-Asn(Trt)-L-Ser(Bn)-OAllyl 744 
Fmoc-L-Asn(Trt)-L-Ser(Bn)-OAllyl 744. To a solution 
of Fmoc-L-Ser(Bn)-OAllyl 743 (1.0 g, 2.19 mmol, 1.0 
equiv) in CH2Cl2 (60 mL) was added piperidine (1.1 mL, 
10.93 mmol, 5.0 equiv) and the reaction mixture was 
stirred at 25 ºC for 2 h. After this time, the organic solvent 
was removed under reduced pressure and the resulting 
crude product was purified by flash column chromatography (silica gel, 20% EtOAc in 
hexanes → 60% EtOAc in hexanes) to obtain the corresponding amine (373 mg, 73%) as 
a colorless foam: Rf  = 0.10 (silica gel, 80% EtOAc in hexanes); [α]25 D = – 18.7 (c 0.15, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.25 (m, 5 H), 5.90 (ddt, J = 17.2, 10.4, 
5.7 Hz, 1 H), 5.31 (dq, J = 17.2, 1.5 Hz, 1 H), 5.23 (dq, J = 10.5, 2.6, 1.3 Hz, 1 H), 4.65 
– 4.62 (m, 2 H), 4.54 (d, J = 6.5 Hz, 2 H), 3.80 – 3.74 (m, 1 H), 3.74 – 3.66 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 170.7, 137.9, 131.9, 128.4, 127.7, 127.6, 118.5, 73.3, 72.1, 
65.7, 55.0; HRMS (ESI-TOF) m/z calcd for C13H18NO3 [M + H]
+ 236.1287, found 
236.1285. Amine obtained above (220 mg, 0.94 mmol, 1.0 equiv), Fmoc-L-Asn(Trt)-OH 
736 (558 mg, 0.94 mmol, 1.0 equiv), HOBt.H2O (190 mg, 1.40 mmol, 1.5 equiv) and 
EDC.HCl (358 mg, 1.87 mmol, 2.0 equiv) were dissolved in CH2Cl2 (40 mL) and the 
mixture was stirred at 25 ºC for 12 h. After this time, a saturated aqueous NaHCO3 
solution was added and the aqueous phase was extracted twice with CH2Cl2. The 
combined organic layers were washed sequentially with a saturated aqueous NH4Cl 
solution and brine, dried over anhydrous MgSO4, filtered and the solvent evaporated 
under reduced pressure. The crude product was purified by flash column chromatography 
(silica gel, 20% EtOAc in hexanes → 40% EtOAc in hexanes) to obtain to obtain 744 
(609 mg, 80%, 58% overall yield from 743) as a white foam: Rf  = 0.88 (silica gel, 80% 
EtOAc in hexanes); [α]25 D = – 12.4 (c 0.11, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.78 
– 7.74 (m, J = 7.5, 0.7 Hz, 2 H), 7.55 (dd, J = 5.9, 1.6 Hz, 2 H), 7.39 (t, J = 7.4 Hz, 2 H), 
7.32 – 7.16 (m, 23 H), 6.93 (bs, 1 H), 6.43 (d, J = 7.8 Hz, 1 H), 5.86 (ddd, J = 16.1, 10.9, 
5.7 Hz, 1 H), 5.30 (dd, J = 17.2, 1.4 Hz, 1 H), 5.22 (ddd, J = 10.5, 2.5, 1.2 Hz, 1 H), 4.73 
– 4.55 (m, 4 H), 4.46 – 4.40 (m, 1 H), 4.38 – 4.31 (m, 3 H), 4.18 (t, J = 7.2 Hz, 1 H), 3.88 
(dd, J = 9.4, 3.3 Hz, 1 H), 3.53 (dd, J = 9.3, 3.3 Hz, 1 H), 3.12 (dd, J = 15.4, 2.9 Hz, 1 H), 
2.69 (dd, J = 15.6, 5.3 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 171.0, 170.3, 169.6, 
156.3, 144.3, 143.9, 143.7, 141.3, 137.4, 131.6, 128.8, 128.7, 128.4, 128.0, 127.7, 127.6, 
127.1, 125.2, 120.0, 118.6, 73.2, 70.9, 69.2, 67.4, 66.1, 53.1, 51.5, 47.1, 38.3; HRMS 
(ESI-TOF) m/z calcd for C51H48N3O7 [M + H]
+ 814.3492, found 814.3490.  
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7.4.5. Synthesis of Fmoc-D-Thr(tBu)-L-Asn(Trt)-L-Ser(Bn)-OAllyl 745 
Fmoc-D-Thr(tBu)-L-Asn(Trt)-L-Ser(Bn)- 
-OAllyl 745. To a solution of Fmoc-L-Asn(Trt)-L-
Ser(Bn)-OAllyl 744 (498 mg, 0.61 mmol, 1.0 equiv) 
in CH2Cl2 (20 mL) was added piperidine (0.2 mL, 
1.84 mmol, 3.0 equiv) and the reaction mixture was 
stirred at 25 ºC for 4 h. After this time, the organic 
solvent was removed under reduced pressure to obtain the corresponding amine as a white 
solid which was used in the next step without purification. To a solution of the crude 
amine obtained above (~0.61 mmol, 1.0 equiv) in CH2Cl2 (15 mL) was added Fmoc-D-
Thr(tBu)-OH 732 (316 mg, 0.80 mmol, 1.3 equiv) and HOBt.H2O (124 mg, 0.92 mmol, 
1.5 equiv) and the mixture was cooled to 0 ºC. Then, EDC.HCl (235 mg, 1.22 mmol, 2.0 
equiv) was added and the reaction mixture was stirred at 25 ºC for 15 h. After this time, 
a saturated aqueous NaHCO3 solution was added and the aqueous phase was extracted 
twice with CH2Cl2. The combined organic layers were washed sequentially with a 
saturated aqueous NH4Cl solution and brine, dried over anhydrous MgSO4, filtered and 
the solvent evaporated under reduced pressure. The crude product was purified by flash 
column chromatography (silica gel, 10% EtOAc in hexanes → 40% EtOAc in hexanes) 
to obtain 745 (340 mg, 60% over two steps) as a white foam: Rf  = 0.50 (silica gel, 50% 
EtOAc in hexanes); [α]25 D = – 5.88 (c 0.06, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 8.04 
(d, J = 6.6 Hz, 1 H), 7.76 (d, J = 7.5 Hz, 2 H), 7.73 (d, J = 13.3 Hz, 1 H), 7.59 (dd, J = 
7.3, 3.8 Hz, 2 H), 7.39 (t, J = 7.4 Hz, 2 H), 7.32 – 7.16 (m, 22 H), 6.84 (s, 1 H), 5.94 (d, 
J = 4.8 Hz, 1 H), 5.86 (ddd, J = 22.8, 10.8, 5.6 Hz, 1 H), 5.30 (dd, J = 17.2, 1.4 Hz, 1 H), 
5.21 (dd, J = 10.5, 1.2 Hz, 1 H), 4.80 (bs, 1 H), 4.71 – 4.55 (m, 3 H), 4.45 – 4.32 (m, 4 
H), 4.21 (t, J = 7.2 Hz, 1 H), 4.14 (d, J = 5.6 Hz, 2 H), 3.84 (dd, J = 9.5, 3.7 Hz, 1 H), 
3.53 (dd, J = 9.3, 3.3 Hz, 1 H), 3.03 (d, J = 13.7 Hz, 1 H), 2.78 (dd, J = 15.6, 7.2 Hz, 1 
H), 1.19 (s, 9 H), 1.03 (d, J = 6.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 170.7, 169.8, 
169.5, 169.5, 156.0, 144.4, 144.0, 143.7, 141.3, 141.3, 137.5, 131.7, 128.8, 128.3, 127.9, 
127.7, 127.6, 127.1, 127.1, 125.2, 120.1, 118.5, 75.4, 73.2, 70.9, 69.0, 67.0, 66.3, 66.0, 
59.0, 53.1, 49.6, 47.2, 38.9, 28.2, 17.7; HRMS (ESI-TOF) m/z calcd for C59H63N4O9 [M 
+ H]+ 971.4595, found 971.4593.  
 
7.4.6. Synthesis of Fmoc--Ala-D-Thr(tBu)-L-Asn(Trt)-L-Ser(Bn)-OAllyl 746 
Fmoc--Ala-D-Thr(tBu)-L-Asn(Trt)-L-Ser 
(Bn)-OAllyl 746. To a solution of Fmoc-D-
Thr(tBu)-L-Asn(Trt)-L-Ser(Bn)-OAllyl 745 
(527 mg, 0.54 mmol, 1.0 equiv) in CH2Cl2 (20 
mL) was added piperidine (0.16 mL, 1.63 mmol, 
3.0 equiv) and the reaction mixture was stirred 
at 25 ºC for 3 h. After this time, the organic solvent was removed under reduced pressure 
to obtain the corresponding amine as a white foam which was used in the next step 
without purification. To a solution of the crude amine obtained above (~0.54 mmol, 1.0 
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equiv) in CH2Cl2 (20 mL) was added Fmoc--Ala-OH 739 (220 mg, 0.71 mmol, 1.3 
equiv), HOBt.H2O (110 mg, 0.82 mmol, 1.5 equiv), and EDC
.HCl (208 mg, 1.09 mmol, 
2.0 equiv) was added and the reaction mixture was stirred at 25 ºC for 15 h. After this 
time, a saturated aqueous NaHCO3 solution was added and the aqueous phase was 
extracted twice with CH2Cl2. The combined organic layers were washed sequentially with 
a saturated aqueous NH4Cl solution and brine, dried over anhydrous MgSO4, filtered and 
the solvent evaporated under reduced pressure. The crude product was purified by flash 
column chromatography (silica gel, 30% EtOAc in hexanes → 60% EtOAc in hexanes) 
to obtain 746 (285 mg, 57% over two steps) as a white foam: Rf  = 0.40 (silica gel, 80% 
EtOAc in hexanes); [α]25 D = – 13.7 (c 0.25, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 8.04 
(d, J = 7.0 Hz, 1 H), 7.74 (d, J = 7.1 Hz, 2 H), 7.68 (d, J = 8.1 Hz, 1 H), 7.59 (d, J = 7.5 
Hz, 2 H), 7.38 (t, J = 7.3 Hz, 2 H), 7.32 – 7.17 (m, 22 H), 6.85 (bs, 1 H), 6.53 (d, J = 5.8 
Hz, 1 H), 5.86 (ddd, J = 16.1, 11.0, 5.6 Hz, 1 H), 5.56 (t, J = 6.0 Hz, 1 H), 5.30 (dd, J = 
17.2, 1.5 Hz, 1 H), 5.21 (dd, J = 10.4, 1.3 Hz, 1 H), 4.77 (td, J = 7.0, 3.1 Hz, 1 H), 4.67 
(dt, J = 10.2, 3.0 Hz, 1 H), 4.61 (dd, J = 14.8, 5.6 Hz, 2 H), 4.45 – 4.32 (m, 4 H), 4.28 
(dd, J = 5.8, 3.4 Hz, 1 H), 4.23 – 4.16 (m, 2 H), 3.84 (dd, J = 9.5, 3.7 Hz, 1 H), 3.53 (dd, 
J = 9.6, 3.7 Hz, 1 H), 3.45 – 3.40 (m, 2 H), 3.01 (dd, J = 15.7, 3.3 Hz, 1 H), 2.70 (dd, J = 
15.8, 7.1 Hz, 1 H), 2.42 – 2.36 (m, 2 H), 1.18 (s, 9 H), 1.01 (d, J = 6.4 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 171.6, 170.7, 169.9, 169.8, 169.5, 156.5, 144.4, 144.0, 141.3, 137.5, 
131.6, 128.8, 128.4, 127.9, 127.7, 127.6, 127.1, 125.2, 119.9, 118.6, 75.3, 73.0, 70.9, 
69.2, 66.7, 66.1, 65.8, 58.2, 53.1, 49.7, 47.3, 38.6, 36.9, 35.7, 28.2, 18.4; HRMS (ESI-
TOF) m/z calcd for C62H68N5O10 [M + H]
+ 1042.4966, found 1042.4963 
 
7.4.7. Synthesis of Peptide 747 
Peptide 747. To a solution of Fmoc--Ala-D-
Thr(tBu)-L-Asn(Trt)-L-Ser(Bn)-OAllyl 746 (100 
mg, 0.10 mmol, 1.0 equiv) in CH2Cl2 (5 mL) was 
added piperidine (0.03 mL, 0.29 mmol, 3.0 equiv) 
and the reaction mixture was stirred at 25 ºC for 5 h. 
After this time, the organic solvent was removed 
under reduced pressure and the resulting crude 
product was purified by flash column chromatography (silica gel, 60% EtOAc in hexanes 
→ 10% MeOH in CH2Cl2) to obtain the corresponding amine (80 mg, quantitative) as a 
colorless foam: Rf  = 0.10 (silica gel, 10% MeOH in CH2Cl2); [α]25 D = – 8.11 (c 0.08, 
CH2Cl2); 
1H NMR (400 MHz, MeOD) δ 8.04 (bs, 1 H), 7.30 – 7.18 (m, 20 H), 5.94 – 5.81 
(m, 1 H), 5.35 – 5.27 (m, 1 H), 5.22 – 5.16 (m, 1 H), 4.79 (t, J = 5.6 Hz, 1 H), 4.68 (t, J = 
4.0 Hz, 1 H), 4.65 – 4.55 (m, 2 H), 4.50 – 4.35 (m, 3 H), 4.09 (dd, J = 6.3, 3.5 Hz, 1 H), 
3.88 (dd, J = 9.7, 4.4 Hz, 1 H), 3.66 (dd, J = 9.7, 3.8 Hz, 1 H), 3.13 – 3.07 (m, 1 H), 2.98 
(t, J = 5.9 Hz, 2 H), 2.76 (dd, J = 15.9, 5.2 Hz, 1 H), 2.59 – 2.50 (m, 2 H), 1.16 (s, 9 H), 
1.11 (d, J = 6.3 Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 171.9, 171.7, 170.4, 170.3, 
169.8, 144.5, 137.7, 131.8, 128.7, 128.7, 128.0, 127.5, 127.4, 126.4, 117.4, 74.5, 72.9, 
70.4, 68.9, 65.7, 58.7, 53.1, 49.6, 44.5, 38.1, 36.3, 27.3, 18.3; HRMS (ESI-TOF) m/z calcd 
for C47H58N5O8 [M + H]
+ 820.4285, found 820.4283. To a solution of amine obtained 
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above (0.10 mmol, 1.0 equiv) in CH2Cl2 (5 mL) was added 2,4-pentadienoic acid 734 (13 
mg, 0.13 mmol, 1.3 equiv), HOBt.H2O (20 mg, 0.14 mmol, 1.5 equiv), and EDC
.HCl (37 
mg, 0.19 mmol, 2.0 equiv) was added and the reaction mixture was stirred at 25 ºC for 15 
h. After this time, a saturated aqueous NaHCO3 solution was added and the aqueous phase 
was extracted twice with CH2Cl2. The combined organic layers were washed sequentially 
with a saturated aqueous NH4Cl solution and brine, dried over anhydrous MgSO4, filtered 
and the solvent evaporated under reduced pressure. The crude product was purified by 
flash column chromatography (silica gel, 30% EtOAc in hexanes → 100% EtOAc) to 
obtain 747 (45 mg, 53%) as a white foam: Rf  = 0.35 (silica gel, 100% EtOAc); [α]25 D = 
– 19.2 (c 0.21, CH2Cl2); 1H NMR (400 MHz, MeOD) δ 7.30 – 7.17 (m, 20 H), 7.08 (dd, 
J = 15.2, 11.0 Hz, 1 H), 6.41 (dt, J = 16.9, 10.5 Hz, 1 H), 5.93 – 5.80 (m, 2 H), 5.54 (d, J 
= 17.0 Hz, 1 H), 5.40 (d, J = 10.1 Hz, 1 H), 5.30 (ddd, J = 17.2, 3.1, 1.6 Hz, 1 H), 5.18 
(ddd, J = 10.5, 2.7, 1.3 Hz, 1 H), 4.80 (t, J = 5.5 Hz, 1 H), 4.67 (t, J = 4.0 Hz, 1 H), 4.62 
– 4.56 (m, 2 H), 4.52 – 4.38 (m, 2 H), 4.34 (d, J = 3.3 Hz, 1 H), 4.10 (dd, J = 6.3, 3.4 Hz, 
1 H), 3.87 (dd, J = 9.7, 4.3 Hz, 1 H), 3.65 (dd, J = 9.7, 3.8 Hz, 1 H), 3.47 (dd, J = 13.4, 
6.7 Hz, 1 H), 3.37 – 3.32 (m, 1 H), 3.00 (dd, J = 16.0, 6.0 Hz, 1 H), 2.75 (dd, J = 16.0, 
5.2 Hz, 1 H), 2.44 (t, J = 6.5 Hz, 2 H), 1.14 (s, 9 H), 1.09 (d, J = 6.3 Hz, 3 H); 13C NMR 
(100 MHz, MeOD) δ 172.6, 171.7, 170.5, 170.4, 169.7, 167.2, 144.5, 140.5, 137.6, 135.1, 
131.8, 128.7, 128.7, 128.0, 127.5, 127.3, 126.4, 124.7, 123.1, 117.4, 74.5, 72.8, 70.4, 
68.9, 66.6, 65.7, 58.7, 53.1, 49.7, 38.1, 35.7, 35.1, 27.4, 18.4; HRMS (ESI-TOF) m/z calcd 
for C52H62N5O9 [M + H]
+ 900.4548, found 900.4546.  
 
7.4.8. Synthesis of Peptide 742 from Solution Phase 
Peptide 742 from Solution Phase. To a solution of 
peptide 747 (33 mg, 0.04 mmol, 1.0 equiv) in CH2Cl2 (2 
mL) was added Pd(PPh3)4 (4 mg, 0.003 mmol, 0.1 
equiv) and morpholine (0.01 mL, 0.04 mmol, 1.2 equiv). 
The resulting solution was stirred at 25 ºC for 1 h. Then, 
an aqueous 1M HCl solution was added and the aqueous 
phase was extracted with EtOAc. The organic layer was 
washed with brine, dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure to afford acid 742 (34 mg, 
quantitative) as a pale white foam which did not required further purification and whose 
spectroscopic and physical properties were identical to 742 obtained from solid phase 
synthesis: Rf  = 0.25 (silica gel, 10% MeOH in CH2Cl2); [α]25 D = – 15.2 (c 0.23, CH2Cl2); 
HRMS (ESI-TOF) m/z calcd for C49H58N5O9 [M + H]
+ 860.4235 found 860.4233.  
 
7.4.9. Synthesis of Fmoc-D-Isoserine 733 
Fmoc-D-Isoserine 733. D-(+)-malic acid 748 (5.0 g, 37.31 mmol, 
1.0 equiv) was dissolved in 2,2-DMP (37 mL) and TsOH (60 mg, 
0.35 mmol, 0.01 equiv) was added. The reaction mixture was stirred 
for 5 h at 25 ºC. After this time, a saturated aqueous NaHCO3 
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solution was added and the aqueous phase was extracted with CH2Cl2. The organic layer 
was washed with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated 
under reduced pressure to afford the corresponding acetal (5.3 g) as a white solid which 
was used in the next step withouth further purification. Acetal obtained above (100 mg, 
0.68 mmol, 1.0 equiv) was dissolved in SOCl2 (0.8 mL) and the reaction mixture was 
refluxed for 1 h. After this time, excess of SOCl2 was removed under reduced pressure to 
afford the corresponding acyl chloride (122 mg) as a brown oil which was used in the 
next step without further purification. Acyl chloride obtained above (122 mg, 0.64 mmol, 
1.0 equiv) was dissolved in acetone (1 mL) and the mixture was cooled to 0 ºC. Then, a 
solution of NaN3 (41 mg, 0.64 mmol, 1.0 equiv) in water (0.5 mL) was added dropwise 
and the reaction mixture was stirred for 1.5 h. After this time, the acetone was removed 
under reduced pressure. Then, the resulting residue was diluted with water and extracted 
with toluene three times. The combined organic layers were dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure to afford acyl azide 
749 as a yellow oil which was used in the next step without further purification. Acyl 
azide 749 obtained from the previous procedure (804 mg, 4.02 mmol, 1.0 equiv) was 
dissolved in toluene (12 mL) and the mixture was refluxed for 1 h. After this time, the 
solvent was removed under reduced pressure to obtain isocyanate 750 as a brown oil, 
which was used in the next step without further purification. Isocyanate 750 obtained 
above (583 mg, 3.41 mmol, 1.0 equiv) was dissolved in toluene (8 mL) and then FmocOH 
(1.0 g, 5.11 mmol, 1.5 equiv) was added. The reaction mixture was stirred for 15 h at 85 
ºC. After this time, water was added and the aqueous phase was extracted with CH2Cl2. 
The organic phase was washed with brine, dried over anhydrous MgSO4, filtered and the 
solvent evaporated under reduced pressure to afford carbamate 751 (542 mg) as a white 
solid which was used in the next step without further purification. Carbamate 751 
obtained above (542 mg, 1.48 mmol, 1.0 equiv) was dissolved in CH3CN (10 mL) and to 
this solution was added 1N HCl solution (10 mL) at 25 ºC. The reaction mixture was 
heated slowly to 40 ºC and was stirred for 3 h at this temperature. After this time, the 
organic solvent was removed under reduced pressure to afford a white solid, which was 
recollected by filtration and washed with water. Then, the obtained solid was dissolved 
in acetone and stirred for 5 min. After this time, the solution was filter off and to the 
filtrate was added toluene (10 mL) and the resulting solution concentrated under reduced 
pressure until the precipitation of a white solid. Then, the solid was recollected by 
filtration, washed with toluene and dried under vaccumm to afford Fmoc-D-isoserine 733 
(348 mg, 26% over 6 steps) as a white solid which did not required further purification: 
Rf  = 0.1 (silica gel, 100% EtOAc); [α]25 D = + 16.8 (c 0.35, MeOD); 1H NMR (400 MHz, 
MeOD) δ 7.79 (d, J = 7.5 Hz, 1H), 7.66 (d, J = 7.4 Hz, 1H), 7.39 (t, J = 7.5 Hz, 1H), 7.31 
(td, J = 7.4, 1.1 Hz, 1H), 4.37 – 4.29 (m, 1H), 4.26 – 4.19 (m, 1H), 3.52 (dd, J = 13.9, 4.4 
Hz, 1H), 3.37 (dd, J = 13.9, 6.9 Hz, 1H); 13C NMR (100 MHz, MeOD) δ 174.5, 157.6, 
143.9, 141.2, 127.4, 126.8, 124.9, 119.5, 69.6, 66.6, 44.1; HRMS (ESI-TOF) m/z calcd 
for C18H18NO5 [M + H]
+ 328.1185, found 328.1184. 
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7.4.10. Synthesis of Peptide 753 
Peptide 753. Peptide 753 was prepared from CTC resin 
(500 mg, L=1.22 mmol/g, 0.61 mmol, 1.0 equiv) 
according to the same procedure described above for the 
preparation of 742 by sequential coupling of Fmoc-L-
Ser(Bn)-OH 730 (764 mg, 1.83 mmol, 3.0 equiv), 
Fmoc-L-Asn(Trt)-OH 736 (728 mg, 1.22 mmol, 2.0 
equiv), Fmoc-D-Thr(tBu)-OH 732 (485 mg, 1.22 mmol, 
2.0 equiv), Fmoc-D-isoserine 752 (399 mg, 1.22 mmol, 
2.0 equiv) and 2,4-pentadienoic acid 734 (120 mg, 1.22 mmol, 2.0 equiv), to obtain 
peptide 753 (336 mg, 63%) as a pale yellow foam: Rf  = 0.15 (silica gel, 10% MeOH in 
CH2Cl2); [α]25 D = – 5.71 (c 0.07, MeOH); 1H NMR (400 MHz, MeOD) δ 8.62 (bs, 1 H), 
7.32 – 7.16 (m, 20 H), 7.16 – 7.08 (m, 1 H), 6.48 (dt, J = 17.3, 10.3 Hz, 1 H), 6.06 (d, J 
= 15.2 Hz, 1 H), 5.62 – 5.50 (m, 1 H), 5.48 – 5.41 (m, 1 H), 4.55 (t, J = 3.3 Hz, 1 H), 4.27 
(d, J = 3.7 Hz, 1 H), 4.12 – 4.05 (m, 2 H), 3.87 (dd, J = 9.7, 4.4 Hz, 1 H), 3.69 (dd, J = 
9.6, 3.4 Hz, 1 H), 3.62 (dd, J = 13.7, 5.8 Hz, 1 H), 3.52 (dd, J = 13.8, 4.0 Hz, 1 H), 2.99–
2.94 (m, 1 H), 2.75 (dd, J = 16.1, 4.8 Hz, 1 H), 2.31 – 2.25 (m, 1 H), 2.22 – 2.16 (m, 1 
H), 1.16 (s, 9 H), 1.02 (d, J = 6.3 Hz, 3 H); 13C NMR (100 MHz, MeOD) δ 173.4, 173.4, 
171.4, 170.4, 170.1, 167.7, 144.5, 140.9, 137.9, 134.9, 128.7, 127.9, 127.5, 127.3, 127.2, 
126.4, 124.4, 123.4, 74.7, 72.8, 70.9, 70.4, 69.3, 66.4, 57.9, 49.8, 42.9, 37.9, 29.4, 27.3, 
18.2; HRMS (ESI-TOF) m/z calcd for C49H58N5O10 [M + H]
+ 876.4184, found 876.4182. 
 
7.4.11. Synthesis of (R,R)-(-)-Pseudoephedrine 755 
(R,R)-(-)-Pseudoephedrine 755. DIPA (13.5 mL, 96.12 
mmol, 2.24 equiv) and n-BuLi (57 mL, 1.6 M in hexanes, 
91.83 mmol, 2.14 equiv) were added to a solution of LiCl 
(10.8 g, 254 mmol, 5.93 equiv) in THF (60 mL) at -78 ºC. 
The resulting reaction mixture was stirred for 15 min at 0 ºC 
and after this time the reaction was cooled to -78 ºC. Then, a solution of 754 (10.7 g, 
42.91 mmol, 1.0 equiv) in THF (30 mL) was added dropwise over 10 min and the reaction 
mixture was stirred for 1 h at -78 ºC, followed by 15 min at 0 ºC and 10 min at 25 ºC. 
After this time, the reaction was cooled to -78 ºC and MeI (4 mL, 64.37 mmol, 1.5 equiv) 
was added. The resulting mixture was stirred for 1 h at -78 ºC and 1 h at 0 ºC, quenched 
with a saturated aqueous NH4Cl solution and the aqueous phase extracted with EtOAc 
twice. The combined organic layers were washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes) to 
obtain 755 (9.2 g, 81%) as a colorless oil: Rf  = 0.50 (silica gel, 70% EtOAc in hexanes); 
[α]25 D = – 14.3 (c 0.45, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.31 (m, 1H), 4.64 
(d, J = 7.2 Hz, 1H), 4.28 (s, 1H), 2.79 (s, 1H), 2.59 (dq, J = 13.3, 6.7 Hz, 1H), 1.72 – 1.58 
(m, 1H), 1.33 – 1.23 (m, 1H), 1.20 (d, J = 7.0 Hz, 1H), 1.02 (d, J = 6.8 Hz, 1H), 0.92 – 
0.85 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 179.2, 142.7, 128.3, 127.5, 126.2, 77.2, 
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76.6, 36.4, 36.2, 20.6, 17.4, 14.5, 14.2; HRMS (ESI-TOF) m/z calcd for C16H26NO2 [M + 
H]+ 264.1964, found 264.1962. 
 
7.4.12. Synthesis of ,-Unsaturated Ester 758 
,-Unsaturated Ester 758. n-BuLi (87 mL, 1.6 M in hexanes, 
140 mmol, 4.0 equiv) was added to a solution of DIPA (20 mL, 
143 mmol, 4.1 equiv) in THF (60 mL) at -78 ºC and the resulting 
reaction mixture was stirred for 10 min at this temperature, 
followed by 10 min at 0 ºC. After this time, BH3
.NH3 (4.5 g, 147 
mmol, 4.2 equiv) was added in one portion and the reaction mixture was stirred for 15 
min at 0 ºC, 15 min at 25 ºC and then was cooled to 0 ºC. A solution of 755 (9.2 g, 34.93 
mmol, 1.0 equiv) in THF (15 mL) was added over 30 min and the reaction mixture was 
stirred for 2 h at 25 ºC. After this time, the reaction was quenched by the addition of 3N 
HCl solution (90 mL) and was stirred for 30 min at 0 ºC. The aqueous phase was extracted 
with Et2O four times and the combined organic layers were washed sequentially with 3N 
HCl solution (75 mL), 2N NaOH (75 mL) and brine, dried over anhydrous MgSO4, 
filtered and the solvent evaporated under reduced pressure to obtain the corresponding 
alcohol (~28.4 mmol) as a colorless oil which was used in the next step without 
purification. The crude alcohol obtained above (~28.4 mmol) was dissolved in CH2Cl2 
(10 mL) and then PCC (10 g, 48.3 mmol, 1.7 equiv) was added to this solution. The 
reaction mixture was stirred for 2 h at 25 ºC and after this time, the crude mixture was 
filtered through a pad of celite and washed with CH2Cl2. To this solution of the crude 
aldehyde 756 in CH2Cl2 (~29 mmol, ~0.2 M solution) was added Ph3P=CO2Et (20 g, 58.3 
mmol, 2.0 equiv) and the resulting reaction mixture was stirred 15 h at 25 ºC. After this 
time the organic solvent was removed under reduced pressure and the resulting crude 
residue was purified by flash column chromatography (silica gel, 3% EtOAc in hexanes) 
to obtain 758 (2.8 g, 47% over 3 steps) as a colorless oil: Rf  = 0.60 (silica gel, 10% EtOAc 
in hexanes); [α]25 D = + 21.1 (c 0.35, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 6.85 (dd, J 
= 15.7, 7.9 Hz, 1 H), 5.76 (dd, J = 15.7, 1.2 Hz, 1 H), 4.17 (q, J = 7.1 Hz, 2 H), 2.29 (dq, 
J = 13.5, 6.7 Hz, 1 H), 1.38 – 1.23 (m, 7 H), 1.03 (d, J = 6.7 Hz, 3 H), 0.88 (t, J = 7.0 Hz, 
3 H); 13C NMR (100 MHz, CDCl3) δ 166.9, 154.7, 119.5, 60.2, 38.2, 36.3, 20.3, 19.4, 
14.3, 14.1; HRMS (ESI-TOF) m/z calcd for C10H19O2 [M + H]
+ 171.1385, found 
171.1383. 
 
7.4.13. Synthesis of Allylic Alcohol 759 
Allylic Alcohol 759. DIBAL-H (41 mL, 1.0 M in toluene, 41.0 
mmol, 2.5 equiv) was added to a solution of 758 (2.8 g, 16.4 
mmol, 1.0 equiv) in CH2Cl2 (100 mL) at -78 ºC and the reaction 
mixture was stirred for 1 h at this temperature. Then, the reaction 
was quenched by the dropwise addition of MeOH at -78 ºC and the mixture was allowed 
to reach 0 ºC, treated with a saturated aqueous Na+/K+ tartrate solution and diluted with 
CH2Cl2. The resulting mixture was vigorously stirred until a clear separation of both 
Experimental Part   
262 
 
organic and aqueous phases. The organic layer was separated and the aqueous phase was 
extracted with CH2Cl2 three times. The combined organic layers were washed with brine, 
dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. 
The residue was purified by flash column chromatography (silica gel, 10% EtOAc in 
hexanes) to obtain allylic alcohol 759 (1.7 g, 81%) as a colorless oil: Rf = 0.35 (silica gel, 
20% EtOAc in hexanes); []25D = + 5.91 (c 0.09, CH2Cl2); 1H NMR (400 MHz, CDCl3) 
δ 5.60 – 5.56 (m, 2 H), 4.11 – 4.08 (m, 2 H), 2.15 (dt, J = 12.6, 6.4 Hz, 1 H), 1.33 – 1.24 
(m, 4 H), 0.98 (d, J = 6.7 Hz, 3 H), 0.88 (t, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) 
δ 139.4, 127.0, 63.9, 39.1, 36.1, 20.4, 20.4, 14.2; HRMS (ESI-TOF) m/z calcd for C8H17O 
[M + H]+ 129.1279, found 129.1277. 
 
7.4.14. Synthesis of Epoxy Alcohol 760 
Epoxy Alcohol 760. To a suspension of titanium 
tetraisopropoxide (0.9 mL, 3.05 mmol, 0.23 equiv) and 4Å 
molecular sieves (12 g) in CH2Cl2 (60 mL) was added (+)-L-DET 
(0.6 mL, 3.32 mmol, 0.25 equiv) at -50 ºC. After 15 min at this 
temperature, a solution of allylic alcohol 759 (1.7 g, 13.26 mmol, 1.0 equiv) in CH2Cl2 
(30 mL) was added dropwise, followed by the addition, after additional 30 min, of TBHP 
(3.6 mL, 5.5 M solution in decane, 19.89 mmol, 1.5 equiv) at the same temperature. After 
15 h at this temperature, the reaction mixture was quenched with Me2S (4.5 mL, 60.99 
mmol, 4.6 equiv) at 0 ºC, filtered off and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (silica gel, 
10% EtOAc in hexanes) to obtain epoxy alcohol 760 (1.6 g, 84%) as a colourless oil: Rf 
= 0.45 (silica gel, 40% EtOAc in hexanes); []25D = – 21.0 (c 0.4, CH2Cl2); 1H NMR (400 
MHz, CDCl3) δ 3.91 (d, J = 12.4 Hz, 1 H), 3.62 (d, J = 12.5 Hz, 1 H), 2.99 – 2.95 (m, 1 
H), 2.72 (dd, J = 7.2, 2.4 Hz, 1 H), 1.86 (bs, 1 H), 1.39 – 1.29 (m, 4 H), 1.01 (d, J = 6.3 
Hz, 3 H), 0.94 – 0.86 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 61.8, 60.6, 58.4, 35.9, 
35.3, 20.4, 17.2, 14.3; HRMS (ESI-TOF) m/z calcd for C8H17O2 [M + H]
+ 145.1229, 
found 145.1227. 
 
7.4.15. Synthesis of Diol 761 
Diol 761. MeLi (69 mL, 1.6 M in Et2O, 111 mmol, 10.0 equiv) 
was added at 0 ºC to a solution of CuI (10.6 g, 55.47 mmol, 5.0 
equiv) in THF (100 mL) and the resulting mixture was stirred for 
5 minutes. After this time, a solution of epoxy alcohol 24 (1.6 g, 
11.09 mmol, 1.0 equiv) in THF (10 mL) was added at 0 ºC and 
the reaction was stirred at 25 ºC for 15 h. Then, the reaction was quenched by addition of 
MeOH at 0 ºC followed by the addition of saturated aqueous NH4Cl solution. The aqueous 
phase was extracted with Et2O twice and the combined organic layers were washed with 
brine, dried over anhydrous MgSO4, filtered and the solvent evaporated under reduced 
pressure to obtain a 3:1 mixture of opening products in 2- and 3- positions, respectively 
(~55.0 mmol). NaIO4 (1.2 g, 5.55 mmol, 0.5 equiv) was added at 0 ºC to a solution of the 
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crude product obtained above in a 1:1 mixture of THF:H2O (60 mL). The resulting 
suspension was stirred at 25 ºC for 15 h. After this time, the reaction mixture was diluted 
with water and the aqueous phase was extracted with Et2O twice and the combined 
organic layers were washed with brine, dried over anhydrous MgSO4, filtered and the 
solvent evaporated under reduced pressure. The resulting residue was purified by flash 
column chromatography (silica gel, 20% EtOAc in hexanes) to obtain diol 761 (1.1 g, 
62% over 2 steps) as a colorless oil: Rf = 0.35 (silica gel, 50% EtOAc in hexanes); []25D 
= + 10.2 (c 0.20, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 3.73 (dd, J = 10.7, 3.3 Hz, 1 H), 
3.66 (dd, J = 10.6, 7.9 Hz, 1 H), 3.48 (dd, J = 8.9, 2.6 Hz, 1 H), 2.44 (bs, 2 H), 1.92 – 
1.81 (m, 1 H), 1.70 – 1.59 (m, 1 H), 1.40 – 1.25 (m, 3 H), 0.94 – 0.89 (m, 4 H), 0.87 (d, 
J = 6.8 Hz, 3 H), 0.81 (d, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 61.8 60.6, 
58.4, 35.9, 35.3, 20.4, 17.2, 14.3; HRMS (ESI-TOF) m/z calcd for C9H21O2 [M + H]
+ 
161.1542, found 161.1540. 
 
7.4.16. Synthesis of Bis(silyl ether) 762 
Bis(silyl ether) 762. 2,6-Lutidine (2 mL, 17.16 mmol, 2.5 
equiv) was added to a solution of diol 761 (1.1 g, 6.86 mmol, 
1.0 equiv) in CH2Cl2 (30 mL) at 0 ºC and the mixture was stirred 
for 10 min at this temperature. After this time, TBSOTf (3.9 
mL, 17.16 mmol, 2.5 equiv) was added at 0 ºC and the reaction 
mixture was stirred at 25 ºC for 1.5 h. Then, the reaction mixture was diluted with water 
and the aqueous phase was extracted with CH2Cl2 twice. The combined organic layers 
were washed with brine, dried over anhydrous MgSO4, filtered and the solvent evaporated 
under reduced pressure. The resulting residue was purified by flash column 
chromatography (silica gel, 2% EtOAc in hexanes) to obtain 762 (2.6 g, 97%) as a 
colorless oil: Rf = 0.80 (silica gel, 10% EtOAc in hexanes); []25D = + 11.5 (c 0.50, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 3.68 (dd, J = 9.8, 4.8 Hz, 1 H), 3.49 (dd, J = 6.6, 
2.6 Hz, 1 H), 3.39 (dd, J = 9.8, 7.4 Hz, 1 H), 1.78 (ddd, J = 14.0, 6.9, 4.8 Hz, 1 H), 1.62 
– 1.56 (m, 1 H), 1.36 – 1.12 (m, 5 H), 0.91 – 0.88 (m, 18 H), 0.88 – 0.86 (m, 4 H), 0.83 
(d, J = 6.8 Hz, 3 H), 0.04 (d, J = 1.8 Hz, 6 H), 0.03 (d, J = 1.6 Hz, 6 H); 13C NMR (100 
MHz, CDCl3) δ 65.7, 40.3, 37.2, 35.7, 26.2, 25.9, 25.7, 20.8, 18.5, 18.3, 14.5, 14.3, -2.9, 
-3.8, -3.9, -5.3, -5.4; HRMS (ESI-TOF) m/z calcd for C21H49O2Si2 [M + H]
+ 389.3271, 
found 389.3270. 
 
7.4.17. Synthesis of Alcohol 763 
Alcohol 763. CSA (1.6 g, 6.79 mmol, 1.0 equiv) was added to a 
solution of 762 (2.6 g, 6.79 mmol, 1.0 equiv) in a mixture of 
CH2Cl2:MeOH (1:1, 150 mL) at 0 ºC and the reaction mixture was 
stirred at this temperature for 40 min. After this time, a saturated 
aqueous NaHCO3 solution was added and the aqueous phase was 
extracted with CH2Cl2 twice. The combined organic layers were washed with brine, dried 
over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
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resulting residue was purified by flash column chromatography (silica gel, 10% EtOAc 
in hexanes) to obtain 763 (1.1 g, 60%) as a colorless oil: Rf = 0.60 (silica gel, 50% EtOAc 
in hexanes); []25D = + 18.3 (c 0.60, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 3.67 – 3.55 
(m, 2 H), 3.51 (dd, J = 5.4, 3.9 Hz, 1 H), 2.60 (bs, 1 H), 1.92 – 1.81 (m, 1 H), 1.68 – 1.58 
(m, 1 H), 1.48 – 1.33 (m, 2 H), 1.29 – 1.07 (m, 3 H), 0.96 (d, J = 7.0 Hz, 3 H), 0.92 (s, J 
= 2.9 Hz, 9 H), 0.91 – 0.87 (m, 5 H), 0.11 (s, 3 H), 0.08 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 81.3, 66.3, 38.1, 37.6, 35.3, 26.1, 20.9, 18.3, 16.4, 15.2, 14.4, -3.9, -4.1; HRMS 
(ESI-TOF) m/z calcd for C15H35O2Si [M + H]
+ 275.2406, found 275.2405. 
 
7.4.18. Synthesis of Aldehyde 764 
Aldehyde 764. To a solution of alcohol 763 (1.0 g, 3.64 mmol, 1.0 
equiv) in CH2Cl2 (30 mL) was added Dess-Martin periodinane (3.0 
g, 7.29 mmol, 2.0 equiv) at 0 ºC. The reaction mixture was stirred 
at 25 ºC for 3 h and, after this time, the reaction mixture was 
quenched with a 1:1 mixture of a saturated aqueous NaHCO3 
solution/Na2S2O3 1 M. The solution was stirred for 20 min and then, the organic layer 
was separated. The aqueous phase was extracted with CH2Cl2 and the combined organic 
extracts were washed with brine, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The resulting residue was purified by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) to obtain 764 (940 mg, 95%) as a 
colorless oil: Rf = 0.80 (silica gel, 10% EtOAc in hexanes); []25D = + 11.4 (c 0.15, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 9.77 (d, J = 2.9 Hz, 1 H), 3.76 – 3.73 (m, 1 H), 
2.58 – 2.50 (m, 1 H), 1.64 (dtd, J = 13.6, 6.8, 2.9 Hz, 1 H), 1.45 – 1.34 (m, 3 H), 1.29 – 
1.19 (m, 2 H), 1.07 (d, J = 7.1 Hz, 3 H), 0.91 – 0.89 (m, 5 H), 0.88 (s, 9 H), 0.06 (s, 3 H), 
0.04 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 81.3, 66.3, 38.1, 37.6, 35.3, 26.1, 20.9, 18.3, 
16.4, 15.2, 14.4, -3.9, -4.1; HRMS (ESI-TOF) m/z calcd for C15H33O2Si [M + H]
+ 
273.2250, found 273.2251. 
 
7.4.19. Synthesis of Polyketide Fragment 729 
Polyketide Fragment 729. A solution of (-)-Icp2BOMe (1.4 g, 
4.31 mmol, 1.25 equiv) in Et2O (5 mL) was cooled to 0 ºC and 
then allyl magnesium bromide (4.1 mL, 1.0 M in Et2O, 4.14 
mmol, 1.2 equiv) was added dropwise over 20 min and the 
mixture was stirred for 1 h at 25 ºC. After this time, the mixture 
was cooled to -78 ºC and then a solution of aldehyde 764 (940 mg, 3.45 mmol, 1.0 equiv) 
in Et2O (2.5 mL) was added dropwise over 20 min. The resulting reaction mixture was 
stirred at -78 ºC for 1.5 h and then was stirred for 1h at 25 ºC. After this time, the system 
was cooled to 0 ºC and was added dropwise over 10 min a mixture a a 3.0 M aqueous 
NaOH solution (7 mL) and 30% H2O2 (3 mL), and was followed by the dropwise adittion 
over 3 min of a saturated queous NaHCO3 solution (9 mL). The resulting mixture was 
stirred 15 h at 25 ºC. Then, the organic layer was separated and the aqueous phase was 
extracted with Et2O twice. The combined organic layers were washed with brine, dried 
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over anhydrous MgSO4, filtered and the solvent evaporated under reduced pressure. The 
resulting residue was purified by flash column chromatography (silica gel, 2% EtOAc in 
hexanes) to obtain polyketide fragment 729 (1.0 g, 92%) as a colorless oil: Rf = 0.50 (silica 
gel, 10% EtOAc in hexanes); []25D = + 23.9 (c 0.21, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 5.80 (ddt, J = 17.1, 10.2, 7.1 Hz, 1 H), 5.15 – 5.03 (m, 2 H), 4.15 – 4.10 (m, 1 
H), 3.56 (dd, J = 5.7, 3.0 Hz, 1 H), 2.35 – 2.26 (m, 1 H), 2.15 – 2.05 (m, 1 H), 1.78 – 1.64 
(m, 2 H), 1.51 – 1.32 (m, 2 H), 1.26 – 1.05 (m, 3 H), 0.98 (d, J = 7.1 Hz, 3 H), 0.92 (s, 9 
H), 0.91 – 0.87 (m, 5 H), 0.11 (s, 3 H), 0.09 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
135.5, 116.9, 82.7, 70.6, 39.5, 37.7, 37.5, 35.6, 26.2, 20.8, 18.3, 16.1, 14.4, 11.9, -3.8, -
3.9; HRMS (ESI-TOF) m/z calcd for C18H39O2Si [M + H]
+ 315.2719, found 315.2718. 
 
7.4.20. Synthesis of Alcohol 770 
Alcohol 770. AcOH (0.03 mL, 0.59 mmol, 0.01 equiv) was 
added to a solution of (S,S)-N,N’-bis(3,5-di-
tertbutylsalicyclidene-1,2-cyclohexanediamino)cobalt (II) 
(175 mg, 0.29 mmol, 0.005 equiv) in toluene (5 mL) and the 
reaction mixture was stirred for 1 h at 25 ºC. After this time, toluene and acetic acid in 
excess were removed under reduced pressure and (±)-1,2-epoxyhexane (6 g, 59.89 mmol, 
1.0 equiv) was then added. The resulting mixture was stirred for 30 min and cooled to 0 
ºC. Then, water (0.59 mL, 32.93 mmol, 0.55 equiv) was added and the reaction mixture 
was stirred for 15 h. The crude mixture was subjected to distillation and epoxide 768 was 
collected at 120 ºC (1 atm) (2.0 g, 33%): [α]25 D = – 8.7 (c 1.0, CHCl3), reported330 [α]25 D 
= – 9.0 (c 1.0, CHCl3). A solution of 4-bromo-1-butene (1 mL, 9.98 mmol, 1.0 equiv) and 
Mg turnings (485 mg, 19,97 mmol, 2.0 equiv) in Et2O (15 mL) was added into a stirred 
suspension of CuI (190 mg, 0.99 mmol, 0.1 equiv) in THF (35 mL) at -40 ºC. After 10 
min, a solution of epoxide obtained above (1.0 g, 9.98 mmol, 1.0 equiv) in THF (10 mL) 
was added dropwise and the stirring was continued for 4 h at -40 ºC. After this time, the 
mixture was allowed to reach 25 ºC and a saturated aqueous NH4Cl solution was added. 
The aqueous phase was extracted with Et2O, washed with brine, dried over anhydrous 
MgSO4, filtered and the solvent evaporated under reduced pressure. The crude product 
was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) to 
obtain 770 (45 mg, 67%) as a colorless oil: Rf  = 0.40 (silica gel, 40% EtOAc in hexanes); 
[α]25 D = –15.5 (c 0.18, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.82 (ddt, J = 16.9, 10.2, 
6.7 Hz, 1 H), 4.99 (dddd, J = 19.6, 10.2, 3.5, 1.4 Hz, 2 H), 3.65 – 3.54 (m, 1 H), 2.12 – 
1.99 (m, 2 H), 1.58 – 1.24 (m, 10 H); 13C NMR (100 MHz, CDCl3) δ 138.8, 114.6, 71.9, 
37.2, 36.9, 33.8, 27.8, 25.7, 24.9, 22.8; HRMS (ESI-TOF) m/z calcd for C10H21O [M + 
H]+ 157.1592, found 157.1590. 
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7.4.21. Synthesis of Ester 772 
Ester 772. Cl3C6H2COCl (0.04 mL, 0.23 mmol, 1.2 equiv) was 
added to a solution of Fmoc-N-Methyl-L-Val-OH (771) (81 
mg, 0.23 mmol, 1.2 equiv) and TEA (0.04 mL, 0.29 mmol, 1.5 
equiv) in THF (2 mL) and the mixture was stirred for 30 min. 
Then, a solution of alcohol 770 (30 mg, 0.19 mmol, 1.0 equiv) 
and DMAP (47 mg, 0.38 mmol, 2.0 equiv) in toluene (1.0 mL) 
was added and the reaction mixture was stirred for 1 h. After this time, water was added 
and the aqueous phase was extracted with EtOAc three times. The combined organic 
layers were washed with brine, dried over anhydrous MgSO4, filtered and the solvent 
evaporated under reduced pressure. The crude product was purified by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) to obtain 772 (70 mg, 74%) as a 
colorless oil: Rf  = 0.55 (silica gel, 30% EtOAc in hexanes); [α]25 D = – 20.8 (c 0.30, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3, two rotamers in 1.1/1 ratio) δ 7.77 (d, J = 7.5 Hz, 
2 H), 7.68 – 7.57 (m, 2 H), 7.40 (t, J = 7.5 Hz, 2 H), 7.31 (td, J = 7.5, 1.2 Hz, 2 H), 5.85 
– 5.67 (m, 1 H), 5.05 – 4.84 (m, 2 H), 4.60 – 4.34 (m, 3 H), 4.26 (dd, J = 15.1, 6.9 Hz, 1 
H), 2.91 (s, 3 H), 2.87 (s, 3 H), 2.10 – 1.97 (m, 2 H), 1.61 – 1.46 (m, 4 H), 1.44 – 1.34 
(m, 1 H), 1.29 – 1.18 (m, 5 H), 1.00 (d, J = 6.5 Hz, 2 H), 0.92 – 0.87 (m, 4 H), 0.87 – 0.80 
(m, 3 H), 0.74 (d, J = 6.7 Hz, 2 H); 13C NMR (100 MHz, CDCl3, both rotamers) δ 170.9, 
170.4, 156.9, 156.3, 144.3, 144.1, 143.9, 143.9, 141.4, 141.4, 138.4, 138.3, 127.7, 127.1, 
127.0, 125.0, 124.9, 124.9, 119.9, 119.9, 114.9, 114.8, 74.8, 74.8, 67.7, 67.6, 64.5, 64.2, 
47.3, 33.6, 33.5, 33.4, 33.4, 30.1, 29.9, 29.7, 27.4, 27.3, 27.1, 24.6, 22.5, 19.7, 19.6, 18.8, 
18.6, 13.9; HRMS (ESI-TOF) m/z calcd for C31H42NO4 [M + H]
+ 492.3114, found 
492.3115. 
 
7.4.22. Synthesis of Amine 766 
Amine 766. To a solution of 772 (69 mg, 0.14 mmol, 1.0 equiv) 
in CH2Cl2 (5 mL) was added piperidine (0.04 mL, 0.42 mmol, 
3.0 equiv) and the reaction mixture was stirred at 25 ºC for 3 h. 
After this time, the solvent was removed under reduced 
pressure and the resulting crude product was purified by flash 
column chromatography (silica gel, 20% EtOAc in hexanes) to 
obtain amine 766 (37 mg, quantitative) as a colorless oil: Rf  = 0.30 (silica gel, 30% EtOAc 
in hexanes); [α]25 D = – 12.6 (c 0.15, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.78 (ddt, J 
= 16.9, 10.2, 6.7 Hz, 1 H), 5.07 – 4.95 (m, 2 H), 4.95 – 4.92 (m, 1 H), 2.93 (d, J = 5.7 Hz, 
1 H), 2.40 (s, 3 H), 2.11 – 2.00 (m, 3 H), 1.58 (td, J = 10.0, 4.7 Hz, 4 H), 1.50 – 1.37 (m, 
2 H), 1.37 – 1.29 (m, 6 H), 1.00 – 0.94 (m, 4 H), 0.91 – 0.87 (m, 3 H); 13C NMR (100 
MHz, CDCl3) δ 174.8, 138.3, 114.8, 74.5, 69.7, 35.4, 33.7, 33.5, 33.4, 31.5, 27.5, 24.5, 
22.5, 19.5, 18.5, 13.9; HRMS (ESI-TOF) m/z calcd for C16H32NO2 [M + H]
+ 270.2433, 
found 270.2431. 
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Introducción 
Esta Tesis Doctoral propone el descubrimiento y desarrollo de nuevos fármacos 
inspirados en productos naturales bioactivos que representan plataformas válidas para la 
generación de nuevas entidades químicas de interés farmacéutico. De esta forma, la 
combinación de diversidad estructural y funcional permitiría la identificación de nuevos 
compuestos con mejores perfiles biológicos. Con el fin de seleccionar objetivos sintéticos 
adecuados, nos hemos centrado en productos naturales que pueden ofrecer prometedoras 
expectativas en el campo biomédico, bien por actuar sobre dianas biológicas novedosas 
o bien por contener nuevas estructuras moleculares que pueden representar las bases de 
nuevos scaffolds de interés farmacéutico. Por tanto, este proyecto de Tesis Doctoral 
presenta un programa de trabajo que integraría formación y generación de nuevos 
conocimientos a través del desarrollo de nuevos compuestos con potencial valor 
terapéutico. En particular, los productos naturales seleccionados son compuestos tipo 
policétido, como la (-)-depudecina y ciclopéptidos y ciclodepsipéptidos como las 
solomonamidas A-B y los celebésidos A-C. Además, estos compuestos han sido 
recientemente descubiertos de fuentes naturales poco accesibles que hacen que, por un 
lado, no haya muchos estudios respecto a su química y biología, y, por otro, que, dada la 
escasez de material suficiente y su difícil accesibilidad de sus fuentes naturales, no se 
pueda profundizar mucho sobre su perfil biológico. A pesar de la escasez de materia, las 
primeras pruebas biológicas de estos productos revelaron interesantes propiedades 
biológicas. Estos perfiles biológicos preliminares, unido a la necesidad de disponer de 
más materia para profundizar en el conocimiento de sus actividades biológicas y 
mecanismos de acción, y confirmar sus estructuras y el hecho de que tales compuestos 
presentan esqueletos moleculares totalmente novedosos y sin precedentes, justifican una 
acción investigadora que puede arrojar nuevos conocimientos desde los puntos de vista 
químico y biológico. En esta Tesis Doctoral hemos establecido estrategias sintéticas 
orientadas al objetivo pero con la posibilidad de extender dichas estrategias a la 
construcción de diversidad estructural a través de la generación de análogos. Estas 
estrategias sintéticas comparten una reacción de metátesis de olefinas como etapa clave 
hacia la síntesis de los productos naturales seleccionados.  
 
Las reacciones de metátesis incluyen las reacciones de alquenos, eninos y 
alquinos, junto con múltiples variantes de sistemas de polialquenos o polialquinos como 
precursores involucrados en procesos de cascada. De entre todos ellos, la reacción de 
metátesis de alquenos es la más empleada, en la cual olefinas cíclicas o alquenos lineales 
se forman a través de una metátesis con cierre de anillo (ring-closing metathesis, RCM), 
metátesis cruzada (cross-metathesis, CM), o a través de sus diferentes versiones 
(estereoselectiva, con transposición, RCM con atadura temporal o RRCM). De hecho, 
estas transformaciones ocupan una posición privilegiada en la síntesis orgánica moderna. 
Menos frecuente en uso pero no menos importante son las metátesis de eninos y alquinos, 
que también se han convertido en valiosas reacciones sintéticas con ventajas adicionales 
sobre las metátesis de alquenos, como en el caso de las metátesis de eninos involucradas 
en procesos en cascada o el caso de las metátesis de alquinos debido a la versatilidad del 
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grupo alquino, que permite posteriores transformaciones para expandir la diversidad 
estructural de los productos que pueden ser formados.  
 
Sin duda, detrás del éxito de todos estos procesos se encuentran los catalizadores 
excepcionales que permiten estas transformaciones. Desde el descubrimiento del primer 
catalizador de wolframio-carbeno llevado a cabo por Katz y de la elucidación del 
mecanismo de la metátesis de alquenos realizada por Chauvin en los años 70, las 
innovaciones claves han sido los descubrimientos del catalizador de Schrock en 1990 y 
del catalizador basado en rutenio por Grubbs en 1993. Estos descubrimientos marcaron 
el comienzo de una extraordinaria y emergente carrera hacia catalizadores más eficientes 
en términos de actividad, estabilidad y tolerancia de grupos funcionales. Estos 
catalizadores altamente eficientes son miembros representativos de tres generaciones de 
complejos de rutenio, en las que la introducción de un ligando de carbeno N-heterocíclico 
(NHC) resultó en un incremento de la actividad catalítica y estabilidad térmica de los 
catalizadores. Los catalizadores desarrollados entre 1996-2007 dieron lugar al diseño 
racional de nuevas versiones para permitir procesos de metátesis estereoselectivos y 
estereoretentivos. Como añadido a este amplio arsenal de valiosos catalizadores se 
encuentran el catalizador soluble en agua en forma de complejos de polietilenglicol o los 
catalizadores basados en rutenio soportados sobre superficies activadas, que expanden el 
alcance y las aplicaciones de la química, particularmente respecto a abordar problemas 
medioambientales. Todos estos catalizadores son apropiados para metátesis de alquenos 
y eninos. Interesantemente, para el último caso, el proceso puede ser efectuado también 
por otros catalizadores basados en otros metales de transición, como aquellos basados en 
Pt, Pd o Ir a través de un mecanismo totalmente diferente.  
 
Un caso aparte es la reacción de metátesis de alquinos, la cual a pesar de poseer 
una similitud mecanística con la metátesis de alquenos, requiere de un tipo diferente de 
catalizador. De hecho, en este caso, la variedad de catalizadores disponibles no es tan 
amplia como los desarrollados para metátesis de alquenos. Junto con la destacada 
actividad y estabilidad de los catalizadores mencionados, otras características que han 
sido mejoradas durante la evolución del diseño de los catalizadores es la excepcional 
tolerancia frente a los grupos funcionales que todos estos catalizadores muestran, que a 
su vez los ha posicionado como una de las herramientas sintéticas más poderosas en la 
síntesis orgánica moderna. Consecuentemente, la síntesis total se ha beneficiado 
enormemente de estas reacciones de metátesis, como se ha demostrado por el uso 
extensivo de estas reacciones en sus versiones intra- e intermoleculares. De hecho, el 
número de contribuciones en las que una reacción de metátesis representa la etapa clave 
que permite completar con éxito una síntesis, o bien una herramienta sintética útil y 
eficiente empleada a lo largo del curso sintético, no deja de crecer en la literatura de la 
química orgánica. 
 
De esta forma, las reacciones de metátesis, en sus varias versiones, se han 
convertido en herramientas poderosas y extremadamente valiosas para la formación de 
enlaces carbono-carbono en síntesis orgánica. La multitud de catalizadores disponibles 
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para llevar a cabo estas reacciones, combinado con las distintas transformaciones que 
pueden ser realizadas, ha posicionado a las reacciones de metátesis como una de las más 
importantes de este siglo, reconociendo a sus principales inventores con el Premio Nobel 
de Química en el año 2005. El valor sintético y el gran potencial de estas reacciones se 
deben al tremendo progreso presenciado en los últimos años respecto al diseño y 
desarrollo de catalizadores estables y eficientes basados en complejos metal-carbeno. 
Como consecuencia, estas reacciones presentan un gran alcance, generalidad y gran 
flexibilidad para la diversificación estructural. Además, como prueba de estas 
características se encuentra su uso extensivo en el campo de la química orgánica, con 
particular impacto en la síntesis total de productos naturales. Estas reacciones, en sus 
diferentes modalidades y estrategias se han convertido en una herramienta estándar en los 
laboratorios de química orgánica moderna, siendo determinante en la finalización de una 
amplia gama de productos naturales.  
 
Objetivos 
El objetivo general de este proyecto sería, por tanto, el descubrimiento y desarrollo 
de nuevos fármacos inspirados en productos naturales bioactivos y mediante la 
generación de análogos que, combinando diversidad estructural y funcional, permitan la 
identificación de nuevos compuestos con mejores perfiles biológicos. De esta forma, se 
establecerían los siguientes objetivos específicos que marcarían el desarrollo de este 
proyecto de tesis: (1) Establecimiento de estrategias sintéticas flexibles y convergentes 
para la síntesis total de los productos naturales seleccionados, (2) Implementación de las 
rutas sintéticas establecidas en el objetivo anterior, para la generación de análogos de los 
productos naturales seleccionados, y (3) Evaluación biológica de los productos naturales 
y análogos sintetizados. 
 
Campaña de la Depudecina 
El reconocimiento del rol crucial que poseen las histonas deacetilasas (HDACs) y  
las histonas acetil transferasas (HAT) en la regulación de la expresión genética, que 
ocurre a través de un control estricto del estado de acetilación de las histonas, ha generado 
un gran interés en su uso como nuevos objetivos prometedores para terapias contra el 
cáncer. De esta forma, mientras las histonas acetiladas provocan una expansión local de 
la cromatina, incrementando la accesibilidad de proteínas reguladoras al ADN, las 
histonas deacetiladas cargadas positivamente incrementan sus afinidades con el ADN y, 
por consiguiente, bloquean la transcripción de genes antitumorales. Las HDACs son las 
enzimas responsables de la eliminación del grupo acetilo presente en residuos de lisina 
de histonas y otras proteínas; y están compuestas por 18 isoformas agrupadas en cuatro 
clases diferentes (I-IV). La inhibición de estas enzimas en el contexto de un estado 
epigenético de neoplasia, donde están sobreexpresadas y juegan papeles importantes en 
la progresión del cáncer, lleva a la restauración de un estado epigenético normal e induce 
la expresión de genes supresivos del tumor. Consecuentemente, los inhibidores de 
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HDACs han atraído una considerable atención de la comunidad científica como potentes 
agentes anticancerígenos novedosos. Una indicación de este interés es la gran actividad 
dirigida hacia el diseño y síntesis de inhibidores de HDACs, que han sido clasificados en 
cinco categorías de acuerdo a sus modos de acción. Como consecuencia de esta actividad 
tan intensa, tres de ellos (vorinostat, belinostat y romidespina) han sido aprobados 
recientemente por la FDA para terapias clínicas anticancerígenas, mientras que un 
número importante de otros inhibidores de HDACs se han sometido a ensayos clínicos 
para el tratamiento de una variedad de neoplasias hematológicas y tumores sólidos 
malignos. El hecho de que otras proteínas, incluyendo factores de transcripción, enzimas 
reparadoras del ADN, transductores de señales y mediadores de inflamación, entre otros, 
son también sustratos de las HDACs, demuestra claramente su participación en una 
enorme variedad de procesos biológicos, tales como el ciclo celular y mitosis, reparación 
del ADN dañado, respuestas de estrés celular, degradación proteica, regulación de la 
citoquina, inmunidad, inflamación, angiogénesis, apoptósis e invasión celular. De hecho, 
las HDACs no solo están involucradas en el cáncer, también en otras patologías como las 
enfermedades neurológicas, desórdenes inmunitarios e infecciones. Por otro lado, la falta 
general de selectividad mostrada por los inhibidores actuales de la familia HDAC explica 
los efectos biológicos tan diversos que pueden producir, reduciendo por tanto la ventana 
terapéutica al fomentar efectos secundarios indeseados. 
 
En este contexto, la (-)-depudecina, aislada desde el cultivo del hongo Alternaria 
brassicicola en 1992 y más tarde, desde el patógeno de la hierba Nimbya scirpicola, ha 
sido identificada como un inhibidor selectivo de las histonas deacetilasas I y II con un 
valor de IC50 en el rango de M bajo, de acuerdo a los estudios biológicos llevados a cabo 
por Schreiber et al. Al contrario que en el caso de los inhibidores más representativos de 
HDACs, la depudecina representa un inhibidor único de estas enzimas en virtud de su 
estructura molecular, caracterizada por la presencia de dos anillos de oxirano separados 
por un doble enlace trans. Descubierta originalmente como parte de un screening 
biológico dirigido hacia la identificación de agentes antitumorales con actividad 
detransformadora, la depudecina se identificó como un metabolito bioactivo capaz de 
revertir la morfología de las células tumorales NIH3T3 (firoblasto), que pasó de una 
forma redondeada en las células transformadas a la morfología plana de las células no 
transformadas. La habilidad de la depudecina de regular la arquitectura citoesquelética de 
las células tumorales se debe a la restauración del estrés de la fibra de actina. Esta 
actividad biológica mostrada suscitó un gran interés biomédico y biológico debido a su 
gran potencial como agente antitumoral y como sonda molecular para la investigación de 
secuencias de señalización que regulan el estrés de las fibras de actina, así como para 
entender mejor los roles de las HDACs. Además, la depudecina no solo induce cambios 
morfológicos sino también parada del ciclo celular y diferenciación celular, que podrían 
atribuirse a la inhibición de la HDAC como se mencionó anteriormente. Probablemente, 
la acción inhibidora de la depudecina contra la HDAC es debido a la presencia de los 
anillos de oxirano biológicamente reactivos que bloquearían el sitio activo de las enzimas 
a través de la formación irreversible de un enlace covalente entre los residuos 
nucleofílicos presentes en el sitio activo y los anillos de oxirano. Además, la depudecina 
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también muestra una importante actividad anti-angiogénica que la dota con una potente 
actividad anti-proliferativa contra HUVEC (células endoteliales de las venas umbilicales 
humanas). Finalmente, además de sus propiedades antitumorales, la depudecina también 
fue identificada como un potente agente anti-protozoo contra el Neospora caninum, sin 
provocar ningún efecto secundario a la célula huésped. 
 
A pesar de las interesantes actividades biológicas de la depudecina, así como su 
estructura molecular única, es bastante sorprendente que solo una síntesis total haya sido 
publicada hasta la fecha por el grupo de Schreiber en 1995. Aunque esta síntesis fue un 
síntesis lineal muy larga, pudo proveer de cantidades suficientes de (-)-depudecina 
sintética para realizar más estudios biológicos. Impulsados por sus impresionantes 
actividades biológicas y atractiva estructura, decidimos iniciar un programa de 
investigación dirigido hacia la síntesis de la depudecina natural y análogos. Nuestro plan 
sintético culminó recientemente con una síntesis total lineal basada en el uso de una nueva 
clase de sales de sulfonio quirales, desarrollados en nuestros laboratorios, para la 
construcción estereoselectiva de los anillos de oxirano contenidos en el producto natural. 
La síntesis contó con 17 etapas y un 19% de rendimiento global desde el (+)-metil D-
lactato. Con el objeto de mejorar y facilitar el acceso a la depudecina natural, así como a 
análogos adicionales para realizar más ensayos biológicos, decidimos explorar una 
alternativa sintética basada en una estrategia de metátesis de olefinas cruzada como una 
aproximación más corta y convergente. 
 
En nuestro proyecto de la depudecina hemos llevado a cabo una nueva síntesis de 
la (-)-depudecina, que mejora ampliamente a nuestra síntesis lineal previa. Mientras la 
primera síntesis total, publicada por Schreiber, requirió 23 etapas lineales desde el (-)-
dietil D-tartrato, con un rendimiento global del 0.7%, nuestra primera síntesis lineal desde 
(+)-Methyl D-lactato se consiguió en 17 etapas con un 19% de rendimiento global. Como 
continuación de nuestro trabajo previo, hemos desarrollado una segunda ruta sintética 
hacia la depudecina utilizando una reacción de metátesis de olefinas cruzada como la 
etapa clave, que fue completada con éxito en una manera convergente para proveer la (-
)-depudecina en solo 12 etapas y con un 26% de rendimiento global desde (+)-Methyl D-
lactato. Además, la ruta sintética permite modificaciones estereoquímicas y funcionales, 
permitiendo la preparación de dos estereoisómeros de la (-)-depudecina, la 10-epi-
depudecina y su enantiómero, que representan análogos únicos que permitirán evaluar la 
influenca de la estereoquímica sobre la actividad biológica, así como la homodepudecina. 
Además, hemos completado el set de análogos con la preparación de varios análogos 
truncados. Los productos sintetizados (-)-depudecina, (+)-depudecina y los análogos 
truncados han sido evaluados biológicamente contra varias líneas celulares tumorales, 
incluyendo células endoteliales. Los resultados obtenidos de las evaluaciones biológicas 
nos han permitido completar un estudio preliminar de relación estructura-actividad (SAR) 
para este interesante producto natural, concluyendo que: a) la estereoquímica en C-10 del 
producto no es esencial para la actividad biológica, b) la presencia de al menos un grupo 
epóxido es clave en la actividad biológica, no siendo necesaria la presencia simultánea de 
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ambos grupos epóxidos, y c) el sistema de alcohol alílico terminar no es esencial, 
pudiendo ser susituido por su isómero. 
 
Campaña de las Solomonamidas 
El descubrimiento de nuevos productos naturales ofrece oportunidades 
importantes para la identificación y desarrollo de nuevos leads y scaffolds en química 
médica, así como un reto fascinante para los químicos orgánicos en virtud de su 
diversidad estructural y complejas estructuras moleculares que muchos de ellos 
presentan. En particular, el mundo marino representa una fuente excepcional rica de 
nuevos metabolitos bioactivos con estructuras sin precedentes, fascinantes perfiles 
biológicos y potencial valor terapéutico. Los organismos marinos y más específicamente 
las esponjas, que son consideradas las mayores fuentes de productos naturales sin 
descubrir, producen una variedad de metabolitos únicos con unos perfiles biológicos muy 
amplios, debido a las condiciones que difieren significativamente de los ambientes 
terrestres, incluyendo entornos agresivos, exigentes y competitivos que permiten la 
producción de potentes moléculas activas.  
 
Entre la infinidad de fuentes marinas de productos naturales, particularmente 
productiva es la esponja marina Theonella swinhoei, que ha demostrado ser una fuente 
impesionante de metabolitos secundarios, proveyendo al menos nueve clases diferentes 
de productos naturales. Además del importante y muy conocido policétido swinhólido, 
descubierto hace 30 años, el género Theonella es conocido por proveer una gama enorme 
de productos naturales tipo peptídicos bioactivos, incluyendo péptidos acíclicos 
(politeonamidas y koshikamidas), ciclopéptidos (kombamida, orbiculamida, 
barangamida, cupolamida o pertamidas, entre otros), péptidos bicíclicos de gran tamaño 
de anillo como las teonellamidas, depsipéptidos (koshikamidas, papuamidas, nagahamida 
o teopapuamida) y glicopéptidos. Como una prueba más del valor del género Theonella 
como una fuente excelente de nuevos péptidos, Zampella et al. recientemente aislaron 
dos nuevos ciclopéptidos denominados solomonamidas A y B, desde una colección de las 
islas Solomon. Estos ciclopéptidos de 15 miembros poseen estructuras moleculares 
únicas y, además, la solomonamida A mostró una potente actividad anti-inflamatoria, 
provocando una importante reducción del 60% de la inflamación en modelos animales 
con una muy baja dosis de 100 μg/Kg. Desafortunadamente, la extrema escasez de las 
solomonamidas ha impedido una evaluación biológica completa. De hecho, la actividad 
anti-inflamatoria de la solomonamida B no fue evaluada debido a la limitada cantidad que 
se aisló. Es importante destacar que los descubridores de estos compuestos, tras recolectar 
unos 207 gramos de esponja seca Theonella Swinhoei en una región cerca de las islas 
Solomon, en el océano Pacífico, solo obtuvieron 6.5 mg de solomonamida A y 3.6 mg de 
solomonamida B, tras un laborioso proceso de aislamiento y purificación. Un análisis 
espectroscópico exhaustivo de ambos compuestos facilitó la elucidación de sus complejas 
estructuras cíclicas, revelando la presencia de tres amino ácidos convencionales (D-Ala, 
Gly and L-Ser) y una unidad sin precedentes, el ácido 4-amino(2’-amino-4’-hidroxifenil)-
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3,5-dihidroxi-2-metil-6-oxohexanoico (ADMOA) y el correspondiente 5-deoxi derivado 
(AHMOA) para las solomonamidas A y B, respectivamente, y para las cuales Zampella 
et al. propusieron una biosíntesis cuyo posible origen sería una unidad de 6-hidroxi 
triptófano. Las configuraciones absolutas de las solomonamidas naturales fueron 
establecidas de manera provisional, como las más probables, a través del empleo de una 
combinación de métodos espectroscópicos y teóricos.  
 
La escasez de las solomonamidas aisladas desde la fuente natural es un 
inconveniente para realizar ensayos biológicos más profundos. La dificultad de acceder a 
grandes cantidades de estos compuestos hace muy difícil conocer con más detalle sus 
perfiles biológicos y mecanismos de acción, y justifica una síntesis química en el 
laboratorio de estos productos naturales. De esta forma, la síntesis química de estos 
inexplorados compuestos podría representar la solución para proveer suficiente cantidad 
de material como para llevar a cabo estudios biológicos más extensos, así como para 
confirmar sus estructuras inicialmente propuestas. Como consecuencia, cuando iniciamos 
este proyecto de investigación en el año 2016, las solomonamidas habían suscitado interés 
con la publicación de algunas aproximaciones sintéticas, incluyendo la síntesis de un 
deoxi análogo de la solomonamida B. En paralelo con el desarrollo de nuestro trabajo de 
investigación, nuevas aproximaciones sintéticas fueron publicadas, culminando con la 
síntesis total de la solomonamida B y, más tarde, con la síntesis total de la solomonamida 
A, llevadas a cabo por el grupo de Reddy. Recientemente, el mismo grupo ha publicado 
la preparación de varios estereoisómeros de macrociclos de solomonamidas, por 
variación de la estereoquímica del fragmento no peptídico AHMOA. Más importante, la 
síntesis total de la solomonamida B permitió una revisión de la estructura inicialmente 
propuesta, con la corrección de las configuraciones en las posiciones C-3 y C-4 llevando 
al isómero-(3S, 4S) en lugar de la configuración propuesta (3R, 4R) para la solomonamida 
B. Desde el punto de vista sintético, la síntesis se basó en una reacción clave de Heck 
intramolecular para obtener el núcleo macrocíclico de las solomonamidas. Teniendo en 
cuenta que la configuración relativa y absoluta de los tres estereocentros presentes en el 
fragmento policétido fueron establecidos por métodos computacionales por Zampella et 
al., el grupo de Reddy decidió realizar la síntesis del isómero-(3S, 4S) en lugar del 
inicialmente propuesto (3R, 4R), confirmando la nueva estructura propuesta para la 
Solomonamida B. 
 
Como la estructura de la solomonamida B fue inicialmente establecida derivada 
de la solomonamida A, esta última también necesitaba una revisión. Como ambos 
productos comparten la misma ruta biosintética, los tres estereocentros (2S, 3S y 4S) 
presentes en la solomonamida B deberían estar presentes en la solomonamida A, dejando 
un único estereocentro en la posición C5 del fragmento ADMOA cuya estereoquímica 
absoluta debía ser confirmada, siendo establecida inicialmente como 5R. Con este 
objetivo, Reddy et al. llevaron a cabo la síntesis del isómero-(3S, 4S, 5S), en lugar de la 
configuración inicialmente propuesta (3R, 4S, 5R), confirmando la nueva estructura 
asignada para la solomonamida A. 
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Nuestro interés en el descubrimiento y desarrollo de nuevos potenciales leads 
basados en compuestos tipo ciclopeptídicos y ciclodepsipeptídicos nos incitó a iniciar un 
programa de investigación dirigido hacia la síntesis total de esta nueva e inexplorada clase 
de ciclopéptido. Con el fin de establecer una estrategia sintética flexible y divergente 
capaz de proveer no solo los productos naturales, sino también acceder a una serie de 
análogos para estudios biológicos, buscamos explorar la reacción de metátesis con cierre 
de anillo (RCM) como la etapa clave para la construcción del macrociclo de 15 miembros. 
Esta etapa de ciclación sería seguida por una fase de oxidación, que incorporaría los 
grupos funcionales necesarios para alcanzar el estado de oxidación final encontrado en 
los productos naturales. Desde una perspectiva estratégica, consideramos que la 
construcción del núcleo macrocíclico en el enlace 4,5 sería capaz de proveer un rápido 
acceso no solo a los productos finales, sino también a análogos desde intermedios 
avanzados, permitiendo la obtención fácil de numerosos scaffolds. Además, es digno de 
mencionar que esta estrategia sintética utiliza materias de partidas simples, evitando la 
construcción del residuo complejo de ADMOA, que puede ser generado en estapas más 
avanzadas de la síntesis a través de una epoxidación de las olefinas precursoras, seguido 
de un proceso de apertura del anillo de oxirano para introducir el grupo amina. De acuerdo 
a esto, nuestra estrategia diseñada en términos retrosintéticos se basa en la desconexión 
de la amida del residuo de L-serina, seguido por la eliminación de los grupos funcionales, 
que serían introducidos mediante manipulaciones oxidativas (fase de oxidación) de los 
productos de metátesis resultantes (fase de ciclación). Como los presentes estudios 
sintéticos se iniciaron antes de la publicación de Reddy, tomamos como objetivo las 
estructuras inicialmente propuestas para las solomonamidas.  
 
En esta Tesis Doctoral se ha llevado a cabo una exploración sintética extensa 
dirigida hacia las solomonamidas basada en una metátesis con cierre de anillo como 
reacción clave para un rápido y eficiente acceso a los núcleos macrocíclicos de estos 
productos naturales. Como resultado de este estudio sintético se ha establecido un proceso 
de cierre de anillo eficiente que procede en altos rendimientos y con completa 
estereoselectividad. Durante el curso de estos esfuerzos sintéticos nos hemos encontrado 
con obstáculos inesperados que han surgido a lo largo de la ruta sintética, principalmente 
los siguientes: 1) la reactividad del grupo hidroxilo en la posición bencílica; 2) la 
reactividad de las diolefinas que contienen alcoholes alílicos y homoalílicos o que 
contienen un sistema de carbonilo ,-insaturado en la catálisis de rutenio; y 3) la 
reactividad de las olefinas macrocíclicas respecto a los reactivos oxidantes. Además, no 
solamente hemos explorado el alcance y limitaciones de la metátesis con cierre de anillo 
en la síntesis del núcleo macrocíclico de las solomonamidas, también hemos identificado 
varios precursores estructuralmente relacionados con las solomonamidas que poseen 
significantes citotoxicidades contra varias líneas celulares tumorales, incluyendo células 
endoteliales, en el rango de M bajo. De esta forma, hemos llevado a cabo un estudio del 
potencial antiangiogénico  de los precursores sintéticos de solomonamidas. Uno de 
precursores fue seleccionado para una caracterización más profunda de su potencial 
antiangiogénico in vitro, mostrando que puede inhibir algunas etapas clave del proceso 
de angiogénesis, incluyendo la proliferización, migración e invasión de células 
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endoteliales, y disminuye su capacidad de degradar las proteínas de la matriz extracelular. 
Además, el potencial antiangiogénico de este compuesto se confirmó a través de dos 
modelos in vivo, la membrana corioalantoidea de pollo y la membrana de pez zebra. 
Nuestros resultados muestran una actividad biológica nueva e interesante de este 
precursor de solomonamida como un inhibidor de la persistente y desregulada 
angiogénesis que caracteriza al cáncer y otras patologías. En conclusión, la química 
descrita destaca los beneficios de la reacción de metátesis de olefinas en el campo de la 
síntesis total de productos naturales, destacando convergencia y flexibilidad para la 
diversidad estructural y ha permitido la identificación de compuestos bioactivos con 
interesantes propiedades antitumorales. Además, estas evaluaciones biológicas 
preliminares de compuestos relativamente simples, ausentes de algunos grupos 
funcionales presentes en los productos naturales, presagian prometedoras propiedades 
antitumorales para las solomonamidas naturales y los califica como nuevos scaffolds de 
interés biológico y medicinal. Finalmente, se han iniciado varios esfuerzos sintéticos 
hacia la síntesis total de las estructuras revisadas de las solomonamidas basados en una 
estrategia de transposición de Overman. La finalización de la síntesis de los productos 
naturales, el diseño de nuevos análogos y estudios biológicos más profundos que permitan 
elucidar el mecanismo de su actividad anti-tumoral y anti-angiogénica se encuentran en 
progreso. 
 
Campaña de los Celebésidos 
La naturaleza es una enorme fuente de nuevos productos naturales que son clave 
en el descubrimiento de nuevos fármacos. Como una nueva demostración de la 
impresionante fuente de metabolitos secundarios de origen marino, tres nuevos 
ciclodepsipéptidos denominados celebésidos A-C han sido aislados de la esponja marina 
Siliquariaspongia mirabilis recolectada en la isla Sulawesi, en Indonesia, por el grupo de 
Bewley. La estructura de estos compuestos ha sido establecida mediante extensivos 
análisis espectroscópicos. Mientras que la configuración absoluta de los amino ácidos se 
determinó a través del método avanzado de Marfey y HPLC quiral, las configuraciones 
relativas del fragmento policétido fueron resueltas por análisis combinado de las 
constantes de acoplamiento J2,3 homonucleares (H-H) y heteronucleares (C-H), ROE y 
cálculos computacionales. Estos productos naturales se caracterizan por ser 
ciclodepsipéptidos de 26 miembros que contienen una cadena policétida denominada 
ácido 7,9-dihidroxi-8,10-dimetiltrideca-2,4-dienoico (Ddtd), y una cadena peptídica que 
presenta cinco residuos de amino ácidos, que incluyen una N-metil valina, una -metil 
asparagina, una D-isoserina, una 3-carbamoil treonina y una serina en el caso del 
celebésido C, y un residuo de fosfoserina en los celebésidos A y B. Curiosamente, la 3-
carbamoil treonina y la fosfoserina son amino ácidos nunca vistos en productos naturales 
de origen marino. 
 
Desde el punto de vista biológico, el celebésido A mostró actividad anti-VIH, con 
un valor de IC50 de 1.9 g/mL, además de citotoxicidad frente a una línea celular de 
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cáncer de colon humano (HTC-116) en el rango de M bajo. Por su parte, el celebésido 
C fue inactivo, mientras que el celebésido B no pudo ser evaluado biológicamente. Una 
vez más, la escasez de estos ciclodepsipéptidos aislados desde la fuente natural es un 
problema para realizar ensayos biológicos más profundos. Por tanto, la síntesis química 
de estos inexplorados ciclodepsipéptidos marinos podría ser la solución para acceder a 
cantidades suficientes de materia para indagar más en sus perfiles biológicos, así como 
en sus mecanismos de acción, y poder confirmar sus estructuras inicialmente propuestas. 
 
La síntesis del fragmento policétido del celebésido A llevada a cabo por nuestro 
grupo de investigación en 2014 representa la única aproximación sintética hacia la cadena 
policétida de los celebésidos hasta la fecha.  Nuestra síntesis se basó en el uso de las sales 
de sulfonio para, mediante reacción con los correspondientes aldehídos, obtener amidas 
glicídicas de manera estereoselectiva, cuyas posteriores reacciones de apertura de los 
anillos de oxirano permitieron generar la unidad policétida con configuración relativa 
syn,anti,syn contenida en los celebésidos, así como en otros productos naturales como el 
YM-47522, el antifúngico basiliskamida y el ciclodepsipéptido langunamida A.  
 
En la presente Tesis Doctoral hemos planeado una estrategia sintética dirigida 
hacia la síntesis de los celebésidos basada en una metátesis de olefinas con cierre de anillo 
para generar el núcleo macrocíclico de 26 miembros de estos productos naturales. En 
nuestra estrategia, hemos empleado la síntesis en fase sólida como una tecnología 
adecuada para un rápido y eficiente acceso al fragmento peptídico contenido en los 
celebésidos, mientras que la cadena policétida del celebésido A ha sido sintetizada de 
manera estereoselectiva a través de una metilación asimétrica, apertura de epóxido y 
alilación asimétrica de Brown como etapas claves. La estrategia sintética descrita para los 
celebésidos permite el acceso a los productos naturales, además de ofrecer la oportunidad 
de generar una amplia gama de análogos de celebésidos a través de la modificación de 
los aminoácidos contenidos en la cadena peptídica durante la síntesis en fase sólida en 
una manera rápida y fácil. La finalización de la síntesis del celebésido A está actualmente 
en marcha y representa nuestra prioridad. 
 
Conclusiones 
Las conclusiones de la Tesis Doctoral se pueden resumir como las siguientes: 
1) Hemos establecido una nueva síntesis total de la (-)-depudecina utilizando una 
reacción de metátesis de olefinas cruzada como etapa clave, llevada a cabo con 
éxito en una manera convergente para proveer (-)-depudecina en solo 12 etapas y 
un 26% de rendimiento global desde (+)-metil-D-lactato. Esta nueva 
aproximación convergente mejora ampliamente a nuestra síntesis lineal previa (17 
etapas, 19% rendimiento global) así como a la síntesis de Schreiber (23 etapas, 
0.7% rendimiento global). 
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2) La ruta sintética desarrollada es susceptible a modificaciones estereoquímicas y 
funcionales, permitiendo la preparación de dos estereoisómeros, la 10-epi-
depudecina y su enantiómero, así como la homodepudecina. Además, hemos 
completado el set de análogos con la preparación de varios análogos truncados de 
depudecina. 
 
3) Los análogos de depudecina sintetizados fueron evaluados biológicamente contra 
varias líneas celulares tumorales, incluyendo células endoteliales, y los resultados 
nos han permitido completar un estudio preliminar de relación estructura-
actividad para este producto natural, concluyendo que: a) la estereoquímica en C-
10 del producto no es esencial en la actividad biológica; b) la presencia de al 
menos uno de los grupos epóxidos es clave en la actividad biológica, pero no es 
necesario la presencia simultánea de ambos; y c) el sistema de alcohol alílico 
terminal no es esencial en la actividad biológica, y puede ser sustituido por su 
isómero. 
 
4) Una exploración sintética muy extensa dirigida hacia las solomonamidas se ha 
realizado basada en una metátesis de olefinas con cierre de anillo como reacción 
clave para un rápido y eficiente acceso a sus núcleos macrocíclicos, procediendo 
en altos rendimientos y con completa estereoselectividad. 
 
5) También hemos identificado varios precursores de solomonamidas que poseen 
una citotoxicidad importante contra varias líneas celulares tumorales, incluyendo 
células endoteliales, en el rango de M bajo. En particular, hemos encontrado que 
un precursor de solomonamida exhibe un potente efecto antiangiogénico in vitro 
e in vivo, y nuestros resultados sugieren la aplicación potencial de los derivados 
de solomonamidas como inhibidores de la persistente y desregulada angiogénesis 
que caracteriza el cáncer y otras patologías. 
 
6) Hemos diseñado una estrategia sintética dirigida hacia los celebésidos que se basa 
en el uso de una metátesis de olefinas con cierre de anillo para generar el anillo 
macrocíclico de 26 miembros que caracteriza a estos productos naturales. En 
nuestra estrategia, hemos utilizado la síntesis en fase sólida como una tecnología 
adecuada para un rápido y eficiente acceso a la cadena peptídica contenida en los 
celebésidos, mientras que el fragmento policétido ha sido sintetizado de manera 
estereoselectiva. 
 
7) La química descrita destaca los beneficios de la reacción de metátesis de olefinas 
en el campo de la síntesis total de productos naturales, otorgando convergencia y 
flexibilidad para la diversidad estructural y ha permitido la identificación de 
compuestos bioactivos con interesantes propiedades antitumorales. 
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Theoretical Calculations 
Minimum energy conformations were calculated in vacuo using the PM3 method found 
in HyperChem 5.0 software. Optimization was performed using Polak-Ribiere algorithm 
until the RMS gradient reached a value below 0.001 kcal/(Å·mol). 
The resulting minimum-energy conformations for compounds 615, 623, 666 and 653 are 
contained in the following .mol files: 
 
Compound 615: 
 
  -HYPER- 09141711283D 
 
 58 60  0  0  0  0  0  0  0  0999 V2000 
   -0.8613    1.8384    1.0385 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.1404    1.6973    0.5259 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.6545    0.3990    0.3587 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.8962   -0.7217    0.6968 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.5795   -0.5720    1.1861 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.0604    0.7376    1.3738 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.9373    0.3464   -0.1478 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.4524   -0.9376   -0.5140 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.0056   -1.6929    0.6490 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.5813   -2.9996    0.9133 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.1452   -3.7154    1.9690 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.1252   -3.1292    2.7697 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.5412   -1.8220    2.5162 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.9848   -1.1058    1.4580 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.2792    1.0313    1.9588 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.3733    1.2797    0.9872 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.2484    1.4062   -0.3376 C   0  0  0  0  0  0  0  0  0  0  0  0 
    0.2122   -1.6961    1.4842 N   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.0402   -3.0147    1.1455 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.0646   -3.4122    0.5644 O   0  0  0  0  0  0  0  0  0  0  0  0 
    1.0894   -4.0270    1.5163 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.2999   -3.7326    0.7887 N   0  0  0  0  0  0  0  0  0  0  0  0 
    0.5739   -5.4402    1.2628 C   0  0  0  0  0  0  0  0  0  0  0  0 
    3.1866   -2.7756    1.2326 C   0  0  0  0  0  0  0  0  0  0  0  0 
    3.1171   -2.3000    2.3838 O   0  0  0  0  0  0  0  0  0  0  0  0 
    4.2354   -2.2661    0.2336 C   0  0  0  0  0  0  0  0  0  0  0  0 
    3.6151   -1.3107   -0.6458 N   0  0  0  0  0  0  0  0  0  0  0  0 
    3.3945    1.7042   -1.2339 C   0  0  0  0  0  0  0  0  0  0  0  0 
    3.6872    0.5928   -2.2247 C   0  0  0  0  0  0  0  0  0  0  0  0 
    4.3666   -0.5972   -1.5711 C   0  0  0  0  0  0  0  0  0  0  0  0 
    5.5185   -0.9542   -1.8786 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.4546    2.8522    1.1873 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.7537    2.5685    0.2603 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.3421   -1.7250    0.5974 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.2862   -0.6640   -1.2224 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.6759   -1.5322   -1.0634 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.7904   -3.4611    0.2990 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.8108   -4.7434    2.1715 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.5674   -3.6957    3.6023 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -7.3085   -1.3551    3.1508 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.3031   -0.0719    1.2553 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.6122    0.2232    2.6681 H   0  0  0  0  0  0  0  0  0  0  0  0 
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    1.1872    1.9609    2.5957 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.3642    1.3850    1.4669 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.0390   -1.5203    2.0192 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.3078   -3.9125    2.6230 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.3450   -4.0333   -0.1574 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.3133   -5.5862    0.1869 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.3402   -6.1934    1.5637 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.3521   -5.5948    1.8679 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.6708   -3.1053   -0.3785 H   0  0  0  0  0  0  0  0  0  0  0  0 
    5.0760   -1.8014    0.8265 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.7980   -0.8584   -0.2922 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.3215    1.9214   -0.6375 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.1519    2.6361   -1.8166 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.3819    0.9763   -3.0191 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.7412    0.2568   -2.7247 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.2673    1.3100   -0.8330 H   0  0  0  0  0  0  0  0  0  0  0  0 
  1  2  4  0  0  0  0 
  1  6  4  0  0  0  0 
  1 32  1  0  0  0  0 
  2  3  4  0  0  0  0 
  2 33  1  0  0  0  0 
  3  4  4  0  0  0  0 
  3  7  1  0  0  0  0 
  4  5  4  0  0  0  0 
  4 34  1  0  0  0  0 
  5  6  4  0  0  0  0 
  5 18  1  0  0  0  0 
  6 15  1  0  0  0  0 
  7  8  1  0  0  0  0 
  8  9  1  0  0  0  0 
  8 35  1  0  0  0  0 
  8 36  1  0  0  0  0 
  9 10  4  0  0  0  0 
  9 14  4  0  0  0  0 
 10 11  4  0  0  0  0 
 10 37  1  0  0  0  0 
 11 12  4  0  0  0  0 
 11 38  1  0  0  0  0 
 12 13  4  0  0  0  0 
 12 39  1  0  0  0  0 
 13 14  4  0  0  0  0 
 13 40  1  0  0  0  0 
 14 41  1  0  0  0  0 
 15 16  1  0  0  0  0 
 15 42  1  0  0  0  0 
 15 43  1  0  0  0  0 
 16 17  2  0  0  0  0 
 16 44  1  0  0  0  0 
 17 28  1  0  0  0  0 
 17 58  1  0  0  0  0 
 18 19  1  0  0  0  0 
 18 45  1  0  0  0  0 
 19 20  2  0  0  0  0 
 19 21  1  0  0  0  0 
 21 22  1  0  0  0  0 
 21 23  1  0  0  0  0 
 21 46  1  0  0  0  0 
 22 24  1  0  0  0  0 
 22 47  1  0  0  0  0 
 23 48  1  0  0  0  0 
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 23 49  1  0  0  0  0 
 23 50  1  0  0  0  0 
 24 25  2  0  0  0  0 
 24 26  1  0  0  0  0 
 26 27  1  0  0  0  0 
 26 51  1  0  0  0  0 
 26 52  1  0  0  0  0 
 27 30  1  0  0  0  0 
 27 53  1  0  0  0  0 
 28 29  1  0  0  0  0 
 28 54  1  0  0  0  0 
 28 55  1  0  0  0  0 
 29 30  1  0  0  0  0 
 29 56  1  0  0  0  0 
 29 57  1  0  0  0  0 
 30 31  2  0  0  0  0 
M  END 
 
Compound 623: 
 
  -HYPER- 09141711293D 
 
 62 64  0  0  0  0  0  0  0  0999 V2000 
   -1.5482    2.2310    1.1603 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.7819    1.9721    0.5861 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.1469    0.6330    0.3587 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.2897   -0.4123    0.7024 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.0199   -0.1399    1.2577 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.6497    1.2103    1.5012 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.3936    0.4616   -0.2077 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.7425   -0.8536   -0.6520 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.2581   -1.7191    0.4498 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.7079   -2.9860    0.6727 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.2336   -3.8088    1.6683 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.3014   -3.3691    2.4505 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.8439   -2.1014    2.2386 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.3256   -1.2789    1.2401 C   0  0  0  0  0  0  0  0  0  0  0  0 
    0.6296    1.6202    2.1474 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.7335    1.9889    1.2256 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.6259    2.2299   -0.0840 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.1297   -1.1835    1.5688 N   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.2021   -2.5008    1.1481 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.1308   -2.9761    0.4727 O   0  0  0  0  0  0  0  0  0  0  0  0 
    1.0115   -3.3958    1.5529 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.2263   -2.9185    0.9377 N   0  0  0  0  0  0  0  0  0  0  0  0 
    0.6895   -4.8412    1.1871 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.9514   -1.8845    1.4890 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.7391   -1.4781    2.6492 O   0  0  0  0  0  0  0  0  0  0  0  0 
    4.0011   -1.2050    0.5984 C   0  0  0  0  0  0  0  0  0  0  0  0 
    3.3390   -0.3209   -0.3225 N   0  0  0  0  0  0  0  0  0  0  0  0 
    2.7873    2.6590   -0.9269 C   0  0  0  0  0  0  0  0  0  0  0  0 
    3.2844    1.5872   -1.9123 C   0  0  0  0  0  0  0  0  0  0  0  0 
    4.0598    0.5022   -1.1736 C   0  0  0  0  0  0  0  0  0  0  0  0 
    5.2794    0.3304   -1.3521 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.2593    3.2768    1.3552 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.4728    2.7819    0.3162 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.6193   -1.4541    0.5539 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.5690   -0.6420   -1.3895 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.8790   -1.3314   -1.1853 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.8493   -3.3309    0.0731 H   0  0  0  0  0  0  0  0  0  0  0  0 
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   -4.8002   -4.8053    1.8381 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.7133   -4.0198    3.2356 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -7.6813   -1.7499    2.8588 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.7442   -0.2751    1.0705 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.0079    0.8353    2.8600 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.4255    2.5270    2.7912 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.7114    2.0864    1.7338 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.6249   -0.9478    2.1816 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.1353   -3.3234    2.6776 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.3837   -3.1696   -0.0108 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.5249   -4.9508    0.0880 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.5177   -5.5171    1.5068 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.2515   -5.1390    1.7099 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.6054   -1.9604    0.0208 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.7103   -0.6418    1.2723 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.4168   -0.0284   -0.0804 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.6535    2.9663   -0.2689 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.4261    3.7720   -1.7429 O   0  0  0  0  0  0  0  0  0  0  0  0 
    4.0258    2.0962   -2.5973 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.1709    1.0149   -2.7571 C   0  0  0  0  0  0  0  0  0  0  0  0 
    0.6627    2.1526   -0.6159 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.0175    4.4240   -1.1615 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.6804    1.8457   -3.3228 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.3938    0.5114   -2.1333 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.5803    0.2737   -3.4850 H   0  0  0  0  0  0  0  0  0  0  0  0 
  1  2  4  0  0  0  0 
  1  6  4  0  0  0  0 
  1 32  1  0  0  0  0 
  2  3  4  0  0  0  0 
  2 33  1  0  0  0  0 
  3  4  4  0  0  0  0 
  3  7  1  0  0  0  0 
  4  5  4  0  0  0  0 
  4 34  1  0  0  0  0 
  5  6  4  0  0  0  0 
  5 18  1  0  0  0  0 
  6 15  1  0  0  0  0 
  7  8  1  0  0  0  0 
  8  9  1  0  0  0  0 
  8 35  1  0  0  0  0 
  8 36  1  0  0  0  0 
  9 10  4  0  0  0  0 
  9 14  4  0  0  0  0 
 10 11  4  0  0  0  0 
 10 37  1  0  0  0  0 
 11 12  4  0  0  0  0 
 11 38  1  0  0  0  0 
 12 13  4  0  0  0  0 
 12 39  1  0  0  0  0 
 13 14  4  0  0  0  0 
 13 40  1  0  0  0  0 
 14 41  1  0  0  0  0 
 15 16  1  0  0  0  0 
 15 42  1  0  0  0  0 
 15 43  1  0  0  0  0 
 16 17  2  0  0  0  0 
 16 44  1  0  0  0  0 
 17 28  1  0  0  0  0 
 17 58  1  0  0  0  0 
 18 19  1  0  0  0  0 
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 18 45  1  0  0  0  0 
 19 20  2  0  0  0  0 
 19 21  1  0  0  0  0 
 21 22  1  0  0  0  0 
 21 23  1  0  0  0  0 
 21 46  1  0  0  0  0 
 22 24  1  0  0  0  0 
 22 47  1  0  0  0  0 
 23 48  1  0  0  0  0 
 23 49  1  0  0  0  0 
 23 50  1  0  0  0  0 
 24 25  2  0  0  0  0 
 24 26  1  0  0  0  0 
 26 27  1  0  0  0  0 
 26 51  1  0  0  0  0 
 26 52  1  0  0  0  0 
 27 30  1  0  0  0  0 
 27 53  1  0  0  0  0 
 28 29  1  0  0  0  0 
 28 54  1  0  0  0  0 
 28 55  1  0  0  0  0 
 29 30  1  0  0  0  0 
 29 56  1  0  0  0  0 
 29 57  1  0  0  0  0 
 30 31  2  0  0  0  0 
 55 59  1  0  0  0  0 
 57 60  1  0  0  0  0 
 57 61  1  0  0  0  0 
 57 62  1  0  0  0  0 
M  END 
 
 
Compound 666: 
 
  -HYPER- 09141711303D 
 
 58 60  0  0  0  0  0  0  0  0999 V2000 
   -1.2823    1.1922    1.1258 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.5345    0.8480    1.6112 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.0193   -0.4521    1.3771 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.2490   -1.4001    0.6997 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.9692   -1.0466    0.2246 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.4950    0.2800    0.4127 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.2817   -0.6905    1.8815 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.8265   -1.9926    1.6153 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.2065   -2.0328    2.1833 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.7194   -3.2572    2.6283 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -8.0187   -3.3294    3.1264 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -8.8094   -2.1816    3.1905 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -8.2981   -0.9599    2.7539 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -7.0004   -0.8839    2.2490 C   0  0  0  0  0  0  0  0  0  0  0  0 
    0.7621    0.7141   -0.1786 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.7010    1.4289    0.4533 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.9375    1.8924   -0.2241 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.1291   -1.9932   -0.3921 N   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.5424   -3.0788   -1.1383 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.7390   -3.3396   -1.3591 O   0  0  0  0  0  0  0  0  0  0  0  0 
    0.5699   -4.0293   -1.6672 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.6631   -3.3462   -2.3150 N   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.0820   -5.0702   -2.5759 C   0  0  0  0  0  0  0  0  0  0  0  0 
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    2.7530   -2.8862   -1.6122 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.7893   -2.9641   -0.3645 O   0  0  0  0  0  0  0  0  0  0  0  0 
    3.9343   -2.3043   -2.4088 C   0  0  0  0  0  0  0  0  0  0  0  0 
    4.7086   -1.3675   -1.6493 N   0  0  0  0  0  0  0  0  0  0  0  0 
    4.1623    1.1301    0.2566 C   0  0  0  0  0  0  0  0  0  0  0  0 
    5.1777    0.9417   -0.8538 C   0  0  0  0  0  0  0  0  0  0  0  0 
    4.6421   -0.0009   -1.9159 C   0  0  0  0  0  0  0  0  0  0  0  0 
    4.1989    0.4184   -3.0020 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.8978    2.2120    1.2870 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.1529    1.5680    2.1642 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.6327   -2.4163    0.5194 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.8605   -2.1607    0.5039 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.1717   -2.7689    2.0954 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.0963   -4.1627    2.5841 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -8.4195   -4.2935    3.4721 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -9.8336   -2.2407    3.5862 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -8.9181   -0.0530    2.8064 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.5898    0.0791    1.9079 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.5990    1.7088    1.5138 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.8490   -1.8564   -0.2413 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.9828   -4.5524   -0.7473 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.6090   -3.2157   -3.2966 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.5430   -4.5886   -3.4714 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.6690   -5.8260   -2.9070 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.8930   -5.5844   -2.0045 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.5784   -1.8123   -3.3594 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.5945   -3.1801   -2.6782 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.8851   -1.6364   -0.7041 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.6489    1.6929    1.0961 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.8588    0.1302    0.6657 H   0  0  0  0  0  0  0  0  0  0  0  0 
    6.1388    0.5487   -0.4310 H   0  0  0  0  0  0  0  0  0  0  0  0 
    5.3942    1.9249   -1.3496 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.0777    2.9889   -0.0239 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.8361    1.7766   -1.3393 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.8937    0.4376   -1.2414 H   0  0  0  0  0  0  0  0  0  0  0  0 
  1  2  4  0  0  0  0 
  1  6  4  0  0  0  0 
  1 32  1  0  0  0  0 
  2  3  4  0  0  0  0 
  2 33  1  0  0  0  0 
  3  4  4  0  0  0  0 
  3  7  1  0  0  0  0 
  4  5  4  0  0  0  0 
  4 34  1  0  0  0  0 
  5  6  4  0  0  0  0 
  5 18  1  0  0  0  0 
  6 15  1  0  0  0  0 
  7  8  1  0  0  0  0 
  8  9  1  0  0  0  0 
  8 35  1  0  0  0  0 
  8 36  1  0  0  0  0 
  9 10  4  0  0  0  0 
  9 14  4  0  0  0  0 
 10 11  4  0  0  0  0 
 10 37  1  0  0  0  0 
 11 12  4  0  0  0  0 
 11 38  1  0  0  0  0 
 12 13  4  0  0  0  0 
 12 39  1  0  0  0  0 
 13 14  4  0  0  0  0 
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 13 40  1  0  0  0  0 
 14 41  1  0  0  0  0 
 15 16  2  0  0  0  0 
 15 58  1  0  0  0  0 
 16 17  1  0  0  0  0 
 16 42  1  0  0  0  0 
 17 28  1  0  0  0  0 
 17 56  1  0  0  0  0 
 17 57  1  0  0  0  0 
 18 19  1  0  0  0  0 
 18 43  1  0  0  0  0 
 19 20  2  0  0  0  0 
 19 21  1  0  0  0  0 
 21 22  1  0  0  0  0 
 21 23  1  0  0  0  0 
 21 44  1  0  0  0  0 
 22 24  1  0  0  0  0 
 22 45  1  0  0  0  0 
 23 46  1  0  0  0  0 
 23 47  1  0  0  0  0 
 23 48  1  0  0  0  0 
 24 25  2  0  0  0  0 
 24 26  1  0  0  0  0 
 26 27  1  0  0  0  0 
 26 49  1  0  0  0  0 
 26 50  1  0  0  0  0 
 27 30  1  0  0  0  0 
 27 51  1  0  0  0  0 
 28 29  1  0  0  0  0 
 28 52  1  0  0  0  0 
 28 53  1  0  0  0  0 
 29 30  1  0  0  0  0 
 29 54  1  0  0  0  0 
 29 55  1  0  0  0  0 
 30 31  2  0  0  0  0 
M  END 
 
 
Compound 653: 
 
  -HYPER- 09141711293D 
 
 62 64  0  0  0  0  0  0  0  0999 V2000 
   -4.2131    1.0331   -0.6592 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.4161    0.5634   -0.1572 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.4591   -0.7327    0.3903 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.3230   -1.5435    0.4160 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.1018   -1.0645   -0.1022 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.0480    0.2566   -0.6283 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.7011   -1.1178    0.8509 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.8115   -2.3820    1.5124 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.3031   -2.3501    2.9155 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.2552   -3.1851    3.3169 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.8239   -3.1740    4.6436 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.4301   -2.3280    5.5715 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.4695   -1.4872    5.1721 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.9056   -1.4984    3.8489 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.8168    0.8388   -1.1479 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.6776    0.9161   -0.4478 C   0  0  0  0  0  0  0  0  0  0  0  0 
    0.5821    1.4549   -1.0123 C   0  0  0  0  0  0  0  0  0  0  0  0 
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   -1.9490   -1.8665   -0.1499 N   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.7480   -3.0966    0.4490 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.6096   -3.7010    1.1118 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.3781   -3.7925    0.2137 C   0  0  0  0  0  0  0  0  0  0  0  0 
    0.7622   -2.9290    0.3890 N   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.4410   -4.4450   -1.1672 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.6031   -3.0596    1.4774 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.3208   -3.7646    2.4633 O   0  0  0  0  0  0  0  0  0  0  0  0 
    2.9511   -2.3170    1.4341 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.8882   -0.9070    1.2156 N   0  0  0  0  0  0  0  0  0  0  0  0 
    1.5992    1.8236    0.0689 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.9732    1.1653   -0.1522 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.8390   -0.3499   -0.0478 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.7050   -1.0794   -1.0531 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.1628    2.0482   -1.0843 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.3255    1.1787   -0.1753 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.3765   -2.5489    0.8627 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -7.9273   -2.5467    1.5108 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.3187   -3.1879    0.9083 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.7525   -3.8419    2.5871 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.9973   -3.8309    4.9527 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -5.0870   -2.3206    6.6163 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -6.9448   -0.8145    5.9005 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -7.7199   -0.8326    3.5256 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.6327    0.5568    0.5945 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.1748   -1.4637   -0.6337 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.3338   -4.6072    1.0058 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.1094   -2.4625   -0.4218 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.4786   -3.6801   -1.9796 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.4511   -5.0961   -1.3300 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.3606   -5.0766   -1.2257 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.5645   -2.7950    0.6144 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.4521   -2.5085    2.4269 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.8447   -0.3163    2.0114 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.7575    3.2260    0.1887 O   0  0  0  0  0  0  0  0  0  0  0  0 
    1.2221    1.5219    1.0910 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.6497    1.5439    0.6684 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.6045    1.5336   -1.4766 C   0  0  0  0  0  0  0  0  0  0  0  0 
    0.3677    2.3588   -1.6443 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.0242    0.6715   -1.6911 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.9879    3.5738   -0.6818 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.9884    1.1641   -2.3319 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.7114    2.6425   -1.5533 H   0  0  0  0  0  0  0  0  0  0  0  0 
    4.6183    1.0716   -1.5577 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.8853    1.2427   -2.1733 H   0  0  0  0  0  0  0  0  0  0  0  0 
  1  2  4  0  0  0  0 
  1  6  4  0  0  0  0 
  1 32  1  0  0  0  0 
  2  3  4  0  0  0  0 
  2 33  1  0  0  0  0 
  3  4  4  0  0  0  0 
  3  7  1  0  0  0  0 
  4  5  4  0  0  0  0 
  4 34  1  0  0  0  0 
  5  6  4  0  0  0  0 
  5 18  1  0  0  0  0 
  6 15  1  0  0  0  0 
  7  8  1  0  0  0  0 
  8  9  1  0  0  0  0 
  8 35  1  0  0  0  0 
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  8 36  1  0  0  0  0 
  9 10  4  0  0  0  0 
  9 14  4  0  0  0  0 
 10 11  4  0  0  0  0 
 10 37  1  0  0  0  0 
 11 12  4  0  0  0  0 
 11 38  1  0  0  0  0 
 12 13  4  0  0  0  0 
 12 39  1  0  0  0  0 
 13 14  4  0  0  0  0 
 13 40  1  0  0  0  0 
 14 41  1  0  0  0  0 
 15 16  2  0  0  0  0 
 15 62  1  0  0  0  0 
 16 17  1  0  0  0  0 
 16 42  1  0  0  0  0 
 17 28  1  0  0  0  0 
 17 56  1  0  0  0  0 
 17 57  1  0  0  0  0 
 18 19  1  0  0  0  0 
 18 43  1  0  0  0  0 
 19 20  2  0  0  0  0 
 19 21  1  0  0  0  0 
 21 22  1  0  0  0  0 
 21 23  1  0  0  0  0 
 21 44  1  0  0  0  0 
 22 24  1  0  0  0  0 
 22 45  1  0  0  0  0 
 23 46  1  0  0  0  0 
 23 47  1  0  0  0  0 
 23 48  1  0  0  0  0 
 24 25  2  0  0  0  0 
 24 26  1  0  0  0  0 
 26 27  1  0  0  0  0 
 26 49  1  0  0  0  0 
 26 50  1  0  0  0  0 
 27 30  1  0  0  0  0 
 27 51  1  0  0  0  0 
 28 29  1  0  0  0  0 
 28 52  1  0  0  0  0 
 28 53  1  0  0  0  0 
 29 30  1  0  0  0  0 
 29 54  1  0  0  0  0 
 29 55  1  0  0  0  0 
 30 31  2  0  0  0  0 
 52 58  1  0  0  0  0 
 55 59  1  0  0  0  0 
 55 60  1  0  0  0  0 
 55 61  1  0  0  0  0 
M  END 
Energies of Computer-generated Conformations for Compounds 615, 623, 666 and 653.  
Compound Energy (Kcal/mol) 
615 -123.301,142 
623 -134.282,212 
666 -123.304,239 
653 -134.288,315 
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Biological Material and Methods 
Material. Bovine aortic endothelial cells (BAEC) were isolated by collagenase digestion, 
and maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing glucose (1 
g/L) supplemented with 10% FBS (DMEM/10% FBS). All the cancer cell lines used in 
this study were obtained from the American Type Culture Collection (ATCC). Human 
fibrosarcoma HT-1080, hepatocellular carcinoma HepG2 and glioblastoma U87MG cells 
were maintained in Eagle's Minimum Essential Medium (EMEM) supplemented with 
10% FBS. Human colon adenocarcinoma HT-29 cells and human osteosarcoma U2OS 
cells were maintained in DMEM containing glucose (4,5 g/L) supplemented with 10% 
FBS. Human breast cancer carcinoma MDA-MB-231, chronic myelogenous leukemia 
KU812F and histiocytic lymphoma U937 cells were maintained in RPMI1640 medium 
supplemented with 10% FBS. Acute promyelocytic leukemia HL-60 cells were 
maintained in RPMI1640 medium supplemented with 20% FBS. All culture medium 
contained glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 μg/mL) and 
amphotericin (1.25 μg/mL) and all cell lines were grown at 37 °C and humidified 5% CO2 
atmosphere. Cell culture media, penicillin/streptomycin and amphotericin B were 
purchased from Biowhittaker (Walkersville, MD, USA) and fetal bovine serum (FBS) 
from BioWest (Kansas, USA). Plastics for cell culture were supplied by NUNC 
(Roskilde, Denmark). Matrigel was purchased from Corning (NY, USA). Chemicals not 
listed in this section were obtained from Sigma-Aldrich (MERK) (Darmstadt, Germany). 
Fertilized chick eggs were purchased from Granja Santa Isabel (Córdoba, Spain). 
Zebrafish (Danio rerio) breeding colony (wild‐type AB strain) was maintained at 28°C. 
 
Cell growth assay. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or 
MTT dye reduction assay in 96-well microplates was used. This assay is dependent on 
the reduction of MTT by mitochondrial dehydrogenases of a viable cell to a blue 
formazan product, which can be measured spectrophotometrically. 2,5 × 103 BAEC, 3 × 
103 HL-60 and KU812F and 2 × 103 HepG2, HT-1080, HT-29, MDA-MB-231, U2OS, 
U937 and U87MG cells in a total volume of 100 μL of their respective growth medium 
were incubated with serial dilutions 1:1 of the tested compounds. After 3 days of 
incubation (37 °C and 5% CO2 in a humid atmosphere), 10 μL of MTT (5 mg/mL in 
phosphate-buffered saline) were added to each well, and the plate was incubated for a 
further 4 h at 37 °C. The resulting formazan was dissolved in 150 μL of 0.04 N HCl/2-
propanol and read at 550 nm. IC50 values were calculated from semi-logarithmic dose-
response plots as those concentrations of compound yielding 50% cell survival, taking 
the values obtained for the control to be 100%. IC50 results are expressed as means +S.D. 
of at least three independent experiments.  
 
Tubular-like structures formation on Matrigel. Cellular suspensions of 5x104 BAE cells 
in serum-free DMEM were added to a 96-well plate coated with 50 µL Matrigel (10.5 
mg/mL) in the presence of the indicated treatments for 5 hours and photographed with a 
microscope camera Nikon DS-Ri2 coupled to a Nikon Eclipse Ti microscope (Nikon, 
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Tokyo, Japan). Each concentration was tested in duplicate and staurosporine 2 µM was 
used as a routine positive assay control. For the disruption assay, tubular-like structures 
were formed following the same protocol for the control conditions and then the indicated 
concentrations of 653 were added. After a further incubation time of 90 min, cultures 
were observed and photographed. Combretastatin-4-phosphate (CA4P) was used as 
positive control of disruptor antiangiogenic drug.  
 
Wound healing assay. Confluent BAEC monolayers in 6-well plates were wounded with 
pipet tips with 2 perpendicular diameters, giving rise to 2 acellular 1 mm-wide lanes per 
well. Then, complete medium in the absence (controls) or presence of different 
concentrations of 653 was added. Wounded areas were observed and photographed after 
0, 4 and 7 hours of incubation with a microscope camera Nikon DS-Ri2 coupled to a 
Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan). The migration of BAEC into the 
cell-free area was quantified by Image J software and represented as the percentage of 
wounded area in the correspondent time normalized to the initial wounded area (time 0) 
for each experimental condition.  
 
Cell invasion assay. Invasion of endothelial cells was assayed by using 8.0 m pore size 
transwell inserts coated with 100 µL of Matrigel 0,12 mg/mL solution. 105 BAE cells, in 
the absence or presence of the indicated concentrations of 653, were added to the upper 
chamber of the transwells in absence of serum, and lower chamber was was filled with 
20% FBS DMEM. After 16 hours incubation, invading cells were fixed in 4% 
paraformaldehide and stained with a 1% crystal violet solution in 2% ethanol. Cells were 
photographed with a microscope camera Nikon DS-Ri2 coupled to a Nikon Eclipse Ti 
microscope (Nikon, Tokyo, Japan). 
 
Zymographic assays for MMP-2 and -9 detection. Zymographies for matrix 
metalloproteinases MMP-2 and MMP-9 activities were performed in both conditioned 
media and cellular extracts of endothelial (BAEC) and tumoral (HT-1080) cell lines. 
Briefly, cells seeded in 6-well plates were incubated in serum-free culture medium with 
0.1% BSA containing 200 KIU of aprotinin/mL and the correspondent treatment. After 
24 h of incubation, conditioned media were collected and cell lysates were obtained. 
Duplicates were used to determine the cell number and samples were normalized for equal 
loading. In order to detect the gelatinolytic activity of MMP-9 and MMP-2, samples were 
loaded in non-reducing SDS/PAGE gels containing gelatine (1 mg/mL). After 
electrophoresis, gels were incubated overnight at 37 ºC immersed in a substrate buffer 
(50 mM Tris/HCl, pH 7.4, supplemented with 1% Triton X-100, 5 mM CaCl2, and 0.02% 
Na3N) and stained with Commassie blue R-250. The bands of gelatinase activity could 
be detected as non-stained bands in a dark, stained background. Size and intensity of the 
bands were quantified using Image J software. A variant of this method was used to obtain 
complementary information about direct inhibition of tested compound on MMP-2 
gelatinase activity: samples of conditioned media of untreated BAEC were submitted to 
gelatin zymography and, after electrophoresis, 20 M of 653 was added to the substrate 
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buffer. Detection of the degrading bands and quantification were performed as described 
above. 
  
Chick chorioallantoic membrane (CAM) Assay. Fertilized chick eggs were incubated 
horizontally at 38C in a humidified incubator, windowed by day 3 of incubation and 
processed by day 8. 653 was added to a 1.2% solution of methylcellulose in water, and 
10 μL drops were dried on a teflon-coated surface under a laminar flow hood. Then, 
methylcellulose discs were implanted onto the CAM, eggs were sealed with adhesive tape 
and returned to the incubator for 48 h. Negative controls were always made with DMSO 
mixed with the methylcellulose and aeroplysinin-1 (3 nmol/CAM) was used as a routine 
positive control of antiangiogenic compound. After the incubation, the CAM was 
examined under a stereomicroscope and photographed with a Nikon DS-Ri2 camera. The 
results were analysed by two different observers, and the assay was scored positive when 
both of them reported a significant reduction of vessels in the treated area.  
 
FGF-2 induced angiogenesis zebrafish yolk membrane (ZFYM) assay. For the FGF-2 
induced angiogenesis zebrafish yolk membrane (ZFYM), 24 hpf embryos were exposed 
to 1-phenyl-2-thiourea (PTU) to prevent the pigmentation. At 48 hpf, embryos were 
manually dechorionated with forceps, anaesthetized with tricaine (0.016 %) and injected 
into the perivitelline space with 2 nL FGF-2 (1 mg/mL). The injection was performed in 
the proximity of developing subintestinal vessels (SIVs) using borosilicate needles and a 
Picospritzer microinjector (Eppendorf, Hamburg, Germany). After injection, embryos 
were incubated for 24 h more in the absence or the presence of 653. Finally, embryos 
were fixed in 4% PFA, stained for endogenous alkaline phosphatase (AP) activity and 
photographed under a Leica MZ16 F stereomicroscope equipped with DFC480 digital 
camera and ICM50 software (Leica, Wetzlar, Germany). Evaluation of the angiogenic 
response was performed by assigning negative (-, no response to FGF-2 injection), 
positive (+, mild response) or very positive (++, strong response) scores to the embryos. 
 
Western-blot analysis. BAE cells were starved in serum-free during 16 hours. After 1 
hour treatment with 653 at 10 and 20 M in the same conditions, cells were induced with 
10% of FBS during 10 minutes. Protein lysates were obtained in RIPA buffer (50 mM 
Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0,25% sodium deoxycholate, 1 mM 
EDTA) containing phosphatase activity inhibitors (30 mM sodium fluoride, 1 mM 
sodium orthovanadate, 30 mM -glycerophosphate) and protease activity inhibitors 
(Complete mini, Roche, Mannheim, Germany). Protein concentration was determined 
usinf Lowry method. Samples were subjected to SDS-PAGE electrophoresis and 
transferred to nitrocellulose membranes. After blocking in TBS-T containing 10% non-
fatty dry milk, membranes were hybridized with primary antibodies overnight at 4˚ (Cell 
Signaling; rabbit anti- Phospho-Akt (Ser473) #9271; rabbit anti-Akt #9272; rabbit anti-
Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (clon D13.14.4E) #4370; rabbit anti-
p44/42 MAPK (ERK1/2) (137F5) #4695; mouse anti-α-Tubulin (DM1A) #3873). 
Following 1 hour incubation with horseradish peroxidase-conjugated secondary 
antibodies (MERK; goat anti- rabbit IgG HRP Linked Whole Antibody #NA934V; goat 
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anti-mouse IgG (whole molecule)–Peroxidase antibody #A4416) at room temperature, 
immunoreactive bands were detected with SuperSignal West Pico Chemiluminescent 
Substrate (Pierce, Rockford, USA) and were quantified by ImageJ software. The 
phosphorilated/total protein ratios were expressed as the percentage of the ratio in serum-
stimulated samples in the absence of 653.  
 
Ethical statement. The animal procedures considered in this project were performed in 
strict compliance with the European Communities Council Directive 2010/63/EU 
regulating the use and care of laboratory animals. Experimental procedures with chick 
embryos were performed at the University of Málaga (Spain) and were conducted in 
accordance with the Spanish Legislation in compliance with European Community 
regulation. The protocols were approved by the Ethics Committee for Animal 
Experiments of the University of Málaga. Zebrafish (Danio rerio) breeding colony (wild‐
type AB strain) was maintained at the Zebrafish Facilities of the University of Brescia 
(Italy). Experimental procedures with zebrafish embryos were performed at the 
University of Brescia and were conducted in accordance with the Italian Legislation for 
the animal experimentation. Efforts were made to reduce the number of animals used and 
minimize animal suffering. Furthermore, animals were anaesthetized when it was likely 
they could be subjected to pain, and they were killed by a method that ensured the least 
effect on their welfare.  
 
Statistical analysis. Results are expressed as mean ± SD of three independent 
experiments. Data sets were checked to follow a normal distribution and statistical 
significance was determined using the two-sided unpaired Student t-test (SPSS software). 
Values of P < 0.05 were considered to be statistically significant. Significance was 
indicated as follows: ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. 
  
 
 
 
